Purinergic Regulation of Respiratory Diseases
SUBCELLULAR BIOCHEMISTRY SERIES EDITOR J. ROBIN HARRIS, University of Mainz, Mainz, Germany
ASSISTANT EDITORS B.B. BISWAS, University of Calcutta, Calcutta, India P. QUINN, King’s College London, London, UK Recent Volumes in this Series Volume 41
Chromatic and Disease Edited by Tapas K. Kundu and Dipak Dasgupta
Volume 42
Inflammation in the Pathogenesis of Chronic Disease Edited by Randall E. Harris
Volume 43
Subcellular Proteomics Edited by Eric Bertrand and Michel Faupel
Volume 44
Peroxiredoxin Systems Edited by Leopold Folhe´ and J. Robin Harris
Volume 45
Calcium Signalling and Disease Edited by Ernesto Carafoli and Marisa Brini
Volume 46
Creatine and Creatine Kinase in Health and Disease Edited by Gajja S. Salomons and Markus Wyss
Volume 47
Molecular Mechanisms of Parasite Invasion Edited by Barbara A. Burleigh and Dominique Soldati-Favre
Volume 48
The Cronin Family of Proteins Edited by Christoph S. Clemen and Ludwig Eichinger
Volume 49
Lipids in Health and Disease Edited by Peter J. Quinn and Xiaoyuan Wang
Volume 50
Genome Stability and Human Diseases Edited by Heinz-Peter Nasheuer
Volume 51
Choloesterol Binding and Cholesterol Transport Proteins Edited by Robin J. Harris
Volume 52
A Handbook of Transcription Factors Edited by Tim Hughes
Volume 53
Endotoxins: Stricture, Function and Recognition Edited by Xiaoyuan Wang and Peter J. Quinn
Volume 54
Conjugation and Deconjugation of Ubiquitin Family Modifiers Edited by Marcus Groettrup
Maryse Picher Editor-in-Chief
Richard C. Boucher Editor
Purinergic Regulation of Respiratory Diseases
Editor-in-Chief Maryse Picher Cystic Fibrosis Pulmonary Research and Treatment Center University of North Carolina 7011 Thurston-Bowles building Chapel Hill, NC 27599 USA
[email protected]
Editor Richard C. Boucher Cystic Fibrosis Pulmonary Research and Treatment Center University of North Carolina 7011 Thurston-Bowles building Chapel Hill, NC 27599 USA
[email protected]
ISSN 0306-0225 ISBN 978-94-007-1216-4 e-ISBN 978-94-007-1217-1 DOI 10.1007/978-94-007-1217-1 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011928079 # Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
INTERNATIONAL ADVISORY EDITORIAL BOARD R. Bittman, Queens College, City University of New York, New York, USA D. Dasgupt, Saha Institute of Nuclear Physics, Calcutta, India A. Holzenburg, Texas A&M University, Texas, USA S. Rottem, The Hebrew University, Jerusalem, Israel M. Wyss, DSM Nutritional Products Ltd., Basel, Switzerland
Nearly half a century has passed since the “Purinergic Nerve Hypothesis” was proposed by Burnstock. The demonstration that ATP is released by nerve endings in a regulated manner and plays a critical role as neurotransmitter raised worldwide controversy and paved the way for the exploration of nucleotides as extracellular messengers. To this date, the number of manuscripts published in the field of “Purinergic Signaling” continues to grow exponentially and has become the main focus of numerous research groups around the world. Families of cell surface receptors named purinoceptors were cloned and identified in most organs and cell types. At the same time, another field of research emerged with the initial studies of Drs. Beaudoin and Zimmermann, who showed that the availability of the purinoceptor agonists is regulated by cell surface enzymes. Twenty years ago, these world leaders launched the “International Symposium on Adenosine and Adenine Nucleotides”, which led to the integration of both fields of purinergic research and groundbreaking discoveries from our basic understanding of cell signaling to therapeutic applications.
The growing list of medical institutions and pharmaceutical companies working together to develop therapeutic approaches based on purinergic signaling is a testimony to the now acclaimed critical importance of these messengers for homeostasis. This book is dedicated to the brave scientists who faced adversity to give birth to this new and exciting era of scientific endeavors.
Preface
Chronic respiratory diseases are complex disorders generally driven by genetic mutations weakening the airways’ ability to respond appropriately to inhaled toxins or pathogens. In the case of cystic fibrosis (CF), functional mutations of the cystic fibrosis transmembrane resistance (CFTR) ion channel impair airway hydration, which fosters the formation of infected mucus plugs requiring mechanical stimulation for clearance. These patients suffer from a progressive and irreversible loss of lung function caused by overwhelming and damaging neutrophilic inflammatory responses. On the other hand, frequent exposure to the toxic components of cigarette smoke is considered the primary cause of chronic obstructive pulmonary disease (COPD). Subjects diagnosed with a1-antitrypsin deficiency are particularly vulnerable to lung destruction by elastases, and to the development of emphysema. Allergic asthma remains a serious challenge, as this disease incorporates multiple genetic factors and environmental stimuli. The patients experience recurrent episodes of breathless, wheezing, coughing and chest tightness triggered by airway hyperresponsiveness (AHR) to allergens. Over the years, the severity of AHR episodes increases, as chronic inflammatory responses to allergens induce extensive airway remodeling and narrowing of the airway passages. Recently, the discovery of significant overlap between the symptoms of these diseases raised serious concerns with respect to our ability to diagnose and treat the patients efficiently. The scientific community has been mandated to open new avenues for the development of discriminative diagnostic tools and customized therapies for these diseases. For decades, the most common diagnostic method used to differentiate asthmatics from COPD patients was AHR induced by inhalation of methacholine. Yet, a third of the COPD patients present significant AHR to this drug. As an alternative, The European Respiratory Society Task Force recently endorsed AHR measurements after inhalation of adenosine monophosphate (AMP) as a more specific diagnosis for asthma than methacholine. This finding spiked the interest of the scientific community for the signaling pathways mediating the effects of AMP in the airways of asthmatic patients. We now know that aerosolized AMP must, first, be dephosphorylated by a cell surface enzyme named ecto 50 -nucleotidase (CD73) in order to
ix
x
Preface
generate adenosine, a signaling molecule of the purinergic network. Upon binding to cell surface receptors, adenosine induces histamine release from mast cells, which initiates AHR in asthmatic patients. This narrow window was only the prelude to what would become a major endeavor to expose the purinergic regulation of airway defenses. In the past 15 years, the persistent exponential increase in the number of publications targeting the purinergic regulation of acute lung injury, mucociliary clearance, inflammation, wound healing, remodeling and lung fibrosis is a testimony to the extensive ramifications of this signaling network in chronic respiratory diseases. Clinical and fundamental studies support the existence of disease-specific aberrances in airway concentrations of the signaling molecules, as well as in expression levels of the receptors and related enzymes in lung tissues of asthmatic, COPD and CF patients. This book is a tribute to this exploding field of research, and promises to come for the development of specific diagnostic tools and therapies for the predominant chronic respiratory diseases affecting the general population. The term “Purinome” was recently ascribed to protein network mediating the effects of extracellular purines and pyrimidines. The composition of each “Purinome” is locally refined by different combinations of signaling molecules (ATP, ADP, Ap4A, adenosine), purinergic receptors, cell surface nucleotide-metabolizing enzymes (ectonucleotidases), and nucleoside/nucleotide channels or transporters. These protein clusters mediate tightly concerted actions invested in the maintenance of homeostasis and airway defenses. In chronic disorders, alterations of their global and dynamic equilibrium contribute to the appearance and/or propagation of pathological states. The vast majority of studies conducted on purinergic signaling are devoted to ATP and its metabolite, adenosine. In a nutshell, the local release of ATP constitutes an alarm signal perceived by surrounding cells through interaction with P2 cell surface receptors. This “communique´” informs the cells to take action according to their specific roles in the restoration of homeostasis. The cells’ alertness is maintained by the presence of local ectonucleotidases which promptly eliminate the ATP signal and restore receptiveness. The ingenuity of this communication network resides in the subsequent initiation of a negative feedback messenger from the dephosphorylation of ATP into adenosine. This signaling molecule binds P1 cell surface receptors to assist to restrain ATP-mediated responses and restore baseline activities. This sophisticated machinery works in concerts with other signaling networks, such as those supported by cytokines and growth factors, to maintain healthy lungs free of infection. However, chronic disorders associated with the maintenance of excess ATP or adenosine in the airways recruits surface receptors which induce or aggravate lung complications, including hyperinflammatory responses, tissue damage and airway remodeling leading to the loss of lung function. This book was meticulously designed to systematically introduce the reader to each element of purinergic network, followed by their integration into a mathematical model. Then, evidence is presented for significant aberrances in the regulation of the signaling molecules in chronic respiratory diseases. Three chapters are dedicated to the detailed description of the major respiratory and inflammatory
Preface
xi
functions regulated by purinergic signaling, and the aspects affected by chronic disorders. Finally, the reader is presented with the animal models and clinical applications currently used for the development of diagnostic and therapeutic approaches chronic respiratory diseases. As editor-in-chief, I wish to thank all contributors for their efforts and the staff of Springer-Verlagh for their professionalism in overseeing this publication. Chapel Hill, NC
Maryse Picher
Contents
1
Nucleotide Release by Airway Epithelia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Eduardo R. Lazarowski, Juliana I. Sesma, Lucia Seminario, Charles R. Esther Jr., and Silvia M. Kreda
1
2
Mechanisms Regulating Airway Nucleotides. . . . . . . . . . . . . . . . . . . . . . . . . . Maryse Picher
17
3
Computational Model for the Regulation of Extracellular ATP and Adenosine in Airway Epithelia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Guilherme J.M. Garcia, Maryse Picher, Peiying Zuo, Seiko F. Okada, Eduardo R. Lazarowski, Brian Button, Richard C. Boucher, and Tim C. Elston
51
4
Regulation of Airway Nucleotides in Chronic Lung Diseases. . . . . . . . Charles R. Esther Jr., Neil E. Alexis, and Maryse Picher
75
5
Nucleotide-Mediated Airway Clearance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Andreas Schmid, Lucy A. Clunes, Mathias Salathe, Pedro Verdugo, Paul Dietl, C. William Davis, and Robert Tarran
95
6
Purinergic Signaling in Wound Healing and Airway Remodeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Albert van der Vliet and Peter F. Bove
7
Purinergic Regulation of Airway Inflammation . . . . . . . . . . . . . . . . . . . . . . Michael Koeppen, Francesco Di Virgilio, Eric T. Clambey, and Holger K. Eltzschig
139
159
xiii
xiv
Contents
8
Animal Models of Airway Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Linda F. Thompson, Maryse Picher, and Michael R. Blackburn
195
9
Therapeutic Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stephen Tilley, Jon Volmer, and Maryse Picher
235
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
277
Contributors
Neil E. Alexis Center for Environmental Medicine, University of North Carolina, Chapel Hill, NC 27599, USA Michael R. Blackburn Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX, USA Richard C. Boucher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Peter F. Bove Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Brian Button Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Eric T. Clambey Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA Lucy A. Clunes Department of Pharmacology, School of Medicine, St George’s University, Grenada, West Indies
xv
xvi
Contributors
C. William Davis Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Paul Dietl Institute of General Physiology, University of Ulm, Ulm 89081, Germany Francesco Di Virgilio Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy Tim C. Elston Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA Holger K. Eltzschig Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA Charles R. Esther Jr. Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC 27599, USA Guilherme J.M. Garcia Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA Michael Koeppen Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA Silvia M. Kreda Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Eduardo R. Lazarowski Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Seiko F. Okada Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Maryse Picher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA
Contributors
Mathias Salathe Division of Pulmonary and Critical Care, University of Miami, Miami, FL 33136, USA Andreas Schmid Division of Pulmonary and Critical Care, University of Miami, Miami, FL 33136, USA Lucia Seminario Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Juliana I. Sesma Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Robert Tarran Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Linda F. Thompson Oklahoma Medical Research Foundation, Oklahoma City, OK, USA Stephen Tilley Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, NC 29799, USA Albert van der Vliet Department of Pathology, University of Vermont, Burlington, VT, USA Pedro Verdugo Department of Bioengineering, University of Washington, Friday Harbor, WA 98195, USA Jon Volmer Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA Peiying Zuo Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA
xvii
Chapter 1
Nucleotide Release by Airway Epithelia Eduardo R. Lazarowski, Juliana I. Sesma, Lucia Seminario, Charles R. Esther Jr., and Silvia M. Kreda
Abstract The purinergic events regulating the airways’ innate defenses are initiated by the release of purines from the epithelium, which occurs constitutively and is enhanced by chemical or mechanical stimulation. While the external triggers have been reviewed exhaustively, this chapter focuses on current knowledge of the receptors and signaling cascades mediating nucleotide release. The list of secreted purines now includes ATP, ADP, AMP and nucleotide sugars, and involves at least three distinct mechanisms reflecting the complexity of airway epithelia. First, the constitutive mechanism involves ATP translocation to the ER/Golgi complex as energy source for protein folding, and fusion of Golgi-derived vesicles with the plasma membrane. Second, goblet cells package ATP with mucins into granules, which are discharged in response to P2Y2R activation and Ca2+-dependent signaling pathways. Finally, non-mucous cells support a regulated mechanism of ATP release involving protease activated receptor (PAR)-elicited G12/13 activation, leading to the RhoGEF-mediated exchange of GDP for GTP on RhoA, and cytoskeleton rearrangement. Together, these pathways provide fine tuning of epithelial responses regulated by purinergic signaling events. Keywords ATP release Airway epithelia Ectonucleotidase Thrombin Mucin
E.R. Lazarowski (*), J.I. Sesma, L. Seminario, and S.M. Kreda Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected];
[email protected];
[email protected];
[email protected] C.R. Esther Jr. Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC 27599, USA e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_1, # Springer Science+Business Media B.V. 2011
1
2
1.1 1.1.1
E.R. Lazarowski et al.
Introduction Definitions: The Purinergic Receptors
The actions of extracellular nucleotides are mediated by two families of receptors: P2X receptors (P2XRs) and P2Y receptors (P2YRs) (reviews: [1–3]). The P2XR family includes seven ATP-gated non-selective cation channels modulated by extracellular Ca2+, Na+, Mg2+ and H+. Their activation mobilizes intracellular Ca2+ and causes membrane depolarization. The P2YR family contains eight G protein-coupled receptors activated by ATP, UTP, ADP, UDP, and/or UDP-sugars (Table 1.1). The metabolite of ATP, adenosine, (ADO) mediates cellular responses through four G protein-coupled P1 receptors: A1Rs, A2ARs, A2BRs and A3Rs (reviews: [4–6]). Their agonist selectivity and signaling properties are summarized in Table 1.1. The purinergic network of human airway epithelia accommodates a discrete subset of purinergic receptors (review: [7]). The predominant nucleotide-sensing receptor in the airways is P2Y2R, which is activated to a similar extent and potency by ATP and UTP. Receptor occupation initiates the breakdown of plasma membrane phosphoinositides by phospholipase C, resulting in the formation of two secondary messengers: inositol 1,4,5 tris-phosphate (InsP3) and diacylglycerol (DAG). Whereas InsP3 triggers the Ca2+ release from intracellular stores, DAG activates protein kinase C (PKC)-dependent signaling cascades. These pathways promote the secretion of mucin (review: [8]), inhibition of the epithelial Na+ channel (ENaC) [8–14] and activation of the Ca2+-activated Cl channel (CaCC) recently identified as (ANO)/TMEM16 [15–17]. Human nasal epithelial cells also express P2Y6Rs, Table 1.1 Agonist selectivity and signaling pathways regulated by purinergic receptors Family Natural agonist Signaling P2X receptors ATP ATP-gated cation channel P2X1–P2X7 P2Y receptors P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12 P2Y13 P2Y14
ADP ATP ¼ UTP UTP UDP ATP ADP ADP UDP-sugars
Gq/PLC Gq/PLC Gq/PLC Gq/PLC Gq/PLC and Gs/AC Gi/AC inhibition Gi/AC inhibition Gi/AC inhibition and ERK activation
Adenosine receptors A1 A2A A2B A3
Adenosine Adenosine Adenosine Adenosine
Gi/AC inhibition Gs/AC activation Gs/AC activation Gi/AC inhibition
PLC phosphlipase C, AC adenylyl cyclase
1 Nucleotide Release by Airway Epithelia
3
which induces CaCC activity with a maximal effect about one-half of P2Y2Rs [18]. A study conducted in human A549 alveolar and BEAS-2B bronchial epithelial cells supports the expression of P2Y14R in human airway epithelial cells, where it participates in highly specific inflammatory responses [19] (see Chap. 7 for details). The presence of P2XRs on airway epithelial surfaces has been documented in various species, including humans (reviews: [20]). Whereas normal bronchial epithelia express P2X4-6 receptors, primary cultures and cell lines from CF patients also express P2X7Rs [21]. The P2X4R was immunolocalized on the apical surface of rabbit tracheal epithelia, on the lower half of the cilia [22]. In the parenchyma, alveolar type 1 cells express P2X4R and P2X7R, the latter being associated with caveolae. The use of selective stable agonists and antagonists suggests that these P2XRs participate in the regulation of ion channels mediating airway hydration (see Chap. 5). However, their contribution remains highly debated because the affinity of the cloned receptors for ATP (EC50 ¼ 10–100 mM) [23] is several orders of magnitude above that of P2Y2Rs regulating the same cellular functions. On the other hand, P2XRs expressed on basolateral epithelial surfaces were found 100-fold more sensitive than those restricted to the apical surface [21]. Furthermore, Rettinger et al. published two detailed studies showing that receptor desensitization masks the nanomolar potency of ATP for P2X1Rs in Xenopus oocytes [24, 25]. These receptors also form heteromers, such as P2X4/6 and P2X4/7 [26], which generally raises their sensitivity to ATP (review: [27]). Clearly, much remains to be uncovered on the properties and roles of P2XRs in the respiratory system. On airway epithelial surfaces, the vast majority of the studies describing ADOmediated responses refer to the A2BR. This P1 receptor has been shown to stimulate the conductance of CFTR [28] and ciliary beat frequency [9]. The A2AR has been identified on human airway epithelia by RT-PCR and using selective agonists and antagonists, where it promotes healing [29, 30] and inflammatory responses [31, 32] (see Chaps. 6 and 7 for details). This summary identifies the purinergic receptors expressed on airway epithelial surfaces, which will facilitate the discussion in the following sections.
1.1.2
Nucleotide and Nucleoside Concentrations on Airway Surfaces
Mucociliary clearance (MCC) represents the first line of defense of the airways against infection, a mechanism known to be tightly regulated by purinergic events taking place within the airway surface liquid (ASL). The signals are initiated by the release of the signaling molecule, ATP, from airway epithelial cells. In vitro studies indicated that resting airway epithelia release ATP at a rate of 300–500 fmolmin1cm2 [33, 34]. The rate of ATP release is counterbalanced by the rate of surface metabolism mediated by ectonucleotidases. This dynamic flow of nucleotides maintains steady-state ASL ATP concentrations around 5–20 nM, which is below the activation threshold of P2Y2Rs [33–35]. However, the metabolism
4
E.R. Lazarowski et al.
of surface ATP continuously generates the signaling molecule ADO, which is maintained at steady-state concentrations capable of activating A2BRs. Indeed, measurements of cyclic AMP production conducted in the presence or absence of ADO-degrading enzymes, revealed that A2BRs are tonically stimulated by endogenous ADO on resting airway epithelial cells in culture [33]. This hypothesis was further validated using sensitive assays for the quantification of ADO within the ASL. Endogenous nucleotides and nucleosides display low intrinsic fluorescence, and UV-based approaches require relatively high concentrations (>0.1 mM) for detection. This limitation was overcome using the chloroacetaldehyde derivatization technique, which quantitatively converts the adenine ring of ADO and its nucleotides into fluorescent 1,N 6-etheno(e)-adenine derivatives, i.e., e-ADO, e-AMP, e-ADP, and e-ATP. The (e)-adenyl purines are separated by HPLC and readily quantified with low nanomolar sensitivity. Using this technique, the concentration of ADO within the ASL of resting epithelial cultures was found in the 100–400 nM range [33], which is above the activation threshold of A2BRs. The recognition that the constitutive1 release of ATP results in physiologically relevant levels of ADO in the ASL suggests a mechanism for the purinergic control of basal MCC activities in resting epithelia, i.e., via A2BR activation. However, the rate of ATP release from airway epithelial cells is enhanced threefold by mechanical stresses, such as rhythmic shear and compression, experienced during tidal breathing or coughing. The resulting transient increase in ASL ATP concentration (100–1,000 nM) is capable of activating P2Y2Rs [36]. Functional studies (e.g. measurement of ASL volume regulation) demonstrated that ATP released from mechanically-stimulated epithelia mediates acute MCC responses via P2Y2R stimulation [36–39]. In summary, airway surfaces initiate purinergic events critical for MCC via ATP release and surface conversion into ADO by ectoenzymes, both inducing specific cell surface receptors and signaling pathways.
1.2
Mechanisms of Nucleotide Release
1.2.1
Constitutive Release of Nucleotides from the Secretory Pathway
1.2.1.1
Lessons Learned from the Yeast
The complex cellular composition of the airways, i.e., ciliated cells and mucinsecreting goblet cells, suggests that several mechanisms and pathways are involved in the release of nucleotides into the airways. Circumstantial evidence supports the involvement of both exocytosis and plasma membrane channels in the cellular 1
We use the term “constitutive” to refer to a release process that occurs in non-stimulated cells.
1 Nucleotide Release by Airway Epithelia
5
Fig. 1.1 Pathways for airway epithelial nucleotide release. Several scenarios account for the constitutive and stimulated release of nucleotides from airway epithelial cells. (i) Nucleotides entering the Golgi lumen via specific transporters are released as a residual cargo product of the constitutive secretory pathway. The fungal venom brefeldin A (BFA) blocks this pathway by disrupting the Golgi apparatus. (ii) Secretory granules (e.g., mucin granules) containing ATP are competent for Ca2+-regulated exocytosis. Bafilomycin Ai (Baf ), an inhibitor of the H+-ATPase that loads ATP into specialized granules in secretory cells, impairs mucin secretion-associated ATP release in goblet cells. (iii) A plasma membrane connenxin/pannenxin-like channel effluxes cytosolic ATP out of the cells
release of nucleotides (Fig. 1.1), but unambiguous support for either vesicular or conductive mechanisms of release in epithelia has only recently begun to surface. Initial evidence for the involvement of the secretory pathway in the release of nucleotides from non-excitatory cells was provided by studies of glucose-dependent ATP release in the yeast Saccharomyces cerevisia [40, 41]. Glucose-dependent ATP release was enhanced in yeast overexpressing Mcd4p, a Golgi-resident transporter postulated to transports ATP to the lumen of the secretory pathway. This mechanism of ATP release was inhibited by the Golgi-disrupting agent brefeldin A [40, 41]. Since ATP release from yeast dramatically decreased when glucose was omitted from the extracellular medium, it was hypothesized that ATP release from these cells reflected an exocytotic mechanism initiated by the activation of a glucosesensing cell surface receptor [40]. The HPLC analysis of adenyl purines released by yeast indicated that, in the absence of glucose, extracellular AMP levels increased robustly as ATP levels decreased, maintaining the net mass of extracellular AMP/ADP/ATP unaffected by glucose [41]. Moreover, short-term removal of glucose from the extracellular medium did not affect the ability of yeast to secrete invertase, a marker of exocytosis [41]. The simplest interpretation of these data is that yeast releases nucleotides constitutively, via vesicle exocytosis, and that the
6
E.R. Lazarowski et al.
energy balance of the cell determines the relative levels of ATP and AMP within the releasable vesicular pool. Additional evidence supporting the involvement of the secretory pathway in the release of nucleotides was generated from the observation that, in most cells, ATP release is accompanied by the release of UDP-sugars. Interest in UDP-sugar release followed the realization that one member of the P2YR family, the P2Y14R, is selectively and potently stimulated by UDP-glucose (UDP-Glc) and other UDPsugars [42]. A series of studies indicated that UDP-Glc is released from a number of cells, including simple cell systems such as yeast and highly differentiated airway epithelial cells [41, 43–45]. The fact that UDP-sugars participate in glycosylation reactions within the secretory pathway suggested that these molecules are released as cargo molecules during the export of glycoconjugates to the plasma membrane, i.e., via the constitutive pathway (Fig. 1.1). This hypothesis has been recently tested at the molecular level. It has been shown that UDP-Glc, UDP-N-acetylglucosamine (UDP-GlcNAc), and other UDP-sugars are synthesized in the cytosol and concentrated in the lumen of the endoplasmic reticulum (ER) and Golgi apparatus to serve as sugar donor substrates for glycosyltransferase reactions [46–48]. UDP, a byproduct of this process, is in turn hydrolyzed to UMP [48]. The entry of UDP-sugars to the ER/Golgi is mediated by ER/Golgi-resident UDP-sugar transporters, which use luminal UMP as antiporter substrate (Fig. 1.1). The UDP-sugar/UMP translocators are multitransmembrane helices that belong to the family of solute carrier SLC35 ER/Golgi nucleotide-sugar transporters [49]. Studies in yeast suggest that the cellular release of UDP-Glc is preceded by its uptake into the ER/Golgi. That is, UDP-Glc release was enhanced in yeast missing the putative nucleotide-sugar transporter encoding gene YMD8 (ymd8D cells), and this release was significantly reduced in ymd8D cells in which Yea4p or HUT1p, the ER-resident UDP-GlcNAc transporter and Golgi UDP-galactose transporter, respectively, were deleted. Thus, UDP-Glc release from yeast is influenced by the rates of ER/Golgi uptake of UDP-GlcNAc and UDP-galactose [41]. Diminished entry of UDP-Glc to the ER/Golgi of YEA4or HUT1-deficient cells likely reflected the decreased availability of the antiporter substrate UMP in the ER/Golgi lumen [48]. However, since Yea4p or HUT1p are not primarily UDP-Glc transporters, the interpretation of these results has remained speculative. The passage of UDP-sugar species through the ER/Golgi before their release was more conclusively established by correlating the amount of UDP-GlcNAc transporter in the ER/Golgi with the cellular release of its substrate, UDP-GlcNAc. By developing an assay which quantifies UDP-GlcNAc concentrations within the low nanomolar range, Sesma et al. demonstrated that yeast, in which the YEA4 gene (yea4D cells) was deleted, display reduced release of UDP-GlcNAc, the natural substrate of Yea4p [45]. Consistent with the role of Yea4p as major ER/Golgi UDP-GlcNAc transporter, the yeaD cells also displayed reduced synthesis of chitin, a glucosamine-rich cell wall component. The reduced UDP-GlcNAc release rate and chitin content of the yeaD cells were returned to normal by complementing the mutant strain with the WT YEA4 gene [45]. The most parsimonious conclusion
1 Nucleotide Release by Airway Epithelia
7
from these studies is that, by facilitating UDP-GlcNAc entry into the ER/Golgi, Yea4p mediates the release of its UDP-sugar substrate from the secretory pathway.
1.2.1.2
Vectorial Release of Nucleotide Sugars from Resting Cells
The above-mentioned studies in yeast paved the way to investigate the role of Golgiderived vesicles in the constitutive release of nucleotide-sugars from airway epithelia. Three gene products, SLC35A3, SLC35B4 and SLC35D2, have been characterized as Golgi-resident UDP-sugar/UMP translocators in humans [49–51]. SLC35D2, also known as HFRC1, is the human homologue to the fruit fly fringe connection (Frc) transporter and may facilitate the transport of UDP-Glc and UDP-GlcNAc into the Golgi [50]. By controlling the entry of UDP-GlcNAc into the Golgi, HFRC1 modulates the surface expression of N-acetylglucosamine-rich glycoconjugates on airway epithelial cells [50]. Consistent with this concept, the human bronchial epithelial cell line 16HBE14o, stably overexpressing HFRC1, displayed enhanced cell surface immunoreactivity towards heparan sulfate and increased apical surface binding of WGA, a lectin that recognizes N-acetylglucosamine and sialic acids in airway epithelia. The overexpression of HFRC1 resulted in an increased rate of mucosal release of UDP-GlcNAc and, to a lesser extent, UDP-Glc release, relative to vectortransformed cells [45]. These studies provide compelling evidence for the contribution of Golgi-derived vesicles to the release of nucleotide-sugars from airway epithelial cells. Measurements of ATP and UDP-sugars release rates in polarized monolayers of human airway epithelial Calu-3 and 16HBE14o cells revealed that the nucleotides accumulate predominantly in the mucosal bath [33, 34, 45], suggesting a membrane specialization for nucleotide release. Similarly to UDP-sugars, ATP is translocated to the ER/Golgi via ATP/AMP antiporters, where it serves as an energy source for protein folding reactions [52, 53]. Therefore, the tonic release of ATP, UDP-sugars, as well as ADP and UDP, likely supports the continuous (“constitutive”) recycling of proteins and glycoconjugates on the apical plasma membrane and the exocytotic release of co-cargo nucleotides (Fig. 1.1).
1.2.2
Calcium-Promoted Release of Nucleotides from Goblet Cells
In addition to the above-described constitutive release, recent studies conducted with goblet-like airway epithelial cells indicated that ATP and UDP-sugars are released concomitantly with MUC5AC, a secretory mucin, during the Ca2+-regulated exocytosis of mucin granules. Electron microscope analysis of polarized Calu-3 cultures indicated that up to 40% of the cells within the monolayer express ~1 mm-diameter electron-translucent granules that resemble the mucin granules of airway mucous
8
E.R. Lazarowski et al.
goblet cells. Subsequent immunostaining and slot blot analysis revealed the presence of MUC5AC granules in the Calu-3 cultures, which were competent for Ca2+regulated exocytosis in the mucosal compartment. The Ca2+-promoted mucin secretion was accompanied by enhanced ATP release into the mucosal bath [44]. The kinetics of ATP release and mucin-granule secretion were similar and triggered by identical stimuli, suggesting that nucleotides are stored within, and released from, mucin granules in goblet cells [44]. Furthermore, bafilomycin A1, which depletes ATP storage granules [54], markedly impaired ionomycin-promoted ATP release from Calu-3 cells [44]. These data are consistent with the possibility that a vesicular/ granular ATP pool contributes to Ca2+-stimulated ATP release. An important corollary derived from these observations is that ATP/mucin-secreting goblet cells produce paracrine signals for P2Y2R-mediated mucin hydration and MCC activities. The Ca2+-dependent mechanism of ATP release identified in Calu-3 monolayers also stimulated the apical release of UDP-Glc [44], which has pathophysiological implications. High concentrations of UDP-Glc (100–1,000 nM) were recently detected in lung secretions from patients with cystic fibrosis (CF) or other goblet cell hyperplasic lung diseases [44, 45]. These concentrations were demonstrated to activate P2Y14Rs, which are highly expressed on inflammatory cells (lymphocytes and neutrophils) [55–57]. Therefore, the sustained accumulation of UDP-Glc in the ASL in conditions associated with goblet cell hyperplasia and/or mucin hypersecretion (asthma, chronic obstructive pulmonary disease or CF) may amplify inflammatory responses.
1.2.3
Regulated ATP Release from Non-Mucous Cells
1.2.3.1
Rho-Dependent Signaling Participates in ATP Release
The mechanisms supporting nucleotide release from non-mucous lung epithelial cells (i.e. ciliated or alveolar cells) remains unclear due to the scarcity of pharmacological approaches known to promote ATP release. While most studies rely on mechanical or osmotic stimuli, the biochemical signals mediating ATP release remain poorly defined. Recent data suggest that in A549 alveolar cells, hypotonicity-induced ATP release involves the mobilization of intracellular Ca2+ [58–60]. However, in human bronchial epithelial (HBE) cultures dominated by ciliated cells, the chelation of intracellular Ca2+ resulted in only a minor inhibition of hypotonic shockelicited ATP release [34]. However, Ca2+ mobilizing agents, such as ionomycin and UTP, promoted only minor release of ATP relative to hypotonic shock, in both HBE and A549 cells [34, 59–61]. These observations suggest that additional and/or alternative signals to Ca2+ mobilization are required upstream of ATP release in non-mucous cells. This notion appears not to be restricted to epithelial cells. For example, studies in 1321N1 human astrocytoma cells demonstrated that Ca2+ mobilization is not sufficient to reach maximal ATP release in response to
1 Nucleotide Release by Airway Epithelia
9
pharmacological stimulation. In these cells, the serine protease thrombin promoted a robust Ca2+-dependent nucleotide release response via activation of the proteaseactivated receptor-1 (PAR1). In contrast, carbachol induced a robust Ca2+ mobilization via the muscarinic receptor M3, but modest ATP release from these cells [62, 63]. A more recent study by Dubyak et al. indicated that G protein coupled receptor-elicited ATP release involves the activation of RhoA, consistent with the notion that PAR1 couples to G12/13 in addition to Gq [64]. Studies conducted on human umbilical vein endothelial cells also support a role for Rho in mechanical stress-induced ATP release. In these cells, both hypotonic stress- and lysophosphatidic acid (LPA)-induced ATP release were abolished by the Rho kinase inhibitor Y27632 [65]. Together, these studies suggested that Rho is a central regulator of ATP release in response to physical and pharmacological stimuli. The presence of Rho-stimulating thrombin receptors in lung epithelia [61, 66] provided a physiological approach to investigate the involvement of this GTPase in epithelial ATP release. Consistent with the above-mentioned studies on astrocytoma and endothelial cells [64, 65], thrombin promoted ATP release from A549 cells, which was accompanied by a rapid (1–3 min) activation of RhoA [61]. In contrast, activation of the Gq/PLC/Ca2+-mobilizing signaling pathway by UTP on P2Y2Rs resulted in negligible ATP release from these cells, and a delayed onset (>15 min) of Rho activation [61]. The involvement of Rho was supported by the observation that ATP release from thrombin-stimulated A549 and HBE cultures decreases in the presence of ROCK inhibitors [61]. These observations were further validated by mutational studies. The transfection of A549 cells with the RhoA mutant RhoA(T19N), which tightly binds RhoGEF (guanine exchange factor of Rho) without promoting downstream effector activation, markedly inhibited thrombin-elicited ATP release [61]. Similar results were obtained in cells transfected with p115RGS, a G12/13-inhibitory protein derived from the RGS (regulatory G-protein signaling) domain of p115-RhoGEF [67]. These studies suggest that thrombinpromoted ATP release on non-mucous lung epithelial cells encompasses PARelicited G12/13 activation, leading to the RhoGEF-mediated exchange of GDP for GTP on RhoA. How Rho/ROCK modulates ATP release remains unclear. However, the wellestablished control that ROCK exerts on the phosphorylation status of the myosin regulatory light chain (RLC) supports the attractive hypothesis that, by promoting cytoskeleton rearrangements, Rho facilitates the plasma membrane insertion and/or activation of an ATP channel, such as connexin/pannexin hemichannels.
1.2.3.2
Connexin/Pannexin Hemichannels: A Pathway for ATP Release
A gap junction, also named intercellular channel, allows direct communication between the cytosol of adjacent cells. In mammalian cells, the hemichannel contributed by each cell is formed by connexin or pannexin proteins (review: [68]). Recent evidence suggested that, unlike connexins, pannexins form single plasma membrane hemichannels (pannexons) rather than junctional channels [69].
10
E.R. Lazarowski et al.
Connexin and pannexin hemichannels have been proposed as diffusion pathways for ATP release under various experimental conditions [70, 71]. First, connexin hemichannels are highly dependent on extracellular Ca2+ ([Ca2+]ex), as they close in the presence of millimolar [Ca2+]ex and open when the [Ca2+]ex is lowered [72–74]. Exposure to low levels of extracellular divalent cations is a well-known procedure to potentiate or trigger the opening of connexin hemichannels leading to ATP release [75, 76]. In contrast, pannexin hemichannels are not gated by [Ca2+]ex [77]. However, they were both reported to conduct ATP [70, 71, 78]. Exposure of A549 cells to thrombin resulted in a robust ATP release response that was inhibited by the non-selective blockers of connexin and pannexin hemichannels, anandamide, flufenamic acid and carbenoxolone [61]. Thrombin-evoked ATP release was accompanied by an increase in cellular uptake of the hemichannel permeable reporter dye, propidium iodide, which was inhibited by the same hemichannel blockers. These results suggest that ATP release from thrombin-stimulated lung epithelial cells occurs via connexin or pannexin hemichannels. A recent study by Ransford and coworkers provides additional support to this hypothesis in airway epithelial cells. These authors reported that ATP release from hypotonic shockstimulated HBE cells was reduced in the presence of non-selective inhibitors of pannexin or after silencing pannexin-1 via shRNA [79]. An important unresolved issue regarding the putative involvement of connexin or pannexin in ATP release is the identification of the signaling pathways that regulate the gating of these hemichannels. Studies in Xenopus oocytes co-expressing pannenxin-1 with P2Y1Rs or P2Y2Rs suggested that pannenxin opens in response to intracellular Ca2+ elevation [80]. This mechanism, however, may not be relevant to airway epithelia since, as explained above, (i) the chelation of intracellular Ca2+ did not inhibit ATP release in hypotonic shock-stimulated HBE cells [34], and (ii) P2Y2R activation does not promote ATP release or propidium iodide uptake in lung epithelial cells [61]. Thus, assuming an involvement of pannexin and/or connexin in ATP release from airway epithelial cells, mechanisms other than intracellular Ca2+ mobilization should regulate the activity of these hemichannels. In this regard, it is noteworthy that the influx of propidium iodide uptake in thrombin-stimulated A549 cells was inhibited by Rho kinase inhibitors [61].
1.3
Conclusions and Future Directions
Nearly two decades have elapsed since the initial observation that extracellular nucleotides and nucleosides promote Cl secretion from airway epithelial cells [81, 82], the initial finding that led to the identification of P2Y2Rs and A2BRs as major purinergic receptors regulating MCC. An interrelated area of active research focuses on the mechanisms of nucleotide release, in particular, the identification of biochemical signals that transduce mechanical forces into ATP release. While clues are emerging, several questions remain unanswered: How do epithelial cells control the constitutive release of nucleotides? To what extent does the Golgi compartment
1 Nucleotide Release by Airway Epithelia
11
contribute to ATP release in resting cells and what is the contribution of conductive/ transporter mechanisms to this release? What are the molecular sensors for shear and compressive stress? How does mechanical stress impart a secondary messengermediated response? How do non-mucous lung epithelial cells release ATP? Finally, what is the contribution of connexin and pannexin hemichannels to ATP release in response to physiologically relevant stimuli and how are they regulated in epithelial cells? These questions are bound to unravel, yet, new avenues of research for the purinergic regulation of airway defenses. Acknowledgments We would like to thank Lisa Brown for editorial assistance of the manuscript. This work was supported by the National Institute of Health (NIH), National Heart, Lung, and Blood Institute (P01-HL034322) and the Cystic Fibrosis Foundation (CFF-SEMINA08FO).
References 1. Burnstock G (2006) Purinergic signaling-an overview. Novartis Found Symp 276:26–48 2. von K€ugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415–432 3. Surprenant A, North RA (2009) Signaling at purinergic P2X receptors. Annu Rev Physiol 71:333–359 4. Fredholm BB (2010) Adenosine receptors as drug targets. Exp Cell Res 316:1284–1288 5. Ciruela F, Albergaria C, Soriano A, Cuffı´ L, Carbonell L, Sa´nchez S, Gandı´a J, Ferna´ndezDuen˜as V (2010) Adenosine receptors interacting proteins (ARIPs): behind the biology of adenosine signaling. Biochim Biophys Acta 1798:9–20 6. Trincavelli ML, Daniele S, Martini C (2010) Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 10:860–877 7. Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262–267 8. Davis CW, Dickey BF (2008) Regulated airway goblet cell mucin secretion. Annu Rev Physiol 70:487–512 9. Morse DM, Smullen JL, Davis CW (2001) Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells. Am J Physiol 280:C1485–C1497 10. Jia Y, Mathews CJ, Hanrahan JW (1997) Phosphorylation by protein kinase C is required for acute activation of cystic fibrosis transmembrane conductance regulator by protein kinase A. J Biol Chem 272:4978–4984 11. Devor DC, Pilewski JM (1999) UTP inhibits Na+ absorption in wild-type and Delta F508 CFTR-expressing human bronchial epithelia. Am J Physiol 276:C827–C837 12. Yue G, Malik B, Yue G, Eaton DC (2002) Phosphatidylinositol 4, 5-bisphosphate (PIP2) stimulates epithelial sodium channel activity in A6 cells. J Biol Chem 277:11965–11969 13. Ma HP, Saxena S, Warnock DG (2002) Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC). J Biol Chem 277:7641–7644 14. Kunzelmann K, Bachhuber T, Regeer R, Markovich D, Sun J, Schreiber R (2005) Purinergic inhibition of the epithelial Na+ transport via hydrolysis of PIP2. FASEB J 19:142–143 15. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJV (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322:590–594 16. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim W-S, Park SP, Lee J, Lee B, Kim B-M, Raouf R, Shin YK, Oh U (2008) TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455:1210–1215
12
E.R. Lazarowski et al.
17. Schroeder BC, Cheng T, Jan YN, Jan LY (2008) Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134:1019–1029 18. Lazarowski ER, Paradiso AM, Watt WC, Harden TK, Boucher RC (1997) UDP activates a mucosal-restricted receptor on human nasal epithelial cells that is distinct from the P2Y2 receptor. Proc Natl Acad Sci USA 94:2599–2603 19. Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC Jr, Luttmann W, Norgauer J, Di Virgilio F, Idzko M (2005) The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion. Am J Respir Cell Mol Biol 33:601–609 20. Barth K, Kasper M (2009) Membrane compartments and purinergic signaling: occurrence and function of P2X receptors in lung. FEBS J 276:341–353 21. Taylor AL, Schwiebert LM, Smith JJ, King C, Jones JR, Sorscher EJ, Schwiebert EM (1999) Epithelial P2X purinergic receptor channel expression and function. J Clin Invest 104:875–884 22. Ma W, Korngreen A, Weil S, Cohen EB, Priel A, Kuzin L, Silberberg SD (2006) Pore properties and pharmacological features of the P2X receptor channel in airway ciliated cells. J Physiol 571:503–517 23. North RA, Surprenant A (2000) Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40:563–580 24. Rettinger J, Schmalzing G (2003) Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations. J Gen Physiol 121:451–461 25. Rettinger J, Schmalzing G (2004) Desensitization masks nanomolar potency of ATP for the P2X1 receptor. J Biol Chem 279:6426–6433 26. Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD (2007) Evidence for functional P2X4/ P2X7 heteromeric receptors. Mol Pharmacol 72:1447–1456 27. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013–1067 28. Boucher RC (2002) An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 54:1359–1371 29. Allen-Gipson DS, Wong J, Spurzem JR, Sisson JH, Wyatt TA (2006) Adenosine A2A receptors promote adenosine-stimulated wound healing in bronchial epithelial cells. Am J Physiol 290:L849–L855 30. Allen-Gipson DS, Spurzem K, Kolm N, Spurzem JR, Wyatt TA (2007) Adenosine promotion of cellular migration in bronchial epithelial cells is mediated by the activation of cyclic adenosine monophosphate-dependent protein kinase A. J Investig Med 55:378–385 31. Morello S, Ito K, Yamamura S, Lee K-Y, Jazrawi E, DeSouza P, Barnes P, Cicala C, Adcock IM (2006) IL-1b and TNFa regulation of the adenosine receptor (A2A) expression: differential requirement for NFkB binding to the proximal promoter. J Immunol 177:7173–7183 32. Sun Y, Wu F, Sun F, Huang P (2008) Adenosine promotes IL-6 release in airway epithelia. J Immunol 180:4173–4181 33. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S, Boucher RC (2004) Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 279:36855–36864 34. Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, Boucher RC (2006) Physiological regulation of ATP release at the apical surface of human airway epithelia. J Biol Chem 281:22992–23002 35. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ, Boucher RC (2000) Basal nucleotide levels, release, and metabolism in normal and cystic fibrosis airways. Mol Med 6:969–982 36. Button B, Boucher RC (2008) Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol 163:189–201 37. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CMP, Lazarowski ER, Zhang L, Collins PL, Pickles RJ, Fredburg JJ, Boucher RC (2005) Normal and cystic fibrosis airway surface
1 Nucleotide Release by Airway Epithelia
38.
39. 40. 41.
42.
43. 44.
45.
46. 47. 48. 49. 50.
51.
52. 53.
54.
55. 56.
13
liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 280:35751–35759 Tarran R, Trout L, Donaldson SH, Boucher RC (2006) Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 127:591–604 Button B, Picher M, Boucher RC (2007) Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol 580:577–592 Zhong X, Malhotra R, Guidotti G (2003) ATP uptake in the Golgi and extracellular release require Mcd4 protein and the vacuolar H+-ATPase. J Biol Chem 278:33436–33444 Esther CRJ, Sesma JI, Dohlman HG, Ault AD, Clas ML, Lazarowski ER, Boucher RC (2008) Similarities between UDP-glucose and adenine nucleotide release in yeast: involvement of the secretory pathway. Biochemistry 47:9269–9278 Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson SJ, Livi GP (2000) A G protein-coupled receptor for UDP-glucose. J Biol Chem 275:10767–10771 Lazarowski ER, Shea DA, Boucher RC, Harden TK (2003) Release of cellular UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol 63:1190–1197 Kreda SM, Okada SF, van Heusden CA, O’Neal W, Gabriel S, Abdullah L, Davis CW, Boucher RC, Lazarowski ER (2007) Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells. J Physiol 584:245–259 Sesma JI, Esther CRJ, Kreda SM, Jones L, O’Neal WK, Nishihara S, Nicholas RA, Lazarowski E (2009) Endoplasmic reticulum/Golgi nucleotide sugar transporters contribute to the cellular release of UDP-sugar signaling molecules. J Biol Chem 284:12572–12583 Perez M, Hirschberg CB (1986) Topography of glycosylation reactions in the rough endoplasmic reticulum membrane. J Biol Chem 261:6822–6830 Parodi AJ (2000) Protein glucosylation and its role in protein folding. Annu Rev Biochem 69:69–93 Berninsone PM, Hirschberg CB (2000) Nucleotide sugar transporters of the Golgi apparatus. Curr Opin Struct Biol 10:542–547 Ishida N, Kawakita M (2004) Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pfl€ ugers Arch 447:768–775 Suda T, Kamiyama S, Suzuki M, Kikuchi N, Nakayama K, Narimatsu H, Jigami Y, Aoki T, Nishihara S (2004) Molecular cloning and characterization of a human multisubstrate specific nucleotide-sugar transporter homologous to Drosophila fringe connection. J Biol Chem 279:26469–26474 Ishida N, Kuba T, Aoki K, Miyatake S, Kawakita M, Sanai Y (2005) Identification and characterization of human Golgi nucleotide sugar transporter SLC35D2, a novel member of the SLC35 nucleotide sugar transporter family. Genomics 85:106–116 Guille´n E, Hirschberg CB (1995) Transport of adenosine triphosphate into endoplasmic reticulum proteoliposomes. Biochemistry 34:5472–5476 Hirschberg CB, Robbins PW, Abeijon C (1998) Transporters of nucleotide sugars, ATP, and nucleotide sulfate in the endoplasmic reticulum and Golgi apparatus. Annu Rev Biochem 67:49–69 Bankston LA, Guidotti G (1996) Characterization of ATP transport into chromaffin granule ghosts: synergy of ATP and serotonin accumulation in chromaffin granule ghosts. J Biol Chem 271:17132–17138 Scrivens M, Dickenson JM (2005) Functional expression of the P2Y14 receptor in murine T-lymphocytes. Br J Pharmacol 146:435–444 Scrivens M, Dickenson JM (2006) Functional expression of the P2Y14 receptor in human neutrophils. Eur J Pharmacol 543:166–173
14
E.R. Lazarowski et al.
57. Fricks IP, Carter RL, Lazarowski ER, Harden TK (2009) Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems. J Pharmacol Exp Ther 330:162–168 58. Boudreault F, Grygorczyk R (2004) Cell swelling-induced ATP release is tightly dependent on intracellular calcium elevations. J Physiol 561:499–513 59. Tatur S, Groulx N, Orlov SN, Grygorczyk R (2007) Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by coreleased uridine nucleotides. J Physiol 584:419–435 60. Tatur S, Kreda S, Lazarowski E, Grygorczyk R (2008) Calcium-dependent release of adenosine and uridine nucleotides from A549 cells. Purinergic Signal 4:139–146 61. Seminario-Vidal L, Kreda S, Jones L, O’Neal W, Trejo J, Boucher RC, Lazarowski ER (2009) Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of Rho- and Ca2+-dependent signaling pathways. J Biol Chem 284:20638–20648 62. Joseph SM, Buchakjian MR, Dubyak GR (2003) Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. J Biol Chem 278:23331–23342 63. Kreda SM, Seminario-Vidal L, Heusden C, Lazarowski E (2008) Thrombin-promoted release of UDP-glucose from human astrocytoma cells. Br J Pharmacol 153:1528–1537 64. Blum AE, Joseph SM, Przybylski RJ, Dubyak GR (2008) Rho-family GTPases modulate Ca2 +-dependent ATP release from astrocytes. Am J Physiol 295:C231–C241 65. Hirakawa M, Oike M, Karashima Y, Ito Y (2004) Sequential activation of RhoA and FAK/ paxillin leads to ATP release and actin reorganization in human endothelium. J Physiol 558:479–488 66. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA (2002) Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 168:3577–3585 67. Hains MD, Siderovski DP, Harden TK (2004) Application of RGS box proteins to evaluate G-protein selectivity in receptor-promoted signaling. Methods Enzymol 389:71–88 68. Scemes E, Suadicani SO, Dahl G, Spray DC (2007) Connexin and pannexin mediated cell-cell communication. Neuron Glia Biol 3:199–208 69. Boassa D, Qiu F, Dahl G, Sosinsky G (2008) Trafficking dynamics of glycosylated pannexin 1 proteins. Cell Commun Adhes 15:119–132 70. Dahl G, Locovei S (2006) Pannexin: to gap or not to gap, is that a question? IUBMB Life 58:409–419 71. Goodenough DA, Paul DL (2003) Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol 4:285–294 72. M€uller DJ, Hand GM, Engel A, Sosinsky GE (2002) Conformational changes in surface structures of isolated connexin 26 gap junctions. EMBO J 21:3598–3607 73. Shestopalov VI, Panchin Y (2008) Pannexins and gap junction protein diversity. Cell Mol Life Sci 65:376–394 74. Go´mez-Herna´ndez JM, de Miguel MP, Larrosa B, Gonza´lez D, Barrio LC (2003) Molecular basis of calcium regulation in connexin-32 hemichannels. Proc Natl Acad Sci USA 100:16030–16035 75. Stout CE, Costantin JL, Naus CC, Charles AC (2002) Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J Biol Chem 277:10482–10488 76. De Vuyst E, Decrock E, Cabooter L, Dubyak GR, Naus CC, Evans WH, Leybaert L (2006) Intracellular calcium changes trigger connexin 32 hemichannel opening. EMBO J 25:34–44 77. Bruzzone R, Barbe MT, Jakob NJ, Monyer H (2005) Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J Neurochem 92:1033–1043
1 Nucleotide Release by Airway Epithelia
15
78. Dubyak GR (2009) Both sides now: multiple interactions of ATP with pannexin-1 hemichannels. Focus on “A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP”. Am J Physiol 296:C235–C241 79. Ransford GA, Fregien N, Qiu F, Dahl G, Conner GE, Salathe M (2009) Pannexin 1 contributes to ATP release in airway epithelia. Am J Respir Cell Mol Biol 41:525–534 80. Locovei S, Wang J, Dahl G (2006) Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. FEBS Lett 580:239–244 81. Mason SJ, Paradiso AM, Boucher RC (1991) Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 103:1649–1656 82. Lazarowski ER, Mason SJ, Clarke L, Harden TK, Boucher RC (1992) Adenosine receptors on human airway epithelia and their relationship to chloride secretion. Br J Pharmacol 106:774–782
Chapter 2
Mechanisms Regulating Airway Nucleotides Maryse Picher
Abstract In the respiratory system, extracellular nucleotides and nucleosides serve as signaling molecules for a wide spectrum of biological functions regulating airway defenses against infection and toxic material. Their concentrations are controlled by a complex network of cell surface enzymes named ectonucleotidases. This highly integrated metabolic network combines the activities of three dephosphorylating ectonucleotidases, namely nucleoside triphosphate diphosphohydrolases (NTPDases), nucleotide pyrophosphatase/phosphodiesterases (NPPs) and alkaline phosphatases (APs). Extracellular nucleotides are also inter-converted by the transphosphorylating activities of ecto adenylate kinase (ectoAK) and nucleoside diphosphokinase (NDPK). Different cell types use specific combinations of ectonucleotidases to regulate local concentrations of P2 receptor agonists (ATP, UTP, ADP and UDP). In addition, they provide AMP for the activity of ecto 50 -nucleotidase (ecto 50 -NT; CD73), which produces the P1 receptor agonist: adenosine (ADO). Finally, mechanisms are in place to prevent the accumulation of airway ADO, namely adenosine deaminases and nucleoside transporters. This chapter reviews the properties of each enzyme and transporter, and the current knowledge on their distribution and regulation in the airways. Keywords Ectonucleotidase CD39 CD73 Ectoenzyme Alkaline phosphatase
2.1
Introduction
Ectoenzymes form a large diverse class of membrane proteins presenting their catalytic site to the extracellular environment. This chapter focuses on ectonucleotidases, which are specialized in the regulation of nucleotides and nucleosides.
M. Picher (*) Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_2, # Springer Science+Business Media B.V. 2011
17
18
M. Picher
The original nomenclature based on their biochemical properties (i.e. substrate specificity, optimum pH and selective inhibitors) was recently refined based on cloning studies. For this reason, several ectonucleotidases were given more than one name over the past 50 years, which considerably hindered literature search. This chapter introduces each ectoenzyme family involved in the purinergic regulation of airway defenses, and reconciles the various aliases encountered in the literature. The detailed description of their structure and crystallography has been reviewed elsewhere and is beyond the scope of this discussion. Our intent is to provide discriminative tools for the study of ectonucleotidases, and a detailed description of their distribution and regulation in the airways. There is increasing functional evidence that ectonucleotidases compete with P2 receptors for a limited pool of endogenously released nucleotides [1, 2]. In essence, the dephosphorylation of surface nucleotides terminates or limits the amplitude of the P2 receptor-mediated responses, either through autocrine or paracrine events. For instance, the expression level of NTPDase2 on rat portal myofibroblasts influences the proliferation of adjacent bile duct epithelial cells promoted by P2Y receptors [3]. The modulatory effects of ectonucleotidases will vary locally with the local sources of nucleotides and the substrate selectivity of the P2 receptors.
2.2
Three Families of ATP-Hydrolyzing Ectonucleotidases
The current literature recognizes three families of cell surface enzymes bound to the plasma membrane with their catalytic sites oriented toward the external milieu: the APs, the NTPDases and the NPPs (review: [4]). While APs have been known for >80 years, the other families were more recently defined following the establishment of molecular biology techniques which found associations to previously unrelated genes. This section provides a brief overview of this historical perspective, which will allow readers to search the literature efficiently using the various aliases assigned to each ectonucleotidase over time. This section focuses on the biochemical characteristics of each enzyme, their distribution in the airways and physiological roles. The impact of pathologies on their regulation will be discussed in Chap. 4.
2.2.1
Alkaline Phosphatases
Alkaline phosphatases (APs; EC 3.1.3.1) have been investigated >80 years in human tissues (review: [5]). For decades, most studies focused on the measurement of AP activity released in body fluids as a diagnostic marker of pathologies and disease severity (review: [6]). Their properties emerged in the 1970s as techniques became available for the investigation of plasma membrane glycoproteins. Based on selective inhibitors, sequence mapping and tissue distribution, four different isoenzymes have been identified (Table 2.1): intestinal AP (IAP), tissue non-specific AP
2 Mechanisms Regulating Airway Nucleotides Table 2.1 Mammalian alkaline phosphatases Protein name Aliases Gene (name; accession #) IAP, IALP Human: ALPI; NM_001631 Intestinal alkaline Mouse: Akp3; NM_007432 phosphatase
19
Inhibitors [IC50; mM] [7] Levamisole [6.8] L-p-bromotetramisole [>50] L-phenylalanine [1.0]
Non-specific alkaline phosphatase
NSAP, TNAP, TNSALP Liver-bonekidney AP
Human: ALPL; NM_000478 Mouse: Akp2; NM_007431
Levamisole [0.03] L-p-bromotetramisole [0.01] L-phenylalanine [30.0]
Placental alkaline phosphatase
PLAP, PLALP
Human: ALPP; NM_001632
Levamisole [1.7] L-p-bromotetramisole [0.3] L-phenylalanine [1.0]
Germ cell alkaline phosphatase
GCALP
Human: ALPP2; NM_031313 n.d.
Embryonic alkaline phosphatase
EAP
Mouse: Akp5; NM_007433
n.d.
(TNAP; NSAP), placental AP (PLAP) and germ-like AP (review: [8]). These enzymes are all encoded by chromosome 2, except for TNAP, which is derived from chromosome 1. They form homodimers bound to cell surfaces by a glycosyl phosphatidyl inositol (GPI) linkage limited to the outer leaflet of the bilayer, which confers lateral mobility [9]. It was suggested that GPI-linked proteins are targeted to the apical surface of polarized epithelia to participate in cell-cell interaction and signal transduction through rapid lateral redistribution. The cell surface density of APs is also locally influenced during infection by phosphatidyl inositol-specific phospholipases C or D released from bacteria to cleave the GPI linkage. Alternatively, the activation of bombesin receptors on nasal epithelia stimulated the release of AP [10], thereby supporting the existence of autocrine secretory mechanisms. These highly versatile enzymes catalyze the removal of terminal phosphate groups from a variety of natural substrates, including nucleotides (ATP, ADP, AMP) and glucose-6-phosphate, as well as pyrophosphate and pyridoxal-50 -phosphate both involved in bone mineralization. An aberrant regulation of pyridoxal-50 -phosphate has been shown to provoke epileptic seizures in patients with hypophosphatasia (review: [8]). In addition, APs regulate signaling events through dephosphorylation of the receptor agonists: lysophosphatidate and ceramide 1-phosphate [11]. Synthetic substrates (b-glycerophosphate, p-nitrophenyl phosphate and p-nitrophenyl thymidine 5monophosphate; PNP-TMP) are commonly used to measure AP activity in body fluids. The AP inhibitors classically presented in biochemical studies should be used with caution, as non-specific interactions occur at high concentrations [7, 12–15]. For instance, 10–20 mM levamisole is routinely used to identify TNAP, which is a sufficiently high concentration to recognize other AP isoforms (Table 2.1). On the other hand, many studies use 1 mM levamisole to exclude the activity of all APs in complex enzyme preparations, which is nearly a log lower than the IC50 of IAP.
20
M. Picher
Since several APs are often co-expressed, the inhibition conditions should be validated at the mRNA level. The recent development of highly specific inhibitors for TNAP [16, 17] and PLAP [18] may provide the necessary tools to elucidate their respective roles. It is widely believed that APs constitute low affinity enzymes with limited ability to regulate low physiological nucleotide concentrations. This misconception was created because biochemists replicated the assay conditions originally used to quantify AP activity in body fluids. Accordingly, purified TNAP documented under alkaline conditions (pH 9–10) with PNP-TMP or ATP presented a lowaffinity catalytic site, with Km values in the 0.5–10.0 mM [19, 20]. More recently, Fortuna and collaborators compared the kinetic properties of purified TNAP under alkaline (pH 10.0) and physiological (pH 7.5) conditions. They confirmed that TNAP exhibits low affinity for ATP at alkaline pH (Km ¼ 8.3 mM), but also high-affinity at physiological pH (Km ¼ 5 mM) [21]. These data, confirmed by independent groups [22–24], indicate that TNAP has the capacity to regulate endogenous ATP concentrations under physiological conditions. Two members of the AP family have been identified in human airway epithelia: TNAP and PLAP. The surface activity and protein expression of TNAP has been detected on the apical surface of the epithelial barrier, from the trachea down to alveoli [25–27]. While it constitutes 85% of the AP activity measured in bronchoalveolar lavage (BAL) fluid, the soluble enzyme is mainly derived from surfactant secretion [28, 29]. In the alveolar region, immunolocalization and functional assays showed that TNAP is only expressed on the apical membrane and lamellar bodies of Type II pneumocytes [30, 31]. In contrast, PLAP is restricted to Type I pneumocytes [14, 25, 32]. Consequently, these APs are used as cell markers during the purification and culture of specific pneumocytes [33]. The biochemical properties of TNAP support a role in the purinergic regulation of airway defenses [26, 27] (Fig. 2.1). On polarized primary cultures of human bronchial epithelial cells, the enzyme exhibits a low-affinity (KM ¼ 717 mM) and a highaffinity (KM ¼ 6 mM) toward AMP at pH 7.5 [26], as reported for purified APs [23, 34]. However, this enzyme competes with CD73 for the conversion of AMP into ADO, and accounts only for 15% of the overall hydrolytic activity toward physiological (<1 mM) concentrations [26]. On the other hand, the contribution of TNAP increased with AMP concentration, suggesting that its primary role is to eliminate excess nucleotides in the ASL during stress situations, such as infection or tissue damage. Furthermore, assays conducted on purified TNAP demonstrated that hydrolytic rates increase with the degree of phosphorylation of the substrate (AMP > ADP > ATP) [19]. This intrinsic property suggests that TNAP may play a significant role in the regulation of physiological ATP concentrations on airway surfaces. Other cell types encountered in the airway tissue express TNAP, including fibroblasts, lymphocytes [35], macrophages and neutrophils (reviews: [36, 37]). Ultracytochemical studies revealed that resting neutrophils restrict TNAP to intracellular membranes [38]. Cell stimulation by the bacterial products formylMet-Leu-Phe (fMLP) or lipopolysaccharide (LPS), or phorbol myristate acetate (PMA; protein kinase C activator), induces the mobilization of TNAP to the
2 Mechanisms Regulating Airway Nucleotides
21
Fig. 2.1 The “Purinome” of human airway epithelia. The apical surface concentrates proteins specialized in the regulation of ATP and adenosine levels named ectonucleotidases. Although the enzymatic network is positioned above the surface for clarity, all enzymes are membrane proteins. This network regulates the availability of ATP for P2Y2 receptors and adenosine for A2B receptors, which mediate various epithelial functions involved in airway defenses against infection: ciliary beating activity, airway hydration and inflammation
surface, particularly at sites of cell-to-cell interaction with endothelial or Type I alveolar cells [38, 39]. This focal surface distribution is consistent with the GPI linkage allowing fluent lateral movement within the outer leaflet of the surface membrane. The gram-negative bacteria invading the airways, including Pseudomonas aeruginosa, also exhibit AP activity. However, the enzyme is confined to the periplasmic region [40]. During normal growth, they slough off outer membrane vesicles with a fraction of their periplasmic content, including b-lactamase, hemolytic phospholipase C, AP and Cif (review: [41]). A recent study showed that these vesicles fuse with lipid rafts in the host plasma membrane and these virulence factors enter the cytoplasm via N-WASP–mediated actin trafficking, where they are distributed to specific subcellular locations to affect host cell biology [42]. This vesicular mode of delivery is particularly interesting given the postulated role of APs in the neutralization of LPS. This endotoxin elicits serious inflammatory reactions that may be lethal, particularly when the compound enters the circulation. The toxic moiety of LPS (lipid A) contains two phosphate groups highly conserved among gram-negative bacteria, and essential for their biological actions (review: [43]). The incubation of LPS with AP causes the formation of monophosphoryl lipid A, which is a weak macrophage activator of low toxicity, compared to diphosphoryl lipid A. The first demonstration of endotoxin dephosphorylation by APs was provided by Holst et al. [44], who used commercially available calf IAP to release inorganic phosphate from the Salmonella minnesota and Escherichia coli LPS. Several in vitro and in vivo studies showed that TNAP and IAP have the capacity to reduce the cell
22
M. Picher
toxicity of LPS and associated inflammatory responses [45–48]. In 1997, Poelstra et al. published two studies showing that endogenous AP neutralizes E. coli LPS at physiological pH [45, 49]. Histochemical analysis of cryostat sections showed that intestinal and renal tissues dephosphorylate E. coli LPS. This enzymatic reaction was blocked by levamisole and the tissue distribution of the released phosphate corresponded to that generated by b-glycerophosphate. In addition, the local intradermal inflammatory reaction (PMN and macrophage infiltration) caused by systemic injection of LPS was strongly attenuated by pre-treatment of the endotoxin with exogenous AP. Since these initial studies, several groups demonstrated the importance of IAP for the maintenance of gut barrier integrity (review: [50]). The therapeutic potential of oral IAP was investigated in colitic rats, which responded by a significant reduction of colonic inflammation in terms of cytokines (TNFa, IL-1b, IL-6) and inflammatory cell influx, and a restoration of normal intestinal wall morphology [51]. A study comparing wild-type and IAP knockout mice showed that IAP also prevents bacterial invasion across the gut mucosal barrier promoted by ischemia-reperfusion [52]. Interestingly, patients with Crohn’s disease and ulcerative colitis exhibit low IAP mRNA levels in intestinal biopsies compared to healthy subjects [51]. These studies motivated the clinical trials currently conducted by AM-Pharma Inc with bovine IAP for the treatment of ulcerative colitis. In the airways, a similar role was proposed for TNAP expressed on airway surfaces against the gram-negative bacteria omnipresent in chronic airway diseases: P. aeruginosa. Commercially available TNAP was found capable of dephosphorylating P. aeruginosa LPS [53]. In addition, pre-treatment of LPS with TNAP markedly reduced the inflammatory reaction of cultured human bronchial epithelial cells, measured by the release of nitric oxide [53]. These data suggest that the uniform expression of TNAP along airway surfaces may constitute a defense mechanism to reduce bacterial toxicity.
2.2.2
Nucleoside Triphosphate Diphosphohydrolases
The existence of cell surface enzymes capable of dephosphorylating ATP and ADP at physiological pH has been documented for over five decades under various aliases: apyrase, ectoATPase, ectoADPase and ATP-diphosphohydrolase (reviews: [4, 54, 55]) (Table 2.2). The identity of these ectonucleotidases was clarified in the 1990s by studies conducted on purified preparations, which revealed that, in many cases, a single enzyme targeted both nucleotides. Given their broad substrate specificity toward purine and pyrimidine nucleotides, the general term nucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5) was adopted in 2000 by the scientific community [62]. Since then, the number of publications describing their properties and tissue distribution has grown exponentially. The identification of NTPDase1 as the lymphocyte cell activation antigen, CD39, was undoubtedly the most important event which raised the interest of the scientific community toward this family of ectonucleotidases.
Table 2.2 Mammalian nucleoside triphosphate diphosphohydrolases (NTPDases) Protein Gene HUMAN Gene Locus name Aliases mouse human Accession number NTPDase1 Apyrase, ENTPD1 10q24 NM_001776, U87967 ATPDase, Entpd1 NM_009848 CD39 NTPDase2 CD39L1, ectoENTPD2 9q34 NM_203468, AF144748 ATPase Entpd2 NM_009849, AY376711 NTPDase3 CD39L3, HB6 ENTPD3 3p21.3 NM_001248, AF034840 Entpd3 NM_178676, AY376710 NTPDase4 UDPase, ENTPD4 8p21 NM_004901, AF016032 LALP70 Entpd4 NM_026174 ENTPD5 14q24 NM_001249, AF039918 NTPDase5 CD39L4, ERUDPase, Entpd5 NM_007647, AJ238636 PCPH NTPDase6 CD39L2 ENTPD6 20p11.2 NM_001247, AY327581 Entpd6 NM_172117 NTPDase7 LALP1, ENTPD7 10q24 NM_020354, AF269255 Entpd7 NM_053103, AF288221 NTPDase8 Liver canalicular, ENTPD8 9q34 NM_198585, AY430414 ecto-ATPase, Entpd8 NM_028093, AY364442 hATPDase Km (ATP) mM 10–17
70–400 75
93
ATP/ADP ratio 1.1–1.3
7.2–22 3.6 – 4.2
1.1
[61]
[58]
[58 – 60]
References [56, 57]
2 Mechanisms Regulating Airway Nucleotides 23
24
M. Picher
Thus far, eight NTPDases have been cloned and functionally characterized using purified protein preparations and heterologous expression (Table 2.2). They share highly conserved sequence domains named “conserved apyrase regions” which define their catalytic properties. Among them, NTPDase1, 2, 3 and 8 are localized in the plasma membrane with their catalytic site facing the extracellular milieu. They are anchored by two transmembrane domains and readily form homooligomers (dimers, trimers and tetramers), which enhances their activity [63]. Other members of this family are sequestered in the Golgi (NTPDase4) and endoplasmic reticulum (NTPDase7), with their catalytic site facing the lumen of the organelle. In the Golgi, NTPDase4 preferentially uses UDP to assist in the import of nucleotide sugars. Finally, the NTPDase5 and 6 isoforms are secreted as soluble enzymes following heterologous expression. The cell surface NTPDases are functionally differentiated based on substrate preferences. While a single catalytic site supports the hydrolysis of triphosphates and diphosphates, each enzyme hydrolyses these two classes of substrates with distinct efficiencies, which influences the transient accumulation of active intermediates (Table 2.2). For instance, NTPDase1 hydrolyses ATP and ADP at similar rates, resulting in little accumulation of ADP for the activation of P2Y1 or P2Y12 receptors. In contrast, NTPDase2 exhibits a strong preference for ATP, allowing ADP to accumulate for an extended period of time before being converted to AMP. NTPDase3 and 8 generate intermediate metabolic profiles. The readers are referred to the original manuscript of Sevigny et al. [58] for a detailed review of the metabolic properties of human and murine cell surface NTPDases. The physiological consequences of these distinct properties on cell signaling depend on the composition of the local “Purinome” in terms of ectonucleotidases and receptors. A considerable number of compounds are known to inhibit the cell surface NTPDases, although most of them also interfere with P2 receptor activation [64, 65] (Table 2.3). Azide was originally described as an inhibitor of the ATPdiphosphohydrolase [74] later identified as NTPDase1 (CD39) [75, 76]. Recent studies showed that azide inhibits NTPDase1 [66] and NTPDase3 [67], but not NTPDase2 and 8 [68, 69], TNAP [77] or NPPs [78]. However, azide is not suited for animal protocols or prolonged exposures, as the compound induces necrotic cell death [79]. The stable analogue of ATP, 6-N,N-diethyl-D-b,g-dibromomethylene ATP (ARL67156; FPL67156), was the first compound developed to inhibit ectonucleotidases without affecting P2 receptors [80]. In fact, ARL67156 exhibits a weak antagonistic effect against P2X receptors and a weak agonist effect on P2Y receptors. This compounds was used to uncover the purinergic elements involved in complex signaling events, such as neurotransmission in vivo [81]. However, recent studies showed that this weak competitive inhibitor is only effective in the presence of endogenous levels of nucleotides (<10 mM) [82]. Also ARL67156 is nearly inactive against NTPDase2 [70, 82], and interacts with members of the NPP family [82]. Therefore, protocols using ARL67156 must be carefully designed to account for these limitations. A capillary electrophoresis method was recently developed for the identification of selective NTPDase inhibitors [70]. The enzymatic reactions are performed within
2 Mechanisms Regulating Airway Nucleotides
25
Table 2.3 Inhibitors of surface nucleoside triphosphate diphosphohydrolases (NTPDases) NTPDase8 Ki NTPDase1 Ki NTPDase2 Ki NTPDase3 Ki – % maximal – % maximal – % maximal – % maximal Inhibitor inhibition References inhibition inhibition inhibition names Azide n.a. – 40–60% No n.a. – 40–60% No [66 – 69] RB2 20.0 – 75% 24.2 1.1 Unknown [70] PPADS 46.0 44.2 3.0 Unknown [70] Suramin 300 65.4 12.7 Unknown [70] ARL 67156 27.0 >1,000 – 50% 112.0 Unknown [70] POM-1 2.6 – n.a. 28.8 – n.a. 3.3 – n.a. Unknown [71] a mabNTPDase3 No No 35 ngml1 n.a. – 0% [72] – 70% PSB-06126 No No 1.5 – 75% Unknown [73] PSB-069 15.7 – 100% 18 – 100% 16.4 – 100% Unknown [73] a This value corresponds to the concentration causing 50% inhibition (IC50)
a capillary inlet using membrane preparations of transfected CHO cells, followed by electrophoretic separation of the reaction products. While this method allows for rapid screening of potent inhibitors, the substrate affinities (Michaelis constants; KM) of NTPDase1, 2 and 3 in this expression system were 76, 203, and 311 mM, respectively. These KM values are considerably higher than reported by classical test tube assays with respect to NTPDase1 and NTPDase3 (Table 2.2), suggesting that the inhibitory constants (Ki) of their inhibitors are also overestimated by this method. Nonetheless, this approach remains extremely useful for the identification of selective NTPDase inhibitors. For instance, the P2 receptor antagonists reactive blue 2, suramin and pyridoxalphosphate-6-azophenyl-20 ,40 -disulfonic acid (PPADS) inhibit NTPDase3 at least 15-fold more efficiently than NTPDase1. The capillary method also led to the identification of a novel class of NTPDase inhibitors, the polyoxometalates [71]. Among them, polyoxotungstate (POM-1) is very attractive for animal studies because of its high stability at physiological pH (>14 days). Nonetheless, it is important keep in mind that this compound is equally potent against NTPDase1 and NTPDase3, which are inhibited ten times more efficiently than NTPDase2. The usefulness of POM-1 would be limited to tissues or cell types expressing either NTPDase1 or NTPDase3. While these polyoxometalates were tested on rat NTPDases [71], POM-1 was also found effective in reducing extracellular ATP metabolism in mice [83, 84]. This technique was also used to evaluate the potential of anthraquinone derivatives of reactive blue 2 [73]. This study identified 1-amino-2-sulfo-4-(1-naphthylamino) anthraquinone as a potent and selective inhibitor of NTPDase3 (Ki ¼ 1.5 mM) having no effect on NTPDase1 and 2 [73]. While these drugs were not tested against NTPDase8, this is a minor complication since the distribution of this isoform is limited to the liver [69, 85]. Sevigny and collaborators recently developed the first monoclonal antibody against human NTPDase3, as shown by immunolocalization of the enzyme in the human pancreas [72]. More importantly, this antibody also selectively inhibits the activity of NTPDase3 [72]. The advantage over synthetic drugs is the high
26
M. Picher
specificity and the lack of side-effects. Incidentally, POM-1 was recently found to inhibit central synaptic transmission in cerebral and hippocampal slices by a mechanism which does not involve NTPDase inhibition [86]. Ultimately, the choice of inhibitor will depend on whether the goal is to prevent the degradation of extracellular nucleotides or to target a specific NTPDase. In the latter, the most appropriate inhibitor would be dictated by the NTPDases co-expressed by the target cell or tissue. Unfortunately, in the case of NTPDase2 and NTPDase8, this field of research still relies on silencing protocols and genetically manipulated animal models to identify their physiological roles. In the respiratory system, the presence of NTPDases was initially inferred by Northern blot analysis of human total lung RNA, which only presented a signal for NTPDase1 [75, 87, 88]. Since then, the expression of NTPDase1 in the lung was confirmed by immunohistochemistry in murine [89], bovine [90] and human [91] tissue, specifically on the endothelial and alveolar epithelial cells. More recently, NTPDase1 and 3 were immunolocalized on the epithelial barrier extending the entire respiratory system, except in the alveolar region for NTPDase3 [91]. These enzymes also exhibited unique epithelial polarities which shifted in opposite directions from the proximal to distal airways. In the tracheo-bronchial area, NTPDase1 was limited to the apical surface, whereas NTPDase3 labeled basolateral surfaces and basal cells. In the distal airways, NTPDase1 was detected on the basolateral surface, whereas NTPDase3 expression was bilateral. Such polarity shifts along the airways have been reported for other proteins, including the water channel, aquaporin3 [92]. The mechanisms regulating the epithelial polarities of the NTPDases in the airways have not been elucidated. However, LPS caused the relocation of liver canalicular NTPDase activity from the apical to basolateral surfaces [93], an enzyme recently identified as NTPDase8 [69]. The fact that thousands of LPS particles are inhaled every day and deposited mainly in the distal airways could explain the gradual polarity shifts of the two NTPDases. The functional expression of NTPDase1 and 3 on airway surfaces was demonstrated by selective assays conducted on polarized primary cultures of human bronchial epithelial cells [91]. Fausther and collaborators developed an assay strategy to differentiate the activities of these two azide-sensitive NTPDases [91]. The same culture wells were assayed in the presence of the monoclonal antibodies against NTPDase3 that selectively inhibit this enzyme activity, then assayed in the presence of azide. The use of a wide range of nucleotide concentrations showed that NTPDase1 predominates (40%) under physiological conditions (<1 mM ATP), while NTPDase3 predominates (70%) in the presence of excess nucleotides generated by cell lysis. These findings were consistent with their catalytic properties, as NTPDase1 is a low-capacity high-affinity enzyme (KM ¼ 10–20 mM [56]), and NTPDase3 is a high-capacity low-affinity enzyme (KM ¼ 90–130 mM [67]). Collectively, their distinct polarities and biochemical properties suggest that these two NTPDases regulate different epithelial functions on airway surfaces. For instance, human airway epithelia package nucleotides into mucin granules, which are released into the ASL by P2Y2R activation [94]. Since NTPDase3 is preferentially located on the mucin-secreting cells of superficial epithelia and submucosal
2 Mechanisms Regulating Airway Nucleotides
27
glands [91], this high-capacity enzyme may regulate the amplification cycles of P2Y2R activation resulting from ATP-induced mucin and nucleotide secretion [95]. The presence of soluble NTPDases in the airway secretions has not been investigated. However, azide-sensitive ATPase activity has been detected in airway surface liquid (ASL) collected from human bronchial epithelial cultures (M. Picher 2004, personal communication). Likewise, shear stress was reported to induce the secretion of ectoATPases from endothelial cells in culture [96], a cell type known to express mainly NTPDase1 as ectonucleotidase (review: [55]). Since the airway surfaces are subjected to considerable mechanical stress, such as rhythmic breathing and coughing, they could potentially release NTPDases into airway secretions. Also, the epithelial cells lining the small ducts of rat pancreas have been shown to secrete particulate NTPDase1 in response to the endogenous peptide cholecystokinin (CCK-8) [97]. These studies raise the possibility that secreted NTPDases may participate in the regulation of airway nucleotides.
2.2.3
Nucleotide Pyrophosphatase/Phosphodiesterases (NPPs)
These ectonucleotidases have the unique ability to generate nucleoside monophosphates from a wide variety of nucleotides and dinucleotides. However, some members were already known under aliases based on their physiological roles. For instance, NPP1 was discovered as a plasma cell differentiation antigen (PC-1), NPP2 as an autocrine motility factor (autotaxin), and NPP3 as a monoclonal antibody RB13-6 against a subset of brain glial cells (gp130RB13-6) (Table 2.4). The nomenclature was simplified in 2000 by numbering each NPP according to their order of discovery (review: [62]). The NPP family now contains seven cell surface ectonucleotidases as single spanning transmembrane proteins in the type I (intracellular C-terminal; NPP4-7) or type II (intracellular N-terminal; NPP1 and NPP3) orientation (reviews: [98, 99]). The N-terminal hydrophobic sequence of NPP2 and NPP4-7 is a signal peptide that mediates uptake into the endoplasmic reticulum during translation. This sequence is removed by the signal peptidase, leaving NPP4–7 anchored to the plasma membrane by a C-terminal transmembrane domain. The NPP2 isoform is encoded by a different chromosome and synthesized as a pre-pro-enzyme. After removal of the N-terminal signal peptide and trimming by a furin-type protease, NPP2 is secreted as a soluble enzyme [100]. Three NPP2 isoforms generated by splicing were identified over the years and recently reviewed ([101]): ATXa was isolated from the human melanoma cell line A2058, ATXb from the Ntera2D1 human teratocarcinoma cell line, and ATXg from rat brain (Table 2.5). Heterologous expression confirmed that NPP1-3 exhibit phosphodiesterase I (EC 3.1.4.1) and pyrophosphatase (EC 3.6.1.9) activities [106] using a single nucleotide binding site [107]. Such versatility allows them to support the metabolism of ATP, UTP, NAD, dinucleotides (i.e. Ap4A), the phosphodiester bond of nucleic acids and the pyrophosphate linkage of nucleotide sugars (i.e. UDP-glucose). The synthetic
NPP3 ENPP3 NPP4 ENPP4 NPP5 ENPP5 NPP6 ENPP6 NPP7 ENPP7
Alkaline sphingomyelinase
B10, gp130RB13-6, PD-1b, NPPb, PDNP3, pdnpno 6p12.3 6p11.2-21.1 4q35.1
Type I
Type I
Type I
Type I
6q22
Type II
NM_178543
NM_153343
NM_021572
NM_014936
NM_005021
Table 2.4 Mammalian nucleotide pyrophosphatase/phosphodiesterases (NPPs) Tertiary Accession Name Additional name structure Gene locus numbers Type II 6q22-23 NPP1 PC-1, PC.1, MAFP, NPPase, NPPg PDNP1, ENPP1 NPPS, Pca-1 NPP2 NPPa, PDNP2, Autotaxin Secreted 8q24.1 BC034961 (ATX), NPP2, ENPP2 ENPP2
Choline phosphate esters (LPC) Choline phosphate esters (LPC) Sphingomyelin
Unknown
Brain, placenta, ovary Intestine
Mononucleotides Dinucleotides LPC Mononucleotides Dinucleotides Unknown
Basophils, prostate, uterus, colon, hepatocytes
Distribution Lymphocytes, bones, cartilage, heart, liver intestine, testis, placenta
Substrates Mononucleotides Dinucleotides
28 M. Picher
2 Mechanisms Regulating Airway Nucleotides Table 2.5 Nucleotide pyrophosphatase/phosphodiesterase 2 isoforms (NPP2s) Name Additional name Accession # Source for original cloning NM_006209 Human melanoma cell ATX a ATX NPP2a, line A2058 [102] ATXmel, Transcript PDN2a variant 1 NM_001040092 Human teratocarcinoma ATX b NPP2b, ATXter cell line Ntera2D1 [103] Transcript variant 2 Human retina cDNA library [104] ATX g PD-1a, NPP2g NM_001130863 Rat brain cDNA [105] Transcript variant 3
29
Splice variant Lacks exon 21
Lacks exons 12, 21
Lacks exon 12
compound p-nitrophenyl-thymidine 5-monophosphate (pNP-TMP) is commonly used as a selective substrate of NPPs. Partially purified NPPs from rat C6 glioma cells [108] and human fetal serum [109] were also reported to hydrolyze ADP. But, since most cell types co-express APs and/or NTPDases with NPPs, the identification of ADP as NPP substrate remains to be verified in transfected cells. Recent investigations identified additional natural substrates providing a high degree of specificity among the NPP isoforms (review: [99]). NPP2 exhibits lysophospholipase-D activity toward lysophosphatidylcholine, which generates the signaling molecule lysophosphatidic acid (LPA). This enzyme also generates the cell mobility factor sphingosine-1-phosphate (S1P) from sphingosylphosphorylcholine. As for the other NPPs, the natural substrates of NPP4-5 remain unknown, whereas NPP6 and 7 hydrolyze phosphodiester bonds from lysophospholipids and sphingomyelin, respectively. To date, the physiological consequences of NPP6 activity have not been established. Regarding NPP7, since sphingomyelin metabolism generates the signaling molecule ceramide, this isoform may influence cell proliferation. On a general note, NPPs experience considerable feedback inhibition, as they bind the phosphorylated products (AMP and LPA) with higher affinity than the substrates. Finally, only NPP1-3 have the capacity to regulate nucleotides, and are therefore relevant for purinergic signaling. The first agents tested as inhibitors of the NPP family were known inhibitors of other ectonucleotidases and P2 receptors as a means to test for specificity and crossinactivation of signaling events on intact cells and tissue. The biochemical characterization of rat heart NPP showed that the enzyme activity is not inhibited by blockers of TNAP (levamisole) or NTPDase1 and 3 (sodium azide), but reduced to about 50% by the P2 receptor antagonist, suramin [78]. The RT-PCR analysis of this preparation supported the expression of NPP2 and NPP3, but not NPP1 in the heart. Likewise the NPP activity of rat C6 glioma cells was inhibited by the P2 receptor antagonists suramin, reactive blue 2, PPADS [110] and b,g-methyleneATP [111]. In contrast, the P1 receptor antagonists CGS15943, 8-phenyl-theophylline, cyclo-pentyltheophylline (CPT) and iso-butylmethylxanthine (IBMX) had no significant effect. These agents were further tested by capillary electrophoresis using NPP1 and NPP3 transfected in COS-7 cells [112]. Suramin inhibited NPP3 activity seven times more efficiently than
30
M. Picher
NPP1, with Ki values in the sub-micromolar range. In contrast, reactive blue inhibited both NPP activities with comparable efficiency. These studies suggest that P2 receptor antagonists affect the availability of their agonists through competitive inhibition. For instance, PPADS raised by threefold the inhibitory effects of ATP on isoproterenol-induced cAMP synthesis in rat C6 glioma cells by a mechanism involving NPP inhibition [110]. Therefore, the scientific community turned to unrelated compounds for the inhibition of this family of ectonucleotidases. More recently, a series of 1,3,4-oxadiazole-2(3H)-thiones and 1,3,4-thiadiazole-2(3H )-thiones were synthesized and evaluated for their inhibitory effects on recombinant NPP1 [113]. While this study presented the first non-competitive inhibitors against NPPs, the most effective compound exhibited a Ki value of 360 mM. With such low efficiency, these compounds should be tested for specificity and possible side-effects. A number of drugs already on the market, or currently tested in clinical trials, have been shown to affect the activity of NPPs. For instance, statins are described as cholesterol-reducing agents with anti-inflammatory properties [114]. The treatment of human blood basophils with cerivastatin and atorvastatin led to the downregulation of NPP3 and reduced their capacity to release histamine in response to IgE [115]. This response is not surprising since NPP3 was first characterized as a basophil-activation antigen whose expression is raised by IgE-mediated cell activation [116]. Whether statins interact with the ectonucleotidase is unknown. Interestingly, the anti-depressant drugs, imipramine, fluoxetine and moclobemide, have been shown to raise the NPP activity of cultured cells from rat salivary glands [117]. Since ATP promotes salivary flow [118], NPP activation may contribute to the common side-effect associated with these drugs, which is dry mouth [119]. Also, FTY720 (fingolimod) is currently in Phase three clinical trial for the treatment of multiple sclerosis [120]. Structurally similar to sphingosine, the phosphorylated form generated in vivo (FTY720-P) interacts with the receptor of SIP, product of NPP2 activity. This drug inhibits the activating effects of S1P on lymphocytes by triggering the internalization and degradation of the receptor, which then fail to migrate from the lymphoid organ to the site of inflammation [121]. Interestingly, FTY720-P also inhibits the activity of NPP2 with a Ki of 200 nM [122], which may explain its anticancer activity [123]. To date, no selective inhibitor of NNP3 has been reported likely due to the lack of evidence for pathological conditions associated with functions or deregulations of this isoform. The presence of NPPs in the respiratory system was first inferred by Northern blot analysis of total lung RNA, which combines genetic material from pneumocytes, fibroblasts, endothelial cells and inflammatory cells. This approach supported the presence of NPP2 and NPP3, but not NPP1, in lung parenchyma [104, 124–126]. In the upper airways, NPP1, NPP2 and NPP3 were all detected in primary cultures of human bronchial epithelial cells by RT-PCR [127]. The cultures exhibited surface NPP activity toward dinucleotides, ADP-ribose and UDP-glucose, as well as competitive activities between dinucleotides and ADP-ribose [128]. While these reactions were concentrated on the apical surface, the basolateral surface populated by basal cells also presented significant NPP activity. The surface expression of NPPs on the epithelial barrier was confirmed by immunolocalization using a polyclonal
2 Mechanisms Regulating Airway Nucleotides
31
antibody developed against NPP proteins purified from bovine intestinal mucosa [129], which express NPP2 and NPP3, but not NPP1 [103, 126, 130]. This antibody labeled the basal cells forming the basolateral surface, as well as columnar cells on the apical surface [129]. In another study, NPP1 was immunodetected in human airway epithelia only as a weak signal in submucosal glands [131]. Collectively, these studies suggest airway epithelial functionally express NPP2 and/or NPP3. Since NPP2 is secreted as a soluble enzyme [100], NPP3 would be responsible for the membranebound activity detected on the apical surface of human airway epithelia [128]. Maurice and collaborators provided key information on the distribution of NPP1 and NPP3 in polarized epithelia [132–134]. Using selective antibodies, they detected NPP3 on the apical surface of hepatocytes and enterocytes, whereas NPP1 was confined to the basolateral surface of hepatocytes [132]. These data are consistent with the proposed apical polarity of NPP3 in human airway epithelia [129]. This group studied the membrane trafficking of NPP3 transfected in two epithelial cell lines, Madin Darby Canine Kidney (MDCK) and human colon adenocarcinoma (Caco-2) cells, by pulse-chase 35S-labeling and immunoprecipitation [134]. Their study revealed cell type specificity in membrane trafficking, as NPP3 was targeted directly to the apical surface in MDCK cells, whereas 50% of the proteins reached the basolateral membrane of Caco-2 cells before being transcytosed to the apical membrane. Numerous studies documented the functional similarities between respiratory and intestinal epithelia (review: [135]), including the polarity of ADO transporters [136]. In human airway epithelia, an indirect trafficking route for NPP3 would reconcile the bilateral distribution of the membrane-bound NPP activity [128] with the absence of NPP1 [131]. On the apical surface, high-affinity NPP3 activity could participate in the purinergic regulation of airway clearance through local regulation of nucleotides (ATP, UTP) and dinucleotides (Ap4A) known to activate P2 receptors [137, 138]. The possible contribution of secreted NPP in human airways should not be neglected, as the presence of NPP2 was confirmed in primary cultures of human bronchial epithelial cells and non-small-cell lung cancer (NSCLC) cell lines by quantitative PCR and Northern blot [139]. Regarding the different splice variants, the expression level of ATXa correlated negatively with the differentiation state of NSCLC cultures. Accordingly, in situ hybridization positioned ATXa only in the poorly differentiated basal cells of superficial epithelia, with weak staining of type II pneumocytes. In another study, ATXa and ATXg were both detected in human lung tissue by RT-PCR [105]. However, quantitative analysis revealed that ATXg represents <10% of the total NPP2 mRNA. Taken together, these studies suggest that the isoform immunodetected in the basal cells of bronchial epithelia corresponds to ATXa. On the other hand, the authors point out that it is impossible to design primers specific for ATXb because of the organization of the isoforms within the NPP2 gene [105]. Therefore, the presence of ATXb in the respiratory system can not be excluded. Incidentally, NPP2 was immunolocalized by confocal microscopy in human bronchial tissue using an antibody which recognizes all three isoforms [140]. The epithelial barrier exhibited a strong signal in the columnar cells, concentrated beneath the apical plasma membrane (Picher 2002, personal communication).
32
M. Picher
As such, the secretion of apical NPP2 (ATXg) would allow the airways to regulate the concentrations of P2 receptor agonists within airway secretions, which contain a variety of receptive inflammatory cells under pathological conditions. The literature is also surging with original studies and reviews on LPA and SIP-1, which occur naturally in the surfactant and BAL fluid (reviews: [141–143]). It is widely accepted that NPP2 stimulates proliferation, migration and survival by its ability to generate LPA. This potent bioactive phospholipid activates G proteincoupled receptors (LPA1-4) on human airway epithelia, which promote fibronectin and cytokine release, cell proliferation, filopodia formation and barrier integrity. On adjacent fibroblasts, LPA stimulates proliferation and collagen gel contraction. It is, therefore, not surprising that this phospholipid was shown to accelerate wound healing in vivo [144]. The second bioactive lipid generated by NPP2, SIP-1, was shown to activate a different family of G protein-coupled receptors (S1P1–5) [145]. These receptors stimulate cytokine secretion from the epithelial barrier [145, 146], promote the activation and recruitment of immune and inflammatory cells, and the proliferation of fibroblasts (review: [147]). Since LPA and SIP-1 concentrations increase dramatically in the BAL fluid under various pathological conditions, these studies highlight the critical importance of NPP2 for the non-purinergic regulation of airway defenses.
2.3
The Cell Surface Transphosphorylating Enzymes
The regulation of extracellular nucleotides by cell surface kinases represents a logical extension of their role in the regulation of intracellular nucleotides, RNA and DNA synthesis. Within mammalian cells, nucleoside diphosphate kinases (NDPKs; E.C. 2.7.4.6) and nucleoside monophosphate kinases (NMPKs) support transphosphorylation reactions in the de novo and salvage pathways (reviews: [148, 149]). The ubiquitous intracellular NDPKs catalyze the reaction: NTP + NDP ↔ NDP + NTP [149]. Among the NMPKs, the activities of adenylate kinases (AKs; E.C. 2.7.4.3) are restricted to adenine-based nucleotides by the reaction: ATP + AMP ↔ ADP + ADP [148]. These enzymes have been proposed to form long distance conduits for ATP from the production sites (i.e. mitochondria) to various consumption sites, including actin-myosin fibers and plasma membrane ATP-sensitive K+ channels [150]. Over the past decade, few studies reported the existence of extracellular AK (ectoAK) and/or NDPK (ectoNDPK) activities at the surface of endothelial cells [151, 152], lymphocytes [152], hepatocytes [153], glomeruli [154], keratinocytes [155], astrocytoma cell [156] and the airway epithelial cells [157–159]. Both enzyme activities were also detected in ASL of human bronchial epithelial cultures and nasal secretions from healthy subjects [158]. Whether these soluble enzymes are different from the membranebound enzymes remains to be determined. The human bronchial epithelial cell line, 16HBE14o-, supports an ectoNDPK activity regulating the relative concentrations of P2 receptor agonists by the
2 Mechanisms Regulating Airway Nucleotides
33
reaction: ATP + UDP ↔ ADP + UTP [157]. In addition, primary cultures of human bronchial epithelial cells express an ectoAK supporting the reaction: ATP + AMP ↔ ADP + ADP [158, 159]. Interestingly, the substrate affinities of these epithelial ectoAK and ectoNDPK are within the range of high-affinity ectonucleotidases (5–25 mM), such as NPPs [108, 128] and NTPDase1 [58], thereby supporting a role in the regulation of P2YR-mediated airway defenses. Functional assays involving the selective inhibitor, Ap5A, demonstrated that ectoAK significantly prolongs the effective concentrations of ATP and ADP (0.1–1.0 mM) for P2Y2Rs on airway surfaces, and reduces the rate of ADO production by sixfold [159]. These results suggest that the transphosphorylase activity of ectoAK propagates P2 receptor agonists along airway surfaces, much like the ATP conduits within the cytoplasm. Following stimulated ATP release, ectoAK competes with the dephosphorylating ectonucleotidases to maintain effective concentrations for P2Y2R activation, which enhances MCC through Ca2+-dependent Cl secretion, mucus secretion and cilia beating (review: [138]). The physiological contribution of ectoAK was demonstrated by a study describing the purinergic regulation of mucin secretion [160]. Human bronchial epithelial cells, grown as xenografts on the back of nude mice, responded to ADP (not UDP) by enhanced mucin secretion. These cells did not respond to 2-MeS-ADP, thereby ruling out the contribution of ADP receptors. Alternatively, the effects of exogenous ADP could be mediated following transphosphorylation into ATP by ectoAK. The recent identification of the gene encoding ectoNDPK led to the development of an anti-NDPK antibody (Nm23-H1; Insight Biotechnology) which inhibits the surface enzyme activity [153]. Together, with the selective ectoAK inhibitor, Ap5A, these pharmacological tools are being used to elucidate the roles of these extracellular kinases. In human hepatocytes, the inhibition of ectoNDPK and ectoAK suppressed the endocytosis of high-density lipoprotein (HDL) mediated by exogenous ADP on P2Y13 receptors [153]. However, their physiological roles should be ascertained under conditions reflecting the relative concentrations of their substrates in the extracellular milieu. The impact of ectoNDPK on cell functions may be lower than anticipated due to the >10-fold lower concentrations of uridine, compared to adenine, nucleotides within the ASL layer. For instance, the addition of Ap5A, but not the anti-NDPK antibodies, stimulated HDL endocytosis in the absence of exogenous substrates [153]. Future studies, using these tools, should reveal their roles in the regulation of airway defenses.
2.4 2.4.1
The Regulation of Airway Adenosine: A Balancing Act Ecto 50 -Nucleotidase
Extracellular ADO stems predominantly from the activities of ectonucleotidases on nucleotides released by activated or damaged cells. Two ectonucleotidases support the last dephosphorylation step: TNAP and ecto 50 -nucleotidase (ecto 50 -NT; CD73;
34
M. Picher
EC 3.1.3.5). Whereas TNAP dephosphorylates ATP, ADP and AMP, the activity of CD73 is limited to monophosphates. Furthermore, the gene encoding CD73 is on a different chromosome (6q14-q21), which generates a dimer attached to cell surfaces by a GPI anchor (reviews: [161, 162]). This enzyme was also named low Km-nucleotidase due to its high affinity for AMP (Km ¼ 3–19 mM) compared to its intracellular counterparts (review: [161]). This ectonucleotidase operates preferentially at neutral pH and is inhibited by the stable ADP analogue named AMPCP (Ki ¼ 5–19 nM). However, since ADP also inhibits the activity of TNAP toward AMP [26], AMPCP is expected to affect both CD73 and TNAP. On cell types expressing both ectonucleotidases, their relative contributions to the production of extracellular ADO should be determined as levamisole-sensitive (TNAP) and levamisole-insensitive (CD73) activities [26]. It is important to mention that CD73 is reported on all mammalian cell types, except granulocytes and monocytes (review: [163]), which has important repercussions for the regulation of ADO-mediated inflammatory responses (see Chap. 7 for details). Polarized epithelia have been documented exhaustively with regard to the properties and physiological roles of CD73, especially in the regulation of fluid transport and barrier integrity (review: [162]). In 2003, the discovery that this ectonucleotidase is also expressed on airway epithelial surfaces [26] paved the way for numerous in vivo studies establishing the importance of ADO for airway defenses [84, 89, 164]. On human bronchial epithelial cultures, CD73 exhibits a bilateral polarity and a substrate affinity within the range of the ATP-hydrolyzing ectoenzymes expressed on these cells (KM ¼ 14 mM) [26]. Furthermore, CD73 accounts for >80% of the total ectoAMPase activity toward physiological (<10 mM) AMP levels, which identified this enzyme as the predominant regulator of airway ADO production.
2.4.2
Adenosine Deaminase
The capacity of human tissue to eliminate extracellular ADO and 20 -deoxyadenosine has been investigated for decades owing to the early discovery that congenital defects in the gene encoding adenosine deaminase (ADA; EC 3.5.4.4) causes severe combined immunodeficiency disease (SCID) (reviews: [165–168]). The cytosolic enzyme is released in the extracellular milieu and has the capacity to bind to cell surfaces on the serine protease known as CD26 (dipeptidyl peptidase IV; E.C. 3.4.14.5). On T lymphocytes, the CD26-ADA1 complex was found essential for cell proliferation by local removal of inhibitory ADO [169]. The ADA-deficient children also exhibit high plasma levels in 20 -deoxydenosine, which causes lymphocyte apoptosis. Hence, both substrates participate in the pathology of SCID. On the other hand, the immunodeficiency virus (HIV-1) has the ability to prevent ADA-CD26 complex formation via interference by the envelope protein gp120, which contributes to the defective T-cell activation noticed in patients with acquired immunodeficiency syndrome (AIDS) [170]. These discoveries strongly motivated the exploration of ADA
2 Mechanisms Regulating Airway Nucleotides
35
correction therapies (see Chaps. 8 and 9 for details). However, the following paragraphs highlight the importance of fundamental research to identify the potential and limitations of these therapeutic applications. The early nomenclature related to ADA and CD26 was derived from SDS-PAGE and Western blot analysis of membrane preparations. The authors identified a band of 35 kDa they named ADA-S, and a band of 280 kDa they named ADA-L (review: [171]). Further analysis revealed that the latter was a protein complex composed of two ADA-S and one glycoprotein called the adenosine deaminase complexing protein (ADCP). This glycoprotein was later identified as CD26 (review: [172]). This information will allow readers to reconcile the early literature with the current notions of ADA-CD26 complexing on cell surfaces. In human tissue, two ADA isoforms were identified based on their distribution, catalytic properties and gene mapping. The gene that encodes ADA1 was mapped to chromosome 20 (20q13.12), which yields a protein essential for the cytosolic purine salvage pathway. This ubiquitous ADA has the ability to bind CD26 [173] and to regulate physiological ADO levels (<10 mM) with a KM in the 20–50 mM range [166]. In addition, some inflammatory and immune cells secrete a second isoform (ADA2) which exhibits a weak affinity for ADO (KM ¼ 2 mM) [174] and lacks the ability to bind cell surface proteins [173]. The ADA2 isoform was originally isolated from the conditioned medium of activated rat macrophages [173]. In the plasma, HIV-infected T-cells [175] and B-cells [176] were also proposed as sources of plasma ADA2. This isoform was recently purified and identified as the cat eye syndrome critical region candidate 1 (CECR1), member of a novel family of ADArelated growth factors [174]. The gene encoding ADA2 was mapped to the same locus as CECR1 (22q11), and sequence analysis revealed that ADA2 is synthesized as a pre-protein containing a signal peptide released during secretion. While ADA2 may not regulate extracellular ADO, it was recently found to affect the differentiation and proliferation states of immune and inflammatory cells [177]. A number of natural and synthesized ADA inhibitors have been developed based on the structure of ADO (review: [167]). For instance, naturally-occurring coformycin and 20 -deoxycoformycin (pentostatin) form nearly irreversible associations with ADA1 (Ki ¼ 1011–1012 M). Pentostatin is commonly used to inhibit cell surface ADA activity in vitro and to investigate lymphoproliferative disorders (review: [178]). However, this compound is also a potent inhibitor of ADA2 activity (Ki ¼ 109 M) [179], which may cause serious side-effects. To date, the best inhibitor available to distinguish the two ADA isoforms remains the specific ADA1 inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), which has been shown not to interfere with ADA2 activity [180, 181]. This molecule inhibits ADA1 by a particular two-step mechanism composed of an initial classic competitive behavior, followed by rearrangement of the two molecules into a tight enzyme-inhibitor complex. In fact, EHNA is currently used to validate novel inhibitors screened from natural extracts by ADA1-immobilized capillary electrophoresis [182]. Since ADA2 inhibitors have not been identified, the activities of the two isoforms are generally determined in terms of EHNA-sensitive (ADA1) and EHNA-insensitive (ADA2) activities measured with a saturable ADO (1-2 mM) concentration.
36
M. Picher
In the respiratory system, the bulk of the literature on ADA is derived from measurements of total ADA activity in the BAL fluid. The enzyme activity is reported abnormally elevated in various disorders, including pulmonary interstitial lung disease, pneumonia, tuberculosis and sarcoidosis [183–188]. While in vivo studies measure total lung ADA in mice (review: [189]), only one study documented the presence of membrane-bound ADA on airway surfaces. Hirsh and collaborators provided a systematic biochemical characterization of ADA activities bound to the apical surface of human bronchial epithelial cultures [136]. The RT-PCR analysis showed that human nasal and bronchial epithelial cells only express the ADA1 isoform. The conversion of ADO into inosine was completely inhibited by EHNA, and exhibited a high affinity (KM ¼ 24 mM) consistent with ADA1. In contrast, both ADA isoforms were detected in lung parenchyma at the mRNA level, likely owing to the presence of monocytes and macrophages. The glycoprotein binding ADA1 to airway surfaces has not been formally identified. Yet, CD26 has been immunolocalized on human airway epithelia [190–193] and alveolar epithelial cells [190]. Together, these data demonstrate that airway surfaces have the capacity to eliminate ADO in close proximity to the receptors located on the epithelial surfaces. In addition, a fraction of the secreted ADA1 remains soluble in the ASL, where it regulates ADO around other cells, including inflammatory cells recruited during infection. In fact, the only information available on the mechanisms mediating ADA1 secretion is derived from inflammatory cells. Monocytes exposed to a PKC activator (PMA) or a calcium ionophore (A23187) exhibit a fourfold decrease in ADA1 secretion in conditioned medium [194]. This signaling mechanism was also demonstrated in neutrophils [195] and thymocytes [196], supporting a major role for the PKC-dependent signaling cascades initiated by P2Y2Rs on inflammatory and epithelial cells. Following ATP secretion, a P2Y2R-mediated stimulation of ADA1 secretion could allow local ADO levels to transiently rise to promote A2BR-mediated cellular responses.
2.4.3
Nucleoside/Nucleobase Transporters
Polarized epithelia counterbalance the accumulation of luminal ADO and inosine using a dual transport system maintaining vectorial flux in the apical-to-basolateral direction. This system requires the concerted efforts of two gene families: Soluble Carrier Family 28 (SLC28) and Soluble Carrier Family 29 (SLC29) (reviews: [197, 198]). The SLC28 family comprises high-affinity Na+-dependent concentrative nucleoside transporters (CNTs) which facilitate ADO uptake against a concentration gradient. In contrast, SLC29 designates equilibrative nucleoside transporters (ENTs) acting as low-affinity facilitated carrier proteins. The SLC28 and SLC29 glycoproteins are all oriented with the N-terminus in the cytoplasm and the C-terminus facing the extracellular milieu, and accommodate 13 and 11 membrane spans, respectively. They exhibit a variety of permeant selectivity, kinetic parameters and distributions. For instance, ENTs are ubiquitous transporters,
2 Mechanisms Regulating Airway Nucleotides
37
whereas CNTs are restricted to the polarized epithelia (reviews: [199, 200]). In the intestinal epithelium, the vectorial flux of ADO is maintained by CNTs promoting ADO uptake on the apical surface, and basolateral ENTs facilitating the release of excess ADO into the bloodstream (review: [201]). In the respiratory system, Hirsh et al. demonstrated that polarized cultures of human bronchial epithelial cells functionally express CNT2 and CNT3 on the apical surface [136]. A survey of their mRNA levels along the airways showed that CNT2 is restricted to nasal passages, whereas CNT3 regulates ADO in nasal and bronchial epithelia [136]. The fact that CNT3 exhibited an affinity for ADO (KM ¼ 17 mM) comparable to that of ADA1 (KM ¼ 24 mM), suggested that both mechanisms contribute to the elimination of airway ADO. However, the bronchial cultures regulated ADO primarily through ADA1 (>80%) due to differences in kinetic efficiencies, which takes into account the maximum velocity of each mechanism. In the nasal epithelia, CNTs play a larger role in the regulation of airway ADO owing to the co-expression of CNT2 and CNT3 [136]. Thus, regional differences in the predominant elimination mechanism are expected along the airways. The functional expression of ENTs on the basolateral surface of airway epithelia has not been reported, but mRNA was detected for ENT1 and ENT2 in the BEAS-2B bronchial epithelial cell line [202]. The active uptake of airway ADO and inosine would supply nucleosides for the nucleotide salvage pathways in these cells lacking the de novo mechanism. On the other hand, the immune and inflammatory cells accumulating on either sides of the barrier during infection would also constitute major sources and sinks for extracellular ADO through ADA1 and ENTs expressed at their surface.
2.5
Functional and Spatial Enzymatic Microenvironments
The integration of all information available on the ectonucleotidases regulating ATP and ADO on airway surfaces revealed the presence of two groups targeting different pools of nucleotides. We learned from in vitro assays conducted on human bronchial epithelial cultures that physiological nucleotide levels (<1 mM) are regulated by a high-affinity low-capacity metabolic chain including NTPDase1, E-NPPs, CD73 and ADA1. Stress situations associated with massive nucleotide release (i.e. emphysema, mechanical ventilation or chronic bacterial infection) may allow low-affinity high-capacity NTPDase3 and TNAP to prevent exaggerated inflammatory responses and apoptosis. From a morphological point of view, high-affinity and low-affinity ectonucleotidases appear to maintain opposite expression gradients along the airways. Highaffinity NTPDase1 [91] and CD73 [26] are particularly abundant in the upper airways, whereas low-affinity NTPDase3 [91] and TNAP [26] are concentrated in distal airways. These regional differences suggest that the composition of the enzymatic network is adjusted along the airways according to local requirements in nucleotide regulation and/or to regulate different defense mechanisms.
38
M. Picher
This model was further refined by considering the various cell types expressed in the respiratory epithelia, which may host different populations of ectonucleotidases. For instance, the immunolocalization of NTPDase3 revealed a preferential association with secretory cells throughout the airways, the highest expression being detected in the luminal membrane of submucosal glands [91]. This association appears specific for mucin-secreting cells because NTPDase3 is not expressed in the alveoli, including surfactant-secreting cells. The recent discovery that mucin granules accumulate high nucleotide concentrations [203] suggests that NTPDase3 may locally regulate the amplification cascades of P2Y2R-mediated mucin secretion. In fact, the expression gradient of NTPDase3 follows that reported for mucin-secreting cells along the airways, their relative abundance in the superficial epithelium increasing toward the alveoli [204]. This morphological feature was confirmed functionally in terms of NTPDase3 activity and mRNA levels measured on the apical surface of cultured nasal, bronchial and bronchiolar epithelial cells [91]. These data suggest that selective inhibitors of NTPDase3 may be beneficial for the treatment of mucus hypersecretion, since this enzyme does not target the physiological nucleotide concentrations regulating airway hydration. The second most important airway defense mechanism, mucociliary clearance (MCC), takes place on the ciliated epithelial cells, which express the epithelial sodium channel (ENaC) [205], CFTR [206], and the water channel aquaporin-5 (AQP5) [92]. Interestingly, these channels share the same cell specificity and expression gradient than high-affinity NTPDase1 [91] and CD73 [26]. Since these enzymes have the capacity to regulate sub-micromolar purine concentrations, they could regulate MCC via P2Y2R-mediated ENaC activation, A2BR-mediated CFTR activation and cilia beating activity [95], as well as CFTR-mediated ENaC inhibition [207]. These epithelial functions will be reviewed in detail in Chap. 5. This type of integrative data analysis introduces the concept of “Purinomes” for airway defenses, which incorporate ectonucleotidases, purinoceptors and effector proteins into functional protein clusters. In conclusion, the distinct biochemical and catalytic properties, cell type specificities and expression gradients exhibited by the ectonucleotidases expressed along the airways alleviate the redundancy anticipated for the co-expression of such closely-related proteins. The information provided in this chapter allows the readers to fully appreciate the complexity and sophistication of the multi-enzyme network regulating ATP and ADO concentrations in the airways.
References 1. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS II, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD (1999) Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010–1017
2 Mechanisms Regulating Airway Nucleotides
39
2. Goepfert C, Imai M, Brouard S, Csizmadia E, Kaczmarek E, Robson SC (2000) CD39 modulates endothelial cell activation and apoptosis. Mol Med 6:591–603 3. Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA (2005) Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J Biol Chem 280:22986–22992 4. Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg’s Arch Pharmacol 362:299–309 5. Moss DW (1992) Perspective in alkaline phosphatase research. Clin Chem 38:2486–2492 6. Henderson RF (2005) Use of bronchoalveolar lavage to detect respiratory tract toxicity of inhaled material. Exp Toxicol Pathol 57:155–159 7. Van Belle H (1976) Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem 22:972–976 8. Milla´n J (2006) Alkaline phosphatases. Purinergic Signal 2:335–341 9. Van Hoof VO, De Broe ME (1994) Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 31:197–293 10. Ali M, Gawin AZ, Baraniuk JN (1996) Effects of bombesin family peptides and antagonists on guinea pig nasal mucosal secretion. J Pharmacol Exp Ther 276:1266–1271 11. Brindley DN, English D, Pilquil C, Buri K, Ling ZC (2002) Lipid phosphate phosphatases regulate signal transduction through glycerolipids and sphingolipids. Biochim Biophys Acta 1582:33–44 12. Borgers M, Thone´ F (1975) The inhibition of alkaline phosphatase by L-p-bromotetramisole. Histochemistry 44:277–280 13. Goldstein DJ, Rogers C, Harris H (1982) A search for trace expression of placental-like alkaline phosphatase in non-malignant human tissues: demonstration of its occurrence in lung, cervix, testis and thymus. Clin Chim Acta 125:63–75 14. Nouwen EJ, Buyssens N, De Broe ME (1990) Heat-stable alkaline phosphatase as a marker for human and monkey type-I pneumocytes. Cell Tissue Res 260:321–335 15. Miyanaga M, Sugimoto H, Komoda T, Nosjean O, Honma K, Nemoto K, Sato T (1996) A variant alkaline phosphatase detected in a patient with lung cancer. Enzyme Protein 49:313–320 16. Sergienko E, Su Y, Chan X, Brown B, Hurder A, Narisawa S, Milla´n JL (2009) Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action. J Biomol Screen 14:824–837 17. Sidique S, Ardecky R, Su Y, Narisawa S, Brown B, Milla´n JL, Sergienko E, Cosford ND (2009) Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). Bioorg Med Chem Lett 19:222–225 18. Lanier M, Sergienko E, Sima˜o AM, Su Y, Chung T, Milla´n JL, Cashman JR (2009) Design and synthesis of selective inhibitors of placental alkaline phosphatase. Bioorg Med Chem 18:573–579 19. Ikehara Y, Mansho K, Takahashi K, Kato K (1978) Purification and characterization of alkaline phosphatase from plasma membranes of rat ascites hepatoma. J Biochem 83:1471–1483 20. Say JC, Ciuffi K, Furriel RP, Ciancaglini P, Leone FA (1991) Alkaline phosphatase from rat osseous plates: purification and biochemical characterization of a soluble form. Biochim Biophys Acta 1074:256–262 21. Fortuna R, Anderson HC, Carty RP, Sajdeja SW (1980) Enzymatic characterization of the matrix vesicle alkaline phosphatase isolated from bovine epiphyseal cartilage. Calcif Tissue Int 30:217–225 22. Demenis MA, Furriel RPM, Leone FA (2003) Characterization of an ectonucleoside triphosphate diphosphohydrolase 1 activity in alkaline phosphatase-depleted rat osseous plate membranes: possible functional involvement in the calcification process. Biochim Biophys Acta 1646:216–225
40
M. Picher
23. Pizauro JM, Ciancaglini P, Leone FA (1993) Allosteric modulation by ATP, calcium and magnesium ions of rat osseous plate alkaline phosphatase. Biochim Biophys Acta 1202:22–28 24. Corbic M, de Coue¨t G, Bertrand O, Cochet S, Erlinger S (1985) Bicarbonate-stimulated ATPase activity of bovine liver alkaline phosphatase. J Hepatol 1:167–178 25. Nouwen EJ, Pollet DE, Eerdekens MW, Hendrix PG, Briers TW, De Broe ME (1986) Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 46:866–876 26. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC (2003) Ecto 50 -nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468–13479 27. Picher M, Burch LH, Boucher RC (2004) Metabolism of P2 receptor agonists in human airways: implications for mucociliary clearance and cystic fibrosis. J Biol Chem 279:20234–20241 28. Capelli A, Cerutti CG, Lusuardi M, Donner CF (1997) Identification of human pulmonary alkaline phosphatase isoenzymes. Am J Respir Crit Care Med 155:1448–1452 29. Henderson RF, Scott GG, Waide JJ (1995) Source of alkaline phosphatase activity in epithelial lining fluid of normal and injured F344 rat lungs. Toxicol Appl Pharmacol 134:170–174 30. DiAugustine RP (1974) Lung concentric laminar organelle. Hydrolase activity and compositional analysis. J Biol Chem 249:584–593 31. Edelson JD, Shannon JM, Mason RJ (1988) Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am Rev Respir Dis 138:1268–1275 32. Xie E, Yang ZQ, Li A (1996) Determination of placental alkaline phosphatase (PLAP) for detecting the damages of alveolar type I cells caused by smoke inhalation. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 12:427–430 33. Swain RJ, Kemp SJ, Goldstraw P, Tetley TD, Stevens MM (2008) Spectral monitoring of surfactant clearance during alveolar epithelial type II cell differentiation. Biophys J 95:5978–5987 34. Fedde KN, Lane CC, Whyte MP (1988) Alkaline phosphatase is an ectoenzyme that acts on micromolar concentrations of natural substrates at physiologic pH in human osteosarcoma (SAOS-2) cells. Arch Biochem Biophys 264:400–409 35. Marquez C, Toribio ML, Marcos MA, de la Hera A, Barcena A, Pezzi L, Martinez C (1989) Expression of alkaline phosphatase in murine B lymphocytes. Correlation with B cell differentiation into Ig secretion. J Immunol 142:3187–3192 36. Baggiolini M (1972) The enzymes of the granules of polymorphonuclear leukocytes and their functions. Enzyme 13:132–160 37. Garattini E, Gianni M (1996) Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Leuk Lymphoma 23:493–503 38. Jiang X, Kobayashi T, Nahirney PC, Garcı´a del Saz E, Seguchi H (1998) An ultracytochemical study on the dynamics of alkaline phosphatase-positive granules in rat neutrophils. Histol Histopathol 13:57–65 39. Jiang X, Kobayashi T, Nahirney PC, del Garcia SE, Seguchi H (1996) Ultracytochemical localization of alkaline phosphatase (ALPase) activity in neutrophils of the rat lung following injection of lipopolysaccharide. Kaibogaku Zasshi 71:183–194 40. Day DF, Ingram JM (1973) Purification and characterization of Pseudomonas aeruginosa alkaline phosphatase. Can J Microbiol 19:1225–1233 41. Kadurugamuwa JL, Beveridge TJ (1997) Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 40:615–621 42. Bomberger JM, Maceachran DP, Coutermarsh BA, Ye S, O’Toole GA, Stanton BA (2009) Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog 5:e1000382
2 Mechanisms Regulating Airway Nucleotides
41
43. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F (1994) Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8:217–225 44. Holst O, Thomas-Oates JE, Brade H (1994) Preparation and structural analysis of oligosaccharide monophosphates obtained from the lipopolysaccharide of recombinant strains of Salmonella minnesota and Escherichia coli expressing the genus-specific epitope of Chlamydia lipopolysaccharide. Eur J Biochem 222:183–194 45. Poelstra K, Bakker WW, Klok PA, Kamps JA, Hardonk M, Meijer DK (1997) Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol 151:1163–1169 46. Bentala H, Verweij WR, Huizinga-van der Vlag A, Huizinga-vander Vlag A, van LoenenWeemaes AM, Meijer DK, Meijer DK, Poelstra K (2002) Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18:561–566 47. Beumer C, Wulferink M, Raaben W, Raaben W, Fiechter Dl, Brands R, Seinen W (2003) Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 307:737–744 48. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T (2002) Alkaline phosphatases reduce toxicity of lipopolysaccharide in vivo and in vitro through dephosphorylation. Clin Biochem 36:455–461 49. Poelstra K, Bakker WW, Klok PA, Hardonk MJ, Meijer DK (1997) A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 76:319–327 50. Geddes K, Philpott DJ (2008) A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135:8–12 51. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, Velders MP, Dijkstra G (2009) Role of alkaline phosphatase in colitis in man and rats. Gut 58:379–387 52. Goldberg RF, Austen WGJ, Zhang X, Munene G, Mostafa G, Biswas S, McCormack M, Eberlin KR, Nguyen JT, Tatlidede HS, Warren HS, Narisawa S, Milla´n JL, Hodin RA (2008) Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci USA 105:3551–3556 53. Picher M, Boucher RC, Picher M, Boucher RC, Picher M, Boucher RC (2003) Detoxification of Pseudomonas aeruginosa lipopolysaccharide in human airways: an inflammatory response mediated by non-specific alkaline phosphatase. Pediatr Pulmonol Suppl 25:271 54. Beaudoin AR, Sevigny J, Picher M (1996) ATP-diphosphohydrolases, apyrases and nucleotide phosphohydrolases: biochemical properties and functions. JAI Press, Greenwich 55. Robson SC, Sevigny J, Zimmermann H (2006) The E-NTPDase family of ectonucleotidases: structure function relationships and pathological significance. Purinergic Signal 2:409–430 56. Christoforidis S, Papamarcaki T, Galaris D, Kellner R, Tsolas O (1995) Purification and properties of human placental ATP diphosphohydrolase. Eur J Biochem 234:66–74 57. Sevigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, Qawi I, Imai M, Zimmermann H, Robson SC (2002) Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99:2801–2809 58. Kukulski F, Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF, Robson S, Kirley TL, Sevigny J (2005) Comparative hydrolysis of P2 receptor agonists by NTPDase 1, 2, 3 and 8. Purinergic Signal 1:193–204 59. Mateo J, Harden TK, Boyer JL (1999) Functional expression of a cDNA encoding a human ecto-ATPase. Br J Pharmacol 128:396–402 60. Knowles AF, Chiang WC (2003) Enzymatic and transcriptional regulation of human ectoATPase/E-NTPDase 2. Arch Biochem Biophys 418:217–227 61. Sevigny J, Robson SC, Waelkens E, Csizmadia E, Smith RN, Lemmens R (2000) Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase. J Biol Chem 275:5640–5647 62. Zimmermann H (2001) Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev Res 52:44–56
42
M. Picher
63. Kirley TL, Crawford PA, Smith TM (2006) The structure of the nucleoside triphosphate diphosphohydrolases (NTPDases) as revealed by mutagenic and computational modeling analyses. Purinergic Signal 2:379–389 64. Gendron FP, Benrezzak O, Krugh BW, Kong Q, Weisman GA, Beaudoin AR (2002) Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition. Curr Drug Targets 3:229–245 65. Munkonda MN, Kauffenstein G, Kukulski F, Levesque SA, Legendre C, Pelletier J, Lavoie EG, Lecka J, Sevigny J (2007) Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists. Biochem Pharmacol 74:1524–1534 66. Leal DBR, Streher CA, Neu TN, Bittencourt FP, Leal CAM, da Silva JEP, Morsch VM, Schetinger MRC (2005) Characterization of NTPDase (NTPDase1; ecto-apyrase; ectodiphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes. Biochim Biophys Acta 1721:9–15 67. Smith TM, Kirley TL (1998) Cloning, sequencing and expression of a human brain ecto-apyrase related to both the ecto-ATPase and CD39 ecto-apyrase1. Biochim Biophys Acta 1386:65–78 68. Shi XJ, Knowles AF (1994) Prevalence of the mercurial-sensitive ectoATPase in human small cell lung carcinoma: characterization and partial purification. Arch Biochem Biophys 315:177–184 69. Fausther M, Lecka J, Kukulski F, Levesque SA, Pelletier J, Zimmermann H, Dranoff JA, Sevigny J (2007) Cloning, purification, and identification of the liver canalicular ectoATPase as NTPDase8. Am J Physiol 292:G785–G795 70. Iqbal J, Vollmayer P, Braun N, Zimmermann H, M€ uller CE (2005) A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal 1:349–358 71. M€uller CE, Iqbal J, Baqi Y, Zimmermann H, R€ ollich A, Stephan H (2006) Polyoxometalatesa new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 16:5943–5947 72. Munkonda MN, Pelletier J, Ivanenkov VV, Fausther M, Tremblay A, K€unzli B, Kirley TL, Se´vigny J (2009) Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3. FEBS J 276:479–496 73. Baqi Y, Weyler S, Iqbal J, Zimmermann H, M€ uller CE (2009) Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 5:91–106 74. Knowles AF, Isler RE, Reece JF (1983) The common occurrence of ATP diphosphohydrolase in mammalian plasma membranes. Biochim Biophys Acta 731:88–96 75. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271:33116–33122 76. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99:1351–1361 77. Ghijsen WE, de Jong MD, van Os CH (1980) Dissociation between Ca2+-ATPase and alkaline phosphatase activities in plasma membranes of rat duodenum. Biochim Biophys Acta 599:538–591 78. R€ucker B, Almeida ME, Libermann TA, Zerbini LF, Wink MR, Sarkis JJ (2007) Biochemical characterization of ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP, E.C. 3.1.4.1) from rat heart left ventricle. Mol Cell Biochem 306:247–254 79. Sato E, Suzuki T, Hoshi N, Sugino T, Hasegawa H (2008) Sodium azide induces necrotic cell death in rat squamous cell carcinoma SCC131. Med Mol Morphol 41:211–220 80. Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, Ingall AH, McKechnie KC, IJzerman AP, Leff P (2005) Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 114:475–481
2 Mechanisms Regulating Airway Nucleotides
43
81. Westfall TD, Kennedy C, Sneddon P (1996) Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156. Br J Pharmacol 117:867–872 82. Le´vesque SA, Lavoie EG, Lecka J, Bigonnesse F, Se´vigny J (2007) Specificity of the ectoATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. Br J Pharmacol 152:141–150 83. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, Eltzschig HK (2007) CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia-reperfusion injury. Circulation 116:1784–1794 84. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri K-C, Eltzschig HK (2009) Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23:473–482 85. Martı´n-Satue´ M, Lavoie EG, Pelletier J, Fausther M, Csizmadia E, Guckelberger O, Robson SC, Se´vigny J (2009) Localization of plasma membrane bound NTPDases in the murine reproductive tract. Histochem Cell Biol 131:615–628 86. Wall MJ, Wigmore G, Lopata´r J, Frenguelli BG, Dale N (2008) The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition. Neuropathology 55:1251–1258 87. Chadwick B, Frischauf AM (1997) Cloning and mapping of a human and mouse gene with homology to ecto-ATPase genes. Mamm Genome 8:668–672 88. Chadwick BP, Frischauf AM (1998) The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster. Genomics 50:357–367 89. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, Eltzschig HK (2007) Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 178:8127–8137 90. Sevigny J, Picher M, Grondin G, Beaudoin AR (1997) Purification and immunohistochemical localization of the ATP diphosphohydrolase in bovine lungs. Am J Physiol 272: L939–L950 91. Fausther M, Pelletier J, Ribeiro CM, Se´vigny J, Picher M (2010) Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am J Physiol 298: L804–L818 92. Kreda SM, Gynn MC, Fenstermacher DA, Boucher RC, Gabriel SE (2001) Expression and localization of epithelial aquaporins in the adult human lung. Am J Respir Cell Mol Biol 24:224–234 93. Zinchuk VS, Okada T, Seguchi H (2001) Lipopolysaccharide alters ecto-ATP-diphosphohydrolase and causes relocation of its reaction product in experimental intrahepatic cholestasis. Cell Tissue Res 304:103–109 94. Kreda SM, Okada SF, van Heusden CA, O’Neal W, Gabriel S, Abdullah L, Davis CW, Boucher RC, Lazarowski ER (2007) Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells. J Physiol 584:245–259 95. Davis CW, Lazarowski E (2008) Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. Respir Physiol Neurobiol 163:208–213 96. Yegutkin G, Bodin P, Burnstock G (2000) Effect of shear stress on the release of soluble ecto-enzymes ATPase and 50 -nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 129:921–926 97. Sørensen CE, Amstrup J, Rasmussen HN, Ankorina-Stark I, Novak I (2003) Rat pancreas secretes particulate ecto-nucleotidase CD39. J Physiol 551:881–892 98. Goding JW, Grobben B, Slegers H (2003) Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 1638:1–19
44
M. Picher
99. Stefan C, Jansen S, Bollen M (2005) NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30:542–550 100. Jansen S, Stefan C, Creemers JWM, Waelkens E, Van Eynde A, Stalmans W, Bollen M (2005) Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasisenhancing lysophospholipase D. J Cell Sci 118:3081–3089 101. Boutin J, Ferry G (2009) Autotaxin. Cell Mol Life Sci 66:3009–3021 102. Murata J, Lee HY, Clair T, Krutzsch HC, Arestad AA, Sobel ME, Liotta LA, Stracke ML (1994) cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem 269:30479–30484 103. Lee HY, Murata J, Clair T, Polymeropoulos MH, Torres R, Manrow RE, Liotta LA, Stracke ML (1996) Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun 218:714–719 104. Kawagoe H, Soma O, Goji J, Nishimura N, Narita M, Inazawa J, Nakamura H, Sano K (1995) Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics 30:380–384 105. Giganti A, Rodriguez M, Fould B, Moulharat N, Coge´ F, Chomarat P, Galizzi JP, Valet P, Saulnier-Blache JS, Boutin JA, Ferry G (2008) Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem 283:7776–7789 106. Rebbe NF, Tong BD, Hickman S (1993) Expression of nucleotide pyrophosphatase and alkaline phosphodiesterase I activities of PC-1, the murine plasma cell antigen. Mol Immunol 30:87–93 107. Clair T, Lee HY, Liotta LA, Stracke ML (1997) Autotaxin is an exoenzyme possessing 50 -nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 272:996–1001 108. Grobben B, Anciaux K, Roymans D, Stefan C, Bollen M, Esmans EL, Slegers H (1999) An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 72:826–834 109. Sakura H, Nagashima S, Nakashima A, Maeda M (1998) Characterization of fetal serum 50 -nucleotide phosphodiesterase: a novel function as a platelet aggregation inhibitor in fetal circulation. Thromb Res 91:83–89 110. Grobben B, Claes P, Roymans D, Esmans EL, Van Onckelen H, Slegers H (2000) Ectonucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists. Br J Pharmacol 130:139–145 111. Joseph SM, Pifer MA, Przybylski RJ, Dubyak GR (2004) Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation. Br J Pharmacol 142:1002–1014 112. Iqbal J, Le´vesque SA, Se´vigny J, M€ uller CE (2008) A highly sensitive CE-UV method with dynamic coating of silica-fused capillaries for monitoring of nucleotide pyrophosphatase / phosphodiesterase reactions. Electrophoresis 29:3685–3693 113. Khan KM, Fatima N, Rasheed M, Jalil S, Ambreen N, Perveen S, Choudhary MI (2009) 1, 3, 4-Oxadiazole-2(3 H)-thione and its analogues: a new class of non-competitive nucleotide pyrophosphatases /phosphodiesterases 1 inhibitors. Bioorg Med Chem 17:7816–7822 114. Goldstein LB (2007) Statins for stroke prevention. Curr Atheroscler Rep 9:305–311 115. Majlesi Y, Samorapoompichit P, Hauswirth AW, Schernthaner G-H, Ghannadan M, Baghestanian M, Rezaie-Majd A, Valenta R, Sperr WR, Buhring H-J, Valent P (2003) Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. J Leukoc Biol 73:107–117 116. B€uhring HJ, Streble A, Valent P (2004) The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 133:317–329
2 Mechanisms Regulating Airway Nucleotides
45
117. Henz SL, Cognato Gde P, Vuaden FC, Bogo MR, Bonan CD, Sarkis JJ (2009) Influence of antidepressant drugs on ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs) from salivary glands of rats. Arch Oral Biol 54:730–736 118. Dehaye JP, Moran A, Marino A (1999) Purines, a new class of agonists in salivary glands? Arch Oral Biol 44:S39–S43 119. Scully C (2003) Drug effects on salivary glands: dry mouth. Oral Dis 9:165–176 120. Brinkmann V (2009) FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158:1173–1182 121. Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295–1301 122. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar W (2008) Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasisenhancing and angiogenic lysophospholipase D. Cancer Lett 266:203–208 123. Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H, Liu L (2010) PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem 111:218–228 124. Jin-Hua P, Goding JW, Nakamura H, Sano K (1997) Molecular cloning and chromosomal localization of PD-Ibeta (PDNP3), a new member of the human phosphodiesterase I genes. Genomics 45:412–415 125. Fuss B, Baba H, Phan T, Tuohy VK, Macklin WB (1997) Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J Neurosci 17:9095–9103 126. Stefan C, Gijsbers R, Stalmans W, Bollen M (1999) Differential regulation of the expression of nucleotide pyrophosphatases/phosphodiesterases in rat liver. Biochim Biophys Acta 1450:45–52 127. Picher M, Boucher RC (2001) Metabolism of extracellular nucleotides in human airways by a multienzyme system. Drug Dev Res 52:66–75 128. Picher M, Boucher RC (2000) Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:255–261 129. Morley DJ, Hawley DM, Ulbright TM, Butler LG, Culp JS, Hodes ME (1987) Distribution of phosphodiesterase I in normal human tissues. J Histochem Cytochem 35:75–82 130. Yano Y, Hayashi Y, Sano K, Shinmaru H, Kuroda Y, Yokozaki H, Yoon S, Kasuga M (2003) Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (E-NPP3/CD203c/PD-I beta/B10/gp130RB13-6) in human colon carcinoma. Int J Mol Med 12:763–766 131. Petersen CB, Nyga˚rd AB, Viuff B, Fredholm M, Aasted B, Salomonsen J (2007) Porcine ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1/CD203a): cloning, transcription, expression, mapping, and identification of an NPP1/CD203a epitope for swine workshop cluster 9 (SWC9) monoclonal antibodies. Dev Comp Immunol 31:618–631 132. Scott LJ, Delautier D, Meerson NR, Trugnan G, Goding JW, Maurice M (1997) Biochemical and molecular identification of distinct forms of alkaline phosphodiesterase I expressed on the apical and basolateral plasma membrane surfaces of rat hepatocytes. Hepatology 25:995–1002 133. Bello V, Goding JW, Greengrass V, Sali A, Dubljevic V, Lenoir C, Trugnan G, Maurice M (2001) Characterization of a di-leucine-based signal in the cytoplasmic tail of the nucleotidepyrophosphatase NPP1 that mediates basolateral targeting but not endocytosis. Mol Biol Cell 12:3004–3015 134. Meerson NR, Bello V, Delaunay JL, Slimane TA, Delautier D, Lenoir C, Trugnan G, Maurice M (2000) Intracellular traffic of the ecto-nucleotide pyrophosphatase/phosphodiesterase NPP3 to the apical plasma membrane of MDCK and Caco-2 cells: apical targeting occurs in the absence of N-glycosylation. J Cell Sci 113:4193–4202 135. Davis CW, Dickey BF (2008) Regulated airway goblet cell mucin secretion. Annu Rev Physiol 70:487–512
46
M. Picher
136. Hirsh AJ, Stonebraker J, van Heusden CA, Lazarowski ER, Boucher RC, Picher M (2007) Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases. Biochemistry 46:10373–10383 137. Saleh A, Picher M, Kammouni W, Figarella C, Merten MD (1999) Characterization of a diadenosine tetraphosphate-receptor distinct from the ATP-purinoceptor in human tracheal gland cells. Eur J Pharmacol 384:91–98 138. Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262–267 139. Yang Y, Mou L-j, Liu N, Tsao M-S (1999) Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21:216–222 140. Gijsbers R, Ceulemans H, Stalmans W, Bollen M (2001) Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem 276:1361–1368 141. van Meeteren LA, Moolenaar WH (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46:145–160 142. Toews ML, Ediger TL, Romberger DJ, Rennard SI (2002) Lysophosphatidic acid in airway function and disease. Biochim Biophys Acta 1582:240–250 143. Zhao Y, Natarajan V (2009) Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal 21:367–377 144. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G (2001) Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol 280:R466–R472 145. Cummings RJ, Parinandi N, Zaiman A, Wang L, Usatyuk PV, Garcia JG, Natarajan V (2002) Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem 277:30227–30235 146. Milara J, Mata M, Mauricio MD, Donet E, Morcillo EJ, Cortijo J (2009) Sphingosine1-phosphate increases human alveolar epithelial IL-8 secretion, proliferation and neutrophil chemotaxis. Eur J Pharmacol 609:132–139 147. Ryan JJ, Spiegel S (2008) The role of sphingosine-1-phosphate and its receptors in asthma. Drug News Perspect 21:89–96 148. Van Rompay AR, Johansson M, Karlsson A (2000) Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 87:189–198 149. Lacombe M-LL, Munier A, Mehus JG, Lambeth DO (2000) The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 32:247–258 150. Dzeja PP, Terzic A (2003) Phosphotransfer networks and cellular energetics. J Exp Biol 206:2039–2047 151. Yegutkin GG, Henttinen T, Jalkanen S (2001) Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions. FASEB J 15:251–260 152. Yegutkin GG, Henttinen T, Samburski SS, Spychala J, Jalkanen S (2002) The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem J 367:121–128 153. Fabre AC, Vantourout P, Champagne E, Terce´ F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO (2006) Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y13mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 63:2829–2837 154. Karczewska J, Martyniec L, Dzierzko G, Stepin´ski J, Angielski S (2007) The relationship between constitutive ATP release and its extracellular metabolism in isolated rat kidney glomeruli. J Physiol Pharmacol 58:321–333 155. Burrell HE, Wlodarski B, Foster BJ, Buckley KA, Sharpe GR, Quayle JM, Simpson AWM, Gallagher JA (2005) Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J Biol Chem 280:29667–29676
2 Mechanisms Regulating Airway Nucleotides
47
156. Lazarowski ER, Homolya L, Boucher RC, Harden TK (1997) Identification of an ectonucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem 272:20402–20407 157. Lazarowski ER, Boucher RC, Harden TK (2000) Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 275:31061–31068 158. Donaldson SH, Picher M, Boucher RC (2002) Secreted and cell-associated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces. Am J Respir Cell Mol Biol 26:209–215 159. Picher M, Boucher RC (2003) Human airway ecto-adenylate kinase. A mechanism to propagate ATP signaling on airway surfaces. J Biol Chem 278:11256–11264 160. Conway JD, Bartolotta T, Abdullah LH, Davis CW (2003) Regulation of mucin secretion from human bronchial epithelial cells grown in murine hosted xenografts. Am J Physiol 284: L945–L954 161. Hunsucker SA, Mitchell BS, Spychala J (2005) The 50 -nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 107:1–30 162. Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006) Physiological roles for ecto-50 nucleotidase (CD73). Purinergic Signal 2:351–360 163. Salmi M, Jalkanen S (2005) Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 5:760–761 164. Volmer JB, Thompson LF, Blackburn MR (2006) Ecto-50 -nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 176:4449–4458 165. Gakis C (1996) Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J 9:632–633 166. Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela EI, Lluis C (1997) Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 52:283–294 167. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E (2001) Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev 21:105–128 168. Hershfield M (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35:25–30 169. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C (1996) Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156:1349–1355 170. Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian A, Franco R (1997) HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to CD26. Adv Exp Med Biol 421:185–192 171. Daddona PE, Kelley WN (1980) Analysis of normal and mutant forms of human adenosine deaminase – a review. Mol Cell Biochem 29:91–101 172. Matteucci E, Giampietro O (2009) Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 16:2943–2951 173. Conlon BA, Law WR (2004) Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol 138:14–20 174. Zavialov AV, Engstrom A (2005) Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 391:51–57 175. Tsuboi I, Sagawa K, Shichijo S, Yokoyama MM, Ou DW, Wiederhold MD (1995) Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections. Clin Diagn Lab Immunol 2:626–630 176. Daddona PE, Kelley WN (1981) Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts. Biochim Biophys Acta 658:280–290
48
M. Picher
177. Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G (2010) Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88:279–290 178. Sauter C, Lamanna N, Weiss MA (2008) Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol 4:1217–1222 179. Niedzwicki JG, Abernethy DR (1991) Structure-activity relationship of ligands of human plasma adenosine deaminase2. Biochem Pharmacol 41:1615–1624 180. Iwaki-Egawa S, Namiki C, Watanabe Y (2004) Adenosine deaminase 2 from chicken liver: purification, characterization, and N-terminal amino acid sequence. Comp Biochem Physiol 137:247–254 181. Andreasyan NA, Hairapetyan HL, Sargisova YG, Mardanyan SS (2005) ADA2 isoform of adenosine deaminase from pleural fluid. FEBS Lett 579:643–647 182. Ji XD, Ye F, Lin P, Zhao S (2010) Immobilized capillary adenosine deaminase microreactor for inhibitor screening in natural extracts by capillary electrophoresis. Talanta 82:1170–1174 183. Dilmac A, Ucoluk G, Ugurman F, Gozu A, Akkalyoncu B, Eryilmaz T, Samurkasoglu B (2002) The diagnostic value of adenosine deaminase activity in sputum in pulmonary tuberculosis. Respir Med 96:632–634 184. Akyol O, Gokbulut I, Koksal N, Akin H, Ozyurt H, Yildirim Z (2001) The activities of purine catabolizing enzymes in plasma and bronchial washing fluid in patients with lung cancer and pneumonia. Clin Biochem 34:251–254 185. Kayacan O, Karnak D, Delibalta M, Beder S, Karaca L, Tutkak H (2002) Adenosine deaminase activity in bronchoalveolar lavage in Turkish patients with smear negative pulmonary tuberculosis. Respir Med 96:536–541 186. Albera C, Mabritto I, Ghio P, Solidoro P, Marchetti L, Pozzi E (1993) Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. Sarcoidosis 10:18–25 187. Orphanidou D, Stratakos G, Rasidakis A, Toumbis M, Samara J, Bakakos P, Jordanoglou J (1998) Adenosine deaminase activity and lysozyme levels in bronchoalveolar lavage fluid in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2:147–152 188. Reechaipichitkul W, Lulitanond V, Patjanasoontorn B, Boonsawat W, Phunmanee A (2004) Diagnostic yield of adenosine deaminase in bronchoalveolar lavage. Southeast Asian J Trop Med Public Health 35:730–734 189. Blackburn MR, Kellems RE, Frederick WA (2005) Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 86:1–41 190. Dinjens WN, ten Kate J, van der Linden EP, Wijnen JT, Khan PM, Bosman FT (1989) Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. J Histochem Cytochem 37:1869–1875 191. Dinjens WN, ten Kate J, Wijnen JT, van der Linden EP, Beek CJ, Lenders MH, Khan PM, Bosman FT (1989) Distribution of adenosine deaminase-complexing protein in murine tissues. J Biol Chem 264:19215–19220 192. Ben-Shooshan I, Kessel A, Ben-Tal N, Cohen-Luria R, Parola AH (2002) On the regulatory role of dipeptidyl peptidase IV (CD26-adenosine deaminase complexing protein) on adenosine deaminase activity. Biochim Biophys Acta 1587:21–30 193. Wesley UV, Tiwari S, Houghton AN (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 109:855–866 194. Iwaki-Egawa S, Yamamoto T, Watanabe Y (2006) Human plasma adenosine 2 is secreted by activated monocytes. Biol Chem 387:319–321 195. van Waeg G, van den Berghe G (1991) Purine catabolism in polymorphonuclear neutrophils. Phorbol myristate acetate-induced accumulation of adenosine owing to inactivation of extracellularly released adenosine deaminase. J Clin Invest 87:305–312 196. Martinez-Valdez H, Cohen A (1988) Coordinate regulation of mRNAs encoding adenosine deaminase, purine nucleoside phosphorylase, and terminal deoxynucleotidyltransferase by phorbol esters in human thymocytes. Proc Natl Acad Sci USA 85:6900–6903
2 Mechanisms Regulating Airway Nucleotides
49
197. Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pfl€ ugers Arch Eur J Physiol 447:735–743 198. Gray JH, Owen RP, Giacomini KM (2004) The concentrative nucleoside transporter family, SLC28. Pfl€ugers Arch Eur J Physiol 447:728–734 199. Griffith DA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153–181 200. Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, Casado FJ (2007) Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 63:97–110 201. Molina-Arcas M, Casado FJ, Pastor-Anglada M (2009) Nucleoside transporter proteins. Curr Vasc Pharmacol 7:426–434 202. Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, Wyatt TA (2009) Ethanol blocks adenosine uptake via inhibiting the nucleoside transport system in bronchial epithelial cells. Alcohol Clin Exp Res 33:791–798 203. Kreda SM, Seminario-Vidal L, van Heusden CA, O’Neal W, Jones L, Boucher RC, Lazarowski ER (2010) Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides. J Physiol 588:2255–2267 204. Kishioka C, Okamoto K, Kim J, Rubin BK (2001) Regulation of secretion from mucous and serous cells in the excised ferret trachea. Respir Physiol 126:163–171 205. Pitkanen OM, Smith D, O’Brodovich H, Otulakowski G (2001) Expression of alpha-, beta-, and gamma-hENaC mRNA in the human nasal, bronchial and distal lung epithelium. Am J Respir Crit Care Med 163:273–276 206. Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas JR, Riordan JR, Boucher RC (2005) Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 16:2154–2167 207. Boucher RC (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58:157–170
Chapter 3
Computational Model for the Regulation of Extracellular ATP and Adenosine in Airway Epithelia Guilherme J.M. Garcia, Maryse Picher, Peiying Zuo, Seiko F. Okada, Eduardo R. Lazarowski, Brian Button, Richard C. Boucher, and Tim C. Elston Abstract Extracellular nucleotides are key components of the signaling network regulating airway clearance. They are released by the epithelium into the airway surface liquid (ASL) to stimulate cilia beating activity, mucus secretion and airway hydration. Understanding the factors affecting their availability for purinoceptor activation is an important step toward the development of new therapies for obstructive lung diseases. This chapter presents a mathematical model developed to gain predictive insights into the regulation of ASL nucleotide concentrations on human airway epithelia. The parameters were estimated from experimental data collected on polarized primary cultures of human nasal and bronchial epithelial cells. This model reproduces major experimental observations: (1) the independence of steady-state nucleotide concentrations on ASL height, (2) the impact of selective ectonucleotidase inhibitors on their steady-state ASL concentrations, (3) the changes in ASL composition caused by mechanical stress mimicking normal breathing, (4) and the differences in steady-state concentrations existing between nasal and bronchial epithelia. In addition, this model launched the study of nucleotide release into uncharted territories, which led to the discovery that airway epithelia release, not only ATP, but also ADP and AMP. This study shows that computational modeling, coupled to experimental validation, provides a powerful approach for the identification of key therapeutic targets for the improvement of airway clearance in obstructive respiratory diseases. Keywords Extracellular nucleotide regulation Mathematical model Cystic fibrosis Airway surface liquid volume regulation Signaling pathway
G.J.M. Garcia (*), P. Zuo, and T.C. Elston Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA e-mail:
[email protected];
[email protected];
[email protected] M. Picher, S.F. Okada, E.R. Lazarowski, B. Button, and R.C. Boucher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_3, # Springer Science+Business Media B.V. 2011
51
52
3.1
G.J.M. Garcia et al.
Introduction
The purinergic regulation of mucociliary clearance (MCC) constitutes the first line of defense against airway infection. Adenine nucleotides are released by the epithelium into the airway surface liquid (ASL), where they are rapidly dephosphorylated into adenosine (ADO), and the latter deaminated into inosine (INO) [1]. The continuous release of nucleotides is counterbalanced by the absorption of ADO and INO, which supplies the nucleotide salvage pathway. Within the ASL, ATP and ADO stimulate all major aspects of MCC, namely cilia beating activity [2, 3], mucin secretion [4, 5] and airway hydration [6]. The importance of purinergic signaling for MCC is evident in patients diagnosed with cystic fibrosis (CF), where abnormal water transport across airway epithelia is responsible for the accumulation of dehydrated and infected mucus plugs [6, 7]. This inability to evacuate mucin is caused by functional mutations in the gene encoding the cystic fibrosis transmembrane regulator (CFTR), which limits chloride and water secretion into the ASL to the activity of the calcium-activated chloride channel (CaCC). Since this channel is activated by P2Y2 receptors [6, 7], metabolically-stable agonists were synthesized to stimulate this pathway, such as Denufosol (INS37217), which is currently in Phase III clinical trial (Inspire Pharmaceutical Inc.) (review: [8]). The maintenance of higher ASL concentrations of endogenous ATP is expected to enhance MCC. The potential of this approach was demonstrated using polarized primary cultures of human bronchial epithelial (HBE) cells obtained from CF patients, where ASL height and mucin transport were restored by mechanical stress-induced nucleotide release [9]. The development of a drug capable of reducing ATP metabolism on airway surfaces requires the identification of the predominant enzyme. Our understanding of the dynamic regulation of ATP on airway surfaces has evolved substantially in the last decade. A series of biochemical studies conducted on HBE cultures uncovered a dozen ectonucleotidases and transporters [10–16]. The complexity of this system warranted the development of a comprehensive mathematical model to identify the therapeutic target that would raise the availability of ATP for the P2Y2 receptor-CaCC signaling pathway. Alternatively, the maintenance of higher ASL ADO concentrations could also stimulate airway clearance in diseases where CFTR activity remains functional, such as chronic obstructive pulmonary disease. This chapter describes the mathematical model we developed for the regulation of airway ATP and ADO [1], which is supplemented by original data and simulations. The model provides insights and testable hypotheses expanding our understanding of ASL nucleotide regulation. First, we summarize the experimental data that were used to develop the model. Then, we explain how the model describes the release, metabolism and uptake of adenine nucleotides by airway epithelia. We also explain how the model was validated through comparison with experimental data, and present model predictions that remain to be tested experimentally. Finally, we discuss the physiological significance of these results and the directions for future work.
3 Computational Model for the Regulation of Extracellular ATP
3.2 3.2.1
53
Mathematical Model Experimental Data
A dynamic model for the regulation of adenine nucleotides within the ASL was developed based on experimental evidence acquired on polarized primary cultures of HBE cells [11–16]. Once released into the ASL, ATP is dephosphorylated by a network of ectonucleotidases into ADP, AMP, ADO, and the latter converted into INO (Fig. 3.1) [1]. Finally, ADO and INO are absorbed by the epithelial cells through the concentrative nucleoside transporter CNT3. The model also incorporates the experimental observation that AMP hydrolysis is inhibited by ATP and ADP. The strength of this model resides in the fact that all experimental data were acquired using the same experimental conditions. All experiments were performed in a physiological buffered solution (pH 7.5) at 37 C, and using polarized primary cultures of HBE cells. This consistency is essential because the kinetic parameters describing nucleotide transport and metabolism are affected by multiple factors, including the pH, temperature, cell type and culture conditions. The ectonucleotidases identified experimentally and included in the model are: nucleoside triphosphate diphosphohydrolases (NTPDases), tissue non-specific alkaline phosphatase (TNAP), nucleotide pyrophosphatase/phosphodiesterases (NPPs), ecto 50 - nucleotidase (ecto 50 -NT; CD73), ecto adenylate kinase (ectoAK) and adenosine deaminase 1 (ADA1). The reactions catalyzed by each of these enzymes are described in Table 3.1 and Fig. 3.1. Since these epithelial surfaces express several enzymes supporting the same reactions, the kinetic parameters of
Fig. 3.1 Nucleotide transport and metabolism in the airway surface liquid (ASL) lining human bronchial epithelia. The epithelial cells release ATP, ADP and AMP at the rates JATP , JADP , and JAMP , respectively. They are dephosphorylated by ectonucleotidases into ADO and INO. Then, the cellular uptake of ADO and INO via the transporter CNT3 occurs at the rates jADO and jINO , respectively. The model also accounts for the inhibition of ADO production by ATP and ADP. The reactions catalyzed by each ectonucleotidase (TNAP, NTPDase1 (CD39), NTPDase 3, NPPs, ectoAK, ecto 50 -NT, and ADA1) and their kinetic parameters are described in Table 3.1
54
G.J.M. Garcia et al.
Table 3.1 Kinetic parameters regulating ASL ATP and adenosine Enzyme/ [A] Reaction transporter Parameters Experiment ð1Þ ð1Þ ATP ! ADP + Pi NTPDase 1/ 2.1, 12 Vmax ,KM highTNAP ð2Þ ð2Þ 8.1, 136 NTPDase 3 Vmax ,K lowTNAP ADP ! AMP + Pi
AMP ! ADO + Pi
NTPDase 1/ highTNAP NTPDase3/ lowTNAP Ecto 50 -NT highTNAP lowTNAP Feed forward inhibition Feed forward inhibition
ADO ! INO
ADA1
ATP ! AMP + PPi
E-NPPs
ATP + AMP ! 2ADP EctoAK (forward) ATP + AMP ← 2ADP EctoAK (reverse) ATP release – ADP release AMP release – ADO uptake CNT3 INO uptake
CNT3
M ð3Þ ð3Þ Vmax KM ð4Þ ð4Þ Vmax ,KM
REF. [15]
[B] Simulation 6.3, 16.3
[15]
15.5, 114.9
14.1, 451
[15]
20.0, 418.0
1.4, 5
[15]
0.5, 2.8
ð5Þ
ð5Þ
9.1, 103
[15]
10.7, 83.9
ð6Þ
ð6Þ
1.8, 14
[14]
1.7, 13.0
ð7Þ ð7Þ Vmax ,KM ð8Þ ð8Þ Vmax ,KM ðinÞ KATP
4.2, 36
[14]
6.2, 27.2
9.8, 717
[14]
11.9, 694.9
7
[14]
28.4
10
[14]
20.4
ð9Þ
0.6, 25
[13]
0.3, 17.0
ð10Þ ð10Þ Vmax ,KM ðf Þ ðfÞ ðfÞ Vmax ,KATP ,KAMP
0.9, 22
[11]
1.2, 28.3
3.8, 23, N/A [12]
2.2, 30.4, 24.7 2.2, 61.8
Vmax ,KM Vmax ,KM
ðinÞ
KADP ð9Þ
Vmax ,KM
ðbÞ
ðbÞ
Vmax , KADP
1.8, 43
[12]
(J/V)ATP (J/V)ADP (J/V)AMP
0.0012 – 0.12, 2.2
[10, 17] 0.0011 0.0131 0.0125 [13, 18] 0.2, 1.2
ðu;1Þ
ðu;1Þ
Vmax ,KM
ðu;2Þ ðu;2Þ Vmax ,KM
–
0.2, 1.2
The units of (J/V) and Vmax are nmol/min/ml; the units of Km are mM [A]Experimental values measured in HBE cultures after addition of 100 mM substrate to apical surface [B]Simulation values that best reproduce the steady-state and transient concentrations obtained after addition of 100 micromolar ATP REF references for the experimental data
each ectonucleotidase were determined by monitoring the hydrolysis rate of ATP, ADP, AMP or ADO in the presence of selective non-competitive inhibitors for the remaining enzymes hydrolyzing the same substrate. The following inhibitors were used: azide (NTPDase1, 3), levamisole (TNAP), b,g-methyleneATP (NPPs), concanavalin A (ecto 50 -NT), diadenosine pentaphosphate (Ap5A; ectoAK) and erythro-9-2-hydroxy-3-nonyl adenine (EHNA; ADA1). After the HBE cultures were pre-treated with the inhibitor(s) of interest, the reactions were initiated by nucleotide addition to the apical surface. The kinetic parameters (Michaelis constants KM and maximal velocities Vmax) of each enzyme were determined from data analysis of the initial linear rate of decay of the substrate. The data acquired over a decade of research are summarized in Table 3.1.
3 Computational Model for the Regulation of Extracellular ATP
55
The model parameters were optimized to reproduce the steady-state concentrations [17] and metabolic time-courses generated by the addition of 100 mM ATP to the ASL [15]. Once the model parameters were obtained, simulations were performed to confirm that the steady-state concentration of ATP is independent of ASL volume, as observed experimentally by Okada et al. [10]. Simulations were also performed to test whether known differences in enzyme expression levels [1, 13–16] between nasal and bronchial epithelia could account for the differences in the steady-state nucleotide concentrations between these tissues [16]. In addition, we tested whether the rapid increase in ATP release rate detected in HBE cultures exposed to cyclic compressive stress mimicking normal tidal breathing was quantitatively consistent with the experimental observation of a corresponding sharp increase in ATP steadystate concentration [9]. Finally, simulations were performed to test whether the model predicts accurately the effects of enzyme inhibition on the ASL nucleotide composition [10].
3.2.2
Model Development
In developing the mathematical model, simplifying assumptions were made: l
l
While most ectonucleotidases hydrolyze both adenine and uridine nucleotides, the model was limited to adenine nucleotides due to the relatively small concentrations of the uridine nucleotides in the ASL (UTP concentration ~15% of ATP concentration [18]). Nucleotide concentrations were assumed to be uniform throughout the ASL since their small size allows them to diffuse very rapidly.
The biochemical network of nucleotide release, metabolism and uptake by airway epithelia is illustrated in Fig. 3.1. To model the dynamics of this system, each nucleotide and nucleoside concentration in the ASL is described by a rate equation of the form: d½X ½X dV ¼ release rate uptake rate þ reaction rates ; dt V dt
(3.1)
where [X] is the time-dependent concentration of the nucleotide/nucleoside X, and dV V is the volume of the ASL. The term ½X V dt describes the change in concentration due to changes in ASL volume when water is transported across the epithelium. Equation 3.1 requires expressions for the rates of release, uptake, and enzymatic reactions for each nucleotide/nucleoside. The constitutive rate of ATP release from resting HBE cultures was determined experimentally as 369 92 fmolmin1cm2 [17]. Since the data were obtained over a surface area SA ¼ 1.12 cm2 and ASL volume V ¼ 0.35 ml [15], the constitutive rate of ATP release was expressed as (J/V)ATP ¼ 1.2 pmol min1cm2. When the model was developed, there was no experimental evidence that airway
56
G.J.M. Garcia et al.
epithelia released ADP or AMP into the ASL. However, we allowed for this possibility and assumed that ADP and AMP are released into the ASL at the rates (J/V)ADP and (J/V)AMP. This hypothesis is discussed in detail in the Results and Discussion sections. The hydrolysis rates of ATP, ADP and ADO were assumed to follow MichaelisMenten kinetics: uj ¼
ðjÞ
Vmax ½S ðjÞ
KM þ ½S
;
(3.2) ðjÞ
where the index j refers to the enzymes j ¼ 1 5; 9 10 listed in Table 3.1, Vmax ðjÞ is the maximum reaction velocity, KM is the Michaelis constant and ½S is the ðjÞ
SA ½EðjÞ
ðjÞ T substrate concentration. The maximum velocity is given by VðmaxÞ ¼ Kcat , V ðjÞ where Kcat is the catalytic rate, and ½EðjÞ is the enzyme concentration per surface T area of cell membrane. All enzymatic reactions were assumed to follow this mathematical form, except for the reversible ectoAK reaction and AMP hydrolysis. The reversible ectoAK reaction (ATP þ AMP ! 2ADP) was assumed to follow a Bi Bi mechanism [19]: ðf Þ
uAK ¼
ðbÞ
Vmax K
ðf Þ
K
ðf Þ
K
ðf Þ
K
ðf Þ
ATP AMP ATP AMP 1 þ ½ATP þ ½AMP þ ½ATP½AMP
Vmax ðbÞ 2 : ðbÞ 2KADP KADP 1 þ ½ADP þ ½ADP
(3.3)
This expression is a generalization of Michaelis-Menten kinetics for a reversible reaction and relies on the same underlying assumptions, that substrate concentrations are assumed to be much larger than the enzyme concentration. Experimental evidence indicates that ATP and ADP competitively bind to enzymes hydrolyzing AMP [14]. To model this effect, AMP hydrolysis was described by Michaelis-Menten kinetics accounting for competitive inhibition: uj ¼
ðjÞ KM
ðjÞ
Vmax ½AMP ; ½ATP ½ADP 1 þ ðinÞ þ ðinÞ þ ½AMP KATP
(3.4)
KADP
where the index j now refers to j ¼ 6,7,8 (Table 3.1). While it is possible that the ðinÞ ðinÞ inhibition constants KATP and KADP are specific to each enzyme, their values were assumed identical for all AMP-hydrolyzing enzymes. Finally, the uptake rates of ADO and INO by CNT3 were modeled by expressions which describe the competition of ADO and INO for the same transporter: j ¼ V ADO
ðu;1Þ
KM
ðu;1Þ
Vmax ½ADO ; ½INO 1 þ ðu;2Þ þ ½ADO KM
(3.5)
3 Computational Model for the Regulation of Extracellular ATP
j ¼ V INO
ðu;2Þ
KM
57
ðu;2Þ
Vmax ½INO : ½ADO 1 þ ðu;1Þ þ ½INO
(3.6)
KM
Using the above expressions for the various rates involved in the system, the nucleotide/nucleoside concentrations are governed by the following equations: d½ATP ¼ dt
X J ½ATP dV uAK ui V ATP V dt i¼1;2;3;10
(3.7)
d½ADP ¼ dt
X X J ½ADP dV þ 2uAK þ ui ui V ADP V dt i¼1;2;3 i¼4;5
(3.8)
d½AMP ¼ dt
X X J ½AMP dV þ ui uAK ui V AMP i¼4;5;10 V dt i¼6;7;8
(3.9)
X d½ADO j ½ADO dV þ u i u9 ¼ dt V ADO i¼6;7;8 V dt d½INO j ½INO dV þ u9 ¼ dt V INO V dt
3.2.3
(3.10)
(3.11)
Analytical Solution for Steady-State Concentrations
Under steady-state conditions, the ASL nucleotide/nucleoside concentrations and ASL volume are constant, so that Eqs. 3.7–3.11 become J 0¼ uAK u1 u2 u3 u10 V ATP
(3.12)
J þ 2uAK þ u1 þ u2 þ u3 u4 u5 V ADP
(3.13)
J 0¼ uAK þ u4 þ u5 þ u10 u6 u7 u8 V AMP
(3.14)
0¼
0¼
j þ u6 þ u 7 þ u8 u9 V ADO
(3.15)
58
G.J.M. Garcia et al.
j 0¼ þ u9 V INO
(3.16)
Summing Eqs. 3.12–3.16 yields J J J j j þ þ ¼0 V ATP V ADP V AMP V ADO V INO
at steady state: (3.17)
This result illustrates that, at steady-state, the total amount of nucleotides released into the ASL (JTOTAL ¼ JATP þ JADP þ JAMP ) is equal to the total amount of nucleosides absorbed by the airway epithelium (jTOTAL ¼ jADO þ jINO ). Solving Eqs. 3.12–3.16 analytically is not possible because of the non-linear nature of the reaction rates. However, most of the non-linearities can be eliminated based on the following considerations. First, the experimental data reveal that the steady-state concentrations of all nucleotides and nucleosides are in the nanomolar range [17], while the Michaelis constants and inhibition constants of all enzymes are in the micromolar range (Table 3.1). Therefore, we can assume that KM ½Sss , so that Eqs. 3.2 and 3.4 become: ðjÞ
uj
Vmax ðjÞ
KM
½Sss
at steady state for j ¼ 1 10;
(3.18)
where ½ ss denotes a steady-state concentration. Under the same assumption (KM ½Sss ), at steady-state the ectoAK reaction rate becomes: uAK
ðf Þ
ðbÞ
Vmax
Vmax 2 ½ATPss ½AMP ss 2 ½ADPss : ðf Þ ðf Þ ðbÞ KATP KAMP KADP
(3.19)
This equation is second-order in ½Sss =KM , while the reaction rates for the other enzymes are first-order (see Eq. 3.18). Therefore, in the limit KM ½Sss (i.e., at steady-state), the ectoAK reaction rate is negligible and we assume uAK ¼ 0 in Eqs. 3.12–3.14. Substituting uAK ¼ 0 and the definition ðJ=V ÞTOTAL ¼ ðJ=V ÞATP þ ðJ=V ÞADP þðJ=V ÞAMP into Eqs. 3.12–3.16, we obtain the following solution for ASL nucleotide concentrations at steady-state: ðJ=VÞATP ; HATP 10 V 10 =KM 1 max ðJ=VÞATP þ ðJ=VÞADP HATP ½ATPss ¼
½ADPss ¼
HADP
(3.20)
;
(3.21)
3 Computational Model for the Regulation of Extracellular ATP
59
ðJ=VÞTOTAL ; (3.22) HAMP 6 7 8 4 6 7 8 4 where HAMP ¼ Vmax =KM =KM =KM ¼ Vmax =KM þ Vmax þ Vmax , HADP þ 5 5 1 1 2 2 3 3 10 10 , and HATP ¼ Vmax þ Vmax þ Vmax þ Vmax . Vmax =KM =KM =KM =KM =KM These equations express in mathematical terms the experimental observation [20] that nucleotide steady-state concentrations reflect a balance between nucleotide release (J=V) and hydrolysis (H). Steady-state concentrations are directly proportional to release rates and inversely proportional to hydrolysis rates (Eqs. 3.20–3.22). To obtain the nucleoside concentrations at steady-state, we assume; ðu;2Þ KM ½INOss , so that the formulas for ADO and INO uptake can be simplified as ½AMPss ¼
ðu;1Þ Vmax ½ADOss j ðu;1Þ V ADO K þ ½ADOss M
at steady state:
(3.23)
j V INO
at steady state:
(3.24)
ðu;2Þ
Vmax ½INOss ðu;2Þ
KM
þ
ðu;2Þ
KM
ðu;1Þ KM
½ADOss
ðu;1Þ
Note that we did not assume KM ½ADOss because the experimental data do not support this assumption (Table 3.1 and [17]). Substituting Eqs. 3.23 and 3.24 into Eqs. 3.15 and 3.16, we find that steady-state ADO concentration is the solution to the quadratic equation: ðu;1Þ
ðu;1Þ HADO ½ADO2ss þ ðVmax þ HADO KM ðu;1Þ ðJ=VÞTOTAL KM
ðJ=VÞTOTAL Þ½ADOss
¼ 0;
(3.25)
while INO concentration at steady-state is given by ½INOss ¼ where HADO ¼
3.2.4
9 Vmax 9 KM
HADO ðu;2Þ
ðu;2Þ
Vmax =KM
½ADOss 1 þ
½ADOss ðu;1Þ
KM
! ;
(3.26)
.
Effects of Enzyme Inhibitors on Steady-State Concentrations
This model can predict which ectonucleotidase inhibitor could potentially stimulate MCC by raising the availability of ATP and ADO for P2Y2 and A2B receptor activation, respectively. To illustrate this application, let us examine the effect of
60
G.J.M. Garcia et al.
enzyme inhibitors on ½ATPss . Assuming that enzyme inhibitors do not affect nucleotide release, Eq. 3.20 implies that: ½ATPInhibitor HATP ss ¼ Inhibitor ; ½ATPss HATP
(3.27)
where ½ATPInhibitor is the steady-state ATP concentration in the presence of an ss enzyme inhibitor, ½ATPInhibitor =½ATPss is the fold increase in ATP steady-state ss P j j Inhibitor ¼ Vmax =KM is the sum of concentration caused by the inhibitor, and HATP j
Vmax =KM for the ATP-hydrolyzing enzymes that were not inhibited. This equation predicts that the inhibition of enzymes that do not hydrolyze ATP, such as ecto 50 -NT and ADA1, has no effect on the steady-state concentration of ATP on airway surfaces. In addition, it shows that steady-state ATP concentration increases the most when enzymes with the largest Vmax =KM are inhibited. Similar conclusions are obtained for the effect of enzyme inhibitors on ADP and AMP steady-state concentrations using Eqs. 3.21 and 3.22 . The model can also be used to investigate how the ADO steady-state concentration is affected by inhibiting ADO hydrolysis or ADO uptake. Using Eqs. 3.2, 3.15 and 3.23, the model predicts that inhibiting ADA1 (u9 ¼ 0): ½ADOInhibitor ¼ ss
ðJ=VÞTOTAL ðu;1Þ
Vmax ðu;1Þ KM
ðJ=VÞTOTAL
;
(3.28)
ðu;1Þ
KM
ðu;1Þ
while CNT3 inhibition (Vmax ¼ 0) leads to ¼ ½ADOInhibitor ss
ðJ=VÞTOTAL HADO
ðJ=VÞTOTAL 9 KM
:
(3.29)
We must mention that model simulations in which CNT3 activity is blocked predict that ASL INO concentrations increase without limit. This behavior is a consequence of the simplifications applied to the model, which does not account for the activity of purine nucleoside phosphorylase. This intracellular enzyme is released into the ASL, where it converts INO into hypoxanthine [13, 21, 22]. There are no empirical data available for this enzyme because, contrary to ADA1, it does not associate with the epithelial surface. Consequently, INO concentration within the ASL is not expected to accumulate in vivo when CNT3 activity is inhibited. Finally, it is interesting to note that the analytical solution identifies the enzymes and transporters that regulate the steady-state nucleotide/nucleoside concentrations. For example, Eqs. 3.28 and 3.29 reveal that the steady-state ADO concentration depends only on the total nucleotide release rate [ðJ=VÞTOTAL ] and the kinetic ðu;1Þ ðu;1Þ 9 9 ,KM ) and CNT3 (Vmax ,KM ). In other words, the parameters of ADA1 (Vmax
3 Computational Model for the Regulation of Extracellular ATP
61
Table 3.2 Enzymes and transporters regulating airway purines ATP ADP AMP ADO INO l l l l l ATP release rate l l l l ADP release rate l l l AMP release rate l l CNT3 l l E-NPPs l l NTPDase 1, 3 l l l TNAP l ecto-50 -NT l l ADA 1 ectoAK A bullet (l) identifies the parameters regulating each ASL component Relationships obtained for steady-state conditions and, therefore, may not hold for transient concentrations encountered after mechanical nucleotide release
model predicts that the steady-state ADO concentration is not influenced by TNAP, NTPDase, NPPs and ecto 5-NT. Table 3.2 summarizes which enzymes and transporters regulate the steady-state concentrations of each nucleotide/nucleoside.
3.2.5
Numerical Solution for Transient and Steady-State Concentrations
In addition to the analytical solution, the model equations (3.7)–(3.11) were solved numerically using MATLAB software (Mathworks, Natick, MA). The parameters were fit so the model would reproduce the transient and steady-state nucleotide concentrations observed in vitro [1]. The term [X]V dV/dt in equations (3.7) to (3.11) was assumed zero in the simulations due to the constant (large) volume employed in the experiments.
3.3 3.3.1
Results Numerical Versus Analytical Solution
The mathematical model predicts transient (Fig. 3.2a) and steady-state (Fig. 3.2b) ASL nucleotide concentrations in close agreement with the experimental data. The best-fit kinetic parameters were generally within the range of their experimental counterparts (Table 3.1). The analytical solution was verified by substituting the kinetic parameters, rates of nucleotide release and nucleoside uptake fitted by the model (column [B] in Table 3.1) into Eqs. 3.20–3.26. The steady-state concentrations calculated via the analytical solution were very similar to those obtained via numerical integration (Fig. 3.2b), thus supporting the assumption that at
62
G.J.M. Garcia et al.
Fig. 3.2 Comparison of model predictions to experimental data. (a) Transient purine concentrations predicted by the model (lines) and measured experimentally (symbols; N ¼ 5) after addition of 100 mM ATP to HBE cultures. (b) Steady-state concentrations were measured experimentally (filled bars: N ¼ 6; S.E.) and predicted either by numerical simulation (gray bars) or analytical solution (empty bars) of the model. The experimental data are from previous publications by our group [15, 17]. The kinetic parameters were obtained by fitting the model predictions to the experimental data in (a) and (b)
steady-state, all enzymes operate in the linear range of Michaelis-Menten kinetics (Eq. 3.18), and the bi-directional reaction of ectoAK does not affect significantly the steady-state concentrations (Eq. 3.19).
3.3.2
Release of ADP and AMP by Airway Epithelia
At steady-state, the amount of nucleotides (ATP, ADP and AMP) released into the ASL is equal to the amount of nucleosides (ADO and INO) taken up by the cells (Eq. 3.17). The constitutive rate of ATP release has been measured experimentally as 1.2 pmolmin1ml1 [17], while the constitutive rate of ADO uptake has been measured as 8.5 pmolmin1ml1 in HBE cultures [1, 17]. In other words, the experimental data suggest that bronchial epithelia absorb ADO at a rate nearly seven times faster than it releases ATP. Since the rate of nucleoside absorption must balance the rate of nucleotide release at steady-state, we concluded that airway epithelia must also release ADP and AMP to account for all the ADO taken up by epithelial cells under resting conditions. The rates of ADP and AMP release were estimated by two different approaches. The data fitting procedure yield ðJ=VÞADP ¼ 13.1 pmolmin1ml1 and ðJ=VÞAMP ¼ 12.5 pmolmin1ml1 (Table 3.1, column [B]). Alternatively, the experimental steady-state concentrations (½ADPss ¼ 39 nM and ½AMPss ¼ 70 nM [17]) and kinetic parameters (Table 3.1, column [A]) were used in Eqs. 3.21–3.22 to predict ðJ=VÞADP ¼ 13.2 pmolmin1ml1 and ðJ=VÞAMP ¼ 3.8 pmolmin1ml1. These two approaches yielded different results because the model parameters that best reproduced the transient (Fig. 3.2a) and steady-state profiles generated by the
3 Computational Model for the Regulation of Extracellular ATP
63
addition of 100 mM ATP on the apical surface (Fig. 3.2b) somewhat differ from the experimental data (compare columns [A] and [B] in Table 3.1). However, for both approaches, the model predicts that airway epithelia release more ADP and AMP than ATP. Using the rates calculated by the second approach, the ratios of ADP and AMP release to ATP release are 11:1 and 3:1, respectively. Alternatively, the data fitting of the transient and steady-state concentrations without assuming ADP and AMP release predicts the ATP release rate to be ~12fold higher than its experimental value [1]. Because similar experimental values of JATP have been reported by various investigators using different techniques [9, 10, 17], we can rule out experimental error as the source of the discrepancy. Therefore, the model predicts that airway epithelia release, not only ATP, but also ADP and AMP. This finding is an important example of the strength of the model, and illustrates how it can be used to guide future research.
3.3.3
Analysis of Steady-State Nucleotide Concentrations
3.3.3.1
Volume-Independence of Steady-State Concentrations
The model identified an important property of airway nucleotide regulation, namely that steady-state concentrations are independent of the ASL volume (V). This prediction follows from the fact that the reaction rates (uj ), nucleotide release rates [ðJ=VÞATP ,ðJ=VÞADP ,ðJ=VÞAMP ] and nucleoside uptake rates [ðj=VÞADO , ðj=VÞINO ] are all inversely proportional to V. Therefore, at steady-state, Eqs. 3.12–3.16 become independent of ASL volume (For the dependence of the reactions rates uj on V, see Eq. 3.2 ). This prediction was validated experimentally on the HBE cultures by measuring steady-state ATP concentrations for a range of ASL volumes (25–500 ml) (Fig. 3.3). This finding is significant for our understanding of ASL volume regulation in the airways of CF patients, where the defective
Fig. 3.3 Volumeindependence of the steadystate ASL ATP concentration. Experimental measurements obtained using soluble luciferase (open squares) or cell-attached Staphylococcus aureus protein A-luciferase (solid squares) on HBE cultures after the addition of 25–500 ml of phosphate-buffered saline (N ¼ 5; S.E.)
64
G.J.M. Garcia et al.
CFTR channel activity maintains the ASL at ~30% of normal volume [6, 7]. The volume independence of steady-state concentrations predicts that ASL dehydration in CF does not concentrate, i.e., does not increase the availability of ADO and ATP for A2B and P2Y2 receptor-mediated mucus clearance.
3.3.3.2
Bronchial Epithelium
The steady-state concentrations of extracellular nucleotide/nucleosides on airway surfaces are dictated by the enzymes’ kinetic parameters, the rates of nucleotide release and nucleoside uptake, as expressed by Eqs. 3.20–3.26. Currently, the steady-state concentrations of ADP, AMP and ADO can not be calculated directly from experimental kinetic parameters because measurements for the release rates of ADP and AMP are not available. In contrast, the steady-state ATP concentration can be determined directly from the experimental kinetic parameters reported in Table 3.1 and their experimental errors [10, 11, 15]. Equation 3.20 predicts that the steady-state concentration of ATP within the ASL of HBE cultures is ½ATPss ¼ 3.6 3.0 nM. This prediction is in close agreement with the experimental value of 2.2 3.0 nM.
3.3.3.3
Nasal Epithelium
A complete set of kinetic parameters, as provided in Table 3.1 for HBE surfaces, is not currently available for human nasal epithelial (HNE) cells. Nonetheless, the available data reveal interesting differences between nasal and bronchial epithelia. In comparison to HBE surfaces, l l l l
ATP and ADP hydrolysis rates are ~1.7 times lower on nasal epithelia [15, 16]; AMP hydrolysis rate is ~2.0 times lower on nasal epithelia [14]; ADO hydrolysis rate is similar on nasal and bronchial surfaces [1, 13]; The rate of ADO uptake is faster in nasal (17.3 0.6 mM), than on bronchial (7.2 0.6 nmolmin1cm2), epithelia [13].
A reasonable assumption is that the Michaelis constants for the enzymatic reactions are independent of the cell type, and thus the values reported for HBE cultures also apply to HNE cultures. In contrast, the expression levels of the enzymes and transporters vary widely between cell types, so that different Vmax values are expected for HNE and HBE cultures. Assuming that all ectonucleotidases hydrolyzing a given substrate are affected in the same proportion, the lower hydrolysis ðjÞ ðjÞ rates measured on nasal cultures suggest that ðVmax ÞBronchial = ðVmax ÞNasal ~ 1.7 for ðjÞ Bronchial ðjÞ Nasal = ðVmax Þ ~ 2 for j ¼ 6 8. j ¼ 1 5; 10 and ðVmax Þ When making the appropriate changes in Eqs. 3.20–3.26 based on the above considerations, the model predicts that the steady-state concentrations of ATP, ADP, and AMP are two times higher on HNE surfaces, but ADO concentration is
3 Computational Model for the Regulation of Extracellular ATP
65
Fig. 3.4 Steady-state concentrations of purines in human bronchial epithelial (HBE) and human nasal epithelial (HNE) cultures. Model predictions of higher ATP, ADP and AMP concentrations on nasal epithelia (due to slower nucleotide metabolism on HNE culture; grey bar) are in agreement with the experimental data (black bar). Similarly, the model prediction of lower ADO concentration on nasal epithelia (due to faster ADO uptake by HNE cells; white bar) is in agreement with the experimental data (red bar). The experimental data were taken from a previous publication by our group [17]
ten times lower, than on bronchial epithelia. These predictions are in close agreement with experimental measurements of steady-state concentrations in the ASL of HNE cultures (Fig. 3.4). The higher steady-state nucleotide concentrations are explained by the lower hydrolysis rates. In contrast, the lower ADO concentration is explained by the higher rate of ADO uptake, resulting from the presence of an additional transporter in the apical membrane of nasal epithelia: CNT2 [13]. Physiologically, such low ADO concentration would support a weak baseline efficiency of fluid secretion by A2BR-CFTR signaling on nasal surfaces, compared to bronchial surfaces. On the other hand, the relatively high ATP levels suggest a more predominant role for P2Y2R-CaCC signaling in the nasal passages. To predict steady-state concentrations on HNE surfaces, we assumed equivalent nucleotide release rates (JATP , JADP , JAMP ) for HNE and HBE cultures. Although no data are currently available for JADP and JAMP , the ATP release rate Nasal of HNE cultures has been reported as JATP ¼ 67 34 fmolmin1ml1[18], Bronchial ¼ 369 92 which is six times lower than for HBE cultures (JATP 1 1 fmolmin ml ). However, the close agreement between the predictions of the Nasal Bronchial Nasal Bronchial ¼ JATP , JADP ¼ JADP , and mathematical model assuming JATP Nasal Bronchial JAMP ¼ JAMP , and the experimental steady-state concentrations in HNE cultures (Fig. 3.4), suggests that nucleotide release rates are similar in HNE and HBE Nasal Bronchial is smaller than JATP , cultures. Indeed, although the experimental value of JATP the experimental evidence to support this difference is insufficient because these measurements were performed under different experimental conditions. Due to Nasal the inherent variability in culture preparations, one must compare JATP and Bronchial using the same protocol and culture type to obtain a reliable comparison, JATP as was done for the differences in enzyme reaction rates [1, 13–16]. In addition, while the ATP release rate of HBE cultures has been confirmed by other
66
G.J.M. Garcia et al.
Bronchial Bronchial investigators (JATP ¼ 227 28 fmolmin1ml1 [10]; JATP ¼ 323 1 1 146 fmolmin ml [9]), the ATP release rate of HNE cells was reported in only one study [18].
3.3.3.4
Effects of Rhythmic Breathing
Rhythmic breathing applies compressive and shear stresses on the airway walls, which stimulate epithelial ATP release and ATP-mediated airway clearance [9, 23]. Cyclic compressive stress (CCS; 20 cmH2O; 20 cycles/min) mimicking normal rhythmic breathing has been shown to restore ASL volume and mucus transport on the dehydrated airway surfaces of HBE cultures from CF patients [9]. These cultures responded to CCS by an 8.6-fold increase in the rate of ATP release. As expressed by Eq. 3.20, and verified by numerical simulation, the model predicts that ½ATPss is directly proportional to JATP at steady-state. Thus, the model predicts that ½ATPss increases by 9.3-fold under CCS, which is in close agreement with the experimental value.
3.3.4
Effects of Enzyme Inhibition
Model simulations were conducted to predict the impact of enzyme inhibitors on the steady-state ASL nucleotide/nucleoside concentrations of HBE cultures using four different scenarios: (A) ectoAK inhibition, (B) inhibition of ATP and ADP hydrolysis, (C) inhibition of AMP hydrolysis, and (D) inhibition of ADO hydrolysis and uptake.
3.3.4.1
Inhibition of Ecto-Adenylate kinase
The analytical analyzes suggest that ectoAK does not influence the steady-state concentrations (Sect. 3.2.4). Numerical solution of the full model confirmed the validity of the approximate expressions (Fig. 3.5a), thus supporting the hypothesis that ectoAK activity is negligible at steady-state. Consistent with this prediction, the ectoAK inhibitor, Ap5A, had only a minor effect on nucleotide levels at steadystate (Fig. 3.5a). To understand the role of ectoAK in the regulation of airway nucleotides, we investigated how ectoAK inhibition affects the metabolism of 100 mM ATP on the apical surface of HBE cultures. The model simulations and experiments were in agreement, as ectoAK inhibition had almost no impact on the transient nucleotide profiles under control conditions (Fig. 3.6a). The impact of ectoAK on ATP metabolism became visible when the cultures were pre-treated with inhibitors of the high-capacity enzymes, TNAP and NTPDase3. As predicted by Eq. 3.19, once ADP concentration became higher than the sum of ATP and AMP concentrations,
3 Computational Model for the Regulation of Extracellular ATP
67
Fig. 3.5 Effects of enzyme inhibition on the steady-state purine concentrations. (a) Impact of ectoAK inhibition. Experimental validation by comparing ASL nucleotide levels before/after incubating HBE cultures with an ectoAK inhibitor (0.5 mM Ap5A; N ¼ 5; SEM). (b) Impact of blocking the high-affinity (NTPDase1, NPPs, highTNAP) or low-affinity (NTPDase3, lowTNAP) ectonucleotidases. Experimental validation by comparing ASL nucleotide levels before/ after incubating HBE cultures with the low-affinity inhibitor cocktail (10 mM levamisole + 10 mM NF-279; n ¼ 5; S.E.). (c) Impact of blocking TNAP or ecto 50 -NT. Experimental data obtained by measuring nucleotide levels before/after incubating cultures with the 10 mM levamisole and 5 mM concanavalin A, respectively (N ¼ 5, P < 0.05). (d) Impact of inhibiting ADO hydrolysis (via ADA1) or ADO uptake (via CNT3). These results await experimental validation
the absence of ectoAK activity accelerated the sequential dephosphorylation of ATP into ADO (Fig. 3.6b). Following ATP release onto airway surfaces, the role of ectoAK would be to prolong P2Y2 receptor activation, and to delay A2B receptormediated responses, by the reaction 2ADP ↔ ATP + AMP.
3.3.4.2
Inhibition of ATP and ADP Hydrolysis
Several ectonucleotidases (NTPDase1, NTPDase3, TNAP, NPPs and ectoAK) have been shown to hydrolyze ATP and/or ADP [12, 16, 24]. Since their Michaelis constants vary from 5 to 717 mM (Table 3.1), we hypothesized that some enzymes regulate physiological nucleotide concentrations (<0.1 mM), while others regulate higher levels reached during tissue injury (0.1–1 mM) or aerosolization of exogenous
68
G.J.M. Garcia et al.
Fig. 3.6 Impact of ectoAK inhibition on the purine concentration profile generated by the addition of 100 mM ATP to HBE cultures. (a) Model simulations (lines) and experimental validation using cultures pre-treated with vehicle control (closed symbols) or an ectoAK inhibitor (0.5 mM Ap5A; open symbols). (b) Impact of blocking ectoAK after having blocked the low-affinity enzymes (lowTNAP and NTPDase 3). Model simulations (lines) and experimental validation on cultures pre-treated with the low-affinity inhibitor cocktail (10 mM levamisole + 10 mM NF-279) without (closed symbols) or with (open symbols) the ectoAK inhibitor (N ¼ 6; SEM < 10% of mean)
nucleotides (1–100 mM) for therapeutic purposes [17, 25–27]. Therefore, the ectonucleotidases expressed on the apical surface of airway epithelia were classified into two groups: (1) low-affinity high-capacity (KM > 50 mM; NTPDase3, lowTNAP) and (2) high-affinity low-capacity (KM < 50 mM; NTPDase1, NPPs, highTNAP and ectoAK). Because the inhibitor levamisole does not distinguish the two catalytic sites of TNAP, both catalytic sites (lowTNAP and highTNAP) were blocked in the model when reproducing the effect of this inhibitor. In agreement with our hypothesis regarding the roles of the low- and highaffinity enzymes, steady-state ATP concentrations were more affected by inhibition of the high-affinity enzyme group (Fig. 3.5b). Although validation of the highaffinity block awaits identification of non-competitive inhibitors for NTPDase1 and NPPs, simulation results for the low-affinity group were validated experimentally (Fig. 3.6b). As expected, the steady-state ADO concentration was not affected by inhibition of either the high- or the low-affinity group (Fig. 3.5b) because none of these enzymes hydrolyze ADO (Table 3.2). To further illustrate that low- and high-affinity enzymes regulate different ranges of nucleotide concentration, we isolated the contributions of lowTNAP and highTNAP to ATP hydrolysis. The simulations showed that lowTNAP dominates during the hydrolysis of 100 mM ATP (Fig. 3.7a), while highTNAP dominates during the hydrolysis of 1 mM ATP (Fig. 3.7b). Experimental validation of these predictions is currently not possible because the catalytic activity of lowTNAP and highTNAP cannot be blocked separately with available inhibitors. However, simultaneous inhibition of low/highTNAP was validated using 10 mM levamisole (Fig. 3.7a, b). These data illustrate how the model can be used to advance our understanding of ASL nucleotide regulation by probing the biochemical network in ways that are not currently available experimentally.
3 Computational Model for the Regulation of Extracellular ATP
69
Fig. 3.7 Contribution of lowTNAP and highTNAP to ATP hydrolysis. Simulations comparing the hydrolysis rates of (a) 100 mM ATP and (b) 1 mM ATP under control conditions (solid black line) after blocking highTNAP (solid red line), after blocking lowTNAP (solid blue line), or after blocking both high/lowTNAP (dashed blue line). Validation conducted on HBE cultures for control conditions (l) and high/lowTNAP inhibition by 10 mM levamisole (□). T1/2 is the halflife of ATP
3.3.4.3
Inhibition of AMP Hydrolysis
We also examined the effects of inhibiting AMP hydrolysis on the ASL composition. The model predicts that TNAP inhibition raises ATP, ADP and AMP concentrations by 1.6-, 1.9- and 2.9-fold, respectively (Fig. 3.5c). This inverse relationship between TNAP activity and the degree of phosphorylation of the substrate was closely reproduced experimentally by levamisole on HBE cultures (Fig. 3.5c). Model simulations of ecto 50 -NT inhibition only increased AMP concentration, in agreement with this enzyme’s substrate specificity [14]. This prediction was reproduced experimentally by exposing HBE cultures to the selective inhibitor concanavalin A (Fig. 3.5c). In contrast to the 1.5-fold increase in AMP concentration predicted by the model, AMP concentration increased 4.3-fold in the presence of concanavalin A. In contrast, inhibiting ecto 50 -NT or TNAP did not influence the steady-state concentration of ADO, in either the model or the experiments (Table 3.2, Fig. 3.5c). These data demonstrate that one of these enzymes is sufficient to maintain steady-state ADO concentrations.
3.3.4.4
Inhibition of ADO Hydrolysis and ADO Uptake
Model simulations predict that nucleotide concentrations on bronchial epithelial surfaces are not affected by the mechanisms mediating ADO elimination, namely ADA1 and CNT3 (Fig. 3.5d, Table 3.2). Likewise, blocking the hydrolysis by ADA1 is expected to raise ADO concentration by only 1.1-fold. In contrast, blocking ADO uptake via CNT3 would raise the steady-state ADO concentration by tenfold (Fig. 3.5d). The impact of CNT3 inhibition predicted by the model must be interpreted with caution because this result relies on kinetic parameters for CNT3 and
70
G.J.M. Garcia et al.
ADA1 estimated by the model, which are considerably different from experimental values (Table 3.1). Model simulations were also conducted using the experimental kinetic parameters of CNT3 and ADA1, and the best estimates for the remaining parameters. Under these conditions, the model predicts fivefold and twofold increases in ½ADOss after CNT3 and ADA1 inhibition, respectively.
3.4
Discussion
This study presents the first mathematical model of extracellular nucleotide and nucleoside regulation in airway epithelia [1]. Based on experimental data accumulated over a decade of research [12, 13, 19, 24, 26, 27], the model describes all known factors regulating nucleotide/nucleoside concentrations in the ASL, namely (a) constitutive ATP release, (b) the conversion of ATP into ADP, AMP and ADO by ectonucleotidases, (c) the elimination of ADO by deamination and cellular uptake, (d) the transphosphorylating activity of ectoAK, and (e) the inhibition of ADO production by ATP and ADP. The model closely reproduces both transient and steady-state concentrations generated on the apical surface of HBE cultures following the addition of 100 mM ATP (Fig. 3.2). The model also reproduces several other experimental observations, including the volume-independence of the steady-state concentrations (Fig. 3.3), the differences in steady-state concentrations between nasal and bronchial epithelia (Fig. 3.4), the 8.6-fold increase in steady-state ATP concentration under mechanical stress mimicking breathing, and the different roles played by low-affinity and high-affinity enzymes (Figs. 3.5b and 3.7). In addition to being consistent with these in vitro observations, the mathematical model provides insightful predictions. First, the model predicted that airway epithelia release ADP and AMP before this phenomenon was demonstrated experimentally. As expressed by Eq. 3.17, the total nucleotide release rate must balance the total nucleoside absorption rate at steady-state. The experimental data initially available suggested that the rate of ADO absorption is nearly sevenfold higher than the rate of ATP release in HBE cells at steady-state. Therefore, we concluded that, in addition to ATP release, there had to be other sources of extracellular ADO. The assumption of ADP and AMP release not only provided an alternative source of extracellular ADO, but also explained the high ADP:ATP and AMP:ATP ratios observed at steady-state (Fig. 3.2b), which were not captured by the model when ATP release was the single source of extracellular nucleotides [1]. This experimental discrepancy motivated efforts to test the possibility of ADP and AMP release from human airway epithelia. Recent advances in our understanding of exocytosis support the notion that nucleotides, other than ATP, are released by a variety of cell types [3, 28–30], including HBE cells [31]. These studies have shown that during maturation, vesicles accumulate ATP, ADP and AMP, which are released by exocytosis. The accumulation of ATP, ADP and AMP into mucin granules was recently demonstrated in the Calu-3 human airway epithelial cell line [32]. The granule composition is also in agreement with the model predictions, as ADP
3 Computational Model for the Regulation of Extracellular ATP
71
and AMP concentrations were nearly tenfold higher than ATP concentrations. This case highlights the benefits of a close collaboration between clinicians, biologists and mathematicians for the advance of medical research. A second important application for this model is the identification of enzyme and transporter inhibitors capable of raising ATP and ADO availability for P2Y2R- and A2BR-mediated airway clearance. The steady-state concentration of ATP increased 4.6-fold when high-affinity enzymes (NTPDase1, NPPs, highTNAP and ectoAK) were inhibited, while steady-state ADO concentration increased tenfold when cellular uptake via CNT3 was inhibited. Both predictions await experimental validation. These results are important in light of recent studies showing that extracellular nucleotide metabolism is accelerated in the ASL of patients with cystic fibrosis, chronic obstructive pulmonary disease and primary ciliary dyskinesia [16]. This metabolic aberrance may compromise the P2Y2 receptor-mediated clearance mechanisms while promoting the deleterious effects of chronically-elevated airway ADO (see Chaps. 8 and 9 for details). In the near future, the aerosolized delivery of enzyme inhibitors could be used as a strategy to improve clearance, while resolving all issues associated with excess ADO, in airway diseases. Some limitations of this work must be acknowledged. First, although the general behavior of the model is not affected by small changes in parameter values, the parameter set that provides the best fit to the experimental data (Table 3.1 column [B]) may vary slightly if a different parameter estimation algorithm is used. Therefore, the parameters listed in Table 3.1 should be viewed as a set of parameters capable of reproducing the experimental data, rather than each individual parameter being precisely correct. Currently, we are applying an ensemble method for parameter estimation [33] to determine to what extent each model parameter is constrained by the data. A second limitation that must be acknowledged is that the biochemical network assumed in the model (Fig. 3.1) may be incomplete. Although the model incorporates all known mechanisms controlling ASL nucleotide concentrations, the inclusion of other ectoenzymes, membrane transporters, or chemical reactions may affect some of our quantitative predictions. However, the close agreement between the model predictions and experimental data is strong evidence for the validity of the model. Extracellular ATP and ADO are important signaling molecules in other organs and tissues, including the heart and kidneys [25, 34–36]. For several decades, ADO transport and metabolism has been studied in heart physiology because of the ability of ADO to control heart rate and coronary blood flow [36–38]. Comprehensive mathematical models have been developed to describe ADO transport and metabolism in heart tissues [38–41]. These models played a crucial role in the discovery that, although ADO controls coronary blood flow during ischemia, a different (so far unknown) molecule controls coronary blood flow during exercise [36, 42]. There are several similarities between these models and the model presented herein, such as extracellular ADO production via ectoenzymes, and ADO uptake via membrane transporters. On the other hand, the heart model accounts for the multiple compartments regulating ADO, namely the cardiomyocytes, endothelium, extracellular space and capillaries, as well as blood flow through a capillary
72
G.J.M. Garcia et al.
network [38–41]. In addition, most heart physiology models do not identify the source of extracellular AMP, which is described in our model as resulting from nucleotide release and hydrolysis by ectoenzymes (Fig. 3.1). Despite these differences, it is likely that mathematical models for nucleotide transport and metabolism in the lungs will benefit from models developed for the heart (and vice-versa) because several ectoenzymes found on HBE surfaces are also present in the myocardium [37].
3.5
Conclusion
A mathematical model was presented for the regulation of two signaling molecules essential for airway defenses: extracellular ATP and ADO. The equations capture the complex behavior of nucleotide release, hydrolysis by ectoenzymes, and ADO uptake by membrane transporters. They reproduce several major in vitro observations, including the steady-state nucleotide concentrations, the effects of cyclic stress mimicking tidal breathing, the effects of enzyme inhibitors, and the differences between bronchial and nasal epithelia. In addition, the model made three insightful predictions: (1) airway epithelia release ADP and AMP, (2) the most significant increase in steady-state ATP concentration is obtained by inhibition of the high-affinity enzymes (NTPDase1, NPPs, highTNAP and ectoAK), and (3) the most significant increase in steady-state ADO concentration is obtained by inhibition of the membrane transporter CNT3. While the first one has, since, been demonstrated experimentally [32], the others await validation. In a near future, this mathematical model will be adapted to predict the regulation of ASL nucleotides in chronic airway diseases, such as cystic fibrosis, with the objective of identifying novel therapeutic strategies. Additionally, we are developing a model of ASL volume regulation by coupling ion channel activity to the stimulation of membrane receptors. We anticipate that mathematical modeling will continue to improve our understanding of the signaling network that regulates MCC under normal and pathological conditions, and to guide the development of effective treatments for lung diseases.
References 1. Zuo P, Picher M, Okada SF, Lazarowski ER, Button B, Boucher RC, Elston TC (2008) Mathematical model of nucleotide regulation on airway epithelia: implications for airway homeostasis. J Biol Chem 283:26805–26819 2. Davis WC (2008) Regulation of mucin secretion from in vitro cellular models. In: Chadwick DJ, Goode JA (eds) Mucus hypersecretion in respiratory diseases. John Wiley & Sons, Chichester, UK, pp 113–125 3. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM (2006) Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 34:527–536
3 Computational Model for the Regulation of Extracellular ATP
73
4. Donaldson SH, Boucher RC (1998) Therapeutic applications for nucleotides in lung disease. In: Turner JT, Wiesman GA, Fedan JS (eds) The P2 nucleotide receptors. Humana Press, Totowa, pp 413–424 5. Marcet B, Boeynaems JM (2006) Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis. Pharmacol Ther 112:719–732 6. Boucher RC (2007) Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 13:231–240 7. Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261:5–16 8. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L (2008) Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulm Pharmacol Ther 21:600–607 9. Button B, Picher M, Boucher RC (2007) Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol 580:577–592 10. Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, Boucher RC (2006) Physiological regulation of ATP release at the apical surface of human airway epithelia. J Biol Chem 281:22992–23002 11. Picher M, Boucher RC (2000) Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:255–261 12. Picher M, Boucher RC (2003) Human airway ecto-adenylate kinase. A mechanism to propagate ATP signaling on airway surfaces. J Biol Chem 278:11256–11264 13. Hirsh AJ, Stonebraker JR, van Heusden CA, Lazarowski ER, Boucher RC, Picher M (2007) Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases. Biochemistry 46:10373–10383 14. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC (2003) Ecto 5’-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468–13479 15. Picher M, Boucher RC (2001) Metabolism of extracellular nucleotides in human airways by a multienzyme system. Drug Dev Res 52:66–75 16. Picher M, Burch LH, Boucher RC (2004) Metabolism of P2 receptor agonists in human airways: implications for mucociliary clearance and cystic fibrosis. J Biol Chem 279:20234–20241 17. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S, Boucher RC (2004) Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 279:36855–36864 18. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ, Boucher RC (2000) Basal nucleotide levels, release, and metabolism in normal and cystic fibrosis airways. Mol Med 6:969–982 19. Valero E, Varon R, Garcia-Carmona F (2006) A kinetic study of a ternary cycle between adenine nucleotides. FEBS J 273:3598–3613 20. Lazarowski ER, Boucher RC, Harden TK (2000) Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 275:31061–31068 21. Bzowska A, Kulikowska E, Shugar D (2000) Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 88:349–425 22. Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, Higashino K, Hada T (2000) Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 60:34–40 23. Tarran R, Button B, Boucher RC (2006) Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol 68:543–561
74
G.J.M. Garcia et al.
24. Burch L, Picher M (2006) E-NTPDases in human airways: regulation and relevance for chronic lung diseases. Purinergic Signal 2:399–408 25. Schwiebert EM, Zsembery A (2003) Extracellular ATP as a signaling molecule for epithelial cells. Biochim Biophys Acta 1615:7–32 26. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR (1996) Effect of uridine 50 -triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 153:1796–1801 27. Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, Kharitonov SA (2005) Effects of aerosolized adenosine 50 -triphosphate vs adenosine 50 -monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 128:1905–1909 28. Knight GE, Bodin P, De Groat WC, Burnstock G (2002) ATP is released from guinea pig ureter epithelium on distension. Am J Physiol 282:F281–288 29. Hirschberg CB, Robbins PW, Abeijon C (1998) Transporters of nucleotide sugars, ATP, and nucleotide sulfate in the endoplasmic reticulum and Golgi apparatus. Annu Rev Biochem 67:49–69 30. Bodin P, Burnstock G (2001) Evidence that release of adenosine triphosphate from endothelial cells during increased shear stress is vesicular. J Cardiovasc Pharmacol 38:900–908 31. Kreda SM, Okada SF, van Heusden CA, O’Neal W, Gabriel S, Abdullah L, Davis CW, Boucher RC, Lazarowski ER (2007) Coordinated release of rime;nucleotides and mucin from human airway epithelial Calu-3 cells. J Physiol 584:245–259 32. Kreda SM, Seminario-Vidal L, van Heusden CA, O’Neal W, Jones L, Boucher RC, Lazarowski ER (2010) Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides. J Physiol 588:2255–2267 33. Battogtokh D, Asch DK, Case ME, Arnold J, Schuttler HB (2002) An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of Neurospora crassa. Proc Natl Acad Sci USA 99:16904–16909 34. Jackson EK, Raghvendra DK (2004) The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu Rev Physiol 66:571–599 35. Paradiso AM, Mason SJ, Lazarowski ER, Boucher RC (1995) Membrane-restricted regulation of Ca2+ release and influx in polarized epithelia. Nature 377:643–646 36. Feigl EO (2004) Berne’s adenosine hypothesis of coronary blood flow control. Am J Physiol 287:H1891–1894 37. Fleetwood G, Coade SB, Gordon JL, Pearson JD (1989) Kinetics of adenine nucleotide catabolism in coronary circulation of rats. Am J Physiol 256:H1565–1572 38. Deussen A (2000) Quantitative integration of different sites of adenosine metabolism in the heart. Ann Biomed Eng 28:877–883 39. Kroll K, Deussen A, Sweet IR (1992) Comprehensive model of transport and metabolism of adenosine and S-adenosylhomocysteine in the guinea pig heart. Circ Res 71:590–604 40. Bassingthwaighte JB, Raymond GM, Ploger JD, Schwartz LM, Bukowski TR (2006) GENTEX, a general multiscale model for in vivo tissue exchanges and intraorgan metabolism. Philos Trans A Math Phys Eng Sci 364:1423–1442 41. Gordon EL, Pearson JD, Slakey LL (1986) The hydrolysis of extracellular adenine nucleotides by cultured endothelial cells from pig aorta. Feed-forward inhibition of adenosine production at the cell surface. J Biol Chem 261:15496–15507 42. Tune JD, Richmond KN, Gorman MW, Olsson RA, Feigl EO (2000) Adenosine is not responsible for local metabolic control of coronary blood flow in dogs during exercise. Am J Physiol 278:H74–84
Chapter 4
Regulation of Airway Nucleotides in Chronic Lung Diseases Charles R. Esther Jr., Neil E. Alexis, and Maryse Picher
Abstract The physiological relevance of the purinergic signaling network for airway defenses is emerging through cumulating reports of abnormal ATP and adenosine (ADO) levels in the airway secretions of patients with asthma, chronic pulmonary obstructive diseases, cystic fibrosis and idiopathic pulmonary fibrosis. The consequences for airway defenses range from abnormal clearance responses to the destruction of lung tissue by excessive inflammation. This chapter reviews the challenges of assessing airway purines in human subjects, and identifies the general trend in aberrant airway composition. Most diseases are associated with an accumulation of ATP and/or ADO in bronchoalveolar lavage, sputum or exhaled breadth condensate. Intriguing is the case of cystic fibrosis patients, which do not accumulate airway ADO, but its precursor, AMP. This observation launched the investigation of ectonucleotidases as target proteins for the correction of airway purine levels in chronic respiratory diseases. This chapter exposes the extensive rearrangement of the enzymatic network taking place in diseased airways, and identifies signaling pathways likely involved in the aberrant regulation of the airway purines. Keywords Bronchoalveolar lavage Sputum Exhaled breath condensate CD39 CD73
C.R. Esther Jr. (*) Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC 27599, USA e-mail:
[email protected] N.E. Alexis Center for Environmental Medicine, University of North Carolina, Chapel Hill, NC 27599, USA e-mail:
[email protected] M. Picher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_4, # Springer Science+Business Media B.V. 2011
75
76
4.1 4.1.1
C.R. Esther Jr. et al.
Introduction Definitions
The previous chapters identified the elements mediating purinergic signaling in the respiratory system, namely the signaling molecules (ATP, ADO), the cell surface receptors mediating their responses (P1 and P2) and the ectonucleotidases responsible for the termination of P2 (ATP) signals and initiation of P1 (ADO) signals. This chapter exposes the readers to the extensive modifications in purinergic signaling experienced by patients diagnosed with chronic respiratory diseases. A critical analysis of the different collection methods for airway secretions is provided with respect to the quantification of highly unstable nucleotides surrounded by cell-attached or soluble ectonucleotidases. The kinetic properties of these enzymes are important to interpret their roles in the regulation of physiological or pathological nucleotide levels. The text will refer to high-affinity low-capacity enzymes (i.e. CD39) as those regulating the physiological (<0.1 mM) nucleotide concentrations, and to low-affinity high-capacity enzymes (i.e. NTPDase3) strategically positioned to avoid tissue damage mediated by excess nucleotides. These definitions will allow the readers to grasp the ramifications of purinergic aberrances in airway diseases.
4.1.2
Assessing Airway Purines in Healthy Human Subjects
A significant challenge in assessing the impact of chronic lung disease on airway purines is to measure their concentrations within airway secretions in vivo. Despite the unquestioned value of in vitro measurements on differentiated airway epithelial cultures, these conditions do not include all factors affecting purine release and metabolism in the living airway. Thus, assessing the relationship between airway purines and chronic lung disease requires airway secretions from human subjects. The most common methods used to collect airway secretions are bronchoalveolar lavage (BAL), sputum collection and exhaled breath condensate (EBC) collection, each with its strengths and limitations. Historically, the most common method of obtaining airway secretions for analysis of cellular and biochemical constituents has been BAL, whereby a sterile saline solution is inserted into an airway using a bronchoscope, then recovered by suction. Investigators have reported BAL fluid measurements of ADO concentrations in the 60 mM range in healthy subjects, after correcting for dilution of airway secretions in BAL fluid using urea concentration [1, 2]. However, these values contrast with measurements conducted in sputum plugs, which estimate ADO concentrations closer to 1 mM after correcting for dilution during sputum processing [3–5]. Such discrepancy may reflect the technical limitations of both collection methods. On the one hand, purine concentrations in BAL fluid may be overestimated due to purine release triggered by the mechanical and osmotic forces generated during lavage, thereby limiting the utility of a urea based dilution
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
77
factor [6]. On the other hand, sputum collection from healthy subjects requires induction via inhalation of a hypertonic salt solution (3–5%), and changes in osmolarity are also known to affect purine release [7, 8] (see Chap. 1 for details). On a physiological note, these two methods target different lung compartments, as BAL samples peripheral airways whereas sputum plugs are limited to central airways [9]. Incidentally, the differences in purine concentrations may reflect the different inflammatory cell profiles of sputum plugs and BAL fluid present even in healthy individuals. This limitation becomes even more problematic for airway diseases, as neutrophils are far more prevalent in sputum (~ 30%) than BAL fluid (~5%) [10, 11]. Therefore, another approach needed to be developed to compare the airway purine concentrations of healthy subjects and patients. Recently, the collection of EBC has been used as a non-invasive method to assess airway purine concentrations. The advantage of this method is that it only requires the subject to breathe normally through a chilled tube, which does not introduce osmotic or mechanical forces that may compromise purine concentrations. However, while EBC ADO has been successfully detected in healthy subjects [12], few studies have used appropriate dilution factors [13, 14]. Interestingly, these estimates suggest that airway ADO levels are in the 1–3 mM range [14], consistent with sputum analysis [3–5]. Nonetheless, these results must be interpreted with caution as the origin and mechanisms by which airway secretions are incorporated into EBC are not fully understood [15]. The low micromolar airway ADO concentrations suggested by sputum and EBC studies are consistent with the physiological signaling processes. The reported EC50 values of A1Rs, A2ARs, and A3Rs on airway cells are in the low to sub-micromolar range [16], suggesting that diseases associated with changes in airway ADO levels would have a significant impact on the purinergic regulation of airway defenses. Airway ADO levels have been relatively well documented in healthy subjects and patients with chronic diseases. In contrast, fewer in vivo measurements have been made of the adenine nucleotides AMP, ADP, and ATP. In general, studies that measured all purines suggest a consistent pattern, in which ADO and AMP levels are similar but tenfold higher than ATP levels, whereas ADP levels fall between those of ATP and AMP. Interestingly, while absolute values vary between BAL fluid, sputum and EBC, this pattern appears to be consistent regardless of the collection method [3, 13, 17].
4.2 4.2.1
Disease-Specific Airway Purine Composition Airway Purines in Allergic Asthmatic Patients
The most thoroughly studied relationship between purines and airway disease has been the role of ADO in asthma. Interest was stimulated by the observation that inhalation of ADO causes significant bronchoconstriction in asthmatic patients, but in not healthy individuals [18]. Since then, hyperresponsiveness to inhaled ADO, or its precursor AMP, has been approved as a diagnostic test for asthma
78
C.R. Esther Jr. et al.
(see Chap. 9 for details). The first evidence that airway ADO concentrations are altered in asthmatics came in 1986, when Mann et al. showed that they experience an acute increase in plasma ADO levels after a bronchial challenge [19]. The increases were typically threefold over baseline and occurred in response to either inhaled methacholine or an allergen. A more recent study corroborated these findings and demonstrated that exercise induces an approximately twofold increase in plasma ADO in asthmatic patients [20]. In both cases, increases in plasma ADO were associated with decreases in lung function, suggesting that the measured changes in blood reflected alterations in airway physiology. Therefore, Driver et al. explored the possibility that asthma also influences airway ADO concentrations. They reported that BAL fluid from asthmatics contains approximately threefold higher ADO concentrations compared to healthy subjects. The relationship between ADO and asthma was refined by a series of EBC measurements conducted by the Horvath group in Budapest. They showed that airway ADO levels are increased 1.5-fold in steroid naı¨ve asthmatics and subjects with allergic rhinitis, relative to healthy subjects or asthmatics well controlled on inhaled steroid therapy [12, 21]. Furthermore, ADO concentrations increased an additional twofold after exercise in asthmatics, but not in healthy subjects [22]. However, since no dilution factor was included in these studies, definitive estimates of airway ADO concentrations could not be obtained, nor could variations in dilution of airway secretions in EBC be excluded in the differences observed between groups. Nonetheless, a similar concentration range was recently reported for EBC from asthmatic patients using a mass spectrometric method to quantify ADO and urea as a dilution marker [14]. They reported a twofold increase in EBC ADO in asthmatics, compared to healthy controls. Whereas the presence of excess ADO in the airways of asthmatic patients is now well established, there has been comparatively little investigation of other purines. Idzko et al. recently demonstrated in asthmatics that localized infusion of an allergen into a lobar lung segment during bronchoscopy resulted in a tenfold increase in BAL fluid ATP levels compared to saline challenged segment [23]. Interestingly, the rise in ATP level was not observed immediately, but 24 h after the challenge. Similar findings in BAL fluid were obtained from ovalbumin sensitized/challenged mice as an animal model of asthma [23]. However, sputum ATP concentrations were normal in asthmatics well controlled on inhaled steroid therapy [24], as reported for EBC ADO [12]. Together, these studies suggest that the high airway ATP and ADO concentrations detected in asthmatic patients, not under steroid therapy, may represent markers of inflammation and, thus, should occur in other chronic inflammatory diseases.
4.2.2
Airway Purines in Chronic Obstructive Pulmonary Disease
Epidemiologists now recognize the existence of an “Overlap Syndrome” between asthmatic and COPD patients, which includes airway bronchoconstriction to inhaled ADO in the case of smokers with COPD [25, 26]. This observation suggests
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
79
that airway ADO concentrations may also be elevated in COPD patients. A recent analysis of EBC revealed that airway ADO concentrations are elevated in smoking COPD subjects [27]. The ADO concentrations correlated with disease severity, including GOLD status and forced expiratory volume in 1 s (FEV1). Modest increases in BAL fluid ADO were observed in healthy smokers compared to nonsmoking healthy subjects [1], suggesting that elevated ADO may be a general marker of airway inflammation. Measurements of ATP concentrations in EBC revealed non-significant differences between healthy non-smokers, healthy smokers and COPD patients [28]. However, this data interpretation may be biased since ATP concentrations in the COPD samples were not corrected for dilution. More recently, ATP concentrations measured in the BAL fluid were significantly higher in smokers and ex-smokers with COPD and than in healthy subjects who never smoked [29]. These data were confirmed using an in vivo model of cigarette smoke-induced emphysema [30]. Furthermore, neutrophil activation by cigarette smoke extract induced ATP release and CXCL8 secretion, the latter being prevented by the ATP-metabolizing enzyme, apyrase. Since smoking is a major determinant in the development of COPD, these studies suggest that excess airway ATP plays a role in the pathology of the disease.
4.2.3
Airway Purines in Cystic Fibrosis and Pulmonary Fibrosis
Like asthma and COPD, cystic fibrosis (CF) is characterized by chronic airway inflammation. However, these patients suffer extensive lung damage and remodeling due to the overwhelming recruitment of neutrophils, which by far exceeds that observed in asthma or COPD. Since neutrophils are known to release large amounts of nucleotides during their migration and activation (review: [31]), CF patients are expected to maintain excess purines throughout the respiratory system. The first evidence of abnormal purine regulation in CF patients emerged from a study reporting high plasma ATP levels in CF patients, compared to healthy subjects [32]. Likewise, nasal lavage from CF patients presented twofold higher ATP levels than from healthy subjects, although the differences did not reach statistical significance [33]. More definitive evidence of elevated airway purines in CF were derived from a complete survey of purine concentrations in sputum, BAL fluid and EBC [3]. Unlike asthma and COPD, ADO concentrations in CF sputum and BAL fluid did not differ from those of healthy subjects. In contrast, ATP and AMP concentrations in airway secretions were orders of magnitude higher in CF, than in healthy, subjects. The ADO precursor, AMP, accounted for 70–80% of total purines in the CF airway secretions. Regression analysis revealed that ATP and AMP concentrations correlated closely with neutrophil counts in both sputum and BAL fluid, suggesting that these purines are biomarkers of neutrophilic inflammation. These findings are consistent with other studies demonstrating that activated neutrophils release ATP and accumulate AMP, in part because these cells do not express CD73 at their surface to convert AMP into ADO [34]. Maintenance
80
C.R. Esther Jr. et al.
of high AMP concentrations in the airways of CF patients was recently confirmed in EBC [13], although differences between CF and healthy subjects were less impressive than those measured in sputum or BAL fluid. Idiopathic pulmonary fibrosis (IPF) is joining ranks with the respiratory diseases characterized by excess airway nucleotides. In a recent study, Riteau et al. reported BAL fluid ATP levels more than fivefold higher in IPF patients than in healthy subjects [35]. Such remarkably high ATP levels, compared to asthma, CF and COPD, may result from the extensive lung tissue damage typical of this disease (review: [36]). On the other hand, the BAL fluid ATP concentrations were dramatically higher in IPF patients during acute exacerbation, implying that the activated immune and inflammatory cells recruited to the airways constitute significant sources of the nucleotide.
4.3
Disease Specific Aberrances in the Enzymatic Network
In healthy airways, the adenine nucleotides detected in the airway surface liquid (ASL) originate predominantly from the continuous epithelial release of ATP, ADP and AMP, which are dephosphorylated into ADO by ectonucleotidases. Afterward, ADO is converted into inosine by adenosine deaminase 1 (ADA1), and they both return to the cytosol through nucleoside transporters. Accordingly, ATP and ADO levels on airway surfaces are maintained by a delicate balance between the rates of nucleotide release, metabolism and uptake (see Chaps. 2 and 3 for details). In chronic diseases, the complexity of ATP and ADO regulation is amplified by the recruitment of immune and inflammatory cells, which constitute additional sources of nucleotides, ectonucleotidases and transporters. Furthermore, these network components are affected by hypoxia, oxidative stress, pathogens and inflammatory mediators. This section summarizes our current understanding of the mechanisms responsible for the purine levels reported in the airway secretions of patients with chronic respiratory diseases.
4.3.1
Selective Directionality of Enzyme Deregulation
The most compelling evidence for an abnormal regulation of airway nucleotides in chronic respiratory diseases was provided by immunolocalization in tissue sections from healthy donors and CF patients. Fausther et al. demonstrated that the respiratory system co-expresses two nucleoside triphosphate diphosphohydrolases: NTPDase1 (CD39) and NTPDase3 [37]. This study revealed that these ectonucleotidases are seldom encountered on the same cell surface. Whereas CD39 was widely distributed in fibroblasts, epithelial and endothelial cells, NTPDase3 was restricted to superficial epithelia and submucosal glands. Cystic fibrosis affected many aspects
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
81
of nucleotide regulation in human airways. On bronchial epithelia, the enzymatic network was remodeled for the regulation of higher airway nucleotide concentrations, by a decrease in high-affinity CD39 activity and an up-regulation of lowaffinity high-capacity NTPDase3. Further examination indicated that CF also causes opposite epithelial polarity shifts of the two ectonucleotidases, as CD39 has relocated to basolateral surfaces and NTPDase3 adopted a bilateral distribution. This study exposed a remarkable plasticity of the enzymatic network in the respiratory system. The CF lung complications result from functional mutations weakening clearance mechanisms and the persistent inflammatory arsenal deployed in response to recurrent infection. An in vitro strategy was developed to identify the mechanisms responsible for the aberrant expression of the NTPDases on CF airway epithelia [3]. The first set of experiments was designed to isolate the impact of genetic mutations using polarized primary cultures of human bronchial epithelial (HBE) cells maintained under aseptic conditions. The cultures were assayed 4–5 weeks after confluence to eliminate residual inflammatory responses to in vivo infection. Cultures from healthy donors (N), and patients with a1-antitrypsin deficiency (aAT), CF or primary ciliary dyskinesia (PCD), were assayed with 1 mM ATP to saturate the catalytic sites for a quantitative measure of total ectoATPase activity. Comparative analysis indicated that all diseases accelerate ATP metabolism in the order: N < PCD < CF < aAT [38]. This finding was inconsistent with the high airway ATP concentrations reported in CF patients [3]. An explanation emerged when the enzymes responsible for this enhanced metabolism were identified as NTPDase3 [37] and tissue non-specific alkaline phosphatase (TNAP) [38]. These two highcapacity ectonucleotidases are known to eliminate high micromolar ATP concentrations efficiently, but they lack the ability to regulate physiological levels (see Chap. 2 for details). On HBE cultures, CF is associated with higher surface activity and mRNA levels of NTPDase3 [37]. TNAP is functionally up-regulated by threefold in airway diseases, following the same potency order as total ectoATPase activity: N < PCD < CF < aAT [38]. Collectively, the up-regulations of TNAP and NTPDase3 account for the enhanced capacity of airway surfaces to eliminate excess micromolar nucleotide concentrations, locally reached during extensive tissue injury or bacterial killing. Airway surfaces regulate sub-micromolar ATP concentrations using high-affinity enzymes, namely CD39 [37], ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs) [39] and ectoAK [40]. Because these enzymes bind more tightly to their substrate, they reach maximum velocity at a lower concentration than TNAP and NTPDase3. Thus, assays conducted with 1 mM ATP would mask the impact of chronic airway diseases on these ectonucleotidases. Selective assays revealed that CD39 activity and mRNA levels are ~ 50% lower on CF, than on normal, HBE cultures [37]. These data were consistent with the reduced immunodetection of CD39 in CF airway tissue [37]. Since this enzyme accounts for 40% of the total highaffinity ectoATPase activity of HBE surfaces [37], its down-regulation could contribute to the high airway ATP levels of CF patients [3]. More importantly, these metabolic aberrances were detected on aseptic epithelia, suggesting that CF patients are born with an abnormal purinergic regulation of airway defenses.
82
C.R. Esther Jr. et al.
The second set of experiments was designed to test the contribution of chronic infection and inflammation to the deregulation of airway nucleotides by exposing HBE cultures to airway secretions from CF patients. Secretions pooled from several patients were centrifuged to eliminate live bacteria that would rapidly decimate these cultures. Nonetheless, the supernatant from mucopurulent material (SMM) contains all bacterial products, inflammatory mediators and reactive oxygen species (ROS) encountered on airway surfaces in vivo [41]. After 4 days of SMM exposure, normal and CF HBE cultures exhibited considerable airway remodeling in the form of mucus cell metaplasia [37]. Overall, SMM significantly amplified the CD39 down-regulation and NTPDase3 up-regulation observed on the aseptic CF cultures, and provoked similar, but milder, changes in normal epithelia. Altogether, these two sets of experiments suggest that the airways of CF patients maintain high ATP concentrations, in part, because they have a reduced capacity to regulate physiological nucleotide levels via CD39 [3]. During chronic infection, immune and inflammatory cells recruited to the airways become important partners in the regulation of airway purines. In CF, neutrophils account for more than 90% of the cells accumulating in the airway secretions (review: [42]). They constitute a major source of extracellular ATP, which they released to mediate autocrine responses and cell-cell communications (review: [31]). Like airway epithelia, neutrophils predominantly use CD39 to metabolize ATP into AMP, but they lack CD73 to convert AMP into ADO [43]. Accordingly, the most abundant purine accumulating in their surroundings is expected to be AMP, compared to ADO in the airways of healthy subjects. This scenario is consistent with the sputum compositions of healthy subjects (ADO >> AMP > ADP > ATP) and CF patients (AMP >> ATP > ADO > ADP) [44]. The sputum plugs, collected from the central airways, constitute micro-domains for the regulation of airway purines due to the absence of CD73 activity on the neutrophils. On the other hand, the BAL fluid of CF patients is expected to contain higher ADO levels than the sputum plugs because this collection method samples peripheral airways. The close proximity of epithelial CD73 in small airways, coupled to less densely packed neutrophils, would allow for a more efficient dephosphorylation of AMP into ADO. Incidentally, Esther et al. reported that CF patients maintain ADO levels twofold lower in sputum than in the small airways sampled by BAL procedure [44]. Hence, one should expect differences in purine composition between sputum plugs and BAL fluid in the case of CF patients because of the neutrophilic airway inflammation. In this regard, it is important to mention the extreme variability in CD73 expression among cells recruited to the airways. Whereas macrophages efficiently mediate the dephosphorylation of AMP into ADO, neutrophils and eosinophils depend on the epithelium [45, 46]. Therefore, differences in sputum ADO levels among diseases should correlate positively with the percent macrophages in the order: asthma > COPD > CF (reviews: [42, 47]), unless the expression level of CD73 is affected under pathological conditions. Blackburn et al. demonstrated that chronic respiratory diseases, indeed, modify the expression of CD73 [48]. In COPD and IPF patients, the capacity of lung homogenate to accumulate extracellular ADO increased with CD73 mRNA levels and with disease severity. This up-regulating effect on CD73 was also detected
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
83
in vitro in HBE cultures of CF patients, which exhibited more than threefold higher surface activity and mRNA levels [49]. These authors also documented the impact of these diseases on ADA1, which is responsible for the elimination of lung and airway ADO [50]. In contrast to CD73, the expression of ADA1 was not affected by COPD or IPF, but its activity decreased with disease severity. Unfortunately, they used pentostatin to differentiate ADA1, from ADA2, activity at a concentration (1 mM) that also inhibits ADA2 (Ki ¼ 109 M) [51]. The latter isoform, derived from monocytes/macrophages, has recently been identified as a growth factor with residual ADA activity only detected with high micromolar ADO [52]. Since lung homogenate likely contains ADA2 from monocytes and macrophages, the impact of these diseases on ADA1 remains undetermined. To date, the most selective inhibitor of ADA1 remains EHNA (see Chap. 2 for details). Nonetheless, platelets collected from rats following cigarette smoke exposure exhibited the same metabolic aberrance. This major determinant of COPD accelerated the production of circulating ADO by CD73 activity, while reducing its elimination rate by ADA1 [53]. In this case, an ADA1 inhibitor was not necessary since platelets do not express ADA2. These studies suggest that high airway ADO levels, in COPD patients [27], result from the combined effects of high CD73, and low ADA1, activities in lung tissue.
4.3.2
Epithelial Polarity Shifts and Expression Gradients
A phenomenal breakthrough in our understanding of purinergic regulation in the respiratory system was provided by immunolocalization of CD39 and NTPDase3 [37]. In normal human tissue, close examination of the epithelial barrier revealed a gradual and opposite shift in the epithelial polarity of the two ectonucleotidases toward the alveolar region. Whereas bronchial epithelia confine CD39 activity to their apical surface, the enzyme is expressed on the basolateral of the small airways. In contrast, the polarity of NTPDase3 shifts from basolateral surfaces in upper airways to a bilateral distribution in the distal airways. This behavior is not restricted to the ectonucleotidases, as the water channel, aquaporin3, exhibits a polarity shift in the basolateral-to-apical direction toward the alveoli [54]. This is a powerful revelation, as it modifies our perception of purinergic signaling to account for regional differences in network composition along the barrier. A consequence of these polarity shifts is the existence of expression gradients on the apical surface of the epithelial barrier, which concentrate CD39 in the upper airways and NTPDase3 in the peripheral airways. Interestingly, earlier studies reported similar expression gradients for the ectonucleotidases TNAP and CD73 [55]. From these studies emerges a fascinating pattern in the distribution of the ectonucleotidases, as high-affinity enzymes (CD39 and CD73) are concentrated in the upper airways, whereas low-affinity enzymes (NTPDase3 and TNAP) are concentrated in the distal airways. It was surprising to see NTPDase3 expression end so abruptly before the terminal bronchioles [37]. In the alveoli, high ATP concentrations appear to be regulated by placental alkaline phosphatase (PLAP) on the Type 1 [56–58], and TNAP on the Type 2 (surfactant-secreting) epithelial cells [59, 60].
84
C.R. Esther Jr. et al.
This spatial organization predicts that large airways are more efficient at regulating physiological nucleotide levels, whereas small airways are specialized in the removal of excess purines in areas of intense mucin/surfactant and nucleotide release [61–63] (see Chap. 2 for details). The factors maintaining region specific epithelial polarities for ectonucleotidases along airway surfaces were identified by immunolocalization of CD39 and NTPDase3 in airway tissue from CF patients and, in vitro studies designed to reconstitute the disease on airway epithelial cultures [37]. In the chronic respiratory disease, both enzymes adopt the epithelial polarity of normal distal airways throughout the respiratory tract. Whereas HBE cultures from CF patients presented the epithelial polarity of normal HBE cultures, chronic exposure to SMM established the in vivo polarity of CD39 and NTPDase3 typical of the CF diseases in, both, normal and CF cultures. These experiments demonstrated that the relocation of ectonucleotidases is part of the airways’ responses to infection. The fact that distal airways from healthy subjects adopt a similar epithelial polarity of the enzymes as those of CF patients is consistent with the notion that these small diameter airways are particularly susceptible to particle deposition. The hundreds of bacterial products inhaled every day are likely to maintain these areas in state of danger awareness which warrants the positioning of CD39 and NTPDase3 to strategic defense positions. The role of CD39 on the basolateral side of the epithelial barrier could be to reduce neutrophil entry into the airways in response to ATP released locally from leukocytes gathering in the interstitium (see Chap. 7 for details). In CF, the overwhelming neutrophilic airway inflammation [42] may result from a failure to regulate their recruitment due to CD39 down-regulation. On the apical surface, the up-regulation and mobilization of the high-capacity NTPDase3 could protect against the deleterious effects of high micromolar nucleotides in areas of intense bacterial killing or tissue damage, which are known to induce apoptosis through P2X7Rs (review: [64]). Whereas P2X7Rs are not detected in normal HBE cells, they are functionally expressed on CF airway epithelia [65]. It is also noteworthy that NTPDase3 is preferentially expressed on mucous cells, which co-release mucin and nucleotides [61, 62]. Since P2Y2R activation induces mucin secretion (review: [66]), NTPDase3 could locally regulate the amplification cycles of P2Y2R-mediated mucin and ATP release.
4.3.3
Interactive Effects of Hypoxia and Oxidative Stress
Respiratory insufficiency is considered among the most serious complications of patients with obstructive lung diseases. The major causes include lung destruction for COPD or emphysema, airway narrowing and bronchoconstriction for asthma. As for CF, the patients’ inability to clear the viscoelastic mucopurulent material invariably leads to airway obstruction by hypoxic mucus plugs, which often requires mechanical stimulation for clearance (review: [67]). In all diseases, the
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
85
sporadic and intermittent low oxygen tension experienced by the epithelial surfaces could contribute to the aberrant airway purine concentrations. Oxygen deprivation is well known to induce the coordinated up-regulation of CD39, CD73 and A2BRs (review: [68]). Intestinal epithelial cells react to hypoxia by a fivefold increase in the expression of both enzymes [69]. In blood vessels, the resulting excess ADO reduces inflammatory responses (i.e. leukocyte adhesion) and vascular leakage (review: [68]). Eventually, ADA1 activity increases, as a delayed response, to restore normal ADO levels until CD39 and CD73 expression return to baseline. The fact that COPD and asthmatic patients, but not CF patients, exhibit high airway ADO levels, suggests disease specificity in the impact of hypoxia. Airway epithelial cells possess all the necessary machinery to enhance purinergic signaling in areas of low oxygen tension. Hypoxia influences gene expression through activation of the transcription factor hypoxia-inducible factor-1a (HIF-1a). Low oxygen causes the stabilization of a-subunit and its dimerization with HIF-1, which triggers the translocation of HIF-1a to the nucleus to stimulate the expression of barrier-protective elements, including CD73 [69]. Nitric oxide (NO) is emerging as a positive regulator of HIF-1a-mediated responses. In A549 alveolar epithelial cells, respiratory syncytial virus raised CD73 expression through HIF1a stabilization which required NO secretion [70, 71]. Actually, so many factors activate inducible NO synthase (iNOS) in human airway epithelia (viruses, bacteria and cytokines) that BAL fluid levels of NO are elevated in chronic inflammatory diseases, like asthma [72]. Surprisingly, CF patients exhibit low iNOS and airway NO levels, compared to healthy subjects [73, 74]. In CF, a failure to initiate NO-dependent CD73 up-regulation in response to a pathogen could impair the ADO-mediated mucociliary clearance and allow excessive inflammatory responses (see Chaps. 5 and 7 for details). Colgan et al. demonstrated that hypoxia uses a different transcription factor to up-regulate CD39 [75]. On endothelial cells, both, site-directed mutagenesis and antisense oligonucleotides targeting the SP1 transcription factor caused a complete loss of hypoxia inducibility by CD39 [75]. In human airway epithelia, this transcription factor is being targeted for the suppression of excessive inflammatory responses in CF patients [76]. If SP1 is proven important for CD39 expression in these cells, this therapeutic approach could aggravate its down-regulation in CF patients [37]. The general consensus that hypoxia accelerates the conversion of airway ATP into ADO is consistent with chronic respiratory diseases known to maintain high levels of the signaling molecule, such as COPD and asthma, but not with CF. On the other hand, chronic and intermittent hypoxia is associated with oxidative stress (review: [77]). This airway complication is amplified, in CF, by functional mutations in the Cftr gene which maintain the epithelia under oxidative stress [78]. Airway epithelia respond to pathogens and cytokines by a small oxidative burst to assist in bacterial killing, which is ended by scavengers and antioxidant enzymes (review: [79]). Chronic conditions, like intermittent hypoxia, tilt the “reductionoxidation” (redox) balance toward oxidants, which activate elements of various signaling cascades affecting gene expression. In a murine model of asthma, the
86
C.R. Esther Jr. et al.
antioxidant L-2-oxothiazolidine-4-carboxylic acid inhibited the translocation of NFkB to the nucleus, which reduced the expression of pro-inflammatory cytokines and adhesion molecules [80]. Oxidative stress also impairs the activities of surface proteins through lipid peroxidation, which operates independently from gene expression. Numerous in vivo studies suggest that chronic oxidative stress may be responsible for the suppression of CD39, and up-regulation of CD73, detected in the airways of CF patients [37, 49]. For instance, the glomerular CD39 activity of kidney grafts is reduced in patients with delayed diuresis after renal transplant [81] or renal xenotransplant [82]. In renal biopsies from patients with chronic allograft neuropathy [83], or after ischemia-reperfusion [81], a reduction in CD39 activity occurred concomitant with an increase in CD73 activity. The involvement of oxidative stress was demonstrated using activated neutrophils, which reduced ectoADPase activity in perfused rat kidneys by a mechanism sensitive to antioxidant enzymes [84]. On endothelial cells, CD39 activity was inhibited by an oxidation system (xanthine oxidase/xanthine), which was prevented in the presence of ROS scavengers [85]. Furthermore, the inhibitory effect of TNFa on CD39 activity was prevented by antioxidants [86]. These data suggest that oxidative stress reduces the activity and mRNA expression of CD39 in chronic respiratory diseases. Of note, the intra-tracheal instillation of LPS or influenza was reported to raise the mRNA expression of CD39 in the total lung [87, 88]. However, airway infection recruits immune and inflammatory cells, most of which express CD39. Hence, analysis of gene expression in total lung does not distinguish the responses of recruited and resident cells. In the airways of CF patients, immunolocalization showed that CD39 is down-regulated in the epithelial barrier, but up-regulated in inflammatory cells and fibroblasts [37]. The up-regulation of CD39 on CF airway neutrophils was confirmed at the mRNA level [89]. The selective decrease in CD39 activity on the epithelial barrier of CF patients suffering from the damaging effects of an overwhelming airway neutrophilia supports a protective role against leukocyte adhesion and/or transmigration, as documented extensively for the endothelial barrier (review: [46]) (see Chap. 7 for details).
4.3.4
Amplification Loops for ATP and Adenosine Formation
The discovery that most chronic respiratory diseases are characterized by elevated ATP and/or ADO concentrations in the airway secretions supports the existence of amplification pathways for the production of extracellular ATP and ADO. The first study exploring this signaling mechanism was conducted on skin cancer cells by periodic treatment with exogenous ATP over the course of 2 weeks [90]. Time-course analysis revealed the coordinated up-regulation of ectoATPase, ectoADPase and ectoAMPase activities [90]. More recent studies targeted the response of
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
87
specific ectonucleotidases to stable agonists of the purinergic receptors. Narravula et al. demonstrated that the stable ADO analogue, 5-N-ethylcarboxamidoadenosine (NECA), caused a time- and dose-dependent increase in the expression and surface activity of CD73 [91]. The promoter region of the Cd39 and Cd73 contains a cAMPresponsive element (CRE) which allows A2BR activation to raise gene expression through the formation of the cAMP secondary messenger [92, 93]. Since airway epithelial surfaces express CD73 and A2BRs (review: [66]), the excess ADO detected in the airways of COPD patients and steroid naı¨ve asthmatics [12, 21, 27] could be, in part, maintained by this amplification system. There is also evidence that high airway ATP and ADO levels are maintained by PKC-dependent signaling pathways. A survey of the literature generated over 40 papers which support the widespread up-regulating effect of PKC activation on CD73 in the heart, endothelial and epithelial cells [94–96]. Other studies revealed the additive up-regulating effects of cAMP and PKC on the up-regulation of NPPs and TNAP [97, 98]. Given the fact that P2Y2R activation induces cellular responses through PKC on airway epithelial and inflammatory cells, this signaling cascade could also allow excess ATP to promote ADO accumulation by the coordinated up-regulation of ectonucleotidases. This amplification system for airway ADO would be particularly problematic for respiratory diseases combining excess ATP and ADO, like COPD, since A2BRs and P2Y2Rs appear to amplify each others responses.
4.4
Conclusions
The abovementioned information suggests that chronic respiratory diseases are generally associated with the accumulation of ATP in the airway secretions, likely from bacterial killing and the intense purinergic signaling taking place on the epithelial and inflammatory cells. However, a consensus could not be reached for airway ADO, as high levels are reported in asthmatic and COPD patients, but not in CF patients. Instead, CF is associated with high levels of AMP, the precursor of ADO. This discrepancy raised the possibility that chronic diseases also affect the ectonucleotidases regulating the sequential dephosphorylation of released nucleotides into ADO. Collectively, the scientific evidence provided in this chapter exposes the elegance and receptivity of the enzymatic network regulating ATP and ADO in the respiratory tract. The alarm signal triggered by a pathogen on the epithelial barrier, not only affects the activity and expression of the ectonucleotidases, but causes their relocation to strategic positions to regulate the stimulatory effects of ATP on mucin secretion and inflammatory responses. Chronic respiratory diseases, characterized by severe neutrophilia, may be trapped in an amplification pattern of oxidative stress which reduces CD39 expression and facilitates neutrophil recruitment to the airways.
88
C.R. Esther Jr. et al.
References 1. Driver AG, Kukoly CA, Ali S, Mustafa SJ (1993) Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148:91–97 2. Factor P, Mutlu GM, Chen L, Mohameed J, Akhmedov AT, Meng FJ, Jilling T, Lewis ER, Johnson MD, Xu A, Kass D, Martino JM, Bellmeyer A, Albazi JS, Emala C, Lee HT, Dobbs LG, Matalon S (2007) Adenosine regulation of alveolar fluid clearance. Proc Natl Acad Sci 104:4083–4088 3. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 4. Versluis M, van den Berge M, Timens W, Luijk B, Rutgers B, Lammers JW, Postma DS, Hylkema MN (2008) Allergen inhalation decreases adenosine receptor expression in sputum and blood of asthma patients. Allergy 63:1186–1194 5. Li Y, Wang W, Parker W, Clancy JP (2006) Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am J Respir Cell Mol Biol 34:600–608 6. Haslam PL, Baughman RP (1999) Report of ERS task force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 14:245–248 7. Chen Y, Shukla A, Namiki S, Insel PA, Junger WG (2004) A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors. J Leukoc Biol 76:245–253 8. Aleu J, Martin-Satue M, Navarro P, Perez de Lara I, Bahima L, Marsal J, Solsona C (2003) Release of ATP induced by hypertonic solutions in Xenopus oocytes. J Physiol 547:209–219 9. Alexis NE, Hu SC, Zeman K, Alter T, Bennett WD (2001) Induced sputum derives from the central airways: confirmation using a radiolabelled aerosol bolus delivery technique. Am J Respir Crit Care Med 164:1964–1970 10. Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, Bianchi A, Michetti G (2000) Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 162:1172–1174 11. Sutinen S, Riska H, Backman R, Sutinen SH, Froseth B (1995) Alveolar lavage fluid (ALF) of normal volunteer subjects: cytologic, immunocytochemical, and biochemical reference values. Respir Med 89:85–92 12. Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G, Herjavecz I, Horvath I (2002) Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 20:1393–1398 13. Esther CR Jr, Jasin HM, Collins LB, Swenbery JA, Boysen G (2008) A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Commun Mass Spectrom 22:701–705 14. Esther CR Jr, Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, Boucher RC (2009) Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol 296:L987–993 15. Hunt J (2007) Exhaled breath condensate: an overview. Immunol Allergy Clin North Am 27:587–596 16. Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443–448 17. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S, Boucher RC (2004) Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 279:36855–36864 18. Cushley MJ, Tattersfield AE, Holgate ST (1983) Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 15:161–165
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
89
19. Mann JS, Holgate ST, Renwick AG, Cushley MJ (1986) Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma. J Appl Physiol 61:1667–1676 20. Vizi E, Huszar E, Csoma Z, Boszormenyi-Nagy G, Barat E, Horvath I, Herjavecz I, Kollai M (2002) Plasma adenosine concentration increases during exercise: a possible contributing factor in exercise-induced bronchoconstriction in asthma. J Allergy Clin Immunol 109:446–448 21. Vass G, Huszar E, Augusztinovicz M, Baktai G, Barat E, Herjavecz I, Horvath I (2006) The effect of allergic rhinitis on adenosine concentration in exhaled breath condensate. Clin Exp Allergy 36:742–747 22. Csoma Z, Huszar E, Vizi E, Vass G, Szabo Z, Herjavecz I, Kollai M, Horvath I (2005) Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction. Eur Respir J 25:873–878 23. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MAM, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC, Lambrecht BN (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13:913–919 24. Loughlin CE, Esther CRJ, Lazarowski ER, Alexis NE, Peden DB (2010) Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics. Respir Med 104:29–33 25. Oosterhoff Y, de Jong JW, Jansen MA, Koeter GH, Postma DS (1993) Airway responsiveness to adenosine 5’-monophosphate in chronic obstructive pulmonary disease is determined by smoking. Am Rev Respir Dis 147:553–558 26. Gibson PG, Simpson JL (2009) The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 64:728–735 27. Esther CR Jr, Lazaar A (2009) Airway adenosine is elevated in COPD and correlates with disease severity. Am J Respir Crit Care Med 179:A3764 28. La´za´r Z, Husza´r E´, Kullmann T, Barta I, Antus B, Bikov A, Kollai M, Horva´th I (2008) Adenosine triphosphate in exhaled breath condensate of healthy subjects and patients with chronic obstructive pulmonary disease. Inflamm Res 57:367–373 29. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Durk T, Zissel G, Ferrari D, Di Virgilio F, Sorichter S, Lungarella G, Virchow JC, Idzko M (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934 30. Mortaz E, Braber S, Nazary M, Givi ME, Nijkamp FP, Folkerts G (2009) ATP in the pathogenesis of lung emphysema. Eur J Pharmacol 619:92–96 31. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, Inoue Y, Woehrle T, Zhang Q, Hauser C, Junger WG (2010) Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci Signal 3:ra45 32. Lader AS, Prat AG, Jackson GRJ, Chervinsky KL, Lapey A, Kinane TB, Cantiello HF (2000) Increased circulating levels of plasma ATP in cystic fibrosis patients. Clin Physiol 20:348–353 33. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ, Boucher RC (2000) Basal nucleotide levels, release, and metabolism in normal and cystic fibrosis airways. Mol Med 6:969–982 34. Lennon PF, Taylor CT, Stahl GL, Colgan SP (1998) Neutrophil-derived 50 -adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 188:1433–1443 35. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VFJ, Marchand-Adam S, Crestani B, Ryffel B, Couillin I (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182(6):774–783 36. Harari S, Caminati A (2010) IPF: new insight on pathogenesis and treatment. Allergy 65:537–553
90
C.R. Esther Jr. et al.
37. Fausther M, Pelletier J, Ribeiro CM, Se´vigny J, Picher M (2010) Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am J Physiol 298: L804–L818 38. Picher M, Burch LH, Boucher RC (2004) Metabolism of P2 receptor agonists in human airways: implications for mucociliary clearance and cystic fibrosis. J Biol Chem 279:20234–20241 39. Picher M, Boucher RC (2000) Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:255–261 40. Picher M, Boucher RC (2003) Human airway ecto-adenylate kinase. A mechanism to propagate ATP signaling on airway surfaces. J Biol Chem 278:11256–11264 41. Ribeiro CM, Paradiso AM, Schwab U, Perez-Vilar J, Jones L, O0 Neal WK, Boucher RC (2005) Chronic airway infection/inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J Biol Chem 280:17798–17806 42. Downey DG, Bell SC, Elborn JS (2009) Neutrophils in cystic fibrosis. Thorax 64:81–88 43. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG (2008) Ectonucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283:28480–28486 44. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Pedrosa Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 45. Resnick MB, Weller PF (1993) Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 8:349–355 46. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 50 -triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358–404 47. Ichinose M (2009) Differences of inflammatory mechanisms in asthma and COPD. Allergol Int 58:307–313 48. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR (2010) Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 5:e9224 49. Picher M, Alexis NE, Button B, Esther CR Jr, van Heusden C, Lazarowski ER, Boucher R (2006) Establishment of chronically-elevated adenosine and cytokine-adenosine amplification pathways on CF airway epithelia. Purinergic Signal 4:S111 50. Hirsh AJ, Stonebraker J, van Heusden CA, Lazarowski ER, Boucher RC, Picher M (2007) Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases. Biochemistry 46:10373–10383 51. Niedzwicki JG, Abernethy DR (1991) Structure-activity relationship of ligands of human plasma adenosine deaminase2. Biochem Pharmacol 41:1615–1624 52. Zavialov AV, Engstrom A (2005) Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 391:51–57 53. Thome´ GR, Mazzanti CM, Ahmed M, Correˆa M, Spanevello RM, Maldonado PA, Luchese C, Cargnelutti D, Morsch VM, Duarte MM, Fiorenza AM, Nogueira CW, De Bona KS, Moretto MB, Da Luz SC, Mazzanti A, Schetinger M (2009) Activity of ectonucleotidases and adenosine deaminase in rats exposed to cigarette smoke. Inhal Toxicol 21:906–912 54. Kreda SM, Gynn MC, Fenstermacher DA, Boucher RC, Gabriel SE (2001) Expression and localization of epithelial aquaporins in the adult human lung. Am J Respir Cell Mol Biol 24:224–234 55. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC (2003) Ecto 50 -nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468–13479 56. Nouwen EJ, Buyssens N, De Broe ME (1990) Heat-stable alkaline phosphatase as a marker for human and monkey type-I pneumocytes. Cell Tissue Res 260:321–335
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
91
57. Xie E, Yang ZQ, Li A (1996) Determination of placental alkaline phosphatase (PLAP) for detecting the damages of alveolar type I cells caused by smoke inhalation. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 12:427–430 58. Nouwen EJ, Pollet DE, Eerdekens MW, Hendrix PG, Briers TW, De Broe ME (1986) Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 46:866–876 59. DiAugustine RP (1974) Lung concentric laminar organelle. Hydrolase activity and compositional analysis. J Biol Chem 249:584–593 60. Edelson JD, Shannon JM, Mason RJ (1988) Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am Rev Respir Dis 138:1268–1275 61. Kreda SM, Okada SF, van Heusden CA, O’Neal W, Gabriel S, Abdullah L, Davis CW, Boucher RC, Lazarowski ER (2007) Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells. J Physiol 584:245–259 62. Kreda SM, Seminario-Vidal L, van Heusden CA, O’Neal W, Jones L, Boucher RC, Lazarowski ER (2010) Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides. J Physiol 588:2255–2267 63. Kishioka C, Okamoto K, Kim J, Rubin BK (2001) Regulation of secretion from mucous and serous cells in the excised ferret trachea. Respir Physiol 126:163–171 64. Di Virgilio F (2007) Purinergic signaling in the immune system. Purinergic Signal 3:1–3 65. Taylor AL, Schwiebert LM, Smith JJ, King C, Jones JR, Sorscher EJ, Schwiebert EM (1999) Epithelial P2X purinergic receptor channel expression and function. J Clin Invest 104:875–884 66. Davis CW, Lazarowski E (2008) Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. Respir Physiol Neurobiol 163:208–213 67. de Castro-Silva C, de Bruin VM, Cavalcante AG, Bittencourt LR, de Bruin PF (2009) Nocturnal hypoxia and sleep disturbances in cystic fibrosis. Pediatr Pulmonol 44:1143–1150 68. Van Linden A, Eltzschig HK (2007) Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Exp Opin Biol Ther 7:1437–1447 69. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-5’-nucleotidase (CD73) regulation by hypoxiainducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110:993–1002 70. Haeberle HA, D€ urrstein C, Rosenberger P, Hosakote YM, Kuhlicke J, Kempf VA, Garofalo RP, Eltzschig HK (2008) Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLoS ONE 3:e3352 71. Kilani MM, Mohammed KA, Nasreen N, Tepper RS, Antony VB (2004) RSV causes HIF-1alpha stabilization via NO release in primary bronchial epithelial cells. Inflammation 28:245–251 72. Barnes PJ, Liew FY (1995) Nitric oxide and asthmatic inflammation. Immunol Today 16:128–130 73. Grasemann H, Ratjen F (1999) Cystic fibrosis lung disease: the role of nitric oxide. Ped Pulmonol 28:442–448 74. Zheng S, Xu W, Bose S, Banerjee AK, Haque SJ, Erzurum SC (2004) Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am J Physiol 287: L374–381 75. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP (2009) Central role of Sp1regulated CD39 in hypoxia/ischemia protection. Blood 113:224–232 76. Cabrini G, Bezzerri V, Mancini I, Nicolis E, Dechecchi MC, Tamanini A, Lampronti I, Piccagli L, Bianchi N, Borgatti M, Gambari R (2010) Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Curr Med Chem 17:4392–4404
92
C.R. Esther Jr. et al.
77. Prabhakar NR, Kumar GK, Nanduri J (2009) Intermittent hypoxia-mediated plasticity of acute O2 sensing requires altered red-ox regulation by HIF-1 and HIF-2. Ann NY Acad Sci 1177:162–168 78. Rottner M, Freyssinet JM, Martinez MC (2009) Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res 10:1–11 79. Sen CK (2009) Wound healing essentials: let there be oxygen. Wound Repair Regen 17:1–18 80. Lee YC, Lee KS, Park SJ, Park HS, Lim JS, Park K-H, Im M-J, Choi I-W, Lee H-K, Kim U-H (2004) Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid. FASEB J 18:1917–1919 81. van Son WJ, Wit F, van Balen OL, Tegzess AM, Ploeg RJ, Bakker WW (1997) Decreased expression of glomerular ecto-ATPase in kidney grafts with delayed graft function. Transplant Proc 29:352–354 82. Roush W (1995) New ways to avoid organ rejection buoy hopes. Science 270:234–235 83. Mui KW, van Son WJ, Tiebosch ATMG, van Goor H, Bakker WW (2003) Clinical relevance of immunohistochemical staining for ecto-AMPase and ecto-ATPase in chronic allograft nephropathy (CAN). Nephrol Dial Transplant 18:158–163 84. Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW (1990) Intraglomerular platelet aggregation and experimental glomerulonephritis. Kidney Int 37:1500–1508 85. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, Hancock WW, Bach FH (1997) Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185:153–164 86. Park HS, Kim SR, Lee YC (2009) Impact of oxidative stress on lung diseases. Respirology 14:27–38 87. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri K-C, Eltzschig HK (2009) Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23:473–482 88. Sakai S, Mantani N, Kogure T, Ochiai H, Shimada Y, Terasawa K (2002) Gene expression of cell surface antigens in the early phase of murine influenza pneumonia determined by a cDNA expression array technique. Mediators Inflamm 11:359–361 89. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, Moss RB, Herzenberg LA, Herzenberg LA, Tirouvanziam R (2009) Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci 106:5779–2783 90. Wiendl HS, Schneider C, Ogilvie A (1998) Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis. Biochim Biophys Acta 1404:282–298 91. Narravula S, Lennon PF, Mueller BU, Colgan SP (2000) Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol 165:5262–5268 92. Hansen KR, Resta R, Webb CF, Thompson LF (1995) Isolation and characterization of the promoter of the human 50 -nucleotidase (CD73)-encoding gene. Gene 167:307–312 93. Liao H, Hyman MC, Baek AE, Fukase K, Pinsky DJ (2010) cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem 285:14791–14805 94. Sanada S, Kitakaze M (2004) Ischemic preconditioning: emerging evidence, controversy, and translational trials. Int J Cardiol 97:263–276 95. Zhang QY, Han JY, Zhang H, Tan J (2010) Role of PKC in regulation of CD73 by lysophosphatidylcholine in human endothelial cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi 26:102–104 96. Siegfried G, Vrtovsnik F, Prie D, Amiel C, Friedlander G (1995) Parathyroid hormone stimulates ecto-5’-nucleotidase activity in renal epithelial cells: role of protein kinase-C. Endocrinology 136:1267–1275
4 Regulation of Airway Nucleotides in Chronic Lung Diseases
93
97. Solan JL, Deftos LJ, Coding JW, Terkeltaub RA (1996) Expression of the nucleoside triphosphate pyrophosphohydrolase PC-1 is induced by basic fibroblast growth factor (bFGF) and modulated by activation of the protein kinase A and C pathways in osteoblastlike osteosarcoma cells. J Bone Miner Res 11:183–192 98. Miyamoto K, Horita T, Waki Y, Suzuki R, Yamamoto S, Moritani S (1997) Dual regulation of alkaline phosphatase activity by calcitonin in porcine kidney cells. Biol Pharm Bull 20:1300–1302
Chapter 5
Nucleotide-Mediated Airway Clearance Andreas Schmid, Lucy A. Clunes, Mathias Salathe, Pedro Verdugo, Paul Dietl, C. William Davis, and Robert Tarran
Abstract A thin layer of airway surface liquid (ASL) lines the entire surface of the lung and is the first point of contact between the lung and the environment. Surfactants contained within this layer are secreted in the alveolar region and are required to maintain a low surface tension and to prevent alveolar collapse. Mucins are secreted into the ASL throughout the respiratory tract and serve to intercept inhaled pathogens, allergens and toxins. Their removal by mucociliary clearance (MCC) is facilitated by cilia beating and hydration of the ASL by active ion transport. Throughout the lung, secretion, ion transport and cilia beating are under purinergic control. Pulmonary epithelia release ATP into the ASL which acts in an autocrine fashion on P2Y2 (ATP) receptors. The enzymatic network describes in Chap. 2 then mounts a secondary wave of signaling by surface conversion of ATP into adenosine (ADO), which induces A2B (ADO) receptor-mediated responses. This chapter offers a comprehensive description of MCC and the extensive ramifications of the purinergic signaling network on pulmonary surfaces.
A. Schmid and M. Salathe Division of Pulmonary and Critical Care, University of Miami, Miami, FL 33136, USA e-mail:
[email protected];
[email protected] L.A. Clunes Department of Pharmacology, School of Medicine, St George’s University, Grenada, West Indies e-mail:
[email protected] P. Verdugo Department of Bioengineering, University of Washington, Friday Harbor, WA 98195, USA e-mail:
[email protected] P. Dietl Institute of General Physiology, University of Ulm, Ulm 89081, Germany e-mail:
[email protected] C.W. Davis and R. Tarran (*) Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected];
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_5, # Springer Science+Business Media B.V. 2011
95
96
A. Schmid et al.
Keywords CFTR Mucociliary clearance Mucin secretion P2Y2 receptors A2B receptors
5.1
Introduction
The respiratory tract serves as a conduit to bring air to the alveoli, sterilizing and humidifying it in the process, whilst the alveoli act as the primary site for gas exchange. Mucociliary clearance from the respiratory tract constitutes the first line of defense against airway infection (1): Mucus lining the airways traps inhaled pathogens and propels them towards the mouth where they can be expectorated. Transport of this mucus requires regulated mucin secretion, maintenance of cilia beating and adequate hydration of airway surfaces by ion transport processes. Mucin hypersecretion and/or abnormal regulation of ion transport leads to concentration/dehydration of mucus, plugging of the airways and chronic infections. Based on the actions of the airways, the alveolar surfaces are normally free from infection. However, due to their minuteness, alveoli would collapse if their surface tension was not reduced by surfactant, a small, hydrophobic lipid-like molecule. Despite these different functions, all regions of the airways are under purinergic regulation. In section 5.2 we shall discuss how ASL secretion is mediated via CFTR, CaCC and ENaC. In sections 5.3 and 5.4 we shall discuss the regulation of mucin and surfactant secretion respectively and in section 5.5 we shall discuss how ciliary beating is modulated.
5.2 5.2.1
Airway Hydration Definitions
ASL height (volume) is regulated by ion channels that control the mass of salt and water on airway surfaces [1]. The regulation of pulmonary hydration is a highly adaptable mechanism exhibiting dramatic changes before and after birth. In the fetal lung, airway Cl secretion dominates [2, 3] and this fluid secretion drives expansion of the developing lung by providing the distending pressure for air space development [4]. At birth, the lung switches from a secretory to an absorbing organ [5]. The fluid filling the lungs is reabsorbed by the actions of the epithelial sodium channel (ENaC) allowing the lungs to become filled with air [4]. From this point, pulmonary hydration is maintained by a balance between secretive and absorptive mechanisms. The ion channels responsible for fluid secretion and absorption on pulmonary surfaces are under a tight and complex regulation by various mediators, including adenine nucleotides. This section describes each channel contributing to the maintenance of the PCL, and their complex regulation by the purinergic signaling network.
5 Nucleotide-Mediated Airway Clearance
5.2.2
Fluid Secretion
5.2.2.1
The CFTR Chloride Channel
97
Evidence that Cl secretion across the apical membrane of airway epithelia provides the driving force for fluid secretion into the lumen emerged from studies on the fetal lamb [2] Cl is taken into the epithelia via the Na+-K+-2Cl co-transporter, which is itself driven by an inwardly-directed Na+ gradient that is maintained by the Na+-K+-ATPase pump (Fig. 5.1). Since the ASL Cl concentration is ~3 fold greater than intracellular Cl, there is no chemical gradient for Cl secretion [5a]. However, inhibition of ENaC or activation of basolateral K+ channels both serve to hyperpolarize the epithelia, providing an electrical driving force for Cl secretion. During Cl secretion, Na+ follows paracellularly to preserve electroneutrality. Water then follows by osmosis causing an increase in ASL height. However, since pulmonary epithelia are highly permeable to water, the net NaCl concentration does not change and remains isotonic with plasma [5b]. Thus, it is the
Fig. 5.1 Chloride secretion provides the driving force for the hydration of pulmonary surfaces. Under basal conditions, the Na+-K+-ATPase pump generates a large electrochemical gradient to facilitate apical Na+ entry via ENaC. The intracellular Cl concentration is maintained above its equilibrium potential by the inward activity of the Na+-K+-2Cl contransporter, with K+ being recycled through basolateral channels [6]. Under these conditions, Cl is at near-electrochemical equilibrium across the apical membrane so there is little net Cl secretion. However, following inhibition of ENaC, the apical membrane is hyperpolarized, generating sufficient electrical gradient for Cl secretion. This hyperpolarization may be further augmented by activation of basolateral K+ channels. Pulmonary ion transport is tightly regulated by purinergic signaling: ATP, released by either mechanical stress or by cell injury stimulates P2Y2Rs. This action simultaneously raises intracellular Ca2+ to activate CaCC and depletes cells of PIP2 to inhibit ENaC. Together, these actions generate net Cl and fluid secretion. Ectonucleotidases then convert ATP into ADO, which binds A2BRs to activate CFTR and inhibit ENaC, again promoting net fluid secretion and pulmonary hydration
98
A. Schmid et al.
amount, rather than the concentration of NaCl that is altered in the ASL during Cl secretion. Under steady-state conditions, airway fluid secretion is mediated primarily by the cystic fibrosis transmembrane regulator (CFTR). This Cl channel belongs to a family of ATP-binding cassette (ABC) proteins composed of two membrane-spanning domains (MSD1 and 2), two nucleotide-binding domains (NBD1 and NBD2) and a regulatory domain (R) [7]. This multifunctional protein also regulates other ion channels, including the outwardly rectifying chloride channel (ORCC) [8], CaCC [9] and ENaC [10]. The signaling events leading to CFTR activation involve cell surface G protein-coupled receptors (GPCRs) which stimulate adenyl cyclase, leading to cyclic AMP (cAMP) production, and protein kinase A (PKA) activation [11–13]. Two GPCRs are known to mediate CFTR activation on the apical surface of human airway epithelia by this pathway: A2B receptors (A2BRs) and b2 adrenergic receptors. Their endogenous agonists have been shown to stimulate Cl secretion through CFTR and subsequently increase fluid secretion (review: [14]). Nonetheless, biochemical and electrophysiological studies demonstrated that CFTR is activated primarily by A2BRs in human airways. Patch clamp studies on the Calu-3 human bronchial epithelial cell line showed that the Cl channel activity of CFTR is abolished by the non-specific ADO receptor antagonist, 8-(p-sulfophenyl) theophylline (8-spt) [15]. Similar results were obtained by preventing the endogenous formation of ADO using a,b-methyleneADP (AMPCP), an inhibitor of ecto 50 -NT (CD73) [15]. Also, exogenous adenosine deaminase (ADA) reduced cAMP levels in resting primary cultures of human nasal and bronchial epithelial cells [16]. Clancy and collaborators showed that the signaling pathways responsible for ADO-mediated CFTR activation also involve prostanoids [17]. Arachidonic acid stored in cell membranes is released by phospholipase A2 activity and metabolized into the mediators, prostaglandins and leukotrienes, by the actions of cyclooxygenases (COX) (review: [18]). The authors showed that A2BR activation induced the apical secretion of prostaglandins from airway epithelial cultures [17]. While COX inhibition by indomethacin reduced A2BR-mediated CFTR activation, arachidonic acid directly stimulated the channel. This study opens a new realm of possibilities for the purinergic regulation of MCC. Functionally, resting airway epithelial cultures maintain surface ADO levels (350 nM) [16] above the activation threshold (~100 nM) of A2BRs [19]. Whereas airway epithelial cells do not release ADO [20], the ectonucleotidase network metabolizes constitutively released ATP at a rate sufficient to maintain baseline A2BR-mediated CFTR activation. The importance of the A2BR-CFTR axis for airway hydration under steady-state conditions was validated by confocal microscopy studies in which ASL height was monitored on human bronchial epithelial (HBE) cultures before and after addition of 8-spt or ADA [16]. These agents caused severe dehydration the epithelial surfaces, as they depleted the ASL from a height of 7 to 4 mm, which corresponds to the height of folded cilia.
5 Nucleotide-Mediated Airway Clearance
99
The concept of protein clusters for the A2BR-CFTR-PKA axis was introduced by a study conducted on patches of apical membranes from Calu-3 cells [21]. First, the co-localization of CFTR and A2BRs within a patch was demonstrated by the effects of exogenous ADO, 8-spt and ADA on the channel activity. Second, cAMP analogues increased the open probability of CFTR, indicating that PKA is also associated to the plasma membrane, in close proximity with the channel. This study also identified the PKA isoform as PKA-II, which is anchored at specific subcellular sites by A kinase anchoring proteins. These observations suggest that CFTR activity is controlled by ADO generated locally from ATP release and metabolism, and that A2BR-mediated cAMP production activates PKA in close proximity to CFTR. An alternative signaling mechanism was proposed for CFTR activation on human airway epithelia. Kunzelmann et al. provided evidence that ATP stimulates CFTR via P2Y2R activation [22]. This signaling cascade involves Gq/11 and phospholipase C (PLC) activation, but not protein kinase C (PKC) or calmodulindependent kinase (CAMK). This mode of activation would not be significant under the baseline conditions provided by static epithelial cultures, which maintain ASL ATP concentrations below the activation threshold for P2Y2Rs. However, stress-induced ATP release, like breathing, would raise the contribution of P2Y2R-mediated CFTR activation for airway hydration.
5.2.2.2
The Calcium-Activated Chloride Channel (CaCC)
In the early 1990s, studies showed that extracellular nucleotides (ATP and UTP) have the capacity to stimulate Cl secretion from airway epithelial cells which lack CFTR [23–25]. Since this response was mediated by an increase in cytosolic Ca2+ concentration [Ca2+]i, these channels were named Ca2+-activated Cl channels (CaCC) [26]. Under steady-state conditions, the [Ca2+]i is insufficient to support CaCC activity. However, several purinoceptors have been shown to induce Ca2+-dependent signaling pathways in human airways, namely P2Y2Rs, P2Y6Rs, and likely P2X4Rs [19, 27, 28] (see Table 1.1 of Chap. 1 for details). However, therapeutic approaches to enhance Cl secretion in airway diseases are focused on P2Y2Rs, which are less susceptible to desensitization by excess agonist [29]. The identity of the CaCC was recently confirmed by three independent groups as TMEM16, member of a family of anion selective channels with eight transmembrane domains named anoctamins [30–32]. The development of specific polyclonal antibodies confirmed the localization of TMEM16 on the apical surface of airway epithelia [33]. Functional studies showed that P2Y2R activation induces Ca2+ mobi lization and (ANO)/TMEM16-associated Cl current [30–32] whilst TMEM16A knockdown with silencing RNA or knockout. Interestingly, this channel was not detected at the mRNA level in alveolar Type 2 cells [34], supporting regional differences in the regulation of fluid secretion.
100
A. Schmid et al.
While most studies on the purinergic regulation of CaCC address the P2Y2R, the P2Y6 (UDP) receptor present on the apical surface of human nasal epithelial cells [35] has been shown to stimulate Cl secretion through a synergistic increase of both [Ca2+]i and cAMP intracellular levels [36]. Even so, the contribution of this pathway would be rather limited given the relatively small concentrations of uridine nucleotides (<15%), compared to adenine nucleotides on airway surfaces [37].
5.2.3
Fluid Absorption: The Epithelial Na+ Channel
The active transport of Na+ from the ASL into the cytosol provides the main driving force for the removal of fluid from the airspace [38, 39]. The transepithelial absorption of Na+ involves two distinct steps. First, Na+ is pumped from the cell into the interstitial space by the Na+-K+-ATPase located on the basolateral membrane (Fig. 5.1). This enzyme maintains the electrochemical Na+ and K+ gradients across the plasma membrane by pumping Na+ outside and pumping K+ inside, against their concentration gradients [40]. Second, this active removal of Na+ from the cell provides the electrochemical gradient for ASL Na+ to enter the cell through the amiloride-sensitive epithelial Na+-channel (ENaC). The primary structure of ENaC is composed of three homologous subunits entitled a, b, and g-ENaC [41, 42], which are all expressed in respiratory epithelia. The murine models support differences in the roles of the three subunits. An artificial ‘knock-out’ of a-ENaC is associated with respiratory failure and death within 48 h of birth, due to an inability to clear lung fluid. In contrast, the deletion of b- or g-ENaC does not cause overt pulmonary pathology, although the lungs of mice lacking the g subunit clear fluid more slowly [43]. Heterologous expression revealed an absolute requirement of a-ENaC for Na+ channel activity, but maximal activity is only reached by co-expression of all subunits [41]. In contrast, ENaC overexpressing mice exhibit airway dehydration [44]. Airway hydration has previously been shown to directly influence mucus clearance rates in vitro [44a]. The critical role of ENaC in airway hydration and mucus clearance is further illustrated by the genetic disorder Type 1 pseudohypoaldosteronism (review: [45]). This disorder is caused by mutations in the a, b and g subunits of ENaC which impair channel activity, leading to decreased Na+ absorption. Importantly, except wheezing, which disappears after the first 5 years of life, pseudohypoaldosteronism patients exhibit greatly accelerated rates of mucus clearance and are free from airway infection [46, 46a], emphasizing the importance of ENaC activity in regulating mucus clearance. On airway surfaces, ENaC is regulated by a balance between membranebound proteases and soluble protease inhibitors released into the ASL (review: [47]). To be activated, ENaC must undergo proteolytic cleavage by intracellular furin-type proteases and/or extracellular channel-activating proteases (CAPs) [48–51]. For instance, a site in the extracellular loop of the
5 Nucleotide-Mediated Airway Clearance
101
g-ENaC (RKRK186) was identified as a prostasin-mediated cleavage site for ENaC activation [50, 51]. These effects are counteracted by soluble protease inhibitors acting as volume sensors. During ASL depletion, they respond to an increase in their concentration by inhibiting ENaC to reduce salt and water absorption. This response is reversed by dilution of the ASL with phosphatebuffered saline [52]. The short palate, lung, and nasal epithelial clone 1 (SPLUNC1) was recently identified as a candidate protease inhibitor by MALDI-MS/MS mass spectrometric analysis of ASL proteins collected with trypsin-coated beads [53]. On HBE cultures, recombinant SPLUNC1 inhibited ENaC activity, whereas the knockdown of SPLUNC1 by silencing RNA resulted in a failure to regulate ENaC activity and ASL volume. The purinergic regulation of ENaC has been reported in both native and cultured airway epithelial cells [54–56]. In all cases, ATP was shown to inhibit the channel activity through P2Y2R activation. While early studies excluded the role of intracellular Ca2+ or PKC, recent evidence suggests that P2Y2R activation inhibits ENaC through the PLC-dependent hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2). The existence of physical interaction between PIP2 and ENaC was demonstrated by immunoprecipitation in tracheal epithelial cells [57]. The impact of PIP2 on Na+ absorption was shown by generating mutations in the PIP2 binding domain of b-ENaC, which reduced the channel activity [57]. In Xenopus oocytes, co-expression of a,b,g-ENaC and P2Y2Rs supported the inhibition of ENaC activity by ATP [57]. The contribution of PLC was verified using neomycin, which prevents the hydrolysis PIP2 by PLC by high-affinity binding to the substrate. On tracheal epithelia, neomycin was able to block the inhibitory effect of ATP on ENaC activity [57]. Altogether, these studies demonstrate that purinergic signaling enhances airway hydration via the ATP-P2Y2R-PLC signaling cascade, which reduces ENaC activity by removal of the PIP2 secondary messenger. Interestingly, ENaC’s mode of regulation appears to differ between the airways and the alveolus: Whilst ENaC is negatively regulated by CFTR in the airways [57a], which may reflect both altered sensitivity to cAMP [10] and altered proteolytic cleavage [52, 57b], CFTR has little effect on ENaC activity in alveolar epithelia [34].
5.3 5.3.1
Regulation of Mucin Secretion by Human Goblet Cells Definitions
Mucus, a substance both revered and reviled, plays a crucial role in lung innate defense. It lubricates the luminal surface of the airways, screens the bounding epithelium and ensnares inspired particulates and pathogens. Materials bound up in mucus are cleared from the airways by a mechanism known as mucociliary clearance (MCC) [58]. The gel-forming mucins comprising the molecular
102
A. Schmid et al.
scaffolding of mucus are large glycoproteins secreted as linear, disulfide-linked polymers [59]. They are secreted onto airway surfaces from submucosal glands and goblet cells, which are the mucous secretory cells of the superficial epithelium in the human upper airways. In the healthy lung, MUC5AC is secreted from goblet cells and MUC5B from the glands. But this pattern changes under pathophysiological conditions, as MUC5AC appears in glands and MUC5B in goblet cells [59]. Together, aberrances in the release and composition of mucins are responsible for much morbidity in all obstructive diseases of the airways. Since mucins are critical components of the MCC system, it is imperative to understand the regulatory system underlying their synthesis and secretion. Mucin secretion from submucosal glands has been known for some time to be under neural control [60]. Goblet cell activation, however, was very poorly understood until the discovery that ATP activates Cl secretion in the airways [23, 24, 61], which stimulated the first studies on the role of purinergic agonists in regulated mucin secretion [62, 63]. At present, all three components of the MCC system in healthy human lungs are known to be under the powerful control of purinergic agonists: mucin secretion, airway hydration and cilia beating activity [64, 65]. Purinergic agonists had uncertain sources in the airways in the 1990s, but ATP, UTP, and UDP-sugars are now known to be released from the airway epithelium itself [37, 66, 67], especially following mechanical stimulation [65, 66, 68–71]. This chapter focuses on the purinergic and cellular messenger pathways mediating mucin secretion from airway goblet cells, particularly the role of Ca2+.
5.3.2
P2Y2R-Dominant Airway Goblet Cell Mucin Secretion
The current body of data indicates strongly that ATP and UTP are the predominant goblet cell mucin secretagogues in the airways. Indeed, no other agonist has been shown to be as consistently or as robust a mucin-eliciting agonist as ATP and UTP (and ATPgS), including muscarinic agonists, other purinergic agonists and those signaling via cyclic nucleotides [72–75]. ATP was initially shown to stimulate mucin secretion in cultures of hamster tracheal epithelial cells and in explanted canine tracheal epithelium [62, 63]. Later, we found that UTP was an equally effective mucin secretagogue in explanted nasal turbinate epithelium [76]. These findings were repeated in several goblet cell models, and in the airways in vivo, suggesting that ATP and UTP are universally important airway goblet cell secretagogues [72, 73, 77–79]. The fact that P2Y2Rs are expressed in two goblet cell models [72, 80] and sorted to the apical membrane of epithelial cells [81], and that ATP and UTP are equally effective agonists and mucin secretagogues [14, 72, 73, 81–85], suggests this purinoceptor may be primarily responsible for mediating the effects of both agonists. Table 1.1 summarizes the properties of the P2YRs, including their intracellular signaling pathways, epithelial polarity (MDCK cells; [81]) and effects on goblet
5 Nucleotide-Mediated Airway Clearance
103
cell mucin secretion in the airways. The receptor types localized to the apical surface of airway epithelial cells which mediate Ca2+-dependent intracellular signals are P2Y2Rs, P2Y4Rs, and P2Y6Rs, supporting a role for ATP, UTP, and UDP for the regulation of goblet cell mucin secretion. However, UDP has been shown to be inactive as a mucin secretagogue in human bronchial epithelial (HBE) cells grown in xenografts [73]. In primary cultures of HBE cells, the weak mucin secretion elicited by UDP was obliterated by a mixture of enzymes with eliminates UTP contaminants (hexokinase + glucose; [75]). In perfused trachea harvested from P2Y2R null mice, the stimulation of mucin release by ATPgS was reduced by ~80% [86], suggesting that P2Y4Rs play a minor role in mucin secretion. Consequently, the P2Y2R appears to be the major known G protein-coupled receptor (GPCR) regulating goblet cell secretory activity in the airways. Less is known regarding basolaterally situated purinoceptor function in airway goblet cells, as most studies have focused on the luminal exposures. Basolateral exposures to ATP and ADP have been shown to activate goblet cells, suggesting a potential P2Y1R involvement. However, the secretory responses were weak and inconsistent, relative to luminal ATP [63, 84].
5.3.3
Phospholipase C and Regulated Mucin Secretion
Both P2Y2Rs and P2Y4Rs couple to phospholipase C (PLC; Table 1.1), implicating diacylglycerol (DAG), inositol 1,4,5-trisphosphate (IP3) and Ca2+ as cellular messengers in regulated mucin secretion. In fact, existing data suggest these cellular messengers as the only ones involved in mucin secretion (reviews: [74, 84, 87, 88]). The inhibition of PLC by U73122 blocks, both, intracellular Ca2+ signaling and mucin secretion in goblet cells [89, 90]. Interestingly, U73122 nearly obliterated the stimulation of mucin secretion by the tyrosine phosphatase inhibitor, pervanadate, in HBE cultures [90]. This study suggests that PLC is critical for the activation of receptor tyrosine kinase (RYK) pathways signaling to the mucin secretory apparatus (Fig. 5.2). PLC hydrolyzes phosphotidylinositol 4,5 bisphosphate (PIP2) to generate the primary intracellular messengers DAG and IP3. Then, DAG activates protein kinase C (PKC) and/or other typical C1-domain protein effectors such as Munc13 [91, 92], while IP3 mobilizes intracellular Ca2+ [93]. As a matter of fact, PLC is not a single enzyme, but represents a large and diverse enzyme family encoded by 13 isozymes organized into 6 subfamilies (PLC b, g, d, e, Z, z; [94–96]). The different subfamilies possess similar, centrally localized EF hand, catalytic and C2 domains, and are distinguished by their possession of PH or RasGEF targeting domains, as well as regions of unique sequence. This diversity endows a complex signaling system activated by numerous inputs, with DAG, IP3, and intracellular Ca2+ as common outputs, acting cooperatively to stimulate mucin secretion (Fig. 5.2). Regulated mucin secretion proceeds through a series of steps beginning with a secretory granule (SG) positioned close by the apical plasma membrane,
104
A. Schmid et al.
Fig. 5.2 Signaling pathways supporting mucin secretion in airway goblet cells. Phospholipase C (PLC) acts as a keystone signaling node for G protein coupled receptor (GPCR)- and potential receptor tyrosine kinase (RYK)-dependent pathways converge. Thereafter, DAG, IP3, and Ca2+ act coordinately through their respective protein effector molecules to activate the exocytic release of mucin secretory granules
each following step being controlled by cellular messengers and/or their effector proteins. The mm-sized granules must, first, negotiate the layer of cortical actin filament to reach the apical membrane, where they align with docking sites which include the plasma membrane SNARE (soluble N-ethylmaleimide-sensitive factor protein attachment protein receptor) proteins, syntaxin and SNAP-25. The SNARE complex is then assembled (primed) [97]. Then, a suitable Ca2+ signal triggers exocytic membrane fusion and the mucins are released onto the luminal surface. In a recent review [88], we covered the processes of granule transport and actin remodeling, docking and priming/SNARE assembly, and its regulation by DAG and its effectors in considerable detail. In the following section, we focus on the roles of IP3 and Ca2+ in regulated mucin secretion.
5 Nucleotide-Mediated Airway Clearance
5.3.4
105
IP3 and Ca2+ Regulate Mucin Secretion
Many messengers involved in the process of exocytosis are Ca2+ sensitive. The most prominent, initially, is scinderin, which, following its activation by Ca2+, participates in actin filament remodeling relevant to mucin granule transport and positioning to exocytic docking sites on the plasma membrane [88, 98, 99]. Second, all four Munc13 isoforms required to prime the SNARE complex possess two or three C2 domains, which are responsible for the Ca2+-dependent targeting of the proteins to acidic membranes and activation of the priming process [97, 100]. Finally, synaptotagmin serves as Ca2+ sensor and is essential for regulated exocytosis [101–103]. Hence, it is not surprising that mucin secretion from airway goblet cells has been shown in multiple studies and models to be strongly Ca2+ dependent. The initial studies used the ionophore, ionomycin, to mobilize intracellular Ca2+ in goblet cells, most studies showing powerful concentration-dependent increases in mucin release [73, 75, 104]. The one study which failed to demonstrate Ca2+-sensitive mucin secretion [105] used A23187 as ionophore, one that in our experience is not as consistent in its effects as ionomycin due to the complicated indirect mechanism by which this reagent operates [106]. Additionally, we have shown in SPOC1 cells permeabilized with Streptolysin-O, that mucin release is stimulated at bulk Ca2+ concentrations above 1 mM, with an EC50 of 2 mM and peak responses at 3–10 mM [107, 108]. Although intracellular Ca2+ concentration is normally measured in hundreds of nM, the mM values are consistent with other permeabilized secretory cell studies (references in [107]), and with Ca2+ levels in activated cells known to exist at the plasma membrane [109]. Purinergic agonists have also been shown to mobilize Ca2+ intracellularly in goblet cells. The use of conventional widefield fluorescence microscopy and fura-2 on HBE cultures showed that continuous exposure to ATPgS generates a classic Ca2+ response, which rapidly increased from a baseline concentration of ~110 nM to ~260 nM, followed by a decline to a plateau level of ~155 nM [89]. In cultured rabbit tracheal goblet cells viewed by optical sectioning fluorescence microscopy, ATP elicited waves of Cai2+ activity in the cytosol, with a period of 10–15 s [110]. Additionally, loading HBE goblet cells with Ca2+ chelator, BAPTA, prevented both intracellular Ca2+ mobilization and mucin secretion [75, 89]. The chain of events initiated by G protein-coupled receptors, and RYK signaling through PLC, mobilizes Cai2+ from IP3-sensitive intracellular stores and/or the activation of plasma membrane Ca2+ channels. In SPOC1 cells permeabilized with Streptolysin-O in an intracellular buffer containing 0.1 mM Ca2+, 0.3 mM IP3 added exogenously stimulates a substantial heparin-sensitive release of mucin. Interestingly, cells permeabilized with a series of increasing Ca2+ activities in the absence of exogenous IP3 exhibited the usual stepwise increase in mucin release, with peak release at 3–10 mM [108]. These data suggest that IP3 stimulates the release of Cai2+ from intracellular stores in goblet cells, such that the local Ca2+ activity at the mucin granule docking sites is >3 mM. Moreover, this value is fully
106
A. Schmid et al.
consistent with the Ca2+ dissociation constant of 18 mM recently determined for synaptotagmin function in chromaffin cells [111]. Notable in the above experiments with Streptolysin-O-permeabilized SPOC1 cells, is that IP3 elicits mucin secretion under conditions in which intracellular stores are the only possible source of Ca2+. Consistent with this observation, we found in intact HBE goblet cells that ATPgS was equally effective in eliciting an intracellular Ca2+ signal when bathed luminally in Ca2+-free (+ EGTA) or Ca2+-replete media. Therefore, Ca2+ mobilization in goblet cells appears to depend exclusively on intracellular stores [89].
5.3.5
Intracellular Ca2+ Stores: ER and/or Mucin Secretory Granules?
The fact that the initial rise in intracellular Ca2+ concentration, following cell activation, is due exclusively to the release from intracellular stores raises an interesting problem regarding the localization of these stores. The general morphology developed for intestinal goblet cells during the 1980s and early 1990s [112] holds that the endoplasmic reticulum (ER) is restricted to the perinuclear area in the basal region of the cell. In general, the more recent fine structural analysis of airway goblet cells has been interpreted similarly [113]. As shown in the upper panel of Fig. 5.3, there would be no obvious source of Ca2+ near the apical membrane exocytic sites, given that the ER, the generally accepted Ca2+ store, is located basally. This structural design suggests that the mucin secretory granules (SGs) themselves would be the only obvious source of Ca2+ in the apical region. There is evidence both for and against this possibility, as detailed below. The electron microprobe analysis of mucin granules in goblet cells of the slug [Ariolimax; [114]] and the frog palate [Rana; [115]] revealed substantial levels of Ca2+, with 2.3 M/kg and 51 mM/kg, respectively. Both levels are well above the generally accepted cytoplasmic and plasma levels of Ca2+, which could be due to inter-species differences or how the standards were reported. A high mucin granule Ca2+ content is consistent with estimates for most other secretory cells, where intracellular Ca2+ appears to be sequestered predominately in SGs [116, 117]. There is also very good evidence for IP3-sensitive Ca2+ release from mucin granules, as ATP applied to intact goblet cells, and IP3 applied to isolated SGs, both cause Ca2+ release from SGs [110, 118]. Hence, the idea of mucin granules acting as IP3-sensitive Ca2+ stores is not unreasonable. On the other hand, whether SGs express IP3 receptors (IP3Rs), and IP3 induces Ca2+ release from granules by direct mechanisms, remains highly controversial [119–123]. The notion that IP3Rs might exist on SGs originates from a study on pancreatic acinar cells [124]. The initial responses to basolateral acetylcholine, or IP3 injected into the basal area, were both visualized within the cell as high Ca2+ concentrations in the apical pole. These observations suggest an apical-to-basolateral gradient of IP3R
5 Nucleotide-Mediated Airway Clearance
107
Fig. 5.3 Models of Ca2+ distribution for airway goblet cells. Top: The endoplasmic reticulum (ER) is restricted to the perinuclear region in the basal part of the cell, in which case mucin secretory granules (SGs) act as the primary source of IP3-mediated mucin release. Bottom: The ER is distributed throughout the cell, close to the apical membrane, in which case IP3 releases Ca2+ from the ER. Likely, Ca2+ is also released from SGs by tertiary signaling molecules. Recent data shows IP3 receptors restricted to the ER [74]
sensitivity or density. Blondel et al., first reported in 1995 the immunolocalization of IP3Rs on SGs in rat pancreas using an antibody to a synthetic peptide ([125]; review [120]). This notion was later disputed by the fact that these antibodies bind to rat, not human, insulin SGs [123]. Furthermore, immunogold labeling localized IP3Rs in the lumen of SGs, but not the membrane [126]. Independent studies using affinity purified antibodies and cell fractionation techniques subsequently brought arguments against the presence of IP3Rs at the surface of SGs. First, IP3Rs are associated with the ER fraction of endocrine cells, but are absent from isolated SGs [122]. Second, in the exocrine pancreas, IP3R antibodies stain ER but not SGs, while Western blots associate IP3R with a crude membrane-contaminated SG isolate, but not with Percoll-purified SGs [121]. Third, a study which monitored free Ca2+ inside SGs with a targeted aequorin chimera showed that it was insensitive to IP3, but highly sensitive to cytoplasmic pH, in the PC12 neuronal cell line [127]. Finally, we have shown by immunostaining and confocal microscopy in human airway epithelia that IP3Rs colocalize with ER, but not with mucin SGs [128]. The lack of IP3R in mucin SG membranes was not a mucin-related artifact, since the granule membrane marker,
108
A. Schmid et al.
Rab3D, was localized to these membranes and appeared to colocalize with MUC5AC in SG lumens. Interestingly, we found that IP3Rs and the ER, rather than being restricted to the perinuclear region, were instead distributed throughout the apical pole of airway goblet cells, right up to the apical membrane [128] (Fig. 5.3; lower panel). It would be surprising that the high Ca2+ concentrations measured in SGs are not exchangeable with the cytosolic Ca2+, especially given the genuinely good quality of some of the data indicating IP3-sensitive Ca2+ release from SGs, including mucin SGs [110, 116, 118, 119, 129, 130]. However, the above evidence for the absence of IP3R in SG membranes is equally strong. Perhaps the strongest negative evidence, however, came from experiments measuring Ca2+ release from isolated pancreas zymogen granules [121]. Crude isolates were shown to release Ca2+ when stimulated with exogenous IP3, whereas granules purified using a Percoll gradient released Ca2+ only upon exposure to ionomycin. Contrary to the purified isolates, the crude isolates were shown by EM to be contaminated by ER and mitochondria [121].
5.3.6
The Growing Complexity of Ca2+ Signaling
Over the past 5 years, studies on exocytic secretion have exposed the complexity of intracellular Ca2+ signaling. For instance, Ca2+ gradients have been demonstrated around zymogen granules stimulated with IP3, cyclic ADP ribose (cADPR), or nicotinic acid adenine dinucleotide phosphate (NAADP) [131]. In addition, b-cell insulin granules were recently shown to contribute to the clearance of cytosolic Ca2+ after cell stimulation [132]. This study identified b-cell insulin granules as the NAADP-sensitive, thapsigargin-insensitive intracellular acidic Ca2+ store of much recent interest [133, 134]. Hence, the Ca2+ release from SGs induced by IP3 is likely mediated indirectly through a sequence of events initiated by the release of Ca2+ from the ER, and terminated by NAADP or other intracellular messengers causing SG Ca2+ release. However, several artifacts have been noted in these studies. For instance, antibodies can be highly specific and effective, yet they are proteins and need access to their target epitope. They are polyelectrolytes that also possess hydrophobic domains which can restrict diffusion and/or access. Hence, positive immunolabeling can provide strong evidence for the presence of a target antigen, but negative labeling can hardly be taken as evidence ruling out the presence of antigen. Similarly, data from organelle separations using Percoll gradients can also be difficult to interpret. The polyvinylpyrrolidone (PVP) coating of the silica nanoparticles of Percoll binds strongly to polar sites. Therefore, the separation media could affect IP3 receptors in functional assays. Lastly, most Ca2+ measurements made in living cells were acquired using widefield fluorescence microscopy, a technique that yields undeniably valuable data. These data, however, always need to be ‘viewed’ cautiously, as the signal recorded is the integral of fluorescence emitted along the full path of excitation, and it is subject to scattering.
5 Nucleotide-Mediated Airway Clearance
109
Too few observations of complex cells and tissues have been made under the experimentally optimal conditions of two photon excitation to restrict the fluorescence excitation to the plane being imaged within the cell. One, therefore, expects that progress toward resolution of the question of Ca2+ signaling in and around secretory granules will come as techniques and experimental procedures are improved to eventually circumvent these, and other, artifacts.
5.3.7
Ca2+ Release at the Plasma Membrane: How Close Is ‘Close’?
The absolute requirement of Ca2+ for exocytosis to take place, the absence of Ca2+ entry into goblet cells through apical membrane channels, and the apparent restriction of IP3 to the ER, all require the ER to be localized quite close to the apical membrane. In support of this, immunofluorescence, confocal and electron microscopy studies showed that the ER is distributed in the apical pole, visibly close (50 nm) to the apical membrane (Fig. 5.4; [128]). Second, our recent data using SPOC1 rat airway goblet cells permeabilized with Streptolysin-O also indicate a
Fig. 5.4 Juxtaposition of apical endoplasmic reticulum and mucin secretory granules. (a) Electron micrograph of the apical membrane region of a goblet cell, showing the juxtaposition of a mucin secretory granule (SG) and rough endoplasmic reticulum (rER). The arrays of ribosomes reveal rough ER and the intimate relationships between the plasma membrane, granule, rough ER, and mitochondria (M). (b) Activation pathway for regulated mucin secretion in goblet cells. Extracellular ligands in the airway surface liquid layer (bottom) bind GPCRs in the apical membrane that activate Gq and PLCb1, generating secondary messengers: DAG and IP3. DAG activates the exocytic priming protein Munc13-2 (dotted blue arrow, left fork) and PKC effectors. IP3 induces Ca2+ release from the ER in the vicinity of mucin-containing SGs, activating Syt2 at their surface (dotted blue arrow, right fork) and co-activating Munc13 proteins (Reprint from Ref [74]. With permission)
110
A. Schmid et al.
remarkably close juxtaposition of local Ca2+ release to exocytic sites [108]. This study took advantage of the 400-fold faster Ca2+-binding kinetics of BAPTA over EGTA, two Ca2+ chelators with essentially equal binding affinities [135]. In cells exposed to EGTA-based intracellular buffer, IP3 was very effective in stimulating mucin release. In contrast, IP3-induced mucin secretion was nearly abolished when the cells were buffered instead with BAPTA. Because of its faster Ca2+ binding kinetics, BAPTA binds Ca2+ closer to the membranes across which Ca2+ is transported. With the buffer conditions used in our experiments, the inhibition of IP3-induced mucin release by BAPTA indicated a juxtaposition distance between IP3R Ca2+ release channels and the SG exocytic apparatus of <50 nm [108]. Such a short distance between the ER IP3Rs and the plasma membrane-SG SNARE complex would allow the minimal statement that ER Ca2+ release at SG exocytic sites is close enough to potentially trigger Ca2+ release from the granule, though the possibility exists that SG Ca2+ release may involve tertiary messengers, as discussed above.
5.3.8
Synaptotagmin: The Molecular Ca2+ Sensor for Exocytosis
A major difference between the release of vesicle/granule cargo from regulated and constitutive secretory pathways is the requirement of regulated exocytosis for Ca2+ [136] and the intimate association of the SNARE complex with its Ca2+ sensor and triggering protein, synaptotagmin (Fig. 5.5; [102, 137]). Synaptotagmins are a diverse family of some 17 isoforms that share a similar overall
Fig. 5.5 Synaptotagmin-regulated, SNARE-mediated fusion of secretory granule and plasma membranes. Synaptotagmin, activated by Ca2+ interacting with its C2 domains, has bound into acidic phospholipids and is in the process of pulling the two membranes into contact. Compare the separated SNARE components in Fig. 5.4 to appreciate the complexities of assembly (Redrawn from Ref [50]. With permission)
5 Nucleotide-Mediated Airway Clearance
111
structure: a N-terminal transmembrane domain, a variable linker domain and a tandem C-terminal C2 domain. Classically, C2 domains endow Ca2+ dependency to proteins, as Ca2+ neutralizes acidic phospholipids to affect protein targeting to the plasma membrane. However, many C2 domains, instead, mediate protein-protein interactions [138]. The eight synaptotagmins implicated in regulated exocytosis all exhibit Ca2+-dependent phospholipid binding, and several isoforms are expressed in all secretory cells examined [101, 102, 139, 140]. In excitable cells, which possess voltage-gated Ca2+ channels (neurons, neuroendocrine cells, pancreatic b cells, and chromaffin cells), synaptotagmins falling into C2 domain sequence Group A (Syts 1, 2, 9) exhibit low Ca2+ affinities (~10 mM) and high cooperativity, and subserve fast exocytic release which mediates synchronous synaptic signals in neurons. The other exocytic synaptotagmins (Syts 3, 5, 6, 10 in Group B, plus the unique Syt 7) have higher Ca2+ affinities (~1–5 mM) and support slow exocytic release, such as asynchronous synaptic signaling in neurons [141–143]. With this background in mind, it is interesting that the fastest synaptotagmin, Syt 2, is expressed in the two non-excitable cells examined to date, airway goblet cells and mast cells, and was found responsible for the major part of agonistinduced secretion in both cell types [128, 144]. The complex regulation of exocytic fusion by synaptotagmins has yet to be investigated fully as Syt 2 has inhibitory actions at low Ca2+ [143, 145]. But it is clear from these studies that fast synaptotagmins have powerful control over goblet cell and mast cell secretory activities.
5.4 5.4.1
Purinergic Regulation of Surfactant Secretion Definitions
No other secretory product affects viability immediately after birth as severely as surfactant, and its continuous function is indispensable throughout life. Surfactant, short for “surface active agent”, is a lipidic, lipoprotein-like substance, secreted into the lumen of the alveolus. The discovery of surface tension as the major component of retractive forces in the lung was made as early as 1929 [146]. But it was not until the 1950s and early 1960s that active surface material from the lung was isolated and characterized [147, 148]. Its deficiency causes infant respiratory distress syndrome [149]. The lamellar body (LB) was identified as the intracellular storage site of surfactant [150]. It is a large (~1 mm in diameter) vesicle that stores surfactant in an extremely compact, lamellar conformation (review: [151]), and is the characteristic organelle of the alveolar type 2 cells. The first convincing evidence in favour of an exocytotic surfactant release mechanism was provided by electron microscopy (EM) studies [152]. Surfactant consists of lipids (mainly phospholipids) and specific proteins. Its biosynthesis and composition have been reviewed elsewhere in detail [153, 154]. The phospholipid composition of LBs isolated from alveolar type 2 cells is similar to that of whole lung surfactant obtained from bronchoalveolar lavage
112
A. Schmid et al.
(BAL) [155, 156]. Therefore, essentially all alveolar surfactant phospholipids are secreted via exocytosis of LBs [157]. In addition to the phospholipids, four specific proteins (SP-A, SP-B, SP-C, and SP-D) can be obtained by BAL, which account for 10% of dry weight [151, 158]. The small hydrophobic SP-B and SP-C are localized within LBs and co-secreted with the LB content. Both proteins play an important role in squeezing out non-DPPC (dipalmitoyl phosphatidylcholine) elements during film formation and compression, which results in a highly DPPC-enriched surface film coating the alveolar surface [151, 159]. Hence, the exocytotic pathway of SP-B and SP-C appears to match that of lipids. In contrast, the large hydrophilic SP-A and SP-D are secreted largely independently of LB contents. Although SP-A inhibits the exocytosis of LBs in vitro [160], these proteins appear to be mainly involved in pulmonary host defense. This article focuses on the purinergic regulation of LB exocytosis in type 2 cells, which is the best studied and probably the most physiologically relevant purinergic function in the alveolar epithelium.
5.4.2
Does ATP Release Affect Alveolar Pneumocytes?
In 1983, Gilfillan et al. [161] presented the first evidence of extracellular ATP as stimulator of surfactant secretion in the lung using a perfused lung slice preparation. Their work was inspired by the recent discovery of purinergic nerves [162], which utilize ATP as a neuro(co)transmitter and innervate several visceral organs including the lung, terminating at sites close to alveolar type 2 cells [163]. Although a clear physiological role for ATP release from pulmonary purinergic nerves has never been established, ATP emerged as the most potent physiological agonist of surfactant secretion. An autocrine mechanism of purinergic stimulation was proposed after hypotonic swelling in a surrogate cell line of type 2 cells (A549 cells) [164], but it is still obscure whether osmotic cell volume changes of type 2 cells occur in the lung. An interesting hypothesis was recently proposed on the basis of mechanically stretched co-cultures of type 1 and type 2 pneumocytes, whereby type 1 cells would act as mechanosensors and release ATP, which would stimulate type 2 cells in a paracrine way [165]. This idea is consistent with an in situ model showing type 1 cells as the prime alveolar mechano-transducers, based on fluorimetric measurements of cytoplasmic Ca2+ concentration [166]. Whether ATP is, indeed, involved in stretch-induced surfactant secretion in the native lung is not yet known, but it is an intriguing question. Stretch occurring during deep lung inflation is considered the most important, if not the only, physiologically relevant stimulus of surfactant secretion [167–176]. Under these conditions, ATP release from epithelial cells could represent a key element of pulmonary alveolar mechanotransduction. An increase in epithelial basement membrane surface area was repeatedly demonstrated in lungs inflated to high lung volumes, thereby reporting the occurrence of cell stretch in situ [177]. Isolated type 2 pneumocytes respond to a single stretch by Ca2+ mobilization
5 Nucleotide-Mediated Airway Clearance
113
and surfactant release when the surface area is increased by about 10% [178, 179]. It is unlikely that ATP is released from cells subjected to moderate stretch as a result of membrane stress, because this is tolerated without signs of membrane damage [178–181]. However, ATP may exit all cells under conditions of cell damage, and this could be the case in hyperinflation-induced lung injury. Using propidium iodide as a cell-impermeable marker of cell damage, Gajic et al. found signs of reversible cell membrane stress failure in rats ventilated with high tidal volumes [181], and ultrastructural evidence for membrane damage was found in type 2 cells stretched on silastic membranes [180]. Under these conditions, ATP leakage from wounded cells could influence type 2 cells in an autocrine and/or paracrine way. The mechanism of ATP release from unwounded pneumocytes has not been identified. The release of ATP by anion channels was reviewed in detail by Sabirov and Okada [182]. Although various anion channels have been identified in foetal and adult pneumocytes [183], their involvement in ATP release has not yet been demonstrated. Interesting new findings suggest that the purinergic control of surfactant secretion could be stimulated by bacterial lipopolysaccharide (LPS) via an up-regulation of P2Y2Rs (see below), increased Ca2+ signal and a pronounced exocytotic response of LBs to ATP [184]. Hence, sensitization of the purinergic system during infection might amplify the physiological stimuli outlined above.
5.4.3
Purinergic Signaling Cascades in the Type 2 Pneumocyte
Since purines are potent stimuli of surfactant secretion [185–188], these signaling pathways have been intensively investigated and outlined in excellent reviews [153, 189–194]. The predominant role of P2Y2Rs (formerly termed P2U receptors) was determined based on agonist selectivity and the equipotency of ATP and UTP [185, 195]. Whereas ATP and UTP activate signaling cascades coupled to phospholipase C (PLC), ATP also initiates cyclic AMP (cAMP)-dependent signaling pathways [196, 197]. The production of cAMP in response to ATP was inhibited by the broad range ADO (P1) receptor antagonist, 8-phenyltheophylline [197]. Therefore, it was not surprising that surfactant secretion is also stimulated by ADO [186] on Type 2 cells which express all four P1 receptors (A1R, A2AR, A2BR and A3R) [198]. In fact, nearly 40% of the ATP-mediated surfactant secretion was inhibited by this P1 receptor antagonist [197]. Nonetheless, the mechanism by which ADO stimulates surfactant secretion has not been investigated. As detailed for airway epithelial cells, PLC activation in type 2 alveolar cells initiates the breakdown of PIP2 into IP3 and DAG [185] (Fig. 5.2). The only PLC isoform identified in type 2 cells at the mRNA and protein levels is PLC-ß3 [198]. The generation of DAG in response to ATP follows a biphasic pattern over time. The first peak occurs immediately (~10 s) after ATP treatment, and coincides with IP3 formation [185]. The second DAG peak follows with a delay of 10–15 min and coincides with the formation of phosphatidic acid (PA), or phosphatidylethanol in
114
A. Schmid et al.
the presence of ethanol, supporting the activation of a phosphatidylcholine-specific phospholipase D (PLD) [185, 195, 199]. Two PLD isoforms have been identified by RT-PCR in type 2 cells: PLD1 and PLD2 [193]. Their possible involvement in surfactant secretion is discussed below. The ATP-induced DAG formation activates PKC, of which several isoforms have been identified by RT-PCR in type 2 cells [198, 200, 201]. Incidentally, the release of DAG from a caged compound by UV-photolysis, or cell-permeable phorbol esters (TPA, OAG) directly activating PKC, are strong stimulators of surfactant secretion [202, 203]. In fact, phorbol esters degranulate type 2 cells quite effectively without a concomitant elevation of cytoplasmic Ca2+ concentration, but intracellular Ca2+ chelation abolishes this effect [202]. It was therefore proposed that PKC sensitizes the exocytotic machinery for the action of Ca2+ by a yet unknown mechanism [103, 202]. Although the effect of IP3 was never directly investigated in type 2 cells, it is reasonable to assume that IP3 formation accounts for ATP-induced Ca2+ mobilization from intracellular stores [204, 205]. The ATP-induced Ca2+ signal observed in type 2 cells consists of 2 phases, the “peak” and the “plateau” phase, analogous to a multitude of other cell types [202]. The “peak” results from Ca2+ release by intracellular stores, presumably the ER [202]. The “plateau” depends on the presence of extracellular Ca2+ and is most likely a result of Ca2+ entry through the plasma membrane [202]. The “plateau” phase in Type 2 cells is not as stable as in other cell types, but is frequently superimposed by transient Ca2+ elevations of yet unknown origin that coincide with single LB fusions with the plasma membrane [206]. Furthermore, the plasma membrane Ca2+ channels responsible for the ATP-induced “plateau” in type 2 cells have not been identified or characterized.
5.4.4
The Exocytotic Process of Surfactant
The numerous messengers and bioactive compounds generated by the purinergic stimulation of type 2 cells make a single mechanism or molecular target of exocytosis unlikely. In fact, the exocytotic process of surfactant secretion should be divided into three steps: pre-fusion, hemifusion and post-fusion phases (Fig. 5.6). Each phase is regulated differently and rate limiting for the secretion of surfactant. This model was reviewed in detail elsewhere [207] and is shortly summarized here. The pre-fusion phase denotes all events leading to the formation of fusion-competent LBs, including the trafficking and docking of LBs to the plasma membrane, creating morphological and biochemical continuity that enable lipid merger and fusion pore formation. The hemi-fusion phase involves merging of the opposing outer membrane leaflets before a fusion pore forms. The lifetime of hemi-fusion has only been measured in type 2 cells, lasting for up to 9 s under conditions of purinergic stimulation [208]. The downstream effectors of purinergic stimulation regulating the hemi-fusion phase remain unknown. Finally, the post-fusion phase denotes fusion pore expansion and release of LB contents into the alveolar space. Fusion
5 Nucleotide-Mediated Airway Clearance
115
Fig. 5.6 Surfactant exocytotic response to ATP in type II pneumocytes. The three steps of exocytosis (pre-fusion, hemi-fusion, fusion and release) are shown from left to right. Possible actions of secondary messengers after stimulation with ATP at various stages are indicated. A “?” denotes a possible action where experimental evidence is still scarce. This model supports a dual role of actin, as a barrier for release (F-actin), and a helper of release (b-actin monomers). “Polymerizing F-actin” can also push fused LBs forward on top of an actin comet tail, if fusion is transient (“kiss, coat and run”)
pore formation is the instance when the vesicle lumen and the extracellular space become an aqueous continuum, the vesicle membrane and plasma membrane a lipidic continuum. These are the most intensively investigated steps in biological and artificial systems, and hallmarks of exocytosis [209]. The term “fusion” should be clearly distinguished from “release” or “secretion”. In type 2 cells, the fusion of a LB with the plasma membrane can precede surfactant release (secretion) for long periods of time; up to hours under certain conditions (see also below). 5.4.4.1
Purinergic Control of the Pre-fusion Phase
Calcium is a ubiquitous stimulator of exocytotic fusion, and the type 2 pneumocyte is no exception. Fusion of LB with the plasma membrane is a stereotypic response to an elevation in cytoplasmic Ca2+ concentration, stimulated by UV flash photolysis of caged Ca2+ [210], the Ca2+ ionophore ionomycin [211–214], cell stretch [178, 179], or by purinergic stimulation (see above). The threshold Ca2+ concentration for LB fusion is around 320 nM, which is far lower than for cells packaging small vesicles [210]. The mechanisms by which Ca2+ elicits fusion are still unclear. The SNARE proteins named synaptotagmins are major candidates [215], as synaptotagmin II knockout mice display impaired stimulated mucin secretion which shares many features with surfactant secretion [88, 145]. Yet, there is no information available on surfactant secretion in these mice.
116
A. Schmid et al.
Another possible Ca2+ sensor responsible for LB fusion is synexin (annexin VII), which is a GTP hydrolyzing and phospholipids binding protein with fusogenic activity in various cell types [216]. Several studies suggest the involvement of synexin in Ca2+-dependent LB fusion with the plasma membrane [217–221]. This is consistent with the finding that the non-hydrolysable GTP analogue, GTPgS, stimulates LB fusion with the plasma membrane without stimulating LB-LB fusion [222]. Another way by which Ca2+ could mediate LB fusion with the plasma membrane is the disassembly of cortical actin. The idea that exocytotic fusion is limited by the cortical F-actin network, which represents a physical barrier preventing vesicle contact with the plasma membrane, was proposed for non-excitable cells [223]. This idea gained support by recent fusion studies using proteoliposomes and synaptic vesicles, where the SNARE complex, composed of syntaxin 1, SNAP-25, and synaptobrevin, acts as a constitutively active fusion machine, independently of synaptotagmin and Ca2+ [224]. Possible roles for actin in the exocytotic process were recently summarized in an excellent review [225]. A possible Ca2+ sensor for this task is scinderin, which binds phosphatidylserine, PIP2 and actin, and severs actin filaments in a Ca2+-dependent manner [225]. A role for scinderin was demonstrated in mucous cells [226], but information in type 2 cells is yet lacking. However, evidence that disassembly of the actin network does in fact enhance exocytotic LB fusion comes from a study where basal surfactant secretion was augmented after decreasing cellular F-actin levels with the Clostridium botulinum C2 toxin [227]. Among the bioactive lipid metabolites generated by purinergic stimulation that might promote LB fusion, phosphatidic acid is a particularly promising candidate because it induces negative plasma membrane curvature due to its small polar head group in combination with two fatty-acyl side chains [228], possibly promoting lipid merger with the vesicle membrane and hemi-fusion [229]. While direct evidence for this mechanism has never been presented in type 2 cells, it is supported by the observation that some type 2 cells exhibit a biphasic fusion activity (immediately after ATP treatment and >10 min later), where the early response coincides with Ca2+ mobilization, whereas the delayed response occurs at almost resting [Ca2+]c values but at times reported for phosphatidic acid generation (P. Dietl, unpublished observation).
5.4.4.2
Purinergic Control of the Post-fusion Phase
What we know about the release mechanism of surfactant from native type 2 cells in the lung still mainly comes from transmission electron microscopy investigations, where tubular myelin was postulated as the extracellular conversion product of released lamellar bodies [230]. There are numerous publications in which snapshots of the exocytotic process were depicted, some of them showing tubular myelin to originate from secreted LBs. Some of these images display fusion pores of various diameters (1 mm), through which surfactant appears to be squeezed out [193]. However, dynamic features of this process within the lung are still largely obscure.
5 Nucleotide-Mediated Airway Clearance
117
Advanced microscopy techniques enabled the visualization of the entire exocytotic process (fusion pore formation, fusion pore expansion and surfactant release) in primary cultures of type 2 cells [204, 206, 231, 232] or in situ, however with limited resolution [166]. In these ex vivo experiments, tubular myelin cannot be clearly depicted. Moreover, it appears that the hydrophobic, poorly soluble, complex of surfactant must be actively squeezed through a reluctantly opening fusion pore. Several experimental data are in line with this notion. First, fusion pores in type 2 cells have the tendency to expand very slowly [206]. Second, experiments using laser tweezers as force generators have shown that fusion pores in type 2 cells can act as mechanical barriers of surfactant release [233]. Finally, experiments with green fluorescent protein (GFP)-actin-transfected pneumocytes revealed that an actin coat must be formed around the fused LB before surfactant can be squeezed out, apparently by contraction of the actin coat [232]. This is consistent with earlier observations that actin reorganization accompanies LB exocytosis [234, 235]. In type 2 cells, ATP-induced actin coat formation is inhibited by intracellular Ca2+ immobilization with BABTA-AM, or the phospholipase D inhibitor C2 ceramide [232]. In the absence of an actin coat, the cells were unable to secrete surfactant. The fused LBs remained in a “wait” position as filled bags connected with the plasma membrane [232]. This indicates that Ca2+ and phospholipase D activation in response to ATP significantly control the post-fusion phase (release) of surfactant exocytosis. Currently, one of the most intriguing questions remaining is how actin coat formation is limited to the fused LB and does not affect all LBs in a cell stimulated with ATP (Fig. 5.6). There must be spatially and/or temporarily confined processes that cannot spread throughout the cell. Lipid merger and compartment mixing between the limiting LB membrane and the plasma membrane is the most obvious local phenomenon during exocytosis. Yu and Bement recently disclosed a signalling pathway in oocytes involving PLD-dependent DAG incorporation into the granule membrane after fusion, triggering Cdc42/N-WASP-induced actin assembly [236]. Although this still has to be investigated in type 2 cells, PLD appears to control primarily the post-fusion phase, as neither a primary alcohol which inhibits PLD-induced DAG generation, nor the PLD inhibitor C2 ceramide, can block LB fusion activity [196, 232].
5.5 5.5.1
Ciliary Beating Activity Definition: The Cilium
Ciliated cells are located in the conductive airways proximal to the respiratory bronchioles. One ciliated cell in the large airways carries about 200–250 cilia, each with a diameter of 0.3 mm and a length of 6–7 mm [237]. Along the airways, the cilia
118
A. Schmid et al.
shorten gradually with airway diameter, with their length approximating 3.5 mm in the seventh generation bronchi [238]. The core of a cilium is composed of two central microtubules surrounded by nine peripheral doublets of microtubules [239]. Besides these motile scaffolding structures made of tubulin, more than 200 proteins were found in a proteomic analysis of human airway cilia [240]. Some of these proteins provide motion to these structures and their scaffolding, namely the inner and outer dynein arms, the radial and circumferential spokes, and the inter-doublet links [241].
5.5.2
Historical Review
Since the discovery of the ATP molecule in 1929 [242], it has become clear that the continuous intracellular availability of ATP is essential for the maintenance of vital cell functions, including ciliary beating. The stimulating effect of intracellular ATP on flagellar movement was originally demonstrated by injection of ATP into the tail of Amoeba discoides [243]. Another study showed the absolute requirement of intracellular ATP by basolateral permeabilization of ciliated airway epithelial cells. Ciliary beating activity slowed down to a complete stand still after only a few minutes of basolateral perfusion with an ATP-free solution, and recovered as soon as the perfusate was replenished in ATP [244]. The underlying mechanism was elucidated by Gibbons and Rowe [245], who showed that intracellular ATP constitutes the energy source for the motor function of the dynein arms. It is interesting to note that the first description of extracellular signaling by purines was also described in 1929, the year of ATP discovery. The ADO was first purified from yeast nucleic acid and injected into animals while its effects on the heart were studied [246]. It has also been known for over 50 years that apical application of ATP to ciliated epithelia stimulates MCC. First, ATP was shown to accelerate the movement of small pieces of aluminum on dissected ciliated pharyngeal mucosa from the frog Rana Pipiens [247]. However, many scientists held the strong belief that ATP is “too precious” as an energy source for extracellular functions, and thus would not be secreted from cells and “abused” as a signal transduction initiator. Nonetheless, the work of many scientists continued, which led to the discovery of purinergic receptors in 1976 [248]. Shortly thereafter, Burnstock proposed the existence of two types of purinergic receptors, namely P1 and P2, preferentially activated by ADO and ATP, respectively [249]. Since then, three major purinoceptor families have been discovered: P1, P2Y and P2X receptors [250]. Among them, the P2Y2R is widely accepted as the most important purinergic receptor regulating ciliary beating and MCC (reviews: [65]). While the P2Y2R is equally stimulated by UTP and ATP, mammalian cells secrete ATP at a considerably higher rate than UTP [37]. Therefore, ATP and its metabolite ADO are considered the most relevant purinergic agonists for the regulation of ciliary beating in the airways.
5 Nucleotide-Mediated Airway Clearance
5.5.3
119
Importance of Ca2+ for the Regulation of Ciliary Beating
The stimulating effect of extracellular ATP on ciliary motility was first quantified optically using cultured frog palate epithelial cells [251]. However, the signaling events by which ATP caused an increase in ciliary beating frequency (CBF) were undetermined. In the 1980s, studies conducted in multiple mammalian species revealed the sensitivity of CBF to changes in cytosolic Ca2+concentration [Cac2+] [252–254]. These findings guided future research which led to the discovery that the ATP-induced increase in CBF is Ca2+ dependent [35, 36]. Eventually, the development of methods allowing the simultaneous single cell measurements of Cac2+ and CBF revealed that the temporal correlation between the fast increases in both parameters is within one beat cycle, both for purinergic and cholinergic stimulations [255, 256]. In rabbit tracheal epithelial cells, ATP caused a rapid rise in [Cac2+] and CBF within the 0.1–1,000 mM concentration range [257]. This study also showed no change in CBF upon stimulation with ATP after depletion of Ca2+ intracellular stores using thapsigargin. These, and other, experiments proved that this rapid increase in [Cac2+] and CBF, induced by ATP, is largely due to Ca2+ release from intracellular stores (review: [258]). One has to appreciate that the progress in our understanding of the signaling pathways regulating ciliary beating clearly lagged behind those of other cell functions. For instance, inositol triphosphate (IP3) was found to be responsible for the release of Ca2+ from intracellular stores induced by ATP in rat hepatocytes [259], delineating the pathway from purinergic P2Y receptors to PLC and IP3. This signaling cascade was later identified in ciliated cells [260].
5.5.4
Maintenance of Increased Ciliary Beating After Purinergic Stimulation
As a general rule, the stimulation of a ciliated cell by extracellular ATP induces a rapid increase in CBF, reaching a maximum of approximately twice the baseline value (peak) [19, 257]. During continued exposure to ATP, CBF then decreases to a frequency above baseline and remains at this level for a prolonged period of time (plateau). There is widespread agreement in the response of CBF and [Cac2+] during this initial phase of ATP stimulation in mammalian cells, including human airway epithelia (review: [258]). However, there is significant variability in the behavior in CBF and [Cac2+] after this initial peak response between species, and even between different locations (proximal versus distal airways) within the same species. In rabbit tracheal epithelial cells, prolonged ATP exposure generated a biphasic increase in CBF [257]. The initial increase was explained by Ca2+ release from two distinct stores: a small thapsigargin-insensitive store situated in close proximity to the cilia and a larger thapsigargin-sensitive store located within the cytoplasm.
120
A. Schmid et al.
The CBF plateau that followed the CBF peak was caused by Ca2+ influx, as it was not maintained within a Ca2+-free perfusate. While Ca2+store-induced Ca2+ influx clearly plays a role here, a new P2X receptor was also found to be gated by ATP in ciliated cells [261]. Influx of Ca2+ through this P2X receptor seemed partially responsible for the CBF plateau seen during prolonged ATP stimulation, at least in rabbit airway epithelial cells. It was proposed that Ca2+ influx through this receptor activates nitric oxide production, which stimulates CBF [260]. Other mechanisms have been described in different species, and they have not been assembled into a unifying paradigm (review: [258]). For instance, prolonged CBF response to ATP in rabbit epithelial cells was proposed to involve the metabolism of ATP to ADO [262]. However, ADO stimulated CBF and MCC in rabbit airway epithelia via the A3Rs [262], which are not expressed in human airway epithelia. A similar biphasic response for CBF was reported in rat tracheal epithelial cells during prolonged perfusion with apical ATP or UTP [263]. Experiments conducted in Ca2+-free perfusate allowed the development of the CBF peak, but prevented the CBF plateau. Therefore, the P2Y2R-PLC signal mobilizing Ca2+ from intracellular stores would be responsible for the initial peak, while the plateau phase was maintained by, both, P2X and P2Y receptors. The surprising finding was that the distal airway epithelial cells did not respond to ATP or UTP by an increase in CBF or [Cac2+] [263]. But the use of thapsigargin and ionomycin to increase [Cac2+], both, stimulated the ciliary beating activity [263]. These data suggest that the difference is not in the composition of the ciliary apparatus, but rather the lack of purinergic receptors in rat distal airways. Species related differences in the purinergic regulation of CBF are even reported between rodents. Using thin slices of mouse distal airways, Delmotte and Sanderson showed that ATP was able to cause an increase in [Cac2+], but had no effect on CBF [264]. This study suggests that the cilia were already maximally stimulated and could no longer respond to the changing Ca2+ concentration. In human airway epithelia, a prolonged exposure to ATP or UTP induced the general biphasic response, as CBF rose quickly to a transient peak at twice baseline, and then relaxed to a plateau above baseline. However, differences in the regulation of the plateau phase were reported for human epithelia, compared to the abovementioned animal preparations. Morse et al. showed that the plateau was significantly lower in the presence of UTP than ATP [19]. Furthermore, this ATP-induced CBF plateau phase was partially inhibited by a broad range P1 antagonist (8-sulfophenyeltheophylline) effective against A1Rs A2ARs and A2BRs, or a transmembrane adenylyl cyclase (tmAC) inhibitor (SQ22536). It was, therefore, postulated that the ATP-induced CBF plateau was, in part, mediated by the metabolism of ATP into ADO, which signals through A2BRs and tAC in human cells (review: [65]), as opposed to A3Rs in rabbits tracheal epithelial cells [262]. However, a recent study showed that even short-term application of ATP or UTP lead to a post-peak CBF plateau in human airway epithelial cells [265]. These prolonged CBF elevations persisted after removal of ATP or UTP, and were not related to nitric oxide production or ADO receptor activation. Instead, they required the activation of a Ca2+-sensitive tmAC to produce cAMP [265, 266]. In fact, the
5 Nucleotide-Mediated Airway Clearance
121
potentiating effect of cAMP on CBF is well documented [267–269]. Using real-time in vivo cAMP measurements with a PKA-FRET system, Nlend et al. showed that short-term stimulation by ATP or UTP causes concomitant increases in CBF and cytosolic cAMP concentration [266]. Taken together, these studies suggest that the CBF plateau phase triggered by ATP is maintained by cAMP signals. Cyclic AMP is produced by one of the nine known tmAC or by soluble adenylyl cyclase (sAC). Three tmAC isoforms (AC 1, 3 and 8) are stimulated by Ca2+ in different human tissues [271–273], whereas sAC is stimulated by bicarbonate [274, 275] and Ca2+ [276]. At least two Ca2+-sensitive tmAC isoforms (AC1 and AC8) are localized to the apical membrane of ciliated, human tracheo-bronchial epithelial cells [266]. The role of sAC in the purinergic stimulation of CBF remains poorly understood, but some function can be hypothesized. It is important to mention that sAC is the only AC present in cilia [277]. Since this signaling pathway is stimulated by bicarbonate, pathological conditions leading to an acidification of the airways could affect ciliary beat activity. For instance, cystic fibrosis (CF) is associated with abnormal acidification of airway epithelial cells (review: [278]). Salathe and collaborators [279] recently showed that the stimulation of CBF by sAC-derived cAMP is impaired in the cilia of bronchial epithelial cells from CF patients. While the protein levels of sAC were normal, the decrease in CBF measured during apical exposure to HCO3/CO2 was more pronounced in CF [279]. Whether the disease is characterized by hypo- or hyper-acidification of the intracellular compartments remains controversial (review: [278]). Nonetheless, this study highlights the sensitivity of sAC-mediated ciliary beating activity under pathological conditions.
5.6
Mucociliary Clearance in Airway Diseases
The critical role of MCC for airway defenses is highlighted by chronic obstructive respiratory diseases associated with genetic mutations affecting a single element of this complex signaling network. After 70 years, the “sweat chloride test” remains the gold standard for the diagnosis of CF, which emphasizes the importance of deregulated ion channel activities in this disease (review: [280]). Functional mutations targeting the CFTR gene prevent proper folding and trafficking to the apical membrane, resulting in the inability to secrete Cl into the ASL (review: [281]). The epithelia of CF patients also exhibit Na+ hyperabsorption, raising the possibility that CFTR normally restricts ENaC activity. Numerous studies conducted in heterologous expression systems showed that the surface expression of fully functional CFTR suppresses Na+ absorption by ENaC (review: [282]). The most common CFTR mutation reported in CF patients (DF508) targets the NBD1 region. Suaud et al. reported that NBD1 reduces the surface expression of ENaC by a mechanism independent of Cl transport [283]. This line of thoughts was taken further by Gentzsch et al., who recently demonstrated that physical association
122
A. Schmid et al.
between CFTR and ENaC prevents the proteolytic activation of ENaC [284]. Incidentally, the DF508 mutation on NBD1 prevented CFTR association with ENaC, resulting in enhanced Na+ and water hyperabsorption. In contrast, the nasal passages of CF patients exhibit enhanced ATP-mediated Cl secretion by CaCC [55]. The fact that this pathway is unable to compensate for the defective CFTR, despite high ATP levels reported in the airway secretions of CF patients [285], is in line with the physical nature of CFTR-mediated ENaC inhibition. Alternatively, CF up-regulates the ectonucleotidases responsible for ATP metabolism on airway surfaces, which locally reduce the availability of P2Y2R agonists for CaCC activities. In this regard, the metabolically-stable P2Y2R agonist, Denufosol, is currently undergoing phase 3 clinical trial for the treatment of airway obstruction in CF patients [56]. For CF patients, these aberrant channel activities translate into severe dehydration of airway surfaces, as defective Cl release via CFTR and excess Na+ absorption via ENaC maintain an inward osmotic gradient for water. The depletion of the ASL causes a domino effect in terms of complications, as dehydrated mucin strands adhere to epithelial cells, forming viscoelastic plugs which are, often, not cleared by coughing but require mechanical intervention [286]. Furthermore, the adhesive mucus plaques provide a nidus for bacterial colonization, leading to chronic infection and the excessive neutrophilic inflammation responsible for irreversible tissue damage and the loss of lung function. Primary ciliary dyskinesia (PCD) illustrates the importance of ciliary beating for MCC as this autosomal recessive disorder is associated with mutations affecting cilia motion. Functional changes vary from differences in CBF coordination to immobility. The term neonates suffer from respiratory distress due to a failure to rapidly and fully transition to air breathing at birth. The mechanism, although not well understood, may involve a role for cilia movement in the removal of fetal lung liquid. Other features of PCD are similar to CF, including airway obstruction, bacterial infection, bronchiectasis and gradual declines in lung function. However, these symptoms appear later in the life, likely because ion transport mechanisms regulating airway hydration are preserved in PCD patients, allowing for effective cough clearance. In the late stage of the disease, PCD patients may experience lung pathology as severe for CF patients and require lung transplantation. For these reasons, their treatment is often inspired from the protocols ascribed to CF patients. From a purinergic point of view, PCD patients with functional mutations allowing for some cilia motion may benefit from treatments with aerosolized A2BR agonists to raise CBF and clear the accumulating mucin secretions. Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation due to thickening of the bronchiolar wall by fibrosis and epithelial cell enlargement (review: [287]). Regarding MCC, whereas CF impairs hydration and PCD restricts cilia motion, COPD is associated with excess mucin from submucosal gland enlargement, mucous cell hyperplasia and metaplasia (review: [288]). In addition, the COPD patients with a smoking history target all aspects of MCC, as the toxic particles contained in cigarette smoke inhibit cilia function [289],
5 Nucleotide-Mediated Airway Clearance
123
and Cl secretion by CFTR [290] and CaCC [291]. The most compelling evidence that mucus dehydration is a major complication for COPD patients was provided by the study of Dr. Hogg et al., showing mucus adhesion and obstruction of the small airways [292]. Furthermore, since ENaC and CFTR are restricted to ciliated cells on airway epithelia [293], the severe mucus cell metaplasia is expected to weaken the capacity to maintain airway hydration. Eventually, the development of emphysema further hinders MCC as architectural damage allows airway walls to distort and collapse. Consequently, COPD patients also suffer from the inability to clear pathogens, leading to chronic airway infections and inflammation. This disease clearly demonstrates the impact of smoking on airway clearance, and explains the frequent cough reflex of smokers. COPD patients have an advantage over CF patients, which is a chance to improve MCC by giving up smoking, since toxin-related inhibition of ion channel activity appears to be reversible. In contrast, CF patients rely on P2Y2R-dependent CaCC activation, and A2BR-mediated cilia beating activity following the metabolism of ATP into ADO by the local ectonucleotidases. However, experiments conducted on CF airway epithelial cells cultured under static conditions indicated that the ASL does not maintain ATP levels sufficient to activate P2Y2Rs [70]. Exposure of these cultures to cyclic compressive stress mimicking normal tidal breathing induced ATP release and restored mucus transport. This study suggests that the medical devices used to promote MCC through rhythmic mechanical stress function, in part, through ATP release and P2Y2R-induced airway hydration. Hence, physical activity and training exercise are an important part of the clinical management of CF patients to replace the failure of cough clearance (review: [294]). Young CF patients adhering to this program maintain better MCC for extended periods of time, reduced number of exacerbations and delayed loss of lung function. Mucus hypersecretion is a hallmark of asthma and contributes to airway obstruction, wheezing and dyspnea. Nearly 25% of the airway epithelial cells are goblet cells, even in mild disease [295]. In healthy subjects, MUC5AC and MUC5B are secreted by the goblet cells of superficial epithelia and submucosal glands, respectively. As in CF and COPD, asthma is associated with an overexpression of both mucins, and MUC5B appears in the goblet cells (review: [296]). Interestingly, cultured airway epithelial cells were reported to overexpress MUC2 in response to ADO [297]. Yet, mRNA levels of MUC2 remain >20-fold lower than MUC5AC in asthmatic patients. It is, however, intriguing that MUC2 remains undetectable in the airways of CF patients, which maintain normal airway ADO levels [298]. The fact that steroid therapy prevents ATP and ADO from accumulating in the airways of asthmatics [299] supports a protective effect against the development of mucus cell metaplasia and hypersecretion. Likely, similar benefits may be associated with steroid therapy in other chronic airway diseases combining high ATP and/or ADO levels and mucus cell metaplasia, such as COPD [300] and CF [298] (see Chap. 4 for details). Finally, the well documented bronchoconstrictive effects of ADO and AMP in asthmatics are addressed in Chap. 9 from the perspective of a diagnostic application.
124
5.7
A. Schmid et al.
Conclusions
This chapter exposes the widespread ramifications of purinergic signaling in the mechanisms mediating the clearance of airborne pathogens, namely airway hydration, mucin and surfactant secretion, and coordinated ciliary beating activity. The underlying signaling pathways involve the activation of P2Y2Rs and A2BRs following ATP release from epithelial cells, and surface conversion into ADO by local ectonucleotidases. In the absence of stimulation, baseline ASL ADO levels maintain MCC through CFTR activity and cilia beating activity. Normal rhythmic breathing is expected to periodically raise ASL ATP concentrations and activate P2Y2R-dependent pathways to manufacture the mucin sheath. Since mucin strands are released in a densely packed formation, the fluid secreted in response to P2Y2R-CaCC by neighboring ciliated cells may play a critical role in proper mucin hydration and unfolding. Additionally, this excess ATP would provide substrate for ADO formation and enhance A2BR-mediated responses to evacuate excess mucin through coordinated cilia beating activity. Situations calling for an emergency response, such as physical interaction with a pathogen or coughing, would intensify both purinergic routes through robust ATP release responses and metabolism. The importance of this purinergic defense mechanism is outlined by the disastrous consequences of a single mutation on airway clearance. Acknowledgements The authors thank their many colleagues in their respective laboratories whose talents contributed to much of the work described in this review. We also think Edwin Chapman, University of Wisconsin, for permission to redraw Fig. 5.4 and for valuable thoughts on the mechanism of Ca2+/Syt-mediated exocytic fusion. The studies were supported in part by Grant 0120579 to PV from the Biocomplexity Program of the National Science Foundation, Grant HL-063756 to CWD from the National Institutes of Health, and grants to CWD from the North American Cystic Fibrosis Foundation.
References 1. Matsui H, Davis CW, Tarran R, Boucher RC (2000) Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia. J Clin Invest 105:1419–1427 2. Olver RE, Strang LB (1974) Ion fluxes across the pulmonary epithelium and the secretion of lung liquid in the foetal lamb. J Physiol 241:327–357 3. Widdicombe JH (2002) Regulation of the depth and composition of airway surface liquid. J Anat 201:313–318 4. Alcorn D, Adamson TM, Lambert TF, Maloney JE, Ritchie BC, Robinson PM (1977) Morphological effects of chronic tracheal ligation and drainage in the fetal lamb lung. J Anat 123:649–660 5. Strang LB (1991) Fetal lung liquid: secretion and reabsorption. Physiol Rev 71:991–1016 5a. Boucher RC (1994) Human airway ion transport. Am J Respir Crit 150:271–281 5b. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC (2001) The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8:149–158 6. Smith PL, Frizzell RA (1984) Chloride secretion by canine tracheal epithelium: IV Basolateral membrane K permeability parallels secretion rate. J Membr Biol 77:187–199
5 Nucleotide-Mediated Airway Clearance
125
7. Sheppard DN, Welsh MJ (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79:S23–S45 8. Schwiebert EM, Egan ME, Hwang TH, Fulmer SB, Allen SS, Cutting GR, Guggino WB (1995) CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 81:1063–1073 9. Wei L, Vankeerberghen A, Cuppens H, Eggermont J, Cassiman JJ, Droogmans G, Nilius B (1999) Interaction between calcium-activated chloride channels and the cystic fibrosis transmembrane conductance regulator. Pflugers Arch 438:635–641 10. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC (1995) CFTR as a cAMP-dependent regulator of sodium channels. Science 269:847–850 11. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ (1991) Generation of cAMPactivated chloride currents by expression of CFTR. Science 251:679–682 12. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB (1999) CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 79:S145–S166 13. Hanrahan JW, Mathews CJ, Grygorczyk R, Tabcharani JA, Grzelczak Z, Chang XB, Riordan JR (1996) Regulation of the CFTR chloride channel from humans and sharks. J Exp Zool 275:283–291 14. Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262–267 15. Huang P, Gilmore E, Kultgen P, Barnes P, Milgram S, Stutts MJ (2004) Local regulation of cystic fibrosis transmembrane regulator and epithelial sodium channel in airway epithelium. Proc Am Thorac Soc 1:33–37 16. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S, Boucher RC (2004) Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 279:36855–36864 17. Li Y, Wang W, Parker W, Clancy JP (2006) Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am J Respir Cell Mol Biol 34:600–608 18. Gonza´lez-Pe´riz A, Cla`ria J (2007) New approaches to the modulation of the cyclooxygenase2 and 5-lipoxygenase pathways. Curr Top Med Chem 7:297–309 19. Morse DM, Smullen JL, Davis CW (2001) Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells. Am J Physiol Cell Physiol 280: C1485–C1497 20. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC (2003) Ecto 50 -nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468–13479 21. Huang P, Lazarowski ER, Tarran R, Milgram SL, Boucher RC, Stutts MJ (2001) Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc Natl Acad Sci USA 98:14120–14125 22. Faria D, Schreiber R, Kunzelmann K (2009) CFTR is activated through stimulation of purinergic P2Y2 receptors. Pfl€ ugers Arch 457:1373–1380 23. Knowles MR, Clarke LL, Boucher RC (1991) Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325:533–538 24. Mason SJ, Paradiso AM, Boucher RC (1991) Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 103:1649–1656 25. Gabriel SE, Makhlina M, Martsen E, Thomas EJ, Lethem MI, Boucher RC (2000) Permeabilization via the P2X7 purinoreceptor reveals the presence of a Ca2+-activated Cl- conductance in the apical membrane of murine tracheal epithelial cells. J Biol Chem 275:35028–35033
126
A. Schmid et al.
26. Gabriel SE (2002) Calcium-activated Cl- conductance in the airway epithelium. In: Fuller CM (ed) Current topics in membranes. Elsevier Science, San Diego, pp 193–207 27. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Moller S, Edvinsson L, Erlinge D (2002) UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y6 receptors. Am J Physiol 282:H784–H792 28. Zsembery A, Fortenberry JA, Liang L, Bebok Z, Tucker TA, Boyce AT, Braunstein GM, Welty E, Bell PD, Sorscher EJ, Clancy JP, Schwiebert EM (2004) Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry. J Biol Chem 279:10720–10729 29. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492 30. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJV (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322:590–594 31. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim W-S, Park SP, Lee J, Lee B, Kim B-M, Raouf R, Shin YK, Oh U (2008) TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455:1210–1215 32. Schroeder BC, Cheng T, Jan YN, Jan LY (2008) Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134:1019–1029 33. Huang F, Rock JR, Harfe BD, Cheng T, Huang X, Jan YN, Jan LY (2009) Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Natl Acad Sci USA 106:21413–21418 34. Bove PF, Grubb BR, Okada SF, Ribeiro CM, Rogers TD, Randell SH, O’Neal WK, Boucher RC (2010) Human alveolar type II cells secrete and absorb liquid in response to local nucleotide signaling. J Biol Chem Nov 5; 285(45):34939–34949. Epub 2010, Aug 27 35. Lazarowski ER, Homolya L, Boucher RC, Harden TK (1997) Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 272:24348–24354 36. Kottgen M, Loffler T, Jacobi C, Nitschke R, Pavenstadt H, Schreiber R, Frische S, Nielsen S, Leipziger J (2003) P2Y6 receptor mediates colonic NaCl secretion via differential activation of cAMP-mediated transport. J Clin Invest 111:371–379 37. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ, Boucher RC (2000) Basal nucleotide levels, release, and metabolism in normal and cystic fibrosis airways. Mol Med 6:969–982 38. Boucher RC, Stutts MJ, Bromberg PA, Gatzy JT (1981) Regional differences in airway surface liquid composition. J Appl Physiol 50:613–620 39. Matthay MA, Landolt CC, Staub NC (1982) Differential liquid and protein clearance from the alveoli of anesthetized sheep. J Appl Physiol 53:96–104 40. Koefoed-Johnsen V, Ussing HH (1958) The nature of the frog skin potential. Acta Physiol Scand 42:298–308 41. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, Rossier BC (1994) Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 367:463–467 42. Lingueglia E, Renard S, Voilley N, Waldmann R, Chassande O, Lazdunski M, Barbry P (1993) Molecular cloning and functional expression of different molecular forms of rat amiloride-binding proteins. Eur J Biochem 216:679–687 43. Barker PM, Nguyen MS, Gatzy JT, Grubb B, Norman H, Hummler E, Rossier B, Boucher RC, Koller B (1998) Role of gENaC subunit in lung liquid clearance and electrolyte balance in newborn mice. Insights into perinatal adaptation and pseudohypoaldosteronism. J Clin Invest 102:1634–1640 44. Mall M, Grubb BR, Harkema JR, O’Neal WK, Boucher RC (2004) Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10:487–493
5 Nucleotide-Mediated Airway Clearance
127
44a. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC (2001) The relative roles of passive surface and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 118:223–236 45. Bonny O, Hummler E (2000) Dysfunction of epithelial sodium transport: from human to mouse. Kidney Int 57:1313–1318 46. Knight KK, Olson DR, Zhou R, Snyder PM (2006) Liddle’s syndrome mutations increase Na+ transport through dual effects on epithelial Na+ channel surface expression and proteolytic cleavage. Proc Natl Acad Sci USA 103:2805–2808 46a. Kerem E, Bistritzer T, Hanukoglu A, Hofman T, Zhou Z, Bennett W, Machaughlin E, Barker P, Nash M, Quittell L, Boucher R, Knowles MR (1999). Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 341:156–162 47. Gaillard EA, Kota P, Gentzsch M, Dokholyan NV, Stutts MJ, Tarran R (2010) Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases. Pfl€ugers Arch 460:1–17 48. Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC, Gabriel SE (2002) Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem 277:8338–8345 49. Tong Z, Illek B, Bhagwandin VJ, Verghese GM, Caughey GH (2004) Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. Am J Physiol 287:L928–L935 50. Bruns JB, Carattino MD, Sheng S, Maarouf AB, Weisz OA, Pilewski JM, Hughey RP, Kleyman TR (2007) Epithelial Na+ channels are fully activated by furin- and prostasindependent release of an inhibitory peptide from the gamma-subunit. J Biol Chem 282:6153–6160 51. Carattino MD, Hughey RP, Kleyman TR (2008) Proteolytic processing of the epithelial sodium channel gamma subunit has a dominant role in channel activation. J Biol Chem 283:25290–25295 52. Tarran R, Trout L, Donaldson SH, Boucher RC (2006) Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 127:591–604 53. Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, Tarran R (2009) SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci USA 106:11412–11417 54. Inglis SK, Collett A, McAlroy HL, Wilson SM, Olver RE (1999) Effect of luminal nucleotides on Cl- secretion and Na+ absorption in distal bronchi. Pflugers Arch 438:621–627 55. Mall M, Wissner A, Gonska T, Calenborn D, Kuehr J, Brandis M, Kunzelmann K (2000) Inhibition of amiloride-sensitive epithelial Na+ absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am J Respir Cell Mol Biol 23:755–761 56. Devor DC, Singh AK, Lambert LC, DeLuca A, Frizzell RA, Bridges RJ (1999) Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells. J Gen Physiol 113:743–760 57. Kunzelmann K, Bachhuber T, Regeer R, Markovich D, Sun J, Schreiber R (2005) Purinergic inhibition of the epithelial Na+ transport via hydrolysis of PIP2. FASEB J 19:142–143 57a. Boucher RC, Stutts MJ, Knowless MR, Cantley L, Gatzy JT (1986) Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 78(5):1245–1252 57b. Gentzsch M, Dang H, Dang Y, Garcia-caballero A, Suchindran H, Boucher RC, Stutts MJ (2010) The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem 285:32227–32232 58. Knowles MR, Boucher RC (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109:571–577
128
A. Schmid et al.
59. Thornton DJ, Rousseau K, McGuckin MA (2008) Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 70:459–486 60. Wine JJ (2007) Parasympathetic control of airway submucosal glands: central reflexes and the airway intrinsic nervous system. Auton Neurosci 133:35–54 61. Stutts MJ, Chinet TC, Mason SJ, Fullton JM, Clarke LL, Boucher RC (1992) Regulation of Cl- channels in normal and cystic fibrosis airway epithelial cells by extracellular ATP. Proc Natl Acad Sci USA 89:1621–1625 62. Kim KC, Lee BC (1991) P2 purinoceptor regulation of mucin release by airway goblet cells in primary culture. Br J Pharmacol 103:1053–1056 63. Davis CW, Dowell ML, Lethem M, Van Scott M (1992) Goblet cell degranulation in isolated canine tracheal epithelium: response to exogenous ATP, ADP, and adenosine. Am J Physiol 262:C1313–C1323 64. Kunzelmann K, Mall M (2003) Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2:299–309 65. Davis CW, Lazarowski E (2008) Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. Respir Physiol Neurobiol 163:208–213 66. Grygorczyk R, Hanrahan JW (1997) CFTR-independent ATP release from epithelial cells triggered by mechanical stimuli. Am J Physiol 272:C1058–C1066 67. Taylor AL, Kudlow BA, Marrs KL, Gruenert DC, Guggino WB, Schwiebert EM (1998) Bioluminescence detection of ATP release mechanisms in epithelia. Am J Physiol 275: C1391–C1406 68. Hansen M, Boitano S, Dirksen ER, Sanderson MJ (1993) Intercellular calcium signaling induced by extracellular adenosine 50 -triphosphate and mechanical stimulation in airway epithelial cells. J Cell Sci 106:995–1004 69. Homolya L, Steinberg TH, Boucher RC (2000) Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia. J Cell Biol 150:1349–1360 70. Button B, Picher M, Boucher RC (2007) Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol 580:577–592 71. Douillet CD, Robinson WP III, Zarzaur BL, Lazarowski ER, Boucher RC, Rich PB (2005) Mechanical ventilation alters airway nucleotides and purinoceptors in lung and extrapulmonary organs. Am J Respir Cell Mol Biol 32(Douillet CD):52–58 72. Abdullah LH, Davis SW, Burch L, Yamauchi M, Randell SH, Nettesheim P, Davis CW (1996) P2u purinoceptor regulation of mucin secretion in SPOC1 cells, a goblet cell line from the airways. Biochem J 316:943–951 73. Conway JD, Bartolotta T, Abdullah LH, Davis CW (2003) Regulation of mucin secretion from human bronchial epithelial cells grown in murine hosted xenografts. Am J Physiol 284:L945–L954 74. Kim KC, Hisatsune A, Kim DJ, Miyata T (2003) Pharmacology of airway goblet cell mucin release. J Pharmacol Sci 92:301–307 75. Kemp PA, Sugar RA, Jackson AD (2004) Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol 31:446–455 76. Lethem MI, Dowell ML, Van Scott M, Yankaskas JR, Egan T, Boucher RC, Davis CW (1993) Nucleotide regulation of goblet cells in human airway epithelial explants: normal exocytosis in cystic fibrosis. Am J Respir Cell Mol Biol 9:315–322 77. Davis CW, Abdullah LH (1997) In vitro models for airways mucin secretion. Pulm Pharmacol Ther 10:145–155 78. Shin CY, Kim KC, Lee WJ, Jo MJ, Park KH, Dalby R, Ko KH (2000) Inhaled ATP causes mucin release from goblet cells of intact rats. Exp Lung Res 26:1–11 79. Evans CM, Williams OW, Tuvim MJ, Nigam R, Mixides GP, Blackburn MR, DeMayo FJ, Burns AR, Smith C, Reynolds SD, Stripp BR, Dickey BF (2004) Mucin is produced by Clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol 31:382–394
5 Nucleotide-Mediated Airway Clearance
129
80. Kim KC, Park HR, Shin CY, Akiyama T, Ko KH (1996) Nucleotide-induced mucin release from primary hamster tracheal surface epithelial cells involves the P2u purinoceptor. Eur Respir J 9:542–548 81. Wolff SC, Qi A-D, Harden TK, Nicholas RA (2005) Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon. Am J Physiol 288:C624–C632 82. Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341 83. von K€ugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415–432 84. Davis CW (1997) Goblet cells: physiology and pharmacology. In: Rogers DF (ed) Airway mucus: basic mechanisms and clinical perspectives. Berkhauser, Basel, pp 150–177 85. Dubyak GR (2003) Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in different epithelia. Mol Pharmacol 63:773–776 86. Ehre C, Zhu Y, Abdullah LH, Olsen J, Nakayama KI, Nakayama K, Messing RO, Davis CW (2007) nPKCepsilon, a P2Y2-R downstream effector in regulated mucin secretion from airway goblet cells. Am J Physiol 293:C1445–C1454 87. Davis C (2002) Regulation of mucin secretion in in vitro cellular models. Norvatis Found Symp 248:113–125 88. Davis CW, Dickey BF (2008) Regulated airway goblet cell mucin secretion. Ann Rev Physiol 70:487–512 89. Rossi AH, Salmon WC, Chua M, Davis CW (2007) Calcium signaling in human airway goblet cells following purinergic activation. Am J Physiol 292:L92–L98 90. Abdullah LH, Davis CW (2007) Regulation of airway goblet cell mucin secretion by tyrosine phosphorylation signaling pathways. Am J Physiol 293:L591–L599 91. Brose N, Rosenmund C (2002) Move over protein kinase C, you’ve got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 115:4399–4411 92. Colo´n-Gonza´lez F, Kazanietz MG (2006) C1 domains exposed: from diacylglycerol binding to protein-protein interactions. Biochim Biophys Acta 1761:827–837 93. Putney JW (2009) Capacitative calcium entry: from concept to molecules. Immunol Rev 231:10–22 94. Katan M, Rodriguez R, Matsuda M, Newbatt YM, Aherne GW (2003) Structural and mechanistic aspects of phospholipase C gamma regulation. Adv Enzyme Regul 43:77–85 95. Harden TK, Sondek J (2006) Regulation of phospholipase C isozymes by Ras superfamily GTPases. Ann Rev Pharmacol Toxicol 46:355–379 96. Suh PG, Park JI, Manzoli L, Cocco L, Peak JC, Katan M, Fukami K, Kataoka T, Yun S, Ryu SH (2008) Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 41:415–434 97. Siksou L, Varoqueaux F, Pascual O, Triller A, Brose N, Marty S (2009) A common molecular basis for membrane docking and functional priming of synaptic vesicles. Eur J Neurosci 30:49–56 98. Lueck A, Yin HL, Kwiatkowski DJ, Allen PG (2000) Calcium regulation of gelsolin and adseverin: a natural test of the helix latch hypothesis. Biochemistry 39:5274–5279 99. Trifaro´ JM, Gasman S, Gutie´rrez LM (2008) Cytoskeletal control of vesicle transport and exocytosis in chromaffin cells. Acta Physiol 192:165–172 100. Malsam J, Kreye S, S€ ollner T (2008) Membrane traffic in the secretory pathway. Cell Mol Life Sci 65:2814–2832 101. S€udhof TC (2002) Synaptotagmins: why so many? J Biol Chem 277:7629–7632 102. Chapman ER (2008) How does synaptotagmin trigger neurotransmitter release? Annu Rev Biochem 77:615–641 103. Hille B, Billiard J, Babcock DF, Nguyen T, Koh DS (1999) Stimulation of exocytosis without a calcium signal. J Physiol 520:23–31
130
A. Schmid et al.
104. Abdullah LH, Conway JD, Cohn JA, Davis CW (1997) Protein kinase C and Ca2+ activation of mucin secretion in airway goblet cells. Am J Physiol 273:L201–L210 105. Kim KC, Nassiri J, Brody JS (1989) Mechanisms of airway goblet cell mucin release: studies with cultured tracheal surface epithelial cells. Am J Respir Cell Mol Biol 1:137–143 106. Dedkova EN, Sigova AA, Zinchenko VP (2000) Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. Membr Cell Biol 13:357–368 107. Scott CE, Abdullah LH, Davis CW (1998) Ca2+ and protein kinase C activation of mucin granule exocytosis in permeabilized SPOC1 cells. Am J Physiol 275:C285–C292 108. Rossi AH, Sears PR, Davis CW (2004) Ca2+ dependency of Ca2+-independent exocytosis in SPOC1 airway goblet cells. J Physiol 559:555–565 109. Rizzuto R, Pozzan T (2006) Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 86:369–408 110. Nguyen T, Chin W-C, Verdugo P (1998) Role of Ca2+/K+ ion exchange in intracellular storage and release of Ca2+. Nature 395:908–912 111. Nagy G, Kim JH, Pang ZP, Matti U, Rettig J, Sudhof TC, Sorensen JB (2006) Different effects on fast exocytosis induced by synaptotagmin 1 and 2 isoforms and abundance but not by phosphorylation. J Neurosci 26:632–643 112. Specian RD, Oliver MG (1991) Functional biology of intestinal goblet cells. Am J Physiol 260:C183–C193 113. Jeffery PK, Li D (1997) Airway mucosa: secretory cells, mucus and mucin genes. Eur Respir J 10:1655–1662 114. Verdugo P, Deyrup-Olsen I, Aitken M, Villalon M, Johnson D (1987) Molecular mechanism of mucin secretion: I. The role of intragranular charge shielding. J Dent Res 66:506–508 115. Wagner D, Puchelle E, Hinnrasky J, Girard P, Balossier G (1994) Quantitative X-ray microanalysis of P, Ca, and S in the mucus secretory granules of the cryofixed frog palate epithelium. Microsc Res Tech 28:141–148 116. Petersen OH (1996) Can Ca2+ be released from secretory granules or synaptic vesicles? Trends Neurosci 19:411–413 117. Yoo SH (2010) Secretory granules in inositol 1, 4, 5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells. FASEB J 24:653–664 118. Chin WC, Quesada I, Nguyen T, Verdugo P (2002) Oscillations of pH inside the secretory granule control the gain of Ca2+ release for signal transduction in goblet cell exocytosis. Norvatis Found Symp 248:132–141 119. Gerasimenko OV, Gerasimenko JV, Belan PV, Petersen OH (1996) Inositol trisphosphate and cyclic ADP-ribose-mediated release of Ca2+ from single isolated pancreatic zymogen granules. Cell 84:473–480 120. Blondel O, Bell GI, Seino S (1995) Inositol 1, 4, 5-trisphosphate receptors, secretory granules and secretion in endocrine and neuroendocrine cells. Trends Neurosci 18:157–161 121. Yule DI, Ernst SA, Ohnishi H, Wojcikiewicz RJ (1997) Evidence that zymogen granules are not a physiologically relevant calcium pool. Defining the distribution of inositol 1,4,5-trisphosphate receptors in pancreatic acinar cells. J Biol Chem 272:9093–9098 122. Nucifora FC Jr, Sharp AH, Milgram SL, Ross CA (1996) Inositol 1,4,5-trisphosphate receptors in endocrine cells: localization and association in hetero- and homotetramers. Mol Biol Cell 7:949–960 123. Ravazzola M, Halban PA, Orci L (1996) Inositol 1, 4, 5-trisphosphate receptor subtype 3 in pancreatic islet cell secretory granules revisited. Proc Natl Acad Sci USA 93:2745–2748 124. Thorn P (1993) Spatial aspects of Ca2+ signaling in pancreatic acinar cells. J Exp Biol 184:129–144 125. Blondel O, Moody MM, Depaoli AM, Sharp AH, Ross CA, Swift H, Bell GI (1994) Localization of inositol trisphosphate receptor subtype 3 to insulin and somatostatin secretory granules and regulation of expression in islets and insulinoma cells. Proc Natl Acad Sci USA 91:7777–7781
5 Nucleotide-Mediated Airway Clearance
131
126. Meldolesi J, Pozzan T (1995) IP3 receptors and secretory granules. Trends Neurosci 18:340–341 127. Moreno A, Lobato´n CD, Santodomingo J, Vay L, Herna´ndez-SanMiguel E, Rizzuto R, Montero M, Alvarez J (2005) Calcium dynamics in catecholamine-containing secretory vesicles. Cell Calcium 37:555–564 128. Tuvim MJ, Mospan AR, Burns KA, Chua M, Mohler PJ, Melicoff E, Adachi R, AmmarAouchiche Z, Davis CW, Dickey BF (2009) Synaptotagmin 2 couples mucin granule exocytosis to Ca2+ signaling from endoplasmic reticulum. J Biol Chem 284:9781–9787 129. Quesada I, Chin W-C, Steed J, Campos-Bedolla P, Verdugo P (2001) Mouse mast cell secretory granules can function as intracellular ionic oscillators. Biophys J 80:2133–2139 130. Quesada I, Chin W-C, Verdugo P (2003) ATP-independent luminal oscillations and release of Ca2+ and H+ from mast cell secretory granules: implications for signal transduction. Biophys J 85:963–970 131. Gerasimenko JV, Sherwood M, Tepikin AV, Petersen OH, Gerasimenko OV (2006) NAADP, cADPR and IP3 all release Ca2+ from the endoplasmic reticulum and an acidic store in the secretory granule area. J Cell Sci 119:226–238 132. Duman JG, Chen L, Palmer AE, Hille B (2006) Contributions of intracellular compartments to calcium dynamics: implicating an acidic store. Traffic 7:859–872 133. Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A (2002) NAADP mobilizes Ca2+ from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell 111:703–708 134. Mandi M, Bak J (2008) Nicotinic acid adenine dinucleotide phosphate (NAADP) and Ca2+ mobilization. J Recept Signal Transduct Res 28:163–184 135. Smith GD, Dai LX, Miura RM, Sherman A (2001) Asymptotic analysis of buffered calcium diffusion near a point source. Siam J Appl Math 61:1816–1838 136. Hay JC (2007) Calcium: a fundamental regulator of intracellular membrane fusion? EMBO Rep 8:236–240 137. Rizo J, Chen X, Arac¸ D (2006) Unraveling the mechanisms of synaptotagmin and SNARE function in neurotransmitter release. Trends Cell Biol 16:339–350 138. Cho W, Stahelin RV (2006) Membrane binding and subcellular targeting of C2 domains. Biochim Biophys Acta 1761:838–849 139. Craxton M (2004) Synaptotagmin gene content of the sequenced genomes. BMC Genomics 5:43 140. Li C, Davletov BA, S€ udhof TC (1995) Distinct Ca2+ and Sr2+ binding properties of synaptotagmins. Definition of candidate Ca2+ sensors for the fast and slow components of neurotransmitter release. J Biol Chem 270:24898–24902 141. Schonn JS, Maximov A, Lao Y, Sudhof TC, Sorensen JB (2008) Synaptotagmin-1 and -7 are functionally overlapping Ca2+ sensors for exocytosis in adrenal chromaffin cells. Proc Natl Acad Sci USA 105:3998–4003 142. Xu J, Mashimo T, S€ udhof TC (2007) Synaptotagmin-1, -2, and -9: Ca2+ sensors for fast release that specify distinct presynaptic properties in subsets of neurons. Neuron 54:567–581 143. Sun J, Pang ZP, Qin D, Fahim AT, Adachi R, Sudhof TC (2007) A dual Ca2+-sensor model for neurotransmitter release in a central synapse. Nature 450:676–682 144. Melicoff E, Sansores-Garcia L, Gomez A, Moreira DC, Datta P, Thakur P, Petrova Y, Siddiqi T, Murthy JN, Dickey BF, Heidelberger R, Adachi R (2009) Synaptotagmin-2 controls regulated exocytosis but not other secretory responses of mast cells. J Biol Chem 284:19445–19451 145. Pang ZP, Melicoff E, Padgett D, Liu Y, Teich AF, Dickey BF, Lin W, Adachi R, Sudhof TC (2006) Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromuscular synapses. J Neurosci 26:13493–13504 146. Von Neergaard K (1929) Neue Auffassungen uber einen Grundbegriff der Atemmechanik. Z Ges Exptl Med 66:373–394 147. Clements JA (1997) Lung surfactant: a personal perspective. Ann Rev Physiol 59:1–21
132
A. Schmid et al.
148. Pattle RE (1965) Surface lining of lung alveoli. Physiol Rev 45:48–79 149. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 97:517–523 150. Campiche M (1960) Lamellar inclusions of the alveolar cells in the lung of the young rat. Relation between ultrastructure and fixation. J Ultrastruct Res 3:302–312 151. Pe´rez-Gil J (2008) Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 1778:1676–1695 152. Ryan US, Ryan JW, Smith DS (1975) Alveolar type II cells: studies on the mode of release of lamellar bodies. Tisue Cell 7:587–599 153. Rooney SA, Young SL, Mendelson CR (1994) Molecular and cellular processing of lung surfactant. FASEB J 8:957–967 154. Van Golde LM, Batenburg JJ, Robertson B (1988) The pulmonary surfactant system: biochemical aspects and functional significance. Physiol Rev 68:374–455 155. Kikkawa Y, Smith F (1983) Cellular and biochemical aspects of pulmonary surfactant in health and disease. Lab Invest 49:122–139 156. Veldhuizen R, Nag K, Orgeig S, Possmayer F (1998) The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1408:90–108 157. Askin FB, Kuhn C (1971) The cellular origin of pulmonary surfactant. Lab Invest 25:260–268 158. Veldhuizen EJ, Haagsman HP (2000) Role of pulmonary surfactant components in surface film formation and dynamics. Biochim Biophys Acta 1467:255–270 159. Sch€urch S, Green FH, Bachofen H (1998) Formation and structure of surface films: captive bubble surfactometry. Biochim Biophys Acta 1408:180–202 160. Bates SR, Tao J-Q, Notarfrancesco K, DeBolt K, Shuman H, Fisher AB (2003) Effect of surfactant protein A on granular pneumocyte surfactant secretion in vitro. Am J Physiol 285: L1055–L1065 161. Gilfillan AM, Hollingsworth M, Jones AW (1983) The pharmacological modulation of [3 H]-disaturated phosphatidylcholine overflow from perifused lung slices of adult rats: a new method for the study of lung surfactant secretion. Br J Pharmacol 79:363–371 162. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581 163. Welsch U, M€uller W (1980) Electron microscopic studies of reptilian lung innervation. Z Mikrosk Anat Forsch 94:435–444 164. Tatur S, Groulx N, Orlov SN, Grygorczyk R (2007) Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by coreleased uridine nucleotides. J Physiol 584:419–435 165. Patel AS, Reigada D, Mitchell CH, Bates SR, Margulies SS, Koval M (2005) Paracrine stimulation of surfactant secretion by extracellular ATP in response to mechanical deformation. Am J Physiol 289:L489–L496 166. Ashino Y, Ying X, Dobbs LG, Bhattacharya J (2000) [Ca2+]i oscillations regulate type II cell exocytosis in the pulmonary alveolus. Am J Physiol 279:L5–L13 167. Dietl P, Frick M, Mair N, Bertocchi C, Haller T (2004) Pulmonary consequences of a deep breath revisited. Biol Neonate 85:299–304 168. Faridy EE (1976) Effect of distension on release of surfactant in excised dogs’ lungs. Respir Physiol 27:99–114 169. Hildebran JN, Goerke J, Clements JA (1981) Surfactant release in excised rat lung is stimulated by air inflation. J Appl Physiol 51:905–910 170. Massaro GD, Massaro D (1983) Morphologic evidence that large inflations of the lung stimulate secretion of surfactant. Am Rev Respir Dis 127:235–236 171. McClenahan JB, Urtnowski A (1967) Effect of ventilation on surfactant, and its turnover rate. J Appl Physiol 23:215–220 172. Nicholas TE, Barr HA (1981) Control of release of surfactant phospholipids in the isolated perfused rat lung. J Appl Physiol 51:90–98
5 Nucleotide-Mediated Airway Clearance
133
173. Nicholas TE, Power JH, Barr HA (1982) The pulmonary consequences of a deep breath. Respir Physiol 49:315–324 174. Nicholas TE, Power JH, Barr HA (1982) Surfactant homeostasis in the rat lung during swimming exercise. J Appl Physiol 53:1521–1528 175. Nicholas TE, Barr HA (1983) The release of surfactant in rat lung by brief periods of hyperventilation. Respir Physiol 52:69–83 176. Wirtz HR, Dobbs LG (2000) The effects of mechanical forces on lung functions. Respir Physiol 119:1–17 177. Tschumperlin DJ, Margulies SS (1999) Alveolar epithelial surface area-volume relationship in isolated rat lungs. J Appl Physiol 86:2026–2033 178. Frick M, Bertocchi C, Jennings P, Haller T, Mair N, Singer W, Pfaller W, Ritsch-Marte M, Dietl P (2004) Ca2+ entry is essential for cell strain-induced lamellar body fusion in isolated rat type II pneumocytes. Am J Physiol 286:L210–L220 179. Wirtz HR, Dobbs LG (1990) Calcium mobilization and exocytosis after one mechanical stretch of lung epithelial cells. Science 250:1266–1269 180. Felder E, Siebenbrunner M, Busch T, Fois G, Miklavc P, Walther P, Dietl P (2008) Mechanical strain of alveolar type II cells in culture: changes in the transcellular cytokeratin network and adaptations. Am J Physiol 295:L849–L857 181. Gajic O, Lee J, Doerr CH, Berrios JC, Myers JL, Hubmayr RD (2003) Ventilator-induced cell wounding and repair in the intact lung. Am J Respir Crit Care Med 167:1057–1063 182. Sabirov RZ, Okada Y (2005) ATP release via anion channels. Purinergic Signal 1:311–328 183. Olver RE, Walters DV, Wilson SM (2004) Developmental regulation of lung liquid transport. Annu Rev Physiol 66:77–101 184. Garcia-Verdugo I, Ravasio A, de Paco EG, Synguelakis M, Ivanova N, Kanellopoulos J, Haller T (2008) Long-term exposure to LPS enhances the rate of stimulated exocytosis and surfactant secretion in alveolar type II cells and upregulates P2Y2 receptor expression. Am J Physiol 295:L708–L717 185. Griese M, Gobran LI, Rooney SA (1991) ATP-stimulated inositol phospholipid metabolism and surfactant secretion in rat type II pneumocytes. Am J Physiol 260:L586–L593 186. Gilfillan AM, Rooney SA (1987) Purinoceptor agonists stimulate phosphatidylcholine secretion in primary cultures of adult rat type II pneumocytes. Biochim Biophys Acta 917:18–23 187. Dorn CC, Rice WR, Singleton FM (1989) Calcium mobilization and response recovery following P2-purinoceptor stimulation of rat isolated alveolar type II cells. Br J Pharmacol 97:163–170 188. Rice WR (1990) Effects of extracellular ATP on surfactant secretion. Ann NY Acad Sci 603:64–74 189. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA (2007) Regulation of surfactant secretion in alveolar type II cells. Am J Physiol 293:L259–L271 190. Chander A, Fisher AB (1990) Regulation of lung surfactant secretion. Am J Physiol 258: L241–L253 191. Mason RJ, Voelker DR (1998) Regulatory mechanisms of surfactant secretion. Biochim Biophys Acta 1408:226–240 192. Rooney SA (1998) Regulation of surfactant secretion. R.G. Landes Company, Austin 193. Rooney SA (2001) Regulation of surfactant secretion. Comp Biochem Physiol A Mol Integr Physiol 139:233–243 194. Wright JR, Dobbs LG (1991) Regulation of pulmonary surfactant secretion and clearance. Annu Rev Physiol 53:395–414 195. Gobran LI, Xu ZX, Lu Z, Rooney SA (1994) P2u purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells. Am J Physiol 267: L625–L633 196. Gobran LI, Rooney SA (1997) Adenylate cyclase-coupled ATP receptor and surfactant secretion in type II pneumocytes from newborn rats. Am J Physiol 272:L187–L196
134
A. Schmid et al.
197. Warburton D, Buckley S, Cosico L (1989) P1 and P2 purinergic receptor signal transduction in rat type II pneumocytes. J Appl Physiol 66:901–905 198. Gobran LI, Xu Z-X, Rooney SA (1998) PKC isoforms and other signaling proteins involved in surfactant secretion in developing rat type II cells. Am J Physiol 274:L901–L907 199. Rooney SA, Gobran LI (1993) Activation of phospholipase D in rat type II pneumocytes by ATP and other surfactant secretagogues. Am J Physiol 264:L133–L140 200. Chander A, Sen N, Wu AM, Spitzer AR (1995) Protein kinase C in ATP regulation of lung surfactant secretion in type II cells. Am J Physiol 268:L108–L116 201. Gobran LI, Rooney SA (1999) Surfactant secretagogue activation of protein kinase C isoforms in cultured rat type II cells. Am J Physiol 277:L251–L256 202. Frick M, Eschertzhuber S, Haller T, Mair N, Dietl P (2001) Secretion in alveolar type II cells at the interface of constitutive and regulated exocytosis. Am J Respir Cell Mol Biol 25:306–315 203. Sano K, Voelker DR, Mason RJ (1985) Involvement of protein kinase C in pulmonary surfactant secretion from alveolar type II cells. J Biol Chem 260:12725–12729 204. Haller T, Ortmayr J, Friedrich F, Volkl H, Dietl P (1998) Dynamics of surfactant release in alveolar type II cells. Proc Natl Acad Sci USA 95:1579–1584 205. Rice WR, Singleton FM (1987) P2Y-purinoceptor regulation of surfactant secretion from rat isolated alveolar type II cells is associated with mobilization of intracellular calcium. Br J Pharmacol 91:833–838 206. Haller T, Dietl P, Pfaller K, Frick M, Mair N, Paulmichl M, Hess MW, Furst J, Maly K (2001) Fusion pore expansion is a slow, discontinuous, and Ca2+-dependent process regulating secretion from alveolar type II cells. J Cell Biol 155:279–290 207. Dietl P, Haller T (2005) Exocytosis of lung surfactant: from the secretory vesicle to the airliquid interface. Annu Rev Physiol 67:595–621 208. Miklavc P, Albrecht S, Wittekindt OH, Schullian P, Haller T, Dietl P (2009) Existence of exocytotic hemifusion intermediates with a lifetime of up to seconds in type II pneumocytes. Biochem J 424:7–14 209. Jahn R, Lang T, S€ udhof TC (2003) Membrane fusion. Cell 112:519–533 210. Haller T, Auktor K, Frick M, Mair N, Dietl P (1999) Threshold calcium levels for lamellar body exocytosis in type II pneumocytes. Am J Physiol 277:L893–L900 211. Pian MS, Dobbs LG (1994) Activation of G proteins may inhibit or stimulate surfactant secretion in rat alveolar type II cells. Am J Physiol 266:L375–L381 212. Pian MS, Dobbs LG, D€ uzg€ unes N (1988) Positive correlation between cytosolic free calcium and surfactant secretion in cultured rat alveolar type II cells. Biochim Biophys Acta 960:43–53 213. Sano K, Voelker DR, Mason RJ (1987) Effect of secretagogues on cytoplasmic free calcium in alveolar type II epithelial cells. Am J Physiol 253:C679–C686 214. Griese M, Gobran LI, Rooney SA (1993) Signal-transduction mechanisms of ATP-stimulated phosphatidylcholine secretion in rat type II pneumocytes: interactions between ATP and other surfactant secretagogues. Biochim Biophys Acta 1167:85–93 215. Geppert M, Goda Y, Hammer RE, Li C, Rosahl TW, Stevens CF, Sudhof TC (1994) Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse. Cell 79:717–727 216. Caohuy H, Srivastava M, Pollard HB (1996) Membrane fusion protein synexin (annexin VII) as a Ca2+/GTP sensor in exocytotic secretion. Proc Natl Acad Sci USA 93:10797–10802 217. Sen N, Spitzer AR, Chander A (1997) Calcium-dependence of synexin binding may determine aggregation and fusion of lamellar bodies. Biochem J 322:103–109 218. Liu L, Chander A (1995) Stilbene disulfonic acids inhibit synexin-mediated membrane aggregation and fusion. Biochim Biophys Acta 1254:274–282 219. Chander A, Sen N, Spitzer AR (2001) Synexin and GTP increase surfactant secretion in permeabilized alveolar type II cells. Am J Physiol 280:L991–L998
5 Nucleotide-Mediated Airway Clearance
135
220. Chander A, Wu RD (1991) In vitro fusion of lung lamellar bodies and plasma membrane is augmented by lung synexin. Biochim Biophys Acta 1086:157–166 221. Chander A, Sen N, Naidu DG, Spitzer AR (2003) Calcium ionophore and phorbol ester increase membrane binding of annexin a7 in alveolar type II cells. Cell Calcium 33:11–17 222. Mair N, Haller T, Dietl P (1999) Exocytosis in alveolar type II cells revealed by cell capacitance and fluorescence measurements. Am J Physiol 276:L376–L382 223. Muallem S, Kwiatkowska K, Xu X, Yin HL (1995) Actin filament disassembly is a sufficient final trigger for exocytosis in nonexcitable cells. J Cell Biol 128:589–598 224. Holt M, Riedel D, Stein A, Schuette C, Jahn R (2008) Synaptic vesicles are constitutively active fusion machines that function independently of Ca2+. Curr Biol 18:715–722 225. Malacombe M, Bader MF, Gasman S (2006) Exocytosis in neuroendocrine cells: new tasks for actin. Biochim Biophys Acta 1763:1175–1183 226. Ehre C, Rossi AH, Abdullah LH, De Pestel K, Hill S, Olsen JC, Davis CW (2005) Barrier role of actin filaments in regulated mucin secretion from airway goblet cells. Am J Physiol 288:C46–C56 227. Rose F, Kurth-Landwehr C, Sibelius ULF, Reuner Karl H, Aktories K, Seeger W, Grimminger F (1999) Role of actin depolymerization in the surfactant secretory response of alveolar epithelial type II cells. Am J Respir Crit Care Med 159:206–212 228. Kooijman EE, Chupin V, De Kruijff B, Burger KNJ (2003) Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Traffic 4:162–174 229. Zeniou-Meyer M, Zabari N, Ashery U, Chasserot-Golaz S, Haeberle´ AM, Demais V, Bailly Y, Gottfried I, Nakanishi H, Neiman AM, Du G, Frohman MA, Bader MF, Vitale N (2007) Phospholipase D1 production of phosphatidic acid at the plasma membrane promotes exocytosis of large dense-core granules at a late stage. J Biol Chem 282:21746–21757 230. Williams MC (1977) Conversion of lamellar body membranes into tubular myelin in alveoli of fetal rat lungs. J Cell Biol 72:260–277 231. Haller T, Dietl P, Stockner H, Frick M, Mair N, Tinhofer I, Ritsch A, Enhorning G, Putz G (2004) Tracing surfactant transformation from cellular release to insertion into an air-liquid interface. Am J Physiol 286:L1009–L1015 232. Miklavc P, Wittekindt OH, Felder E, Dietl P (2009) Ca2+-dependent actin coating of lamellar bodies after exocytotic fusion: a prerequisite for content release or kiss-and-run. Ann NY Acad Sci 1152:43–52 233. Singer W, Frick M, Haller T, Bernet S, Ritsch-Marte M, Dietl P (2003) Mechanical forces impeding exocytotic surfactant release revealed by optical tweezers. Biophys J 84:1344–1351 234. Tsilibary EC, Williams MC (1983) Actin in peripheral rat lung: S1 labeling and structural changes induced by cytochalasin. J Histochem Cytochem 31:1289–1297 235. van Weeren L, de Graaff AM, Jamieson JD, Batenburg JJ, Valentijn JA (2004) Rab3D and actin reveal distinct lamellar body subpopulations in alveolar epithelial type II cells. Am J Respir Cell Mol Biol 30:288–295 236. Yu HE, Bement WM (2007) Control of local actin assembly by membrane fusion-dependent compartment mixing. Nat Cell Biol 9:149–159 237. Breeze RG, Wheeldon E (1977) The cells of the pulmonary airways. Am Rev Respir Dis 116:705–777 238. Serafini SM, Michaelson ED (1977) Length and distribution of cilia in human and canine airways. Bull Eur Physiopathol Respir 13:551–559 239. Nogales E, Whittaker M, Milligan RA, Downing KH (1999) High-resolution model of the microtubule. Cell 96:79–88 240. Ostrowski LE, Blackburn K, Radde KM, Moyer MB, Schlatzer DM, Moseley A, Boucher RC (2002) A proteomic analysis of human cilia: identification of novel components. Mol Cell Proteomics 1:451–465 241. Satir P, Sleigh MA (1990) The physiology of cilia and mucociliary interactions. Annu Rev Physiol 52:137–155
136
A. Schmid et al.
€ 242. Lohmann K (1929) Uber die Pyrophosphatfraktion im Muskel. Naturwissenschaften 17:624–625 243. Goldacre RJ, Lorch IJ (1950) Folding and unfolding of protein molecules in relation to cytoplasmic streaming, amoeboid movement and osmotic work. Nature 166:497–500 244. Sutto Z, Conner GE, Salathe M (2004) Regulation of human airway ciliary beat frequency by intracellular pH. J Physiol 560:519–532 245. Gibbons IR, Rowe AJ (1965) Dynein: a protein with adenosine triphosphatase activity from cilia. Science 149:424–426 246. Drury AN, Szent-Gyorgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213–237 247. Vorhaus EF, Deyrup IJ (1953) The effect of adenosine triphosphate on the cilia of the pharyngeal mucosa of the frog. Science 118:553–554 248. Burnstock G (1976) Purinergic receptors. J Theor Biol 62:491–503 249. Burnstock G (1978) A basis for distinguishing two types of purinergic receptors. In: Straub RW, Bolis L (eds) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven, New York, pp 107–118 250. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471–1483 251. Ovadyahu D, Eshel D, Priel Z (1988) Intensification of ciliary motility by extracellular ATP. Biorheology 25:489–501 252. Verdugo P (1980) Ca2+-dependent hormonal stimulation of ciliary activity. Nature 283:764–765 253. Girard PR, Kennedy JR (1986) Calcium regulation of ciliary activity in rabbit tracheal epithelial explants and outgrowth. Eur J Cell Biol 40:203–209 254. Di Benedetto G, Magnus CJ, Gray PT, Mehta A (1991) Calcium regulation of ciliary beat frequency in human respiratory epithelium in vitro. J Physiol 439:103–113 255. Salathe M, Bookman RJ (1999) Mode of Ca2+ action on ciliary beat frequency in single ovine airway epithelial cells. J Physiol 520:851–865 256. Evans JH, Sanderson MJ (1999) Intracellular calcium oscillations regulate ciliary beat frequency of airway epithelial cells. Cell Calcium 26:103–110 257. Korngreen A, Priel Z (1996) Purinergic stimulation of rabbit ciliated airway epithelia: control by multiple calcium sources. J Physiol 497:53–66 258. Salathe M (2007) Regulation of mammalian ciliary beating. Annu Rev Physiol 69:401–422 259. Charest R, Blackmore PF, Exton JH (1985) Characterization of responses of isolated rat hepatocytes to ATP and ADP. J Biol Chem 260:15789–15794 260. Uzlaner N, Priel Z (1999) Interplay between the NO pathway and elevated [Ca2+]i enhances ciliary activity in rabbit trachea. J Physiol 516:179–190 261. Korngreen A, Ma W, Priel Z, Silberberg SD (1998) Extracellular ATP directly gates a cation-selective channel in rabbit airway ciliated epithelial cells. J Physiol 508:703–720 262. Taira M, Tamaoki J, Nishimura K, Nakata J, Kondo M, Takemura H, Nagai A (2002) Adenosine A(3) receptor-mediated potentiation of mucociliary transport and epithelial ciliary motility. Am J Physiol 282:L556–L562 263. Hayashi T, Kawakami M, Sasaki S, Katsumata T, Mori H, Yoshida H, Nakahari T (2005) ATP regulation of ciliary beat frequency in rat tracheal and distal airway epithelium. Exp Physiol 90:535–544 264. Delmotte P, Sanderson MJ (2006) Ciliary beat frequency is maintained at a maximal rate in the small airways of mouse lung slices. Am J Respir Cell Mol Biol 35:110–117 265. Lieb T, Frei CW, Frohock JI, Bookman RJ, Salathe M (2002) Prolonged increase in ciliary beat frequency after short-term purinergic stimulation in human airway epithelial cells. J Physiol 538:633–646 266. Nlend MC, Schmid A, Sutto Z, Ransford GA, Conner GE, Fregien N, Salathe M (2007) Calcium-mediated, purinergic stimulation and polarized localization of calcium-sensitive adenylyl cyclase isoforms in human airway epithelia. FEBS Lett 581:3241–3246
5 Nucleotide-Mediated Airway Clearance
137
267. Di Benedetto G, Manara-Shediac FS, Mehta A (1991) Effect of cyclic AMP on ciliary activity of human respiratory epithelium. Eur Respir J 4:789–795 268. Salathe M, Pratt MM, Wanner A (1993) Cyclic AMP-dependent phosphorylation of a 26 kD axonemal protein in ovine cilia isolated from small tissue pieces. Am J Respir Cell Mol Biol 9:306–314 269. Wyatt TA, Spurzem JR, May K, Sisson JH (1998) Regulation of ciliary beat frequency by both PKA and PKG in bovine airway epithelial cells. Am J Physiol 275:L827–L835 270. Schmid A, Bai G, Schmid N, Zaccolo M, Ostrowski LE, Conner GE, Fregien N, Salathe M (2006) Real-time analysis of cAMP-mediated regulation of ciliary motility in single primary human airway epithelial cells. J Cell Sci 119:4176–4186 271. Cooper DM, Karpen JW, Fagan KA, Mons NE (1998) Ca2+-sensitive adenylyl cyclases. Adv Second Messenger Phosphoprotein Res 32:23–51 272. Webb JG, Yates PW, Yang Q, Mukhin YV, Lanier SM (2001) Adenylyl cyclase isoforms and signal integration in models of vascular smooth muscle cells. Am J Physiol 281:H1545–H1552 273. Regnauld KL, Leteurtre E, Gutkind SJ, Gespach CP, Emami S (2002) Activation of adenylyl cyclases, regulation of insulin status, and cell survival by G(alpha)olf in pancreatic betacells. Am J Physiol 282:R870–R880 274. Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, Buck J (2000) Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science 289:625–628 275. Steegborn C, Litvin TN, Levin LR, Buck J, Wu H (2005) Bicarbonate activation of adenylyl cyclase via promotion of catalytic active site closure and metal recruitment. Nat Struct Mol Biol 12:32–37 276. Litvin TN, Kamenetsky M, Zarifyan A, Buck J, Levin LR (2003) Kinetic properties of “soluble” adenylyl cyclase. Synergism between calcium and bicarbonate. J Biol Chem 278:15922–15926 277. Schmid A, Sutto Z, Nlend MC, Horvath G, Schmid N, Buck J, Levin LR, Conner GE, Fregien N, Salathe M (2007) Soluble adenylyl cyclase is localized to cilia and contributes to ciliary beat frequency regulation via production of cAMP. J Gen Physiol 130:99–109 278. Haggie PM, Verkman AS (2009) Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. Am J Physiol 296:L859–L867 279. Schmid A, Sutto Z, Schmid N, Novak L, Ivonnet P, Horvath G, Conner G, Fregien N, Salathe M (2010) Decreased soluble adenylyl cyclase activity in cystic fibrosis is related to defective apical bicarbonate exchange and affects ciliary beat frequency regulation. J Biol Chem 285:29998–30007 280. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, LeGrys VA, Massie J, Parad PB, Rock MJ, Campbell PW (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4–S14 281. Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261:5–16 282. Berdiev BK, Qadri YJ, Benos DJ (2009) Assessment of the CFTR and ENaC association. Mol Biosyst 5:123–127 283. Suaud L, Yan W, Carattino MD, Robay A, Kleyman TR, Rubenstein RC (2007) Regulatory interactions of N1303K-CFTR and ENaC in Xenopus oocytes: evidence that chloride transport is not necessary for inhibition of ENaC. Am J Physiol 292:C1553–C1561 284. Gentzsch M, Dang H, Dang Y, Garcia-Caballero A, Suchindran H, Boucher RC, Stutts MJ (2010) The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J Biol Chem Oct 15; 285:32227–32232. Epub 2010, Aug 13 285. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Pedrosa Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956
138
A. Schmid et al.
286. Livraghi A, Randell SH (2007) Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 35:116–129 287. Szilasi M, Dolinay T, Nemes Z, Strausz J (2006) Pathology of chronic obstructive pulmonary disease. Pathol Oncol Res 12:52–60 288. Randell SH, Boucher RC (2006) Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 35:20–28 289. Sisson JH, Papi A, Beckmann JD, Leise KL, Wisecarver J, Brodersen BW, Kelling CL, Spurzem JR, Rennard SI (1994) Smoke and viral infection cause cilia loss detectable by bronchoalveolar lavage cytology and dynein ELISA. Am J Respir Crit Care Med 149:205–213 290. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P (2006) Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 173:1139–1144 291. Virgin FW, Azbell C, Schuster D, Sunde J, Zhang S, Sorscher EJ, Woodworth BA (2010) Exposure to cigarette smoke condensate reduces calcium activated chloride channel transport in primary sinonasal epithelial cultures. Laryngoscope 120:1465–1469 292. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare´ PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653 293. Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas JR, Riordan JR, Boucher RC (2005) Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 16:2154–2167 294. Wilkes DL, Schneiderman JE, Nguyen T, Heale L, Moola F, Ratjen F, Coates AL, Wells GD (2009) Exercise and physical activity in children with cystic fibrosis. Paediatr Respir Rev 10:105–109 295. Shimura S, Andoh Y, Haraguchi M, Shirato K (1996) Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J 9:1395–1401 296. Evans CM, Koo JS (2009) Airway mucus: the good, the bad, the sticky. Pharmacol Ther 121:332–348 297. McNamara N, Gallup M, Khong A, Sucher A, Maltseva I, Fahy JV, Basbaum C (2004) Adenosine up-regulation of the mucin gene, MU2, in asthma. FASEB J 18:1770–1772 298. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 299. Loughlin CE, Esther CRJ, Lazarowski ER, Alexis NE, Peden DB (2010) Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics. Respir Med 104:29–33 300. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Durk T, Zissel G, Ferrari D, Di Virgilio F, Sorichter S, Lungarella G, Virchow JC, Idzko M (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934
Chapter 6
Purinergic Signaling in Wound Healing and Airway Remodeling Albert van der Vliet and Peter F. Bove
Abstract Airway epithelia are continuously damaged by airborne pollutants, pathogens and allergens, and they rely on intrinsic mechanisms to restore barrier integrity. Epithelial repair is a multi-step process including cell migration into the wounded area, proliferation, differentiation and matrix deposition. Each step requires the secretion of various molecules, including growth factors, integrins and matrix metalloproteinases. Evidence is emerging that purinergic signaling promotes repair in human airway epithelia. An injury induces ATP release, which binds P2Y2 receptors (P2Y2Rs) to initiate protein kinase C (PKC)-dependent oxidative activation of TNFa-converting enzyme (TACE), which then releases the membrane-bound ligands of the epidermal growth factor receptor (EGFR). The P2Y2R- and EGFR-dependent signaling cascades converge to induce mediator release, whereas the latter also induces cytoskeletal rearrangement for cell migration and proliferation. Similar roles for purinergic signaling are reported in pulmonary endothelial cells, smooth muscle cells and fibroblasts. In chronic airway diseases, the aberrant regulation of extracellular purines is implicated in the development of airway remodeling by mucus cell metaplasia and hypersecretion, excess collagen deposition, fibrosis and neovascularization. This chapter describes the crosstalk between these signaling cascades and discusses the impact of deregulated purinergic signaling in chronic lung diseases. Keywords Airway remodeling EGFR P2Y2 receptors Migration Wound healing
A. van der Vliet (*) Department of Pathology, University of Vermont, Burlington, VT, USA e-mail:
[email protected] P.F. Bove Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_6, # Springer Science+Business Media B.V. 2011
139
140
6.1
A. van der Vliet and P.F. Bove
Introduction
The respiratory epithelium forms a continuous lining of the airways that interfaces with the environment, and plays a critical role in maintaining a protective physical barrier against common inhaled pollutants and airborne pathogens (reviews: [1, 2]). To optimally perform these functions, the epithelium has evolved into a complex mixture of cell types working together to support the mucociliary clearance of inhaled material. The epithelium also initiates immune and inflammatory responses to an infection by the secretion of mediators and direct interaction with various cell types. The efficiency of these defense mechanisms depends on the healing capacity of the epithelium. Since the airway epithelium is continuously subjected to injurious insults, it must be capable of responding rapidly to an injury in order to restore barrier integrity and to maintain adequate lung defenses [3, 4]. Studies in animal models have shown that epithelial lesions initially provoke rapid dedifferentiation of epithelial cells near the wound edge, which spread and migrate into the wound to cover the denuded area to reestablish a continuous epithelium. Proliferation of epithelial cells in the repaired area and re-differentiation subsequently contribute to the ultimate restoration of a pseudo-stratified and functional mucociliary epithelium [5]. Microarray analysis of bronchoscopy samples, collected from human subjects 7 days after mechanical (brush) injury, revealed the presence of an epithelial “repair transcriptome” characteristic of actively proliferating cells in the process of re-differentiation [6]. Stem cells or progenitor cells exist in various areas of the lung and are believed to contribute to epithelial self-renewal. These cells may also participate in epithelial repair, although their precise role is not known [7, 8]. Our current understanding of epithelial responses to an injury in human airways has changed drastically over the past decade (reviews: [4, 7, 9]). It is well established that EGFRs are essential to the initiation of epithelial responses to damage, as they activate various signaling cascades leading to cytoskeletal rearrangement and the secretion of potent mediators of cell migration, proliferation and differentiation. In contrast, the importance of surface receptors activated by extracellular nucleotides in EGFR-mediated responses only recently emerged from shear common sense and the convergence of their signaling cascades (review: [9]). The inevitable ATP release from lysed cells supported the notion that massive leakage of this precious source of energy may act as an alarm signal for injury. This chapter provides a comprehensive description of the elegant crosstalk taking place between the purinergic mediators, growth factors and oxidative stress to rapidly restore barrier integrity.
6 Purinergic Signaling in Wound Healing and Airway Remodeling
6.2
6.2.1
141
ATP-Dependent Signaling in Epithelial Wound Responses P2YR Regulation of Epithelial Cell Migration and Proliferation
The respiratory epithelium releases ATP during normal tidal breathing, but also in response to various stresses such as mechanical injury, bacterial infection, environmental oxidants, hyperoxia or particulates. This signaling molecule, and its metabolite ADO, are well known to regulate a variety of epithelial functions through activation of purinergic receptors, such as ion transport, cilia beating and the secretion of inflammatory mediators [10–13]. Given that damaged cells release millimolar nucleotides into an injured area, it seems logical that ATP would be involved in repair mechanisms. Indeed, the contribution of purinergic events to epithelial repair has been demonstrated in intestinal and corneal epithelial cultures, where ATP and ADP promote wound closure via P2Y receptors [14–16]. Similar findings were observed in wound repair studies with the BEAS-2B bronchial epithelial cell line and tracheo-bronchial epithelial cells [16, 17]. Airway epithelial monolayers that were wounded, then washed to remove cell debris, exhibited a transient accumulation of extracellular ATP over 40 min, with a peak concentration of 40 nM [17]. Since this protocol excluded the ATP released by cell lysis, it suggests that unwounded epithelial cells release ATP, likely, in response to the mechanical stress caused by the injury. In addition, ATP was measured in condition medium, which underestimates peak concentration reached in a wounded area by several orders of magnitude. Nonetheless, the removal of endogenous ATP with apyrase, or the use of P2Y receptor antagonists, significantly reduced the rate of wound closure. These findings were confirmed by the application of exogenous ATP, or its non-hydrolysable analog ATPgS, which accelerated wound closure [16, 17]. The restoration of barrier integrity is largely mediated by coordinated migration of cell sheets into the wound area. The ability of ATP to promote migration was shown by quantitative Transwell assay, as epithelial cell migration was inhibited by apyrase or P2Y receptor antagonists [17]. Purinergic signaling also regulates the proliferation of human airway epithelial cells. In the A549 human alveolar epithelial cell line, nucleotides stimulated BrdU incorporation with a potency profile of ATP ¼ ADP > UDP ¼ UTP. This response suggests a mixed involvement of P2Y 2Rs and P2Y6Rs [18], which were identified in A549 cells by RT-PCR [19]. In contrast, ATP inhibited the proliferation of an adenocarcinoma-derived cell line from a human lung bronchial tumor (LXF-289) [20]. The potency profile (ATP ¼ ADP ¼ ATPgS >> UTP, UDP) does not support major roles for P2Y2Rs or P2Y6Rs. Nonetheless, this epithelial response was insensitive to P2X receptor agonists. RT-PCR analysis revealed that these cells express the P2 receptors encountered in primary cultures of human airway epithelial cells (P2Y2Rs, P2Y6Rs and P2X4Rs), but also P2Y11Rs (ATP > ADP >> UTP)
142
A. van der Vliet and P.F. Bove
[21] and P2Y13Rs (ADP > ATP) [22]. The aberrant purinergic regulation of wound healing by LXF-289 cells appears to be caused by receptors not normally expressed by human airway epithelia.
6.2.2
P2YR-Dependent Signaling in Pulmonary Vascular Remodeling
Purinergic signaling mediates neovascularization and vascular remodeling under hypoxic conditions associated with pulmonary hypertension [23], a common complication in asthma and chronic obstructive pulmonary disease (COPD) (review: [24]). Using a Transwell migration assay, P2Y2R activation was shown to induce the directional migration of vascular smooth muscle cells [25]. Furthermore, an upregulation of P2Y2Rs was linked to intimal hyperplasia in collared carotid arteries [26]. On isolated endothelial cells from the vasa vasorum microvessels, ATP was shown to dramatically stimulate DNA synthesis, cell migration and Matrigel tube formation, most likely via P2Y1Rs [27]. Interestingly, these purinergic responses were not observed in the pulmonary artery or aortic endothelial cells, suggesting that they are specific for small vessels [27]. In addition, hypoxia-induced ATP release from endothelial cells stimulated proliferative responses in the adventitial fibroblasts through activation of P2X and P2Y receptors [28]. These studies suggest that ATP is an important autocrine and paracrine mediator of vascular remodeling through endothelial cell and fibroblast proliferation, and adventitial thickening. In asthma, neovascularization and angiogenesis are critical events in the development of airway hyperresponsiveness.
6.3
6.3.1
Signaling Mechanisms Involved in P2YR-Mediated Responses Signaling Pathways: Ca2+ Mobilization and MAPK Activation
As mentioned earlier, the effects of extracellular nucleotides on epithelial cell migration and proliferation are primarily mediated by P2YRs, which represent a large family of G protein-coupled receptors (GPCRs) (reviews: [10, 29]). Among them, the P2Y2Rs couple to Gq, which stimulates phospholipase C b (PLCb) activity toward plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2), leading to the formation of two secondary messengers: diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) [12, 30] (Fig. 6.1). Whereas DAG propagates cellular responses via novel protein kinase C isoforms (nPKCs), the activation of IP3 receptors on the endoplasmic reticulum triggers Ca2+ release into the cytoplasm
6 Purinergic Signaling in Wound Healing and Airway Remodeling
143
Fig. 6.1 The P2Y2R-dependent signaling cascade. Injury or mechanical stress induces ATP release from epithelial cells, which binds P2Y2R coupled to the Gq subtype of G protein. Signaling through Gq activates phospholipase C (PLC), which cleaves membrane PIP2 into IP3 and DAG. The IP3 binds endoplasmic reticulum (ER) receptors, leading to Ca2+ mobilization and the activation of conventional protein kinase C isoforms (cPKCs). In contrast, DAG activates novel PKCs (nPKC) associated with the Raf/MEK/ERK1/2 signaling cascade. Other G protein coupled receptors (GPCRs), such as the thrombin receptor, are coupled to G12 and Rho to activate phospholipase D (PLD). This signaling pathway converges on the P2Y2R-dependent signaling cascade via DAG activation
and the activation of conventional PKCs (cPKCs). Other P2YRs couple to Gi, which signal through adenylate cyclase inhibition [30], such as the P2Y14Rs newly discovered on airway epithelia [31]. The complex process of cell migration involves coordinated activations of various signaling pathways in different regions of the cell [32, 33] (Fig. 6.1). At focal adhesions, the arginine-glycine-aspartic acid (RGD) domain of P2Y2Rs binds to clustered integrins (avb3 and avb5) [34]. This interaction allows P2Y2Rs coupled to G0 or G12 to activate ERK1/2-dependent signaling pathways essential for directed chemotaxis [34–36]. In 1321N1 astrocytoma cells, mutations in the RGD domain prevented UTP-induced chemotaxis [35]. On the other hand, RGD does not regulate the Gq-mediated Ca2+ mobilization, suggesting that P2Y2Rs initiate different processes depending on their cellular location. The purinergic regulation of cell migration is supported by physical interaction between P2Y2Rs and filamin A in vascular smooth muscle cells, determined by yeast two-hybrid
144
A. van der Vliet and P.F. Bove
screening [37], and the fact that mutations in this actin-binding protein prevented migration [38]. The proliferative responses induced by ATP in vasa vasorum endothelial cells and adventitial fibroblasts are mediated by multiple parallel signaling pathways, including the activation of ERK1/2 the transcription factor Egr1, and the PI3K-Akt-mTOR-p70 S6K signaling cascade [28, 39]. These signaling cascades provided the first evidence of convergence points between P2Y2R- and EGFR-dependent signaling pathways, which will be described in the following sections.
6.3.2
P2YR-Mediated Gene Regulation and Wound Responses
The localized activation of ERK1/2 by adhesion signals or growth factors has been shown to control organelle structure and cytoskeletal dynamics [32, 40], and to mediate the transcriptional activation of various genes critical in wound responses. Among these genes, MMP-9 is a type IV collagenase typically induced and activated during epithelial injury [41], and an important mediator of epithelial migration and repair [42, 43]. The expression of MMP-9 in airway epithelia is induced by the EGFR-dependent activation of ERK1/2 and PI3K/Akt signaling cascades involving nuclear translocation of the AP-1 and NFkB transcription factors [44, 45] (Fig. 6.2). Recent study shows that the induction and activation of MMP-9, in response to airway epithelial cell injury, is suppressed by P2YR antagonists or apyrase [17]. This study identified MMP-9 activation as one mechanism by which ATP-mediated P2YR activation promotes cell migration and wound repair. This purinergic signal also contributes to the up-regulation of IL-8 [46, 47], potent neutrophil chemoattractant [41]. The humanized airway xenograft model in nude mice reproduces the regeneration dynamics of injured airway epithelia, and exhibits increased epithelial production of MMP-7, MMP-9 and IL-8 [41]. These mediators work in concert to promote epithelial repair by enhancing cell migration and the recruitment of inflammatory cells to protect the wounded area against bacterial invasion [41, 48]. Finally, P2YR activation also promotes the synthesis and release of prostaglandin E2 (PGE2) by the Ca2+-mediated activation of phospholipase A2 (PLA2) [49] (Fig. 6.1), which is also a potent mediator of cell migration [50].
6.3.3
P2YR-Mediated Transactivation of EGFR-Dependent Signaling
Studies conducted with human corneal and airway epithelial cells showed that wound healing and cell migration are initiated through transactivation of the EGFR by the ligands HB-EGF and TGFa [15, 16, 51–53]. Membrane-bound
6 Purinergic Signaling in Wound Healing and Airway Remodeling
145
Fig. 6.2 The P2Y2R-mediated transactivation of EGFR in the airway epithelium. ATP released from the epithelium initiates a series of events through P2Y2Rs which lead to Ca2+ mobilization and PKC activation, which collectively stimulate the production of hydrogen peroxide (H2O2) from dual oxidase-1 (DUOX1) co-localized apically. Then TACE cleaves transforming growth factor alpha (TGFa) off the apical membrane, which then binds and activates the epidermal growth factor receptor (EGFR). The EGFR-dependent signaling cascades lead to ERK1/2 activation, which induces the expression of healing compounds including, cytokines (IL-8), matrix metalloproteinases (MMP-9) and growth factors. On the other hand, the PI3K/PDK-1/AKT cascade leads to cytoskeletal rearrangement, focal adhesion formation and migration of the cells into the wound in response to the mediators expressed via ERK1/2. For clarity, all components were placed in the same membrane, even through EGFRs are located on the basolateral surface of polarized airway epithelia
TGFa and HB-EGF engage in juxtacrine signaling between neighboring cells, whereas their soluble forms are potent chemoattractants and mitogens. In intact epithelia, the membrane-bound ligands are localized at the apical surface, and are segregated from basolaterally located EGFRs by the tight junctions [54, 55]. An epithelial injury disrupts the tight junctions and allows EGFR transactivation by solubilized ligands, which induces ERK1/2- and PI3K/Akt-dependent repair responses, including proliferation and migration [53–55]. Several mechanisms have been shown to support the GPCR-mediated activation of EGFRs (review: [56, 57]). In 1321N1 astrocytoma cells, a ligand-independent
146
A. van der Vliet and P.F. Bove
mechanism was proposed, whereby P2Y2Rs bind and activate the tyrosine kinase, Src, which phosphorylates EGFR [58]. In these cells, dual immunofluorescence labeling revealed that exogenous UTP induces the clustering of P2Y2Rs and EGFRs to facilitate EGFR activation. In corneal epithelial cultures, Block et al. identified two mechanisms for EGFR activation, depending on the distance from the wound [59]. Time-lapse microscopy analysis revealed that ATP functions as a long range messenger to activate EGFR in cells distant (>0.5 cm) from the wounded area. The signaling pathway involved ATP-mediated activation of phospholipase D (PLD) by an unknown receptor. Near the edge, EGFR activation was insensitive to apyrase, but required phosphorylation by Src kinases. On the airway surfaces, this concept of ATP as a long distance messenger was proposed earlier by Homolya et al. [60]. Their study showed that gentle mechanical stimulation of a single cell induced waves of Ca2+ mobilization even in cells on the opposite side of the wound, which were inhibited by the ATP-hydrolyzing apyrase. Human airway epithelia support a ligand-dependent mechanism for GPCRmediated EGFR activation (Fig. 6.2). This path requires sheddases of the A Disintegin And Metalloproteinase family (ADAM) to solubilize the membrane-bound EGFR ligands (HB-EGF, TGFa) [57, 61]. The injury-related ATP release promotes the P2YR-mediated activation of ADAM-17, also known as TNFa-converting enzyme (TACE), and the subsequent membrane release of EGFR ligands [16, 62]. For this reason, the remaining discussion on the purinergic regulation of EGFRmediated wound healing focuses on this ligand-dependent signaling pathway.
6.3.4
NADPH Oxidase Activation in ATP-Mediated Stress/Wound Responses
The signaling cascades initiated by P2YR activation to induce EGFR transactivation were recently shown to require the oxidation of membrane-bound proteins (reviews: [63, 64]). Airway epithelial cells express two NADPH oxidase homologues, dual oxidase-1 and -2 (DUOX1 and DUOX2). Their principal function is to generate hydrogen peroxide (H2O2), which diffuses into the extracellular milieu to assist in bacterial killing. In addition, H2O2 regulates reduction-oxidation (redox) signaling pathways by the oxidative activation or inactivation of secondary messengers. In human airway epithelia, DUOX1 was immunolocalized to the apical membrane [65] with TACE and the membrane-bound EGFR ligands. While studying the regulation of mucin secretion, Nadel et al. discovered a DUOX1-dependent signaling pathway for EGFR transactivation in human bronchial epithelial cells [66–68]. They showed that neutrophil elastase, cigarette smoke and PKC activation all increase MUC5AC expression by a signaling cascade involving the DUOX1-mediated oxidative activation of TACE, which induces the release of membrane-bound TGFa for EGFR transactivation (Fig. 6.2). Since ATP is amongst the most potent stimuli for mucin secretion, other groups tested the role of P2Y2R-dependent PKC activation for EGFR transactivation. First, Forteza et al. showed that ATP, but not ADP,
6 Purinergic Signaling in Wound Healing and Airway Remodeling
147
stimulates the apical production of H2O2 in polarized cultures of human airway epithelial cells, which was inhibited by the NADPH oxidase inhibitor, diphenyleneiodonium (DPI) [65]. In these cells, an injury induced H2O2 production, MMP-9 secretion and wound closure, which were all prevented by P2YR antagonists, apyrase or DPI [17]. Through carefully designed stepwise analysis, P2YRs were found to initiate the following signaling cascade on human airway epithelia: PKC/DUOX1/ H2O2/TACE/ pro-TGFa/ TGFa-EGFR [17, 52, 62, 69]. Collectively, these studies provide evidence that nucleotide release, initiated by epithelial damage or infection, initiates wound healing processes through P2YR-induced EGFR transactivation. The association between purinergic signaling and NADPH oxidase activation is not unique to airway epithelial cells, as similar links are emerging for cellular stress responses in macrophages, eosinophils and thyroid tumor cells [70–72]. For example, ATP release and purinergic signaling were recently implicated in neutrophil chemotaxis in response to fMLP, in association with neutrophil NADPH oxidase activation [73] (see Chap. 7 for details). Moreover, injury-induced ATP release and stimulation of P2-like receptors mediate wound responses in plants by mechanisms similarly linked to NADPH oxidase and the expression of wound response genes [74, 75]. Recently, ATP release in plant roots was found associated with regions of active growth and cell expansion, events also critically dependent on NADPH oxidase activation and oxidant generation [76]. In this respect, it is intriguing that the expression levels of P2Y2Rs and DUOX1 follow the same patterns over time in mammalian lung tissue during development [77, 78], both increasing during late gestation. These studies suggest a role for ATP-P2YRs-DUOX1 signaling during alveolar development.
6.4
6.4.1
Adenosine: Mediator of Migration and Neovascularization The ATP Metabolite, Adenosine, Promotes Migration and Angiogenesis
The release of ATP during cell injury or mechanical stress also raises the airway surface concentrations in its breakdown products, ADP, AMP and adenosine (ADO), generated by the activities of ectonucleotidases (see Chap. 2 for details) [79]. Among them, ADO is a signaling molecule which induces various cellular responses by the activation of the P1 family of G protein-coupled receptors (A1Rs, A2ARs, A2BRs, and A3Rs) (reviews: [80–82]). The general misconception that ADO does not contribute significantly to the wound healing mechanisms is based on two major factors. First, studies which compare the effects of exogenous ATP and ADO on wound closure, cell migration or proliferation generally used high micromolar concentrations of these agonists. The use of high (0.1 mM) ADO concentrations yielded no wound healing responses
148
A. van der Vliet and P.F. Bove
on epithelial cells of the airways [16, 18], the cornea [15] or the intestinal wall [14]. In contrast, carefully designed dose–response curves revealed that sub-micromolar levels of ADO (1 nM–1 mM) stimulate migration in human bronchial epithelial cells [83], and proliferation in airway smooth muscle cells [84]. In fact, higher concentrations had no effect on these wound healing responses [83, 84]. Furthermore, the maximal responses generated by ATP and ADO on the migration rates were, both, in the threefold range on BEAS-2B human bronchial epithelial cells [16, 83]. In this respect, the studies reporting a lack of response to apyrase should be revisited, since the metabolic elimination of the P2Y2R signaling would provide additional ADO for A2AR activation. The second argument for the limited role of ADO in the regulation of airway epithelial repair was based on the general notion that these cells normally express mainly (>90%) A2BRs, based on the RT-PCR analysis of mRNA level [85, 86], whereas healing properties are generally ascribed to A2ARs. However, A2ARs were functionally detected on the basolateral surface of human bronchial epithelial Calu3 cells with the selective agonist, CPCA [85]. Furthermore, using selective agonists for each ADO receptor, Allen-Gipson et al. demonstrated that ADO stimulates wound closure via A2AR activation on the BEAS-2B bronchial epithelial culture [87]. This signaling event led to the activation of protein kinase A (PKA), and selective inhibitors of PKA (KT-5720) reduced healing. In contrast, selective agonists of A1Rs and A3Rs induced PKC activation and reduced the wound closure rates [83, 87]. To this effect, it is interesting that PKA activation was shown to induce the migration of bronchial epithelial cells by disruption of the focal adhesions via inactivation of the small GTP binding protein Rho [88]. Collectively, these studies demonstrate that A2AR-mediated PKA activation is responsible for the stimulating effect of ADO on the migration of human airway epithelial cells into an injured area, by a mechanism involving cytoskeletal rearrangement. This signaling pathway also promotes extracellular matrix formation in the alveolar region. In the A549 human alveolar cell line, ADO induced the expression of fibronectin by a PKA-dependent signaling pathway involving cAMP production and the transcription factor cAMP Response Element Binding (CREB) protein [89]. Fibronectin is an essential component of the extracellular matrix also acting as a mediator of adhesion, migration and differentiation. Likewise, fibronectin was shown to induce cell proliferation and inhibit apoptosis in human bronchial epithelial cells [90]. In the vasculature, ADO is also an important mediator of cell migration and proliferation, especially during hypoxia. An emerging concept is that ADO released from hypoxic tissues has an important role in driving angiogenesis (review: [91]). The nucleoside may, either, affect endothelial cells directly, or stimulate the release of vascular endothelial growth factor (VEGF) from adjacent parenchymal cell, which binds VEGF receptor 2 on endothelial cells to stimulate proliferation and migration. In addition, ADO also directly stimulates collagen matrix formation. Collectively, these data are consistent with an in vivo study on external (dorsal excision) and internal (air pouch model) injury repair, indicating that ADO promotes healing, based on the A2AR agonist CGS-21680 and A2AR knockout mice [92].
6 Purinergic Signaling in Wound Healing and Airway Remodeling
149
Hence, the contribution of ADO to the purinergic regulation of injury repair mechanisms should be investigated further to determine any interaction with EGFR-dependent signaling pathways, and the specific cellular functions, besides migration, which could be modulated by the A2AR-PKA-Rho signaling cascade.
6.4.2
Concerted Wound Responses by ATP and Adenosine Receptors
Since both ATP and ADO appear to be important for epithelial and endothelial cell migration and wound closure, the cell surface regulation of ATP metabolism may be critical for coordinated and directed cell migration, which involves a complex array of signaling pathways in various parts of the cell [33, 93]. The importance of extracellular purine metabolism was recently illustrated in studies demonstrating that cellular migration, angiogenesis or chemotaxis was impaired in cells lacking nucleoside triphosphate diphosphohydrolase 1 (NTPDase1, CD39), a surface enzyme that can hydrolyze ATP and ADP into AMP [94–96] (see Chap. 2 for details). For example, an in vivo study showed that Matrigel plugs containing growth factor implanted in mouse tissue are rapidly populated by monocyte/macrophages, endothelial cells and pericytes, and they also developed new vessels [96]. All these responses were impaired in CD39 knockout mice. In addition, the migration of microglia was stimulated by ATP [94]. Yet, ATP-mediated migration was impaired in microglia from CD39–/– mice and could be restored by addition of ADO [94]. Similarly, studies of neutrophils showed that CD39 localizes to the leading edge of polarized cells during chemotaxis to promote local ATP hydrolysis to ADO. Whereas ATP-P2Y2R signaling maintains the directionality of chemotaxis, ADO-A3R signaling accelerates the migration [73, 95] (see Chap. 7 for details). Based on these studies, it is plausible that regulated ATP hydrolysis may be important for optimal endothelial or epithelial wound responses, which remains to be ascertained.
6.5
Purinergic Receptors in Lung Injury, Mucus Metaplasia and Fibrosis
The integrity of the respiratory epithelium is often compromised in chronic diseases, such as asthma, COPD, idiopathic pulmonary fibrosis (IPF) or cystic fibrosis (CF), due to the repetitive injurious insults, ineffective or excessive repair. Structural changes include the disruption of gap junctions, partial shedding, basal or goblet cell hyperplasia and squamous metaplasia [7, 97, 98]. The process of epithelial regeneration upon injury is complex and involves the dedifferentiation of neighboring cells, which spread and migrate into denuded areas, after which proliferation and
150
A. van der Vliet and P.F. Bove
re-differentiation restore the functional epithelium. In asthma, several of these processes may be dysfunctional and result in a chronic and/or ineffective wound healing (review: [97]). Histological studies of bronchial biopsies typically show increased signs of airway epithelial damage with epithelial shedding, consistent with the presence of clusters of sloughed epithelial cells in the sputum [4, 99]. The large airways of asthmatic subjects also feature goblet cell hyperplasia, which is responsible for the excessive mucus production that contributes to airway obstruction. Goblet cell hyperplasia is also observed in bronchial biopsies from smokers with chronic bronchitis or COPD, although they are typically not associated with the loss of epithelial cells, but with an abnormal epithelial morphology characterized by squamous cell metaplasia (review: [99]). The parenchyma of IPF patients is particularly inflicted by extensive alveolar injury, mucus cell hyperplasia, excess matrix deposition and myofibroblast activation, leading to sub-epithelial fibrosis and the loss of lung function (review: [100]). The transition of differentiated epithelial cells to a mesenchymal phenotype generates myofibroblasts that play an important role in airway remodeling and fibrosis [101, 102]. These studies highlight the major contribution of aberrant epithelial repair in airway diseases. The airways of asthmatic, CF and COPD patients all accumulate abnormally high levels of ATP. Excess airway ADO is also reported in asthmatic and COPD, but not in CF, patients [13, 81, 103–106] (see Chap. 4 for details). Considering the stimulating effects of ATP and ADO on the migration and proliferation of many lung cell types, it is quite feasible that excess purines may be involved in the functional and structural changes gradually taking place in chronic airway diseases. For instance, P2Y2R activation is well known to stimulate mucin secretion in human airway epithelia (review: [107]). Yet, a study conducted on primary cultures of human bronchial epithelial cells does not support a role for these receptors in the development of mucin-related remodeling, as UTP, but not ATP, up-regulated the expression of MUC5B and MUC5AC [108]. In contrast, human nasal epithelial cells up-regulated MUC5AC in response to ATP in a dose-dependent manner [109]. This response required the activation of PLCb3, AKT and ERK1/2, but not PKC, ruling out P2Y2Rs. It is unfortunate that they did not consider the contribution of the ADO generated from ATP metabolism, especially since this epithelial response also involved CREB activation, which requires an increase in cAMP production induced only by A2ARs or A2BRs among the purinergic receptors. Considerable evidence exists for a major role of excess extracellular ADO in the development of epithelial injury and remodeling, as demonstrated by animal models of chronic lung inflammation (review: [80]) (see Chap. 8 for details). Mice lacking adenosine deaminase (ADA), the enzyme responsible for the elimination of intracellular and extracellular ADO, develop severe complications, including the infiltration of macrophages and eosinophils, mucus hypersecretion, fibrosis and airway hyperresponsiveness [110–112]. Interestingly, strong similarities in phenotypes were noted between ADA–/– mice and IL-13 transgenic mice, which were ascribed to an interactive regulation of ADO and IL-13 in lung tissue. While ADA–/– mice exhibit high total lung ADO and IL-13 levels [113], IL-13 transgenic mice maintain high ADO levels and low ADA activity [110, 114]. The existence of an ADO-IL-13
6 Purinergic Signaling in Wound Healing and Airway Remodeling
151
amplification cycle of production is consistent with the typical airway remodeling of asthmatic patients. Their epithelial cells combine higher expression and activation of EGFR with an increased constitutive activation of Signal Transducer and Activator of Transcription (STAT)-1 and STAT6, which induce IL-13 expression (reviews: [115, 116]). Incidentally, long-term exposure to IL-13 induces mucus cell metaplasia on cultures of human bronchial epithelial cells [117, 118]. In addition, IL-13 dramatically modifies the differentiation process of ciliated cells [117]. Screening of mRNAs differentially expressed during mucociliary differentiation showed that several components involved in cell polarization (RhoA, G25K, bcatenin) were down-regulated in the presence of the cytokine, which functionally translated as lower ciliary beating frequencies. As such, factors which maintain high airway concentrations of IL-13 are expected to prevent ciliated cell differentiation and promote mucus hypersecretion. Incidentally, prolonged exposure to the stable ADO receptor agonist, NECA, raised the expression of IL-13 in primary cultures of human bronchial epithelial cells [119], supporting an indirect mechanism of airway remodeling for chronically-elevated airway ADO. Also, we presented evidence that ATP-P2YR signals activate EGFR, which induces the secretion of pro-fibrotic mediators, such as IL-13 and TGFb1 (review: [120]). In chronic inflammatory lung diseases, the excessive activation of these signaling pathways would induce abnormal or defective epithelial repair and remodeling, and eventually cause the loss of lung function.
6.6
Conclusion
The collective findings summarized in this Chapter establish important roles for ATP and ADO in various injury repair mechanisms for the airways and the vasculature, by the activation of a variety of purinergic receptors. While these mechanisms may be critical for normal wound responses and repair processes, such as epithelial regeneration or neovascularization, inappropriate regulation of purine release and/or metabolism in asthma, CF and COPD appear to precipitate the progression of lung complications. The crosstalk and convergence points identified between the purinergic and EGFR-dependent signaling pathways may eventually lead to the identification of novel targets for the prevention and/or reduction of the inadequate and problematic responses to injury.
References 1. Kato A, Schleimer RP (2007) Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 19:711–720 2. Bartlett JA, Fischer AJ, McCray PBJ (2008) Innate immune functions of the airway epithelium. Contrib Microbiol 15:147–163
152
A. van der Vliet and P.F. Bove
3. Erjefalt JS, Persson CG (1997) Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 52:1010–1012 4. Knight DA, Holgate ST (2003) The airway epithelium: structural and functional properties in health and disease. Respirology 8:432–446 5. Park KS, Wells JM, Zorn AM, Wert SE, Laubach VE, Fernandez LG, Whitsett JA (2006) Transdifferentiation of ciliated cells during repair of the respiratory epithelium. Am J Respir Cell Mol Biol 34:151–157 6. Heguy A, Harvey BG, Leopold PL, Dolgalev I, Raman T, Crystal RG (2007) Responses of the human airway epithelium transcriptome to in vivo injury. Physiol Genomics 29:139–148 7. Coraux C, Roux J, Jolly T, Birembaut P (2008) Epithelial cell-extracellular matrix interactions and stem cells in airway epithelial regeneration. Proc Am Thorac Soc 5:689–694 8. Rawlins EL, Ostrowski LE, Randell SH, Hogan BL (2007) Lung development and repair: contribution of the ciliated lineage. Proc Natl Acad Sci USA 104:410–417 9. Burgel PR, Nadel JA (2008) Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 32:1068–1081 10. Ahmad S, Ahmad A, White CW (2006) Purinergic signaling and kinase activation for survival in pulmonary oxidative stress and disease. Free Radic Biol Med 41:29–40 11. Lazarowski ER, Boucher RC, Harden TK (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 64:785–795 12. Schwiebert EM, Zsembery A (2003) Extracellular ATP as a signaling molecule for epithelial cells. Biochim Biophys Acta 1615:7–32 13. Caruso M, Holgate ST, Polosa R (2006) Adenosine signaling in airways. Curr Opin Pharmacol 6:251–256 14. Dignass AU, Becker A, Spiegler S, Goebell H (1998) Adenine nucleotides modulate epithelial wound healing in vitro. Eur J Clin Invest 28:554–561 15. Klepeis VE, Weinger I, Kaczmarek E, Trinkaus-Randall V (2004) P2Y receptors play a critical role in epithelial cell communication and migration. J Cell Biochem 93:1115–1133 16. Yin J, Xu K, Zhang J, Kumar A, Yu FS (2007) Wound-induced ATP release and EGF receptor activation in epithelial cells. J Cell Sci 120:815–825 17. Wesley UV, Bove PF, Hristova M, McCarthy S, van der Vliet A (2007) Airway epithelial cell migration and wound repair by ATP-mediated activation of dual Oxidase 1. J Biol Chem 282:3213–3220 18. Schafer R, Sedehizade F, Welte T, Reiser G (2003) ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol 285: L376–L385 19. Communi D, Paindavoine P, Place GA, Parmentier M, Boeynaems JM (1999) Expression of P2Y receptors in cell lines derived from the human lung. Br J Pharmacol 127:562–568 20. Schafer R, Hartig R, Sedehizade F, Welte T, Reiser G (2006) Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor kappaB1 and mitogen-activated protein kinase pathways. FEBS J 273:3756–3767 21. Communi D, Robaye B, Boeynaems J-M (1999) Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol 128:1199–1206 22. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems J-M, Gonzalez NS (2003) Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 64:104–112 23. Gerasimovskaya EV, Davie NJ, Ahmad S, Tucker DA, White CW, Stenmark KR (2005) Extracellular adenosine triphosphate: a potential regulator of vasa vasorum neovascularization in hypoxia-induced pulmonary vascular remodeling. Chest 128:608S–610S 24. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH (2003) Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 123:222–243
6 Purinergic Signaling in Wound Healing and Airway Remodeling
153
25. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau AP (2001) Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res 89:772–778 26. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner JT, Sturek M, Gonzalez FA, Weisman GA (2002) Functional P2Y2 nucleotide receptors mediate uridine 50 -triphosphateinduced intimal hyperplasia in collared rabbit carotid arteries. Circulation 106:2720–2726 27. Gerasimovskaya EV, Woodward HN, Tucker DA, Stenmark KR (2008) Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vasorum endothelial cells. Angiogenesis 11:169–182 28. Gerasimovskaya EV, Ahmad S, White CW, Jones PL, Carpenter TC, Stenmark KR (2002) Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth. Signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor. J Biol Chem 277:44638–44650 29. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM (2000) Advances in signaling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. Cell Signal 12:351–360 30. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492 31. Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC Jr, Luttmann W, Norgauer J, Di Virgilio F, Idzko M (2005) The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion. Am J Respir Cell Mol Biol 33:601–609 32. Chodniewicz D, Klemke RL (2004) Guiding cell migration through directed extension and stabilization of pseudopodia. Exp Cell Res 301:31–37 33. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR (2003) Cell migration: integrating signals from front to back. Science 302:1704–1709 34. Chorna NE, Chevres M, Santos-Berrios C, Orellano EA, Erb L, Gonzalez FA (2007) P2Y2 receptors induced cell surface redistribution of alpha(v) integrin is required for activation of ERK 1/2 in U937 cells. J Cell Physiol 211:410–422 35. Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA, Erb L (2005) The P2Y2 nucleotide receptor interacts with alpha v integrins to activate Go and induce cell migration. J Biol Chem 280:39050–39057 36. Liao Z, Seye CI, Weisman GA, Erb L (2007) The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12. J Cell Sci 120:1654–1662 37. Yu N, Erb L, Shivaji R, Weisman GA, Seye CI (2008) Binding of the P2Y2 nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. Circ Res 102:581–588 38. Fox JW, Lamperti ED, YZ Ek_io lu, Hong SE, Feng Y, Graham DA, Scheffer IE, Dobyns WB, Hirsch BA, Radtke RA, Berkovic SF, Huttenlocher PR, Walsh CA (1998) Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron 21:1315–1325 39. Gerasimovskaya EV, Tucker DA, Weiser-Evans M, Wenzlau JM, Klemm DJ, Banks M, Stenmark KR (2005) Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of rapamycin, and p70 S6 kinase signaling pathways. J Biol Chem 280:1838–1848 40. Pullikuth AK, Catling AD (2007) Scaffold mediated regulation of MAPK signaling and cytoskeletal dynamics: a perspective. Cell Signal 19:1621–1632 41. Coraux C, Martinella-Catusse C, Nawrocki-Raby B, Hajj R, Burlet H, Escotte S, Laplace V, Birembaut P, Puchelle E (2005) Differential expression of matrix metalloproteinases and interleukin-8 during regeneration of human airway epithelium in vivo. J Pathol 206:160–169 42. Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, Kaplan H, Birembaut P, Tournier JM (1999) Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol 146:517–529
154
A. van der Vliet and P.F. Bove
43. Bove PF, Wesley UV, Greul AK, Hristova M, Dostmann WR, van der Vliet A (2007) Nitric oxide promotes airway epithelial wound repair through enhanced activation of MMP-9. Am J Respir Cell Mol Biol 36:138–146 44. Adiseshaiah P, Vaz M, Machireddy N, Kalvakolanu DV, Reddy SP (2008) A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J Cell Physiol 216:405–412 45. Okamoto T, Valacchi G, Gohil K, Akaike T, van der Vliet A (2002) S-nitrosothiols inhibit cytokine-mediated induction of matrix metalloproteinase-9 in airway epithelial cells. Am J Respir Cell Mol Biol 27:463–473 46. McNamara N, Gallup M, Sucher A, Maltseva I, McKemy D, Basbaum C (2006) AsialoGM1 and TLR5 cooperate in flagellin-induced nucleotide signaling to activate Erk1/2. Am J Respir Cell Mol Biol 34:653–660 47. Fu Z, Bettega K, Carroll S, Buchholz KR, Machen TE (2007) Role of Ca2+ in responses of airway epithelia to Pseudomonas aeruginosa, flagellin, ATP, and thapsigargin. Am J Physiol 292:L353–L364 48. Gillitzer R, Goebeler M (2001) Chemokines in cutaneous wound healing. J Leukoc Biol 69:513–521 49. Marcet B, Libert F, Boeynaems JM, Communi D (2007) Extracellular nucleotides induce COX-2 up-regulation and prostaglandin E2 production in human A549 alveolar type II epithelial cells. Eur J Pharmacol 566:167–171 50. Savla U, Appel HJ, Sporn PH, Waters CM (2001) Prostaglandin E(2) regulates wound closure in airway epithelium. Am J Physiol 280:L421–L431 51. Boucher I, Yang L, Mayo C, Klepeis V, Trinkaus-Randall V (2007) Injury and nucleotides induce phosphorylation of epidermal growth factor receptor: MMP and HB-EGF dependent pathway. Exp Eye Res 85:130–141 52. Koff JL, Shao MX, Kim S, Ueki IF, Nadel JA (2006) Pseudomonas lipopolysaccharide accelerates wound repair via activation of a novel epithelial cell signaling cascade. J Immunol 177:8693–8700 53. Block ER, Matela AR, SundarRaj N, Iszkula ER, Klarlund JK (2004) Wounding induces motility in sheets of corneal epithelial cells through loss of spatial constraints: role of heparin-binding epidermal growth factor-like growth factor signaling. J Biol Chem 279:24307–24312 54. Vermeer PD, Panko L, Welsh MJ, Zabner J (2006) erbB1 functions as a sensor of airway epithelial integrity by regulation of protein phosphatase 2A activity. J Biol Chem 281:1725–1730 55. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ (2003) Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422:322–326 56. Luttrell LM, Daaka Y, Lefkowitz RJ (1999) Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 11:177–183 57. Rozengurt E (2007) Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213:589–602 58. Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Perez LI, Gonzalez FA, Seye CI, Weisman GA, Erb L (2004) Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J Biol Chem 279:8212–8218 59. Block ER, Klarlund JK (2008) Wounding sheets of epithelial cells activates the epidermal growth factor receptor through distinct short- and long-range mechanisms. Mol Biol Cell 19:4909–4917 60. Homolya L, Steinberg TH, Boucher RC (2000) Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia. J Cell Biol 150:1349–1360 61. Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol 291:C1–C10
6 Purinergic Signaling in Wound Healing and Airway Remodeling
155
62. Boots AW, Hristova M, Kasahara DI, Haenen GR, Bast A, van der Vliet A (2009) ATP-mediated activation of the NADPH oxidase DUOX1 mediates airway epithelial responses to bacterial stimuli. J Biol Chem 284:17858–17867 63. van der Vliet A (2008) NADPH oxidases in lung biology and pathology: host defense enzymes, and more. Free Radic Biol Med 44:938–955 64. Terada LS (2006) Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 174:615–623 65. Forteza R, Salathe M, Miot F, Conner GE (2005) Regulated hydrogen peroxide production by Duox in human airway epithelial cells. Am J Respir Cell Mol Biol 32:462–469 66. Shao MXG, Nadel JA (2005) Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 175:4009–4016 67. Shao MXG, Nakanaga T, Nadel JA (2004) Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol 287:L420–L427 68. Shao MXG, Nadel JA (2005) Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci 102:767–772 69. Nakanaga T, Nadel JA, Ueki IF, Koff JL, Shao MX (2007) Regulation of interleukin-8 via an airway epithelial signaling cascade. Am J Physiol 292:L1289–L1296 70. Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, Ojcius DM (2007) ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem 282:2871–2879 71. Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M, Kelley MR, Quadrifoglio F, Tell G (2005) Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res 33:4379–4394 72. Dichmann S, Idzko M, Zimpfer U, Hofmann C, Ferrari D, Luttmann W, Virchow C Jr, Di Virgilio F, Norgauer J (2000) Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca2+ mobilization and actin reorganization in human eosinophils. Blood 95:973–978 73. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792–1795 74. Song CJ, Steinebrunner I, Wang X, Stout SC, Roux SJ (2006) Extracellular ATP induces accumulation of superoxide via NADPH oxidases in Arabidopsis. Plant Physiol 140:1222–1232 75. Jeter CR, Roux SJ (2006) Plant responses to extracellular nucleotides: cellular processes and biological effects. Purinergic Signal 2:443–449 76. Kim SY, Sivaguru M, Stacey G (2006) Extracellular ATP in plants. Visualization, localization, and analysis of physiological significance in growth and signaling. Plant Physiol 142:984–992 77. Cheung KK, Ryten M, Burnstock G (2003) Abundant and dynamic expression of G proteincoupled P2Y receptors in mammalian development. Dev Dyn 228:254–266 78. Fischer H, Gonzales LK, Kolla V, Schwarzer C, Miot F, Illek B, Ballard PL (2007) Developmental regulation of DUOX1 expression and function in human fetal lung epithelial cells. Am J Physiol 292:L1506–L1514 79. Burch LH, Picher M (2006) E-NTPDases in human airways: regulation and relevance for chronic lung diseases. Purinergic Signal 2:399–408 80. Mohsenin A, Blackburn MR (2006) Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 12:54–59 81. Brown RA, Spina D, Page CP (2008) Adenosine receptors and asthma. Br J Pharmacol 153 (1):S446–S456 82. Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315–1323
156
A. van der Vliet and P.F. Bove
83. Allen-Gipson DS, Spurzem K, Kolm N, Spurzem JR, Wyatt TA (2007) Adenosine promotion of cellular migration in bronchial epithelial cells is mediated by the activation of cyclic adenosine monophosphate-dependent protein kinase A. J Investig Med 55:378–385 84. Michoud M-C, Napolitano G, Maghni K, Govindaraju V, Cogo A, Martin JG (2002) Effects of extracellular triphosphate nucleotides and nucleosides on airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol 27:732–738 85. Szkotak AJ, Ng AM, Man SF, Baldwin SA, Cass CE, Young JD, Duszyk M (2003) Coupling of CFTR-mediated anion secretion to nucleoside transporters and adenosine homeostasis in Calu-3 cells. J Membr Biol 192:169–179 86. Rollins BM, Burn M, Coakley RD, Chambers LA, Hirsh AJ, Clunes MT, Lethem MI, Donaldson SH, Tarran R (2008) A2B adenosine receptors regulate the mucus clearance component of the lung’s innate defense system. Am J Respir Cell Mol Biol 39:190–197 87. Allen-Gipson DS, Wong J, Spurzem JR, Sisson JH, Wyatt TA (2006) Adenosine A2A receptors promote adenosine-stimulated wound healing in bronchial epithelial cells. Am J Physiol 290:L849–L855 88. Spurzem JR, Gupta J, Veys T, Kneifl KR, Rennard SI, Wyatt TA (2002) Activation of protein kinase A accelerates bovine bronchial epithelial cell migration. Am J Physiol 282: L1108–L1116 89. Roman J, Rivera HN, Roser-Page S, Sitaraman SV, Ritzenthaler JD (2006) Adenosine induces fibronectin expression in lung epithelial cells: implications for airway remodeling. Am J Physiol 290:L317–L325 90. Han SW, Roman J (2006) Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappaB. Oncogene 25:4341–4349 91. Feoktistov I, Biaggioni I, Cronstein BN (2009) Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol 193:383–397 92. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN (2002) Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am J Pathol 160:2009–2018 93. Jones MC, Caswell PT, Norman JC (2006) Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol 18:549–557 94. Farber K, Markworth S, Pannasch U, Nolte C, Prinz V, Kronenberg G, Gertz K, Endres M, Bechmann I, Enjyoji K, Robson SC, Kettenmann H (2008) The ectonucleotidase CD39/NTPDase1 modulates purinergic-mediated microglial migration. Glia 56:331–341 95. Corriden R, Chen Y, Inoue Y, Beldi G, Robson S, Insel PA, Junger WG (2008) Ectonucleoside triphosphate-diphosphohydrolase 1 (NTPDASE1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283(42):28480–28486 96. Goepfert C, Sundberg C, Sevigny J, Enjyoji K, Hoshi T, Csizmadia E, Robson S (2001) Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104:3109–3115 97. Holgate ST (2008) The airway epithelium is central to the pathogenesis of asthma. Allergol Int 57:1–10 98. Fedorov IA, Wilson SJ, Davies DE, Holgate ST (2005) Epithelial stress and structural remodelling in childhood asthma. Thorax 60:389–394 99. Jeffery PK (2004) Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1:176–183 100. Scotton CJ, Chambers R (2007) Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132:1311–1321 101. Horowitz JC, Thannickal VJ (2006) Epithelial-mesenchymal interactions in pulmonary fibrosis. Semin Respir Crit Care Med 27:600–612 102. Willis BC, Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol 293:L525–L534
6 Purinergic Signaling in Wound Healing and Airway Remodeling
157
103. Driver AG, Kukoly CA, Ali S, Mustafa SJ (1993) Adenosine in the bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148:91–97 104. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Pedrosa Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 105. Esther CR Jr, Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, Boucher RC (2009) Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol 296:L987–L993 106. Adriaensen D, Timmermans JP (2004) Purinergic signaling in the lung: important in asthma and COPD? Curr Opin Pharmacol 4:207–214 107. Davis CW, Lazarowski E (2008) Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. Respir Physiol Neurobiol 163:208–213 108. Chen Y, Zhao YH, Wu R (2001) Differential regulation of airway mucin gene expression and mucin secretion by extracellular nucleotide triphosphates. Am J Respir Cell Mol Biol 25:409–417 109. Song KS, Lee TJ, Kim KT, Chung KC, Yoon JH (2008) cAMP-responding element-binding protein and c-Ets1 interact in the regulation of ATP-dependent MUC5AC gene expression. J Biol Chem 283:26869–26878 110. Blackburn MR, Datta SK, Kellems RE (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273:5093–5100 111. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE (1996) Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem 271:15203–15210 112. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR (2001) Adenosinedependent airway inflammation and hyperresponsiveness in partially adenosine deaminasedeficient mice. J Immunol 167:4676–4685 113. Chunn JL, Mohsenin A, Young HWJ, Lee CG, Elias JA, Kellems RE, Blackburn MR (2006) Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am J Physiol 290:L579–L587 114. Blackburn K, Lee CG, Young HWJ, Zhu Z, Chunn JL, Kang MJ, Banerjee SK, Elias JA (2003) Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest 112:332–344 115. Kuperman DA, Schleimer RP (2008) Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 8:384–392 116. Tesfaigzi Y (2008) Regulation of mucous cell metaplasia in bronchial asthma. Curr Mol Med 8:408–415 117. Laoukili J, Perret E, Willems T, Minty A, Parthoens E, Houcine O, Coste A, Jorissen M, Marano F, Caput D, Tournier F (2001) IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J Clin Invest 108:1817–1824 118. Okada SF, Zhang L, Kreda SM, Abdullah LH, Davis CW, Pickles RJ, Lazarowski ER, Boucher RC (2010) Coupled nucleotide and mucin hypersecretion from goblet cell metaplastic human airway epithelium. Am J Respir Cell Mol Biol (in press) 119. Hirsh AJ, Stonebraker J, van Heusden CA, Lazarowski ER, Boucher RC, Picher M (2007) Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases. Biochemistry 46:10373–10383 120. Wilson MS, Wynn TA (2009) Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2:103–121
Chapter 7
Purinergic Regulation of Airway Inflammation Michael Koeppen, Francesco Di Virgilio, Eric T. Clambey, and Holger K. Eltzschig
Abstract The immune and inflammatory responses initiated by the interaction of a pathogen with airway surfaces constitute vital mechanisms to eradicate an infection. Sentinel dendritic cells embedded in the mucosa migrate to the lymph nodes to induce immune responses, whereas epithelial cells release chemokines to recruit inflammatory cells engaged in the active destruction of the intruder. All immune and inflammatory cells are regulated by customized purinergic networks of receptors and ectonucleotidases. The general concept is that bacterial products induce ATP release, which activates P2 receptors to initiate an inflammatory response, and is terminated by the conversion of ATP into adenosine (ADO) to initiate P1 receptormediated negative feedback responses. However, this chapter exposes a far more complex purinergic regulation of critical functions, such as the differentiation of naive lymphocytes and the complex maturation and secretion of pro-cytokines (i.e. IL-1b) by the “inflammasome”. This material also reconciles decades of research by exposing the specificity and plasticity of the signaling network expressed by each immune and inflammatory cell, which changes through cell differentiation and in response to infectious or inflammatory mediators. By the end of this chapter, the reader will have a new appreciation for this aspect of airway defenses, and several leads in terms of therapeutic applications for the treatment of chronic respiratory diseases. Keywords Chemotaxis Inflammasome P2X7 Phagocytosis Th17
M. Koeppen, E.T. Clambey, and H.K. Eltzschig Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA e-mail:
[email protected];
[email protected];
[email protected] F. Di Virgilio (*) Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_7, # Springer Science+Business Media B.V. 2011
159
160
7.1
M. Koeppen et al.
Introduction
Although this field has witnessed an explosive development over the latest 10 years, the notion that extracellular ATP and ADO are key regulators of immunity and inflammation is still alien to most immunologists. Strong effort is needed to overcome this stubborn and unjustified scepticism surrounding a vital aspect of immune regulation. The reader is referred to several excellent reviews that have been published lately on this topic [1–13] and to the special issue of “Purinergic signaling in the immune system” [14]. Technical advances are an irreplaceable complement of scientific intuition. The study of extracellular purines and pyrimidines is no exception to this rule, as witnessed by the boost provided to the purinergic hypothesis by the recent development of sensitive and reliable methods to measure ADO and ATP levels in whole tissues, and even in living animals. There is no doubt that the prophetic vision of Geoff Burnstock, which led to the groundbreaking discovery that ATP is an extracellular signaling molecule, opened the realm of purinergic signaling to scientific investigation (review: [15]). Yet, it would be difficult to persuade the scientific community of the crucial biological relevance of this notion without the help of novel techniques providing direct proof that extracellular ADO and ATP accumulate in vivo during pathophysiologically relevant responses. In recent years, Nicholas Dale perfectioned a bioelectrode technique for the measurement of ADO and ATP in conscious animals [16–18]. His group measured ATP and ADO concentration in the hypothalamus of rabbits during systemic inflammation [18]. However, these experiments did not address whether ADO and ATP levels change locally at inflammatory sites. Nevertheless, they document a clear temporal relationship between inflammation and purines within the brain, establishing a strong link between extracellular purine in the hypothalamus and fever, a common symptom of inflammation. Di Virgilio et al. developed a luminescence assay that allows in vivo imaging of extracellular ATP [19, 20]. They hypothesized that a cell expressing an “ecto-luciferase” might be used as an in vivo reporter of local extracellular ATP levels. The anticipation was that “ecto-luciferase-engineered” clones, once inoculated into live mice, would retain their ability to sense the ATP concentration of the tissue microenvironment and signal any change. Firefly luciferase is generally used as a reporter of gene expression [21]. A relevant exception is the recent use of luciferase in plants to measure extracellular ATP during root growth [22, 23]. These investigators constructed a chimera by appending a cellulose-binding peptide to firefly luciferase that was targeted to the plant root cell wall, and allowed recording of ATP levels on the root surface. Di Virgilio et al. followed a similar approach to engineer a construct in which luciferase was inserted between the plasma membrane targeting sequence (N-terminus) and the glycosylphosphatidyl inositol anchor (C-terminus) of the human folate receptor [19]. This construct (referred to as plasma membrane luciferase, pmeLUC) localizes to the plasma membrane of mammalian cells to measure ATP in the pericellular space (Fig. 7.1).
7 Purinergic Regulation of Airway Inflammation
161
Fig. 7.1 Structure and localization of the plasma membrane luciferase (pmeLUC) construct. (a) The structure comprises full length luciferase inserted in-frame between the N-terminal leader sequence (26 amino acids) and C-terminal glycosyl phosphatidyl inositol (GPI) anchor (28 amino acids) of the folate receptor. (b) Schematic rendering of cell surface localization of pmeLUC, where the enzyme measures ATP concentration near P2 receptors and ectonucleotidases (EctoATPases). (c) Immunofluorescence and (d) fluorescence-activated cell sorting (FACS) analysis of human embryonic kidney (HEK293) cells transfected with pmeLUC (HEK293-pmeLUC) or the empty vector (HEK293-mock) (Reproduced with permission from Pellegatti et al. [19])
162
M. Koeppen et al.
Human embryonic kidney 293 (HEK293) cells were stably transfected with pmeLUC, which measured the in vivo ATP content of interstitium with a detection threshold of 10 mM [19]. In healthy mice, the luminescence is basically undetectable, confirming the long-standing notion that physiological ATP levels in the extracellular space are in the sub-micromolar range. However, in two models of inflammation, cancer (Fig. 7.2a) and experimental colitis (Fig. 7.2b), luciferase-dependent light emission is very bright and long lasting, an unequivocal indication of a high ATP concentration in the microenvironment [20]. While it is obvious that these findings await confirmation in additional models of inflammation, they provide direct proof that ATP accumulates and can be quantitatively measured at sites of tissue injury or inflammation. Calibration of the luminescence signal
Fig. 7.2 Quantification of interstitial ATP concentration using the plasma membrane luciferase (pmeLUC) in murine models of cancer and inflammation. The nude mice were inoculated with HEK293 cells stably transfected with pmeLUC, injected with D-luciferin and imaged by IVISCaliper total body luminometer. (a) Mice bearing a human ovarian carcinoma. Reproduced with permission from Pellegatti et al. [20]. (b) Mice with colitis developed over 6 days by addition of dextran sodium sulphate to the drinking water
7 Purinergic Regulation of Airway Inflammation
163
indicates an extracellular ATP concentration in the 100 mM level, i.e. sufficient to activate even the low-affinity P2X7R. On the basis of this evidence, we can safely conclude that intracellular ATP is abundantly released into the interstitium under pathological conditions. Why? A simplistic explanation would be that ATP release is the mere epiphenomenon of cell damage or cell death. Given that the cytoplasm contains millimolar ATP, cell injury or cell death are expected to cause large increases in interstitial ATP concentration. Accruing evidence shows that the immune system has learned to exploit damage-induced ATP release as an early signal of cell damage [3, 24]. Many small molecules, normally sequestered within the cytoplasm, are released to act as damage or distress signals to alert the immune system of an impending danger, such as during trauma or infection [25]. These molecules recruit immune cells, prime them for effector functions, re-direct their differentiation, modulate their interaction with pathogens, and trigger the final steps in cytokine secretion. Extracellular nucleotides, especially ATP, are uniquely suited to perform these functions for the following reasons. First, their extracellular concentration under resting conditions is negligible, while the intracellular concentration is very high, which maintains a high signal-to-noise ratio. Second, nucleotides are water soluble, thus easily diffusible in the watery extracellular milieu. Third, once outside the cell, nucleotides are quickly destroyed by ectonucleotidases to promptly terminate each signal. Fourth, nucleotides interact with a family of highly selective receptors with a wide range of affinities, thus conferring high flexibility to the signaling network. Last but not least, ATP hydrolysis produces ADO, which has a remarkable immunosuppressive activity, and may act as a feedback signal to stop inflammation. A very elegant and definitive demonstration of the undisputable importance of purinergic signaling in pulmonary inflammatory diseases was provided by the elegant study of Idzko et al. [26], who showed that an allergen challenge causes the accumulation of ATP in the bronchoalveolar (BAL) fluid of asthmatic individuals and mice with experimentally-induced asthma. When they lowered (BAL) fluid ATP levels by instillation of the ectonucleotidase named apyrase, they documented a significant reduction of all signs of inflammatory responses to the allergen. A wide range of P2 receptor antagonists also exhibited strong antiinflammatory activities. Finally, they showed that high airway ATP levels initiate a Th2 type of inflammatory response characteristic of asthma, through the recruitment and activation of myeloid dendritic cells. This study unequivocally proves the pivotal role of purinergic signaling in the initiation and regulation of lung inflammation. Numerous groups are currently actively involved in the elucidation of the complex purinergic regulation of immune and inflammatory functions, and it would be unrealistic to cover them all in this section. Our primary goal is merely to highlight the beauty of the dualistic principles behind purinergic signaling, as an integrative mechanism involving ATP release, its conversion to ADO by ectonucleotidases, and the myriad of receptors mediating their actions in a timely fashion.
164
7.2
M. Koeppen et al.
General Structure of the Purinergic Network
Extracellular nucleotides regulate immune and inflammatory cells through different combinations of P2Y and P2X surface receptors (review: [1]). The first class is composed of G protein-coupled receptors responding to ATP (P2Y2R, P2Y11R) or ADP (P2Y1R, P2Y12R). Others are activated by pyrimidines, namely P2Y2Rs (ATP ¼ UTP), P2Y4Rs (UTP) and P2Y6Rs (UDP), although these agonists are released at concentrations less than 10% that of the purines. These cells also express members of the P2X family, which are ATP-gated non-selective cation channels. Signal transduction is mediated by rapid influx of Na+ and Ca2+, and efflux of K+, which depolarizes the membrane and raises the intracellular Ca2+ concentration ([Ca2+]i). They are inhibited by oxidized ATP, and activated by benzoylATP (BzATP), which shows little or no activity on P2Y receptors. In the extracellular space, ADO interacts with members of the P1 receptor family which all utilize intracellular cyclic AMP (cAMP) as secondary messenger [27–29]. The baseline ADO levels activate predominantly high-affinity A1Rs and A2ARs, whereas cell lysis or activation will raise ADO levels through ATP release and metabolism, and tilt the balance in favor of the low-affinity A2BRs and A3Rs [30–33] (Table 7.1). An additional level of sophistication is provided by the fact that a member of each subgroup will stimulate (A2ARs and A2BRs) or inhibit (A1Rs and A3Rs) the adenylate cyclase activity responsible for cAMP production [10] (Fig. 7.3). Thus, the amplitude and directionality of cellular responses to ADO are affected by local changes in extracellular concentration and the type of P1 receptor(s) expressed on any given cell [32, 34–40]. It is also important to mention that their expressions are modified under pathological conditions, especially A2ARs and A2BRs, which are highly susceptible to hypoxia, ischemia and lung injury [32, 35, 36, 38–43]. This information emphasizes the need for carefully designed experiments to decipher the role of ADO in the regulation of immune and inflammatory responses. All immune and inflammatory cells co-express several P1 and P2 receptors at their surface, which respond to different concentration ranges of ATP and ADO (Table 7.1). This complex purinergic regulation is amplified by the presence of highly efficient surface enzymes, named ectonucleotidases, which mediate the rapid conversion of P2 receptor agonists (ATP, ADP) into the P1 receptor agonist, ADO. Most immune and inflammatory cells utilize the CD39-CD73 tandem to convert extracellular ATP into ADO. Whereas CD39 dephosphorylates ATP and ADP into AMP, CD73 completes the dephosphorylation of AMP into ADO (see Chap. 2 for details) (review: [44]). Initially, local ATP release may activate, both, low-affinity P2X receptors and high-affinity P2Y receptors, the latter remaining active longer as ATP is gradually eliminated. In contrast, baseline ADO levels are generally sufficient to partially activate high-affinity A1Rs and A2ARs. Following ATP release, the local accumulation ADO would transiently recruit the activities of low-affinity A2BRs and A3Rs. This dynamic view of the purinergic signaling network should be kept in mind while the reader tackles the literature, as studies addressing each receptor individually may distort the overall impact of a signal.
7 Purinergic Regulation of Airway Inflammation
165
Table 7.1 Classification of the purinergic receptors in immune and inflammatory cells (References from the review: [81]) Affinity Receptor Ligand (EC50) mM Cell distribution ADO 0.18–0.53 Neutrophils, Monocytes/Macrophages A1 Dendritic Cells A2A ADO 0.56–0.95 Neutrophils, Monocytes/Macrophages Dendritic Cells, T and B Lymphocytes A2B ADO 16.2–64.1 Neutrophils, Monocytes/Macrophages T Lymphocytes ADO 0.18–0.53 Neutrophils, Monocytes/Macrophages A3 Dendritic Cells, T Lymphocytes P2X1 ATP 0.05–1.0 Neutrophils, Monocytes/Macrophages Dendritic Cells, T Lymphocytes, NK cells P2X2 ATP 1–30 ATP 0.3–1.0 P2X3 P2X4 ATP 1–10 Neutrophils, Monocytes/Macrophages, Dendritic Cells, T Lymphocytes, NK cells ATP 1–10 Neutrophils, Monocytes/Macrophages P2X5 Dendritic Cells, T Lymphocytes P2X6 ATP 1–12 ATP 100–780 Neutrophils, Monocytes/Macrophages P2X7 Dendritic Cells, T and B Lymphocytes NK cells P2Y1 ADP 8 Neutrophils, Monocytes/Macrophages Dendritic Cells, T Lymphocytes UTP ¼ ATP 0.14–0.23 Neutrophils, Monocytes/Macrophages P2Y2 Dendritic Cells, T Lymphocytes P2Y4 UTP >> ATP,UDP 2.5 (UTP) Neutrophils, Monocytes/Macrophages Dendritic Cells, T Lymphocytes P2Y6 UDP 0.3 Neutrophils, Monocytes/Macrophages UTP 6.0 Dendritic Cells, T Lymphocytes ATP 17 Neutrophils, Monocytes/Macrophages P2Y11 Dendritic Cells, T and B Lymphocytes P2Y12 ADP 0.07 Monocytes/Macrophages, T Lymphocytes ADP 0.06 Monocytes/Macrophages P2Y13 ATP 0.26 Dendritic Cells, T Lymphocytes P2Y14 UDP-glucose 0.1–0.5 Neutrophils Dendritic Cells, T Lymphocytes
7.3
Bringing Cells to the Scene of the Crime
Nucleotide release being so exquisitely sensitive to cell activation or damage, it would be surprising if airway defenses had not learnt to exploit gradients of extracellular nucleotides to recruit immune and inflammatory cells at sites of infection or tissue injury. The finding that pathogen-derived soluble factors induce ATP release from most of these cells [14, 37, 45–47] supports a critical role in
166
M. Koeppen et al.
Fig. 7.3 Signaling pathways of the adenosine (ADO) receptors. In most cells, the activation of Gi-coupled A1Rs and A3Rs inhibits adenylate cyclase (AC), leading to a reduction of intracellular cyclic AMP (cAMP) concentrations, whereas the Gs-coupled A2ARs and A2BRs cause the opposite effect. In some cell types, receptors coupled to Gq stimulate phospholipase C (PLC), which increases inositol (1,4,5)-triphosphate (IP3) production. The references are from excellent reviews: [27–29]
chemotaxis. This section describes how P2 (ATP) and P1 (ADO) receptors provide fine tuning of the directionality and speed of migration through ATP release and conversion into ADO by the CD39–CD73 tandem.
7.3.1
Resident Dendritic Cells: The Sentinels
As first line of innate defenses, resident immature dendritic cells (imDCs) are embedded within the mucosa, where they monitor airway surfaces for danger signals, such as dying cells and microorganisms (review: [48]). Upon internalization of an antigen, they migrate to the lymph nodes, where they activate naı¨ve T lymphocytes to initiate primary immune responses. The migration of dendritic cells is usually studied in vitro using isolated blood monocytes, which differentiate into imDCs by incubation with granulocyte-macrophage colony-stimulating factor (GM-CSF) [49]. These imDCs will mature in the presence of bacterial products, like lipopolysaccharide (LPS), or a cocktail of pro-inflammatory cytokines. Both, in vitro and in vivo studies demonstrated that the migration of imDCs to the lymph nodes is orchestrated by a complex purinergic network which evolves during maturation. The imDCs express P2Y1Rs, P2Y2Rs, P2Y4Rs and P2X7Rs (review: [1]). Idzko et al. showed that P2Y receptor agonists, including ATP, stimulate the migration of imDCs, but this response is lost during maturation [50]. This group recently identified the P2 receptor responsible for imDCs migration as P2Y2R [51]. The P2Y2R–/– mice exhibited significantly milder allergic airway inflammation, which was explained by a defective migration of blood myeloid imDCs. The stimulating effect of ATP on the chemotaxis of imDCs is rapidly terminated by their CD39-CD73 enzymatic machinery [52]. On the other hand, the resulting
7 Purinergic Regulation of Airway Inflammation
167
ADO has also been shown to interact with P1 receptors on DCs, namely A1Rs, A2ARs and A3Rs (review: [1]). On imDCs, ADO stimulates migration through activation of the adenylate cyclase suppressing receptors: A1Rs and A3Rs [53]. Interestingly, the maturation process taking place during chemotaxis causes an up-regulation of A2ARs and a down-regulation of A3Rs, which shifts cellular responses toward cAMP accumulation [49]. Incidentally, Hofer et al. showed that incubation of mouse skin explants with the stable ADO analogue named 50 -(Nethylcarboxamido)-adenosine (NECA) suppresses the emigration of mature DCs [49]. These studies highlight the amazing adaptability of purinergic signaling during the migration of DCs. Whereas ATP and ADO both stimulate chemotaxis of imDCs, the signal for arrival to the lymph nodes would be provided to mature DCs through changes in ADO receptor expression.
7.3.2
Monocytes and Macrophages
The purinergic networks of monocytes and macrophages are among the most extensively studied due to their critical role in the detection and destruction of apoptotic cells and invading pathogens (review: [1]). Elliott et al. demonstrated that the enzymatic removal of extracellular nucleotides, by apyrase (commercial form of CD39), abolished the capacity of supernatant from apoptotic cells to attract monocytes [54]. Likewise, the monocytes of CD39–/– mice showed no migratory response to ATP [55]. These studies showed that extracellular nucleotides are essential for monocytes to reach apoptotic cells. Interestingly, Lambert et al. discovered that their chemotaxis is stimulated by low ATP concentrations, whereas higher concentrations are inhibitory [56]. Therefore, migration rates are expected to gradually decrease as they move through higher ATP concentrations and closer to the site of apoptosis. The concentration-dependent directionality of ATP effects on the recruitment of monocytes is an important point which has clouded the views regarding the role of its metabolite, ADO. It is well established that monocytes and macrophages express CD39 and CD73 at their surface, which effectively dephosphorylate ATP into ADO (review: [1]). Therefore, the use of apyrase to remove ATP and ADP is expected to raise ADO concentrations around the monocytes, due to the highly efficient local CD73 activity. Incidentally, high ADO levels have been shown to inhibit the migration of monocytes [57, 58]. As they move toward the site of apoptosis in an increasing concentration of ATP, the apparent inhibitory effect of ATP would be mediated, indirectly, by surface conversion into ADO, and the increasing concentration of this P1 receptor agonist. In essence, the nucleotides released during apoptosis would act as a “find-me” signal for phagocytes, and the conversion of ATP into ADO as a signal of arrival. Purinergic signaling also stimulates the migration of monocytes toward a site of infection, as pathogens release nucleotides in response to cationic proteins
168
M. Koeppen et al.
released by inflammatory cells [59]. Furthermore, an in vitro study recently showed that monocytes respond to bacterial products by ATP release [60]. The removal of ATP and ADP, using apyrase, impeached on the cells ability to navigate toward the bacterial chemoattractant, C5a [60]. In a mouse model of C5a-induced peritonitis, apyrase was reported to impair monocyte recruitment to the site of infection [60]. This indirect, yet essential, mode of purinergic regulation has been documented in details for neutrophil chemotaxis, as will be discussed in the following section.
7.3.3
Polymorphonuclear Granulocytes
The migration of polymorphonuclear granulocytes (eosinophils, neutrophils and basophils) also falls under the control of purinergic networks. Animal studies have been very useful in identifying cell types targeted by extracellular nucleotides. For instance, P2Y2R–/– mice exhibited an impaired ability to recruit eosinophils to the lungs in response to an ovalbumin sensitization/challenge, routinely used to produce the general features of allergic asthma [51]. Interestingly, the eosinophils of asthmatic patients overexpress P2Y2Rs, which amplifies ATP-induced migration and the production of reactive oxygen species (ROS). On the other hand, asthmatic patients are well known to maintain high airway ADO levels [61–63]. While these cells express A1Rs, A2ARs and A3Rs, the impact of ADO on chemotaxis appears to be mediated by A3Rs (review: [64]). Knight et al. studied the pharmacology of blood eosinophils and determined that chemotaxis, triggered by platelet-activating factor (PAF), is inhibited by antagonists of A3Rs (2Cl-IB-MECA), but not A1Rs (CCPA) or A2ARs (CGS21860) [65]. In addition, tissue implantation of the A3R antagonist, MRS1523, prevented the development of lung eosinophilia in a mouse model of chronically-elevated lung ADO (ADA–/– mice) [66]. These studies are consistent with the pro-inflammatory reputation of A3Rs, and suggest that vascular injection of P1 receptor agonists or antagonists that would tilt the balance toward cAMP production, in eosinophils, could suppress airway inflammatory responses in asthma. The most fascinating discoveries on the purinergic regulation of chemotaxis were made for neutrophils, which offer a comprehensive mechanistic view of long-distance migration. Recent advances in our understanding of extracellular nucleotide metabolism corrected the original belief that neutrophils release AMP [47, 67]. Timecourse analysis of conditioned medium by HPLC demonstrated that neutrophils activated by the bacterial product, N-formyl-methionyl-leucylphenylalanine (fMLP), release ATP, which is rapidly converted into AMP [37, 68]. Mechanisms of ATP release from neutrophils are currently under intense investigation, which is beyond the scope of this chapter (review: [69]). In a very elegant study, Chen et al. studied the purinergic regulation of neutrophil chemotaxis using an imaging technique that monitored extracellular ATP levels around live cells during migration [68]. They observed that ATP is released predominantly from the protruding region at the front end (known as leading edge) of a migrating neutrophil, as it moves toward fMLP. The mechanical stress exerted
7 Purinergic Regulation of Airway Inflammation
169
by membrane deformation in this area of the cell membrane would be responsible for the local ATP release. The fact that apyrase nearly abolished chemotaxis supported a critical role for P2 receptors in the promotion of neutrophil migration. Quantitative PCR analysis showed that neutrophils express predominantly P2Y2Rs, A2ARs and A3Rs [68]. Based on this information, Chen et al. conducted a series of experiments to determine their respective roles in neutrophil migration [68]. Immunostaining revealed that P2Y2Rs are distributed uniformly on the surface of latent and activated neutrophils, which would allow them to act as gradient sensors to regulate the directionality of migration. This concept is supported by the lack of orientation of activated neutrophils in the presence apyrase, and neutrophils derived from P2Y2R–/– mice, in an fMLP gradient concentration. A survey of the ectonucleotidases expressed at the surface of human neutrophils suggests that the local conversion of extracellular ATP into ADO is mediated by CD39 and tissue non-specific alkaline phosphatase (TNAP) [70]. The ADO-generating enzyme generally expressed by immune and inflammatory cells, CD73, was not detected at the mRNA level. While the end product of CD39 activity is AMP, TNAP dephosphorylates ATP, ADP and AMP into ADO (review: [71]). The efficiency of TNAP toward ATP is notoriously lower than the other ectonucleotidases over a wide concentration range [72]. In contrast, Picher et al. demonstrated that TNAP dephosphorylates AMP more rapidly than CD73 at the concentrations (0.1 mM) [73] reached at the sites of inflammatory or infection [20] (Figs. 7.2–7.3). The selective expression of a high-capacity ADO-producing enzyme on neutrophils may represent an adaptation to optimize cellular functions in a nucleotide-rich environment. The activation of neutrophils with fMLP recruits CD39 to the leading edge, close to the site of ATP release [70]. A role for ATP metabolism in the purinergic regulation of neutrophil migration was inferred from studies in which CD39 activity was suppressed. The inhibitors, ARL67156 and sodium metatungstate (POM1), reduced migration speed, but not their ability to orient in an fMLP gradient [70]. An in vivo model of neutrophil migration revealed that they migrate 80% more slowly in CD39–/– than in wild-type mice. These data supported a role for ADO as regulator of migration speed during neutrophil chemotaxis. Incidentally, neutrophils express all P1 receptors (review: [1]). The fact that agents stimulating cAMP production reduce the mobility of human neutrophils [74, 75] supports an inhibitory role for A2ARs and/or A2BRs. In contrast, the A3Rs are normally sequestered in the intracellular compartment, but rapidly mobilized to the surface by a chemoattractant [68]. Furthermore, they localize preferentially at the leading edge, with ATP release, CD39 and P2Y2Rs. Antagonists of A3Rs reduced the speed of migration of neutrophils, but not their capacity to align in a chemotactic gradient [68]. In a murine model of sepsis, the lungs of A3R–/– mice accumulated less neutrophils than the wild-type mice [76]. A critical role for lowaffinity A3Rs, instead of high-affinity A1Rs, to suppress cAMP-mediated cellular responses is consistent with the abundance of ADO generated at the leading edge from ATP release and metabolism by the CD39-TNAP tandem. Collectively, these studies demonstrate that an infection triggers a reorganization of the purinergic network at the surface of activated neutrophils, allowing ATP
170
M. Koeppen et al.
release and metabolism to orchestrate two aspects of migration: directionality by ATP (P2Y2Rs) and speed by ADO (A3Rs). Based on the critical role of the P2Y2R as a vasodilator, therapies aiming to reduce neutrophilic airway inflammation using selective antagonists should be administered intraperitoneal to avoid the development of vascular complications, such as hypertension. This case highlights the importance of a broad understanding of purinergic signaling to design appropriate pre-clinical and clinical trials.
7.4
Phagocytosis of Apoptotic Cells and Pathogens
Circulating neutrophils and monocytes are cooperative partners in the phagocytic apparatus of innate immunity (review: [77]). They migrate to sites of trauma or infection to internalize and destroy apoptotic cells and pathogens. Given their common origin, they share many functions, including phagocytosis, antimicrobial and immunomodulatory activities. Yet, they acquire distinct features during differentiation, resulting in different levels of antimicrobial capacities and cytotoxicity, tissue localization and lifespan. Also, an important function of macrophages is the proper clearance of apoptotic neutrophils to avoid massive discharge of cytotoxic molecules on airway surfaces. Neutrophils eliminate pathogens by the processes of phagocytosis, degranulation and oxidative burst. Their cytoplasm contains secretory granules filled with cytotoxic molecules (reactive oxygen species, proteinases, cationic peptides). In most cases, they engulf the pathogen into a phagolysosome, which becomes highly toxic as granules fuse and empty their content. This mechanism maintains the microbicidal molecules confined into the cell until neutrophils are disposed off by macrophages. Occasionally, neutrophils initiate an extracellular killing mechanism for exceedingly large pathogens or unresolved infection. An oxidative burst initiates a cell death program leading to the formation and release of neutrophil extracellular traps (NETs) made of DNA strands and the cytotoxic granule proteins [78, 79]. This groundbreaking discovery was recently summarized in a review which includes a video explaining the methods used to study NETs (review: [80]). In respiratory diseases, characterized by excessive neutrophilic inflammation or oxidative stress, this secondary mechanism may become a precipitating factor in the destruction of the airways by microbicidal agents. This section provides an overview of the purinergic regulation of bacterial killing and phagocytosis. Since hundreds of studies addressed the purinergic regulation of bacterial killing, the readers are referred to an excellent review for most references to lighten the text [81]. Numerous studies have reported that ATP enhances phagocytosis and oxidative burst in neutrophils (review: [81]). Pharmacological characterization of P2Y receptors suggests that only P2Y2Rs are functionally expressed on human neutrophils [82]. The P2Y2R-mediated intracellular Ca2+ mobilization failed to induce cell degranulation, but primed the neutrophils for inflammatory mediator-induced elastase release and oxidative burst. Neutrophils were also shown to functionally
7 Purinergic Regulation of Airway Inflammation
171
express P2X7Rs [83]. The selective agonist, BzATP, directly induced an oxidative burst by the production of superoxide. The surface conversion of ATP into ADO amplifies bacterial killing by phagocytosis through high-affinity A1Rs (EC50 ¼ 0.2–0.5 mM) (review: [81]). However, exceedingly high ADO levels would favor extracellular killing, as the low-affinity A2ARs (EC50 ¼ 0.5–1.0 mM) has been shown to suppress phagocytosis, but to induce oxidative burst. Purinergic signaling imposes a similar bimodal regulation of bactericidal activities on macrophages (review: [81]). Whereas low micromolar ATP inhibits the secretion of proteolytic enzymes and stimulates phagocytosis via P2Y2Rs, high micromolar ATP recruits the activities of P2X7Rs to mediate opposite responses and tilt the balance toward extracellular killing. The importance of P2X7Rs is demonstrated by protocols interfering with receptor activation (monoclonal antibody or recombinant P2X7R), which reduced the capacity of human monocytes to phagocytose Staphylococcus aureus and Escherichia coli [84]. Likewise, low ADO levels preferentially bind the high-affinity A1Rs to amplify ATP-mediated phagocytosis. Interestingly, the relatively weak bactericidal capacity of macrophages may result from the distinct behavior of the low-affinity A2ARs, which do not amplify, but rather suppress the oxidative burst induced by P2X7Rs. Purinergic signaling also regulates the initial cell-cell interactions between the phagocytes and apoptotic cells or bacteria. Extracellular nucleotides (ATP, UTP, ADP and UDP) were shown to enhance the adhesion of macrophages to apoptotic cells by an up-regulation of b2 integrin CD11b/CD18 (Mac-1) and the vitronectin receptor (avb3, CD51/CD61) [85], which facilitates phagocytosis. Assays conducted with agonists and antagonists implicate the high-affinity P2X1Rs or P2X3Rs (EC50 ¼ 0.05–1 mM) in these responses [81]. A similar activation of Mac-1 by ATP and ADP has been reported for neutrophils [74, 86], although the mechanism has not been elucidated. Collectively, these studies demonstrate that purinergic signaling normally favors bacterial killing by phagocytosis. In situations of serious infection, excess of ATP and/ or ADO may be perceived as an alarm signal to initiate the more agressive extracellular mode of killing, mediated by pathogen entrapment and destruction within the NETs.
7.5
7.5.1
Complex Roles of P2X7Rs in Dendritic Cells/Macrophages The Regulation of IL-1b Maturation and Secretion
Phagocytosis and killing are only some aspects of the complex chain of events set in motion by pathogen recognition in immune cells. Additional fundamental reactions precede, proceed alongside and follow phagocytosis to optimize pathogen handling and amplify immune responses. In this context, cytokine and chemokine secretion is crucial. Therefore, it is not surprising that extracellular ATP keeps under such
172
M. Koeppen et al.
a tight control the maturation and release of IL-1b, a first-wave cytokine secreted very early to modulate all phases of inflammation [81, 87]. The production of IL-1b by mononuclear phagocytes is controlled at the transcriptional, translational, maturation and secretion levels. Bacterial products induce the transcription of the IL-1b gene and the cytoplasmic accumulation of pro-IL-1b. The maturation of the pro-cytokine occurs within a multi-protein platform named “inflammasome” [88]. Secretion follows soon after maturation, but the route for release is still controversial. As it turns out, extracellular ATP acting at the P2X7R is one of the most potent stimuli for inflammasome activation, and by consequence for IL-1b maturation [89]. The detailed mechanism coupling P2X7Rs to the inflammasome is not entirely uncovered, and might involve a perturbation in intracellular K+ homeostasis [90], and/or the plasma membrane protein pannexin-1 [91, 92]. However, irrespectively of the mechanism of activation, there is no doubt that a functional P2X7R is essential for the activation of the inflammasome by extracellular ATP [93]. Intriguingly, there is a striking difference in requirement for P2X7Rs between extracellular or intracellular pathogens for IL-1b maturation. Extracellular ATP and P2X7Rs are required for S. aureus and E. coli (extracellular pathogens), but not for Salmonella typhimurium or Listeria monocytogenes (intracellular pathogens) [94]. These intracytoplasmic pathogens may get in direct contact with inflammasome components to trigger complex assembly [94, 95]. It is important to mention that extracellular ATP is an incomplete stimulus for IL1b secretion, as it requires priming by bacterial products (typically LPS) [96, 97]. This is due to the inability of ATP to cause IL-1b gene transcription and mRNA translation. Nevertheless, once pro-IL-1b is present in the cytoplasm, ATP is an incredibly efficient stimulus for externalization of the mature cytokine. Two models have been proposed for IL-1b secretion: the modified lysosome pathway [98], and the microvesicle route [99]. The first model proposes that pro-IL-1b and procaspase-1 are targeted to a specialized lysosomal compartment before exocytosis. The second model maintains that pro-IL-1b and IL-1b are loaded into plasma membrane-derived microvesicles simply shed into the extracellular environment. In any case, P2X7R is the trigger for release in both models. Analysis of microvesicles shed from ATP-stimulated DCs showed that inflammasome components are also loaded into this compartment following activation, as if the whole inflammasome is secreted with IL-1b [100], and possibly delivered to the target cell. The immune system has evolved a sophisticated range of checks and controls to prevent undue activation in response to infection. The body is continuously exposed to foreign microorganisms, which are not always harmful (e.g. commensal bacteria), and against which it might even be detrimental to mount an immune response. To prevent inappropriate and potentially harmful reactions, innate immunity has evolved a two-step control mechanism: (a) the detection of the foreign microorganism, (b) and the verification of its actual pathogenicity. In other words, the presence of a pathogen does not induce an inflammatory response without unequivocal proof of its tissue-damaging activity [101]. For this purpose, two classes of molecules have been identified: pathogen-associated molecular patterns (PAMPs)
7 Purinergic Regulation of Airway Inflammation
173
signal the presence of the microorganism upon binding to Toll-like receptors (i.e. LPS), and damage-associated molecular patterns (DAMPs) signal cell injury using different receptors (review: [102]). According to this two-step process, only “PAMP-alerted” and “DAMP-stimulated” phagocytes express full effector function. In DCs, the fact that P2X7R activation only influences the late phases of IL-1b regulation fits well with the properties of a DAMP [11, 24]. Likewise, macrophages primed by LPS respond to P2X7R activation by the secretion of IL-1b and IL-6. However, ATP added prior to LPS inhibits IL-12p40 and TNFa secretion [103]. These data highlight the high degree of specificity of this two-step activation process. An interesting, and yet neglected, target for purinergic signaling in respiratory diseases is the eosinophil. These terminally differentiated effector cells are central to airway defenses against parasites, and in the pathogenesis of allergic diseases, as they secrete a wide array of cytotoxic proteins and inflammatory mediators. Extracellular nucleotides are particularly potent agonists for the secretion of IL-8 and eosinophil cationic proteins (ECP) from human eosinophils [104]. This study also revealed the sophistication of the purinergic regulation, as ECP secretion was mediated via P2Y2Rs, while IL-8 secretion was mediated via P2Y6Rs (UDP) and P2X7Rs. Hence, eosinophils express functional P2X7Rs, whose activity may have relevant effects on lung pathophysiology [105]. Pathogen killing has evolved into a complex process targeting common parasites and the so-called “phagocytosis-resistant” pathogens. Extracellular nucleotides extend their modulatory functions well beyond the initial phases of phagocytosis. Converging evidence from several laboratories demonstrated that intra-phagosomal pathogen killing is enhanced by stimulation of the P2X7R [106–108]. This is of relevance as macrophages are often infected by parasites (Mycobacteria, Leishmania, Chlamidia, Trypanosoma) that have evolved strategies to survive within the phagocytic vacuoles. The capacity of P2X7Rs to facilitate pathogen killing is likely an evolutionary adaptation of our innate immune system in the fight against so-called “phagocytosis-resistant” pathogens. This adaptive mechanism is epitomized by mycobacterial and chlamidial infections [106, 108]. Both pathogens survive within an endocytic compartment that avoids fusion with the lysosomes. Stimulation with ATP greatly accelerates the fusion of this endocytic compartment with lysosomes, leading to rapid killing and digestion of the pathogen.
7.5.2
Formation of Multinucleated Giant Cells and Fibrosis
A fascinating feature of alveolar macrophages is their capacity to fuse into multinucleated giant cells (MGCs) (review: [109]). They are reported in lung tissue of asthmatic, COPD, IPF and CF patients experiencing repetitive gastric aspiration. While the role of MGCs remains unclear in these diseases, they were found responsible for the lung complications of hypersensitivity pneumonitis. Also known as extrinsic allergic alveolitis, this granulomatous inflammatory disease is
174
M. Koeppen et al.
caused by repetitive inhalation of antigenic organic particles, and may develop into a debilitating fibrotic lung disease. In this respect, MGCs may contribute to the development of fibrosis in other respiratory diseases, such as IPF, CF and emphysema. Hypersensitivity granuloma formation is induced by T cell-mediated delayedtype hypersensitivity reactions to the antigenic organic particles invading the lung [110]. The circulating antigen-reactive memory CD4+ T cells migrate into the parenchyma, and they specialize into Th1 cells producing IFNg. This cytokine primes alveolar macrophages to secrete greater amounts of TNFa and IL-1b. The latter induce the autocrine secretion of biologically active mediators that attract young macrophages, promote their maturation and fusion into MGCs, which agglomerate with epithelioid cells to form granulomas. Despite the identification of plasma membrane proteins potentially involved in the formation of MGCs, the mechanism still eludes our understanding. Nonetheless, several lines of evidence implicate P2X7R activation. For instance, induction of monocyte fusion by concanavalin A is inhibited by an irreversible blocker of P2X7Rs (oxidized ATP), or a monoclonal antibody against P2X7Rs [111, 112]. Macrophages with high level of P2X7R expression undergo spontaneous fusion [113]. Furthermore, heterologous expression of P2X7Rs confers fusogenic ability [114]. During the phases preceding cell fusion, they relocate at sites of membraneto-membrane juxtaposition between adjacent cells [114]. Efficient MGC formation appears to require the entire purinergic axis supporting the actions of ATP and ADO, as the fusion of human monocytes is enhanced by selective A1R agonists and blocked by a A1R antagonist [115]. The role of ADO is stressed by the peculiar effect of ATP-hydrolyzing enzymes on MGC formation, as apyrase strongly potentiates the fusion process [113, 114]. These studies suggest that P2X7Rs and A1Rs work in concert to induce MGC formation. Therapies aiming to restore normal P2X7R and/or A1R expression may prevent or reduce the formation of pulmonary fibrosis.
7.6 7.6.1
Complex Purinergic Regulation of Immune Responses Dendritic Cells: Tilting the Th1/Th2 Balance
In view of the central role of DCs at the intersection between innate and acquired immunity, it is not surprising that purinergic signaling exerts such a complex modulatory activity on these cells. The imDCs lodged in airway mucosa respond to bacterial products by initiating their migration to the lymph nodes, during which they undergo maturation (review: [48]). Upon arrival, they secrete cytokines which dictate the differentiation of naı¨ve lymphocytes into T cell helper 1 (Th1) or T cell helper 2 (Th2) cells. In particular, DCs produce high levels of IL-12 to promote Th1 immune responses. This directionality influences the inflammatory responses
7 Purinergic Regulation of Airway Inflammation
175
to airway infection by the recruitment of distinct cell types, such as Th1-type neutrophils for CF and Th2-type eosinophils for asthma. Di Virgilio et al. showed that the presence of low micromolar ATP distorts the maturation process of LPS-exposed DCs towards a Th2 phenotype, depicted by the typical markers: CD54, CD80, CD83, CD86 and MHC-II [116]. These DCs also exhibited an altered pattern of cytokine secretion, with reduced the release of typical pro-inflammatory cytokines (TNFa, IL-1a, IL-1b, IL-6 and IL-12), and enhanced the release of the immunosuppressive cytokine IL-10 [116, 117]. The immunosuppressive effect of ATP is mediated by P2Y11Rs [118], and is amplified through metabolic conversion into ADO by the CD39–CD73 tandem of DCs (review: [81]). Chronic exposure to micromolar ADO stimulated the secretion of IL-10, but inhibited the secretion of TNFa and IL-12 [53, 81]. This phenotype has important physiological consequences for airway defenses against an infection, as ATP-pulsed DCs will promote the differentiation of lymphocytes into Th2, rather than Th1, cells. This observation is highly relevant for chronic diseases associated with high airway ATP concentrations and a predominant Th2 type of airway inflammatory responses, such as asthma. The purinergic regulation of DC maturation and reactivity is crucially dependent on local ATP concentrations. While low micromolar ATP induces a Th2 response and immunosuppression, higher concentrations have a potent Th1-skewing proinflammatory activity, as demonstrated by stimulation of IL-12 secretion [119]. Evidence suggests that the immunostimulating effects of high micromolar ATP are mediated by P2X7Rs. Murine fetal skin-derived DCs, lacking P2X7Rs, exhibited a reduced ability to secrete IL-1b and to activate T lymphocytes [120]. The phenotype of P2X7R-deficient DCs was partially reproduced by CD39–/– mice, as epidermal Langerhans cells lacking the ability to eliminate excess ATP showed a reduced ability to activate T cells [121]. In summary, the purinergic regulation of DC maturation dictates the directionality of lymphocyte maturation in the lymph nodes toward Th1 or Th2 types of inflammatory profiles, which represents a remote control of airway defenses to infection.
7.6.2
The Lymphocytes and Th17 Immune Responses
Although lymphocytes have been extensively tested for responses to purines, our understanding of purinergic signaling in these cells is still rudimentary (review: [81]). Lymphocytes are known to secrete ATP, express P2 receptors and ATP-metabolizing enzymes. Furthermore, ATP triggers various activities, including the shedding of plasma membrane proteins, and bimodal regulations of cell proliferation and IL-2 secretion [1]. Yet, few responses can be unequivocally traced to a specific P2 receptor and/or signal transduction pathway. For instance, while high micromolar ATP exerts a cytotoxic effect on lymphocytes, low concentrations promote cell
176
M. Koeppen et al.
proliferation, likely, via P2Y receptors [122, 123]. Surprisingly, P2X7R is the main P2 receptor mediating ATP-induced growth stimulation in T lymphocytes and leukemic B lymphocytes [124–126]. In addition, the ATP-mediated stimulation of CD23 and L-selectin shedding has been well documented and is highly reproducible, which has important physiological implications, as it prevents lymphocyteendothelium interaction and recruitment to the inflammatory site [127]. Thanks to their exceptionally high ectonucleotidase activity, lymphocytes are likely to regulate autocrine purinergic events, as well as those of interacting cells, such as DCs [128]. This is well epitomized by Foxp3+ Treg lymphocytes, which exhibit high CD39 and CD73 expressions [129, 130], a situation unique among lymphocytes. Their expression is driven by the specific transcription factor Foxp3, and their catalytic activity is enhanced by T cell receptor (TCR) ligation. Thus, activated Treg cells have at their disposal two highly efficient means to downplay immunostimulation: (1) by lowering extracellular ATP concentration; (2) by raising ADO concentration. Not surprisingly, CD39 null mice show signs of immune deviation towards a Th1 phenotype [131]. The investigation of complex immune responses is often biased by unavoidable simplifications of the experimental approach that makes it difficult to identify the final outcome of an immunomodulatory agent, when it depends on a cascade of cellular interactions. Typically, the “immunoshaping” effect of purines is best investigated within well controlled in vivo models (e.g. [26]). Very often, these experimental settings bring together, in a coherent picture, the scattered and apparently unrelated observations from many different sources. This is elegantly demonstrated by the study of Atarashi et al., reporting the ability of ATP to drive the differentiation of Th17 cells in the gut lamina propria [132]. The Th17 cells are key immunosuppressors concentrated in the intestinal mucosa, where they control bacterial and fungal infection [133] (Fig. 7.4). The process that drives Th17 cell differentiation is however undetermined. It is also well known that ATP is secreted by bacteria under resting conditions or in response to microbicidal peptides [134, 135], but the physiological significance remained elusive. An attractive possibility is that ATP release if one of those pathogen-initiated events shaping immune responses to commensal bacteria. In their study, Atarashi et al. showed that ATP released from gut bacteria activates a subset of CD70highCD11clow lamina propria cells to secrete IL-6, IL-23 and TGF-b, thus driving Th17 cell differentiation (Fig. 7.4). Interestingly, the CD39–CD73 machinery of adjacent Foxp3+ Treg lymphocytes has been shown to suppress their IL-17 production [136]. The mechanism required cell-cell contact and could be reproduced by ADO. This study highlights the importance of conducting in vivo studies to investigate the purinergic shaping of mucosal immunity. Cutting edge research is exposing a similar Th17 type of regulation in the airway mucosa (reviews: [137–139]). The differentiation of Th17 cells is normally restricted by Th1 and Th2 cytokines, including IFNg, which is generally low in chronic inflammatory diseases. Incidentally, high sputum IL-17 concentrations, and high numbers of IL-17F-positive epithelial cells are reported in asthmatic and COPD patients [140]. In mice, intranasal instillation of IL-17 receptor agonists
7 Purinergic Regulation of Airway Inflammation
a
177
Bacteria Mucosal lumen
ATP ATP
ATP
Epithelial cells
DC TGF-b
IL-23
IL-6 Th17 lymphocytes
Macrophage
IL-17
Fibroblast
Bacteria
b
Mucosal lumen
ATP
ATP
ATP lnjured epithelial cells ATP
ATP ATP
ATP ATP ATP ATP ATP ATP ATP TGF-b DC
ATP IL-6
Memory Th17 lymphocytes
ATP
IL-23
Activated macrophage
Pathogenic Th17 lymphocytes
IL-17
IL-17
Activated fibroblast
Fig. 7.4 Schematic rendition of the role played by ATP in shaping early phases of immune response. (a) Under physiological conditions, at sites of contact with foreign microorganisms (exemplified by the gut lamina propria), baseline ATP release from the commensal bacteria induces a moderate stimulation of dendritic cells (DCs). This results in low level secretion of IL-6, IL-23 and TGF-b, together generating an immunotolerant microenvironment to prevent immuno-mediated tissue damage. (b) If mucosal damage or massive bacterial infection occurs, large quantities of ATP are released, which stimulate DCs to produce higher amounts of these factors (red), resulting in the expansion of the Th17 lymphocyte population, and activation of resident fibroblasts and macrophages
178
M. Koeppen et al.
induces eosinophilia, mucin hypersecretion and hypereactivity, which summarizes the major features of allergic asthma. In addition, IL-17 stimulates the secretion of neutrophil chemoattractants from airway epithelial cells, and thus, may contribute to the severe neutrophilia of airway diseases. Since airway diseases are characterized by high sputum ATP and/or ADO levels (see Chap. 4 for details), the emergence of Th17 signaling in human airways opens a completely new vector of research for purinergic drug development.
7.7 7.7.1
The Respiratory Epithelium Leukocyte Adhesion and Transmigration
Polymorphonuclear granulocytes are critical mediators of airway defenses that readily invade the interstitial space through endothelial barriers to eliminate pathogens. To avoid a catastrophic accumulation of activated granulocytes in lung tissue, their recruitment is normally balanced by efficient clearance mechanisms. Up until recently, phagocytosis was believed to constitute the main elimination mode for lung granulocytes. However, new data suggest a critical role for their transepithelial migration into the airways, where they are expelled by mucociliary clearance (MCC) (review: [141]). The critical role of MCC is highlighted by the overwhelming neutrophilia observed in the airways of cystic fibrosis (CF) patients, which results from an inherited inability to clear mucins and pathogens. On the other hand, granulocytes will also travel to the airways to target inhaled pathogens. Therefore, an efficient gating of endothelial and epithelial barriers is essential to control the extent of inflammatory responses in the lung and the airways, and to prevent tissue damage by excess bactericidal molecules. The purinergic regulation of neutrophil adherence to the endothelial barrier has been reviewed extensively [81]. On endothelial cells, P2X7R activation induces an up-regulation of E-selectins [142], while P2Y2R activation triggers the up-regulation of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [143, 144]. Neutrophil adhesion to E-selectins and VCAM-1 initiates rolling along the endothelial surface, during which they are primed by ATP to express Mac-1 [145] for firm adhesion via ICAM-1. Simultaneously, ATP is being converted into ADO on the endothelium by the CD39–CD73 tandem. Initially, sub-micromolar ADO activates preferentially the high-affinity A1Rs on neutrophils and endothelial cells, which enhance neutrophil adhesion [146, 147]. Eventually, ADO levels increase and provide a negative feedback through A2AR- and A2BR-mediated cAMP production in the neutrophils, which downregulates Mac-1 (review: [81]). On endothelial cells, these high ADO levels also suppress adhesion by a reduction in VCAM-1 expression.
7 Purinergic Regulation of Airway Inflammation
179
Transmigration is facilitated by the activation of endothelial P2Y2Rs, which raise barrier permeability [148]. There is a general consensus that the increasing ADO levels eventually restore barrier function via A2BRs on the endothelial surface [37, 47]. Also, ADO inhibits the secretion of vascular endothelial growth factor (VEGF) from activated neutrophils, which is a potent inducer of endothelial permeability [149]. The adherent leukocytes have been shown to facilitate their passage by suppressing ADO production via CD73 on endothelial cells [150]. In fact, CD73 was initially identified as endothelial Vascular Adhesion Protein 2 (VAP-2) for lymphocyte adhesion [151], suggesting that CD73 inhibition is mediated by direct physical interaction. Following their passage, the restoration of ADO production would essentially close the gate. These studies indicate that ATP constitutes a pro-inflammatory mediator of neutrophil recruitment, whereas high ADO levels constitute a negative feedback to prevent excessive infiltration. Neutrophil transmigration across airway epithelia involves many factors common to the endothelial barrier (Fig. 7.5) (reviews: [152, 153]). Before adhesion to the basolateral surface can proceed, they must replace their L-selectins by Mac-1. Then, adhesion is initiated by binding of Mac-1 to fucosylated proteoglycans and
Fig. 7.5 Purinergic regulation of neutrophil transmigration across epithelia. Their adhesion to the basolateral epithelial membrane is initiated by binding of Mac-1 to fucosylated glycoproteins or JAM-C. They roll along the epithelial surface and the inter-epithelial tunnel by sequential binding to various epithelial molecules, including CD47 and SIRPa. Once at the tight junction, neutrophil JAML binds the epithelial coxsackie and adenovirus receptor (CAR). Once they have traversed the barrier, they adhere to the apical surface, where they resist fluid flow to constitute a defense barrier against invading microorganisms. Their adhesion is mediated by Mac-1 to ICAM1, and DAF to CD97. Purinergic signaling regulates the transmigration of neutrophils. The ATP released by activated neutrophils disrupts barrier properties, whereas conversion to ADO by the CD39–CD73 tandem terminates transmigration by restoration of the barrier properties
180
M. Koeppen et al.
JAM-C on the epithelial surface, which triggers the phosphorylation of myosin light chain (MLC) of tight junction complex to allow their passage. Transmigration follows by adhesive interactions between CD47 on PMNs and the epithelial surface. The JAM-like proteins (JAML) of neutrophils bind the coxsackie and adenovirus receptor (CAR) at the tight junction to complete their transmigration. Once they pass the tight junction, neutrophils transiently bind ICAM-1 and VCAM1 on the apical surface to provide a protective shield, while they eradicate airway pathogens [154]. Eventually, they undergo apoptosis and phagocytosis by macrophages, or they are cleared from the airways by the mucociliary escalator. On airway surfaces, the purinergic stimulation of mucin secretion interferes with neutrophil adhesion. While the bacterial product, fMLP, induced neutrophil adhesion equally well on endothelial and bronchial epithelial cultures, P2Y2R agonists (ATP, UTP and ATPgS) were 50% less efficient at inducing adherence on bronchial surfaces [155]. The role of mucins in the weak association of neutrophils to the airway surfaces was demonstrated by stable transfection of MUC1 in Chinese Hamster Embryo (CHO) cells [155]. Since MUC1 is an intrinsic plasma membrane protein, extending 0.5 mm into the airway surface liquid (ASL) layer, the authors suggested that this anionic mesh prevents neutrophil binding to the epithelial surface. In this case, how could they reconcile the equipotency of neutrophil adherence to endothelial and epithelial surfaces in response to fMLP? More likely, mucins secreted in response to P2Y2R activation (MUC5B and MUC5AC) [156] form a physical shield preventing neutrophils from adhering to the epithelial surface. This notion is consistent with the mucociliary clearance of neutrophils from the airways. Once they pass the tight junction, neutrophils remaining bound to the epithelial surface would conduct their bactericidal activities, before being released and trapped into the mucin layer for evacuation. During airway infection, there is considerable cell-cell communication between bacteria and epithelial cells, which weakens barrier integrity and promotes bacterial invasion into the interstitium. For instance, Pseudomonas aeruginosa has been shown to functionally express a surface adenosine deaminase. This enzyme activity reduces local ADO concentrations, which allows the bacterium to express the potent barrier-disrupting lectin PA-I [157]. This protein causes lethal sepsis in mice by allowing the passage of exotoxin A across the intestinal barrier [158], and is cytotoxic to human nasal epithelial cells in vitro [159]. These studies demonstrate the critical role of airway ADO in the protection of barrier integrity during infection. The purinergic regulation of neutrophil adherence to the basolateral surface of airway epithelia, and their transmigration into the lumen, has not been documented, despite the importance of this mechanism for the endothelium. In airway diseases, like CF, the large clusters of activated neutrophils observed under the barrier [160], likely, maintain high concentrations of ATP close to the epithelial surface, which is known to enhance barrier permeability in other systems [148]. Considering the problematic hyper-inflammatory responses of these patients to airway infection, this observation highlights the urgency of addressing this gap in our understanding of purinergic signaling.
7 Purinergic Regulation of Airway Inflammation
7.7.2
181
Epithelial Inflammatory Responses
Innate airway defenses are initiated by physical interaction of the bacterium with pattern recognition molecules on the epithelial surface. The pluripotent ion channel, CFTR, has been shown to bind and internalize P. aeruginosa LPS to initiate NFkBdependent inflammatory responses, including the secretion of chemoattractant cytokines to initiate the recruitment of inflammatory cells (review: [161]). In addition, the flagella interact with Toll-like receptor 5 (TLR5) and asialoGM1 to initiate NFkB- and ERK1/2-dependent signaling cascades which induce and/or require ATP release [162, 163]. This nucleotide is generally perceived as a critical mediator of airway clearance, which is released under stress conditions to eliminate a pathogen or irritant by P2Y2R-mediated flushing out of the airways (see Chap. 5). However, the compelling evidence that ATP initiates inflammatory responses in all immune and inflammatory cells paved the way for similar studies on airway epithelia. Inflammatory responses are generally initiated by the “first wave” cytokines, namely IL-1b and TNFa, locally released by resident DCs and macrophages alerted by the presence of an intruder. In the alveolar cell line A549, both IL-1b and TNFa raised the expression of A2ARs via NFkB activation [164]. Since airway epithelia normally express low levels of A2ARs, the initial response to infection primes the airways for injury repair by the ADO-A2AR axis (see Chap. 6). The most documented response of airway epithelia to “first wave” cytokines is the secretion of the potent neutrophil chemoattractant IL-8. Ribeiro et al. reported that the P2Y2R agonist, UTP, stimulates the secretion of IL-8 from cultures of human bronchial epithelial cells [165, 166]. Numerous studies addressed the identity of the secondary messengers mediating this inflammatory response. We are grateful to Dr. van der Vliet, who recently proposed a unifying mechanism for the purinergic regulation of pathogen-induced IL-8 secretion on human airway epithelia [167]. Their collective work recently culminated into an elegant study giving center stage to the DUOX1/EGFR-dependent signaling cascades. They showed that Toll-like receptor activation by bacterial products causes ATP release, which binds P2Y2Rs to induce H2O2 production by DUOX1. The peroxide activates surface sheddases, which solubilize EGFR ligands. The resulting EGFR activation induces ERK1/2 and NFkB activation, which promote IL-8 secretion. Other routes for the purinergic regulation of IL-8 secretion have been proposed in the recent years. For instance, P2Y14Rs were identified on alveolar A549 and bronchial BEAS-2B epithelial cells at the mRNA level, and by their responsiveness to the selective agonist UDP-glucose [168]. Their activation induced Ca2+ mobilization from intracellular stores and IL-8 secretion [168]. In tracheal epithelial cells, TNFa-induced IL-8 secretion was amplified by the selective P2X receptor agonist, BzATP [169]. This receptor family is generally perceived as a minor player due to their relatively low affinity for ATP. Yet, Di Virgilio has clearly shown that high micromolar ATP concentrations are maintained in areas of inflammation (Figs. 7.2–7.3). Furthermore, P2X7Rs are up-regulated on the airway surfaces of
182
M. Koeppen et al.
CF patients [170]. Thus, studies conducted on aseptic epithelial cultures may significantly underestimate the contribution of P2X receptors to airway defenses. Another well known inflammatory cytokine in the airways is IL-6, which binds the epithelium to induce mucin secretion and neutrophil infiltration (review: [171]). Contrary to IL-8, this cytokine is released on the apical (not basolateral) surface to mediate these autocrine responses [172]. On small airway epithelial cells, nucleotides increased IL-6 expression and stimulated secretion with an order of potency typical of P2Y2Rs (ATPgS > ATP ¼ UTP), and the associated phospholipase C (PLC)/MAP kinase-dependent signaling cascades [173]. The ATP-hydrolyzing apyrase partially reduced the effects of ATP, but not metabolically-stable ATPgS. These data suggested that ADO, generated endogenously from the metabolism of ATP on the airway surfaces [72, 73], participates in the regulation of IL-6. Incidentally, ADO was reported to stimulate IL-6 secretion from Calu-3 bronchial epithelial cells [172]. The use of selective receptor antagonists and RNA interference techniques revealed that the ADO receptor causing IL-6 secretion is A2AR. The common belief is that A2BRs are responsible for airway defenses, as in the case of MCC (review: [174]). This notion has been fueled by the relatively high mRNA levels of this ADO receptor, measured on aseptic cultures of airway epithelial cells [175]. However, we mentioned earlier that airway epithelia overexpress A2ARs in response to “first wave” cytokines, IL-1b and TNFa [164]. Given the importance of A2ARs for the regulation of cytokine secretion in inflammatory cells, this receptor should be revisited on airway epithelia under alarm situations which raise its expression, such as infection. The bactericidal capacity of the epithelial barrier is also enhanced by extracellular nucleotides. Pathogens, including P. aeruginosa [176] and Chlamydophila pneumoniae [177], induce the expression of chemokine ligand 20 (CCL20) in human airway epithelial cells, which is released into the ASL to directly mediate bacterial killing (review: [178]). The fact that P2Y2R (ATPgS, UTP, INS365) or P2Y6R (UDP, INS48823) activation was able to mediate both responses on human airway epithelia [179] supports a role for the pathogen-induced nucleotide release in the induction of bactericidal capacity. In allergic diseases, like asthma, IL-19 has been shown to play a significant role in the secretion of Th2 cytokines. Incidentally, airway epithelia constitute a major source of IL-19, where its secretion is stimulated by IL-4 and IL-13 [180]. In bronchial epithelial cells, the stable ADO receptor agonists, NECA, was reported to induce IL-19 secretion by a mechanism involving A2BRs [181]. The amount of IL-19 released in the conditioned medium was sufficient to induce TNFa secretion from monocytes, which signaled back on the epithelial cells to up-regulate A2BRs. This elegant cross-talk between purinergic and inflammatory mediators may amplify the damaging effects of the Th2 inflammation in asthmatic patients. Prostaglandins and leukotrienes are lipid mediators generated from the metabolism of membrane-derived arachidonic acid (review: [182]). They bind cell surface G protein-coupled receptors to regulate inflammatory processes. For instance, leukotrienes induce the recruitment and activation of various inflammatory cells, fibroblast proliferation and myofibroblast differentiation. On the other hand, the prostaglandin PGE2 enhances cell survival and migration, and suppresses
7 Purinergic Regulation of Airway Inflammation
183
pro-fibrotic responses mediated by leukotrienes. An imbalance in the levels of leukotrienes and prostaglandins in BAL fluid is associated with the development of pulmonary fibrosis. Studies showed that purinergic signaling up-regulates eicosanoids in human airway epithelia. In the bronchial cell line BEAS-39, the release of arachidonic acid was stimulated equally by ATP and UTP, supporting a role for P2Y2Rs [183]. In A549 alveolar cells, diadenosine tetraphosphate was implicated in the release of arachidonic acid [184], a dinucleotide known to be converted into ATP on human airway epithelia [185]. Incidentally, P2Y2R agonists (ATP, UTP and INS365) up-regulated by threefold the enzyme responsible for the conversion of arachidonic acid into prostaglandins, cyclooxygenase2 (COX-2), causing an increase in the secretion of PGE2 [186]. The surface metabolism of ATP by ectonucleotidases appears to initiate an amplification wave for this epithelial response. In the human bronchial epithelial cell line, Calu-3, A2BR activation by ADO levels detected in the airways of CF patients [1–10 mM; [63]] induced the apical secretion of arachidonic acid [187] and prostaglandins, but not leukotrienes [188]. Since the A2BR-mediated generation of prostanoids stimulates MCC via CFTR in Calu-3 cells [188], this pathway is expected to participate in innate defenses in diseases not characterized by functional mutations of this ion channel. Furthermore, the purinergic regulation of arachidonic acid metabolism appears to tilt the balance in favor of prostaglandin production, which is expected to enhance the healing capacity and reduce the development of fibrosis. To test this hypothesis, experiments remain to be conducted regarding the impact of ATP on the production and secretion of leukotrienes.
7.8
Conclusion
Our current understanding of the dynamic changes in extracellular ATP and ADO levels, initiated by an infection, allows us to postulate the following chain of events for the purinergic regulation of immune and inflammatory responses. Initially, the accumulation of extracellular ATP, in the presence of near-physiological ADO levels, synergizes with other pro-inflammatory factors to drive immune cell recruitment, cytokine and chemokine release, phagocytosis and the generation of extracellular NETs packed with various bactericidal compounds. An efficient pro-inflammatory action requires ATP levels to rise rapidly above a certain threshold (which in vitro data set at ~50 mM). If this threshold is not reached, yet DCs are exposed to low micromolar ATP for an extended time (12–24 h), they initiate an immunosuppressive response. Eventually, even pro-inflammatory responses, mediated by large releases of ATP, are terminated by the CD39-CD73 metabolic tandem, which also initiates an immunosuppressive response by the resulting ADO. The outcome of inflammatory responses depends on the complex balance between the generation and termination of these crucial events of purinergic regulation. Based on the data presented in this chapter, there is no doubt that understanding this complex interplay will open new avenues for the treatment of inflammatory diseases.
184
M. Koeppen et al.
Acknowledgements This work was supported by United States National Institutes of Health (grants R01-HL092188, R01-DK083385, and R01HL098294) to H.K.E and Deutsche Forschungsgemeinschaft research fellowship to M.K.
References 1. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR (2001) Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587–600 2. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013–1067 3. la Sala A, Ferrari D, Di Virgilio F, Idzko M, Norgauer J, Girolomoni G (2003) Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol 73:339–343 4. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657–682 5. Boeynaems J-M, Communi D (2006) Modulation of inflammation by extracellular nucleotides. J Invest Dermatol 126:943–944 6. Khakh BS (2006) Alan North R: P2X receptors as cell-surface ATP sensors in health and disease. Nature 442:527–532 7. Chen L, Brosnan CF (2006) Regulation of immune response by P2X7 receptor. Crit Rev Immunol 26:499–513 8. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877–3883 9. Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58:58–86 10. Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315–1323 11. Di Virgilio F (2007) Liaisons dangereuses: P2X7 receptor and the inflammasome. Trends Pharmacol Sci 28:465–472 12. Hasko´ G, Pacher P, Deitch EA, Vizi ES (2007) Shaping monocyte and macrophage function by adenosine receptors. Pharmacol Ther 113:264–275 13. Donnelly-Roberts D, McGaraughty S, Shieh C-C, Honore P, Jarvis MF (2008) Painful purinergic receptors. J Pharmacol Exp Ther 324:409–415 14. Di Virgilio F (2007) Purinergic signaling in the immune system. Purinergic Signal 3:1–3 15. Burnstock G (2006) Purinergic signaling-an overview. Novartis Found Symp 276:26–48 16. Llaudet E, Botting NP, Crayston JA, Dale N (2003) A three-enzyme microelectrode sensor for detecting purine release from central nervous system. Biosens Bioelectron 18:43–52 17. Llaudet E, Hatz S, Droniou M, Dale N (2005) Microelectrode biosensor for real-time measurement of ATP in biological tissue. Anal Chem 77:3267–3273 18. Gourine AV, Dale N, Llaudet E, Poputnikov DM, Spyer KM, Gourine VN (2007) Release of ATP in the central nervous system during systemic inflammation: real-time measurement in the hypothalamus of conscious rabbits. J Physiol 585:305–316 19. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F (2005) A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 16:3659–3665 20. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, DV F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3:e2599
7 Purinergic Regulation of Airway Inflammation
185
21. Maggi A, Ciana P (2005) Reporter mice and drug discovery and development. Nat Rev Drug Discov 4:249–255 22. Kim S-Y, Sivaguru M, Stacey G (2006) Extracellular ATP in plants. Visualization, localization, and analysis of physiological significance in growth and signaling. Plant Physiol 142:984–992 23. Weerasinghe RR, Swanson SJ, Okada SF, Garrett MB, Kim SY, Stacey G, Boucher RC, Gilroy S, Jones AM (2009) Touch induces ATP release in Arabidopsis roots that is modulated by the heterotrimeric G-protein complex. FEBS Lett 583:2521–2526 24. Di Virgilio F (2005) Purinergic mechanism in the immune system: a signal of danger for dendritic cells. Purinergic Signal 1:205–209 25. Yeretssian G, Labbe´ K, Saleh M (2008) Molecular regulation of inflammation and cell death. Cytokine 43:380–390 26. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MAM, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC, Lambrecht BN (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13:913–919 27. Eltzschig HK (2009) Adenosine – an old drug newly discovered. Anesthesiology 111:904–915 28. Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770 29. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P (2009) A2B adenosine receptors in immunity and inflammation. Trends Immunol 30:263–270 30. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J (2001) Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98:9983–9988 31. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 388:674–678 32. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK (2007) Cardioprotection by ecto-50 -nucleotidase (CD73) and A2B adenosine receptors. Circulation 115:1581–1590 33. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA (2000) Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275:4429–4434 34. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK (2009) Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 10:195–202 35. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK (2008) A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111:2024–2035 36. Eckle T, Grenz A, Laucher S, Eltzschig HK (2008) A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118:3301–3315 37. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP (2003) Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198:783–796 38. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK (2008) The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 5:e137 39. Hart M, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK (2009) A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182:3965–3968
186
M. Koeppen et al.
40. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP (2006) HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20:2242–2250 41. Douillet CD, Robinson WP III, Zarzaur BL, Lazarowski ER, Boucher RC, Rich PB (2005) Mechanical ventilation alters airway nucleotides and purinoceptors in lung and extrapulmonary organs. Am J Respir Cell Mol Biol 32:52–58 42. Eckle T, Kohler D, Lehmann R, El Kasmi KC, Eltzschig HK (2008) Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118:166–175 43. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP (2009) Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol 182:4957–4964 44. Eltzschig H, Weissm€ uller T, Mager A, Eckle T (2006) Nucleotide metabolism and cell-cell interactions. Meth Mol Biol 341:73–88 45. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F (1997) Purinergic modulation of interleukin-1beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 185:579–582 46. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A (2008) ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Nat Acad Sci USA 105:8067–8072 47. Lennon PF, Taylor CT, Stahl GL, Colgan SP (1998) Neutrophil-derived 50 -adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 188:1433–1443 48. Cook DN, Bottomly K (2007) Innate immune control of pulmonary dendritic cell trafficking. Proc Am Thorac Soc 4:234–239 49. Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, Heufler C (2003) Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Investig Dermatol 121:300–307 50. Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, Girolomoni G, Panther E, Norgauer J (2002) Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100:925–932 51. M€uller T, Robaye B, Vieira RP, Ferrari D, Grimm M, Jakob T, Martin SF, Di Virgilio F, Boeynaems JM, Virchow JC, Idzko M (2010) The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65:1545–1553 52. Berchtold S, Ogilvie ALJ, Bogdan C, Muhl-Zurbes P, Ogilvie A, Schuler G, Steinkasserer A (1999) Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett 458:424–428 53. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, Norgauer J (2001) Expression and function of adenosine receptors in human dendritic cells. FASEB J 15:1963–1970 54. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282–286 55. Goepfert C, Sundberg C, Sevigny J, Enjyoji K, Hoshi T, Csizmadia E, Robson S (2001) Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104:3109–3115 56. Lambert C, Ase AR, Se´gue´la P, Antel JP (2010) Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav Immun 24:1241–1248 57. Pike MC, Snyderman R (1981) Transmethylation reactions are required for initial morphologic and biochemical responses of human monocytes to chemoattractants. J Immunol 127:1444–1449
7 Purinergic Regulation of Airway Inflammation
187
58. Pike MC, Snyderman R (1982) Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell 28:107–114 59. Vylkova S, Sun JN, Edgerton M (2007) The role of released ATP in killing Candida albicans and other extracellular microbial pathogens by cationic peptides. Purinergic Signal 3:91–97 60. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim H-C, Sargin S, Schon P, Schwab A, Hanley PJ (2010) Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal 3:ra55 61. Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G, Herjavecz I, Horvath I (2002) Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 20:1393–1398 62. Vass G, Huszar E, Augusztinovicz M, Baktai G, Barat E, Herjavecz I, Horvath I (2006) The effect of allergic rhinitis on adenosine concentration in exhaled breath condensate. Clin Exp Allergy 36:742–747 63. Esther CR Jr, Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, Boucher RC (2009) Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol 296: L987–L993 64. Brown RA, Spina D, Page CP (2008) Adenosine receptors and asthma. Br J Pharmacol 153: S446–S456 65. Knight D, Zheng X, Rocchini C, Jacobson M, Bai T, Walker B (1997) Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 62:465–468 66. Young HWJ, Molina JG, Dimina D, Zhong H, Jacobson M, Chan L-NL, Chan T-S, Lee JJ, Blackburn MR (2004) A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 173:1380–1389 67. Madara JL, Patapoff TW, Gillece-Castro B, Colgan SP, Parkos CA, Delp C, Mrsny RJ (1993) 50 -adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest 91:2320–2325 68. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792–1795 69. Eltzschig HK, Macmanus C, Colgan SP (2008) Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 18:103–107 70. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG (2008) Ectonucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283:28480–28486 71. Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362:299–309 72. Picher M, Burch LH, Boucher RC (2004) Metabolism of P2 receptor agonists in human airways: implications for mucociliary clearance and cystic fibrosis. J Biol Chem 279:20234–20241 73. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC (2003) Ecto 50 -nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468–13479 74. Zalavary S, Bengtsson T (1998) Adenosine inhibits actin dynamics in human neutrophils: evidence for the involvement of cAMP. Eur J Cell Biol 75:128–139 75. Coffey RG (1992) Effects of cyclic nucleotides on granulocytes. Immunol Ser 57:301–338 76. Inoue Y, Chen Y, Hirsh MI, Yip L, Junger WG (2008) A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 30:173–177 77. Silva MT (2010) When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 87:93–106
188
M. Koeppen et al.
78. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532–1535 79. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A (2007) Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176:231–241 80. Brinkmann V, Goosmann C, Laube B, Zychlinsky A, Abu Abed U (2010) Neutrophil extracellular traps: how to generate and visualize them. J Vis Exp 36:e1724 81. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 50 -triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358–404 82. Meshki J, Tuluc F, Bredetean O, Ding Z, Kunapuli SP (2004) Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y2 receptor. Am J Physiol 286:C264–C271 83. Suh B-C, Kim J-S, Namgung U, Ha H, Kim K-T (2001) P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. J Immunol 166:6754–6763 84. Gu BJ, Saunders BM, Jursik C, Wiley JS (2010) The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of non-opsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood 115:1621–1631 85. Marques-da-Silva C, Burnstock G, Ojcius DM, Coutinho-Silva R (2010) Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages. Immunobiology 216:1–11 86. Miyabe K, Sakamoto N, Wu YH, Mori N, Sakamoto H (2004) Effects of platelet release products on neutrophilic phagocytosis and complement receptors. Thromb Res 114:29–36 87. Dinarello CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20: S1–S13 88. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426 89. Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232 90. Di Virgilio F, Ferrari D, Falzoni S, Chiozzi P, Munerati M, Steinberg TH, Baricordi OR (1996) P2 purinoceptors in the immune system. Ciba Found Symp 198:290–302 91. Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1 [beta] release by the ATP-gated P2X7 receptor. EMBO J 25:5071–5082 92. Pelegrin P, Surprenant A (2007) Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 282:2386–2394 93. Benko S, Philpott DJ, Girardin SE (2008) The microbial and danger signals that activate Nod-like receptors. Cytokine 43:368–373 94. Franchi L, Kanneganti TD, Dubyak GR, Nu´n˜ez G (2007) Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem 282:18810–18818 95. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG (2006) Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126:1135–1145 96. Perregaux D, Gabel CA (1994) Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 269:195–203 97. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castagnoli P, Di Virgilio F (1996) Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 156:1531–1539
7 Purinergic Regulation of Airway Inflammation
189
98. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A (1999) The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 10:1463–1475 99. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15:825–835 100. Pizzirani C, Ferrari D, Chiozzi P, Adinolfi E, Sandona D, Savaglio E, Di Virgilio F (2007) Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 109:3856–3864 101. Nathan C (2002) Points of control in inflammation. Nature 420:846–852 102. Sato S, St-Pierre C, Bhaumik P, Nieminen J (2009) Galectins in innate immunity: dual functions of host soluble b-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol Rev 230:172–187 103. Myrtek D, Muller T, Geyer V, Derr N, Ferrari D, Zissel G, Durk T, Sorichter S, Luttmann W, Kuepper M, Norgauer J, Di Virgilio F, Virchow JC Jr, Idzko M (2008) Activation of human alveolar macrophages via P2 receptors: coupling to intracellular Ca2+ increases and cytokine secretion. J Immunol 181:2181–2188 104. Idzko M, Panther E, Bremer HC, Sorichter S, Luttmann W, Virchow CJJ, Di Virgilio F, Herouy Y, Norgauer J, Ferrari D (2003) Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br J Pharmacol 138:1244–1250 105. Ferrari D, Idzko M, Dichmann S, Purlis D, Virchow CJJ, Norgauer J, Chiozzi P, Di Virgilio F, Luttmann W (2000) P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production. FEBS Lett 486:217–224 106. Molloy A, Laochumroonvorapong P, Kaplan G (1994) Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Gue´rin. J Exp Med 180:1499–1509 107. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS (1997) ATP-Induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z (P2X7) receptors. Immunity 7:433–444 108. Coutinho-Silva R, Stahl L, Raymond M-N, Jungas T, Verbeke P, Burnstock G, Darville T, Ojcius DM (2003) Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation. Immunity 19:403–412 109. Brodbeck WG, Anderson JM (2009) Giant cell formation and function. Curr Opin Hematol 16:53–57 110. Suga M, Yamasaki H, Nakagawa K, Kohrogi H, Ando M (1997) Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 14:131–138 111. Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di Virgilio F (1995) The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J Clin Invest 95:1207–1216 112. Falzoni S, Chiozzi P, Ferrari D, Buell G, Di Virgilio F (2000) P2X7 receptor and polykarion formation. Mol Biol Cell 11:3169–3176 113. Chiozzi P, Sanz JM, Ferrari D, Falzoni S, Aleotti A, Buell GN, Collo G, Virgilio FD (1997) Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. J Cell Biol 138:697–706 114. Lemaire I, Falzoni S, Leduc N, Zhang B, Pellegatti P, Adinolfi E, Chiozzi P, Di Virgilio F (2006) Involvement of the purinergic P2X7 receptor in the formation of multinucleated giant cells. J Immunol 177:7257–7265 115. Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita RG, Salmon J, Cronstein BN (1997) Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 40:1308–1315
190
M. Koeppen et al.
116. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G (2001) Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 166:1611–1617 117. Wilkin F, Stordeur P, Goldman M, Boeynaems JM, Robaye B (2002) Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. Eur J Immunol 32:2409–2417 118. Marteau F, Communi D, Boeynaems J-M, Suarez Gonzalez N (2004) Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells. J Leukoc Biol 76:796–803 119. Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A (2000) Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J Immunol 165:4704–4709 120. Mutini C, Falzoni S, Ferrari D, Chiozzi P, Morelli A, Baricordi OR, Collo G, RicciardiCastagnoli P, Di Virgilio F (1999) Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J Immunol 163:1958–1965 121. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K, Takashima A (2002) CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 8:358–365 122. Filippini A, Taffs RE, Agui T, Sitkovsky MV (1990) Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem 265:334–340 123. El-Moatassim C, Dornand J, Mani JC (1987) Extracellular ATP increases cytosolic free calcium in thymocytes and initiates the blastogenesis of the phorbol 12-myristate 13-acetatetreated medullary population. Biochim Biophys Acta 927:437–444 124. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, Rubini M, Di Virgilio F (1996) An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87:682–690 125. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F (1999) Increased proliferation rate of lymphoid cells transfected with the P2X7 ATP receptor. J Biol Chem 274:33206–33208 126. Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, Cuneo A, Castoldi G, Di Virgilio F, Baricordi OR (2002) P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706–708 127. Gu B, Bendall LJ, Wiley JS (1998) Adenosine triphosphate-induced shedding of CD23 and L-Selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92:946–951 128. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signaling cascade. Biochim Biophys Acta 1783:673–694 129. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen J-F, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265 130. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell’Acqua ML, Rossini PM, Battistini L, Rotzschke O, Falk K (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225–1232 131. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC (2007) CD39 and control of cellular immune responses. Purinergic Signal 3:171–180 132. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K (2008) ATP drives lamina propria TH17 cell differentiation. Nature 455:808–812 133. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821–852
7 Purinergic Regulation of Airway Inflammation
191
134. Koshlukova SE, Lloyd TL, Araujo MW, Edgerton M (1999) Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death. J Biol Chem 274:18872–18879 135. Ivanova EP, Alexeeva YV, Pham DK, Wright JP, Nicolau DV (2006) ATP level variations in heterotrophic bacteria during attachment on hydrophilic and hydrophobic surfaces. Int Microbiol 9:37–46 136. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O’Farrelly C, Tubridy N, Mills KHG (2009) CD39+ Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 183:7602–7610 137. Kawaguchi M, Kokubu F, Fujita J, Huang SK, Hizawa N (2009) Role of interleukin-17F in asthma. Inflamm Allergy Drug Targets 8:383–389 138. Hong SC, Lee SH (2010) Role of th17 cell and autoimmunity in chronic obstructive pulmonary disease. Immune Netw 10:109–114 139. Traves SL, Donnelly LE (2008) Th17 cells in airway diseases. Curr Mol Med 8:416–426 140. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, Woods J, May R, Sleeman MA, Anderson IK, Brightling CE (2010) Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138:1140–1147 141. Erjef€alt J (2005) Transepithelial migration, necrosis and apoptosis as silent and proinflammatory fates of airway granulocytes. Curr Drug Targets Inflamm Allergy 4:425–431 142. Goepfert C, Imai M, Brouard S, Csizmadia E, Kaczmarek E, Robson SC (2000) CD39 modulates endothelial cell activation and apoptosis. Mol Med 6:591–603 143. Seye CI, Yu N, Gonzalez FA, Erb L, Weisman GA (2004) The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J Biol Chem 279:35679–35686 144. Kawai Y, Kaidoh M, Ohhashi T (2008) MDA-MB-231 produces ATP-mediated ICAM-1dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells. Am J Physiol 295:C1123–C1132 145. Freyer DR, Boxer LA, Axtell RA, Todd RF III (1988) Stimulation of human neutrophil adhesive properties by adenine nucleotides. J Immunol 141:580–586 146. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G (1992) Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148:2201–2206 147. Zahler S, Becker BF, Raschke P, Gerlach E (1994) Stimulation of endothelial adenosine A1 receptors enhances adhesion of neutrophils in the intact guinea pig coronary system. Cardiovasc Res 28:1366–1372 148. Tanaka N, Kawasaki K, Nejime N, Kubota Y, Nakamura K, Kunitomo M, Takahashi K, Hashimoto M, Shinozuka K (2004) P2Y receptor-mediated Ca2+ signaling increases human vascular endothelial cell permeability. J Pharmacol Sci 95:174–180 149. Wakai A, Wang JH, Winter DC, Street JT, O’Sullivan RG, Redmond HP (2001) Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock 15:297–301 150. Henttinen T, Jalkanen S, Yegutkin GG (2003) Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto-50 -nucleotidase/CD73-dependent mechanism. J Biol Chem 278:24888–24895 151. Airas L, Hellman J, Salmi M, Bono P, Puurunen T, Smith DJ, Jalkanen S (1995) CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 182:1603–1608 152. Zen K, Parkos CA (2003) Leukocyte-epithelial interactions. Curr Opin Cell Biol 15:557–564 153. Zemans RL, Colgan SP, Downey GP (2009) Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 40:519–535 154. Liu L, Mul FP, Kuijpers TW, Lutter R, Roos D, Knol EF (1996) Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cells is regulated by different mechanisms. Ann NY Acad Sci 796:21–29
192
M. Koeppen et al.
155. Rounds S, Likar LL, Harrington EO, Kim KC, Smeglin A, Heins K, Parks N (1999) Nucleotide-induced PMN adhesion to cultured epithelial cells: possible role of MUC1 mucin. Am J Physiol 277:L874–L880 156. Chen Y, Zhao YH, Wu R (2001) Differential regulation of airway mucin gene expression and mucin secretion by extracellular nucleotide triphosphates. Am J Respir Cell Mol Biol 25:409–417 157. Patel NJ, Zaborina O, Wu L, Wang Y, Wolfgeher DJ, Valuckaite V, Ciancio MJ, Kohler JE, Shevchenko O, Colgan SP, Chang EB, Turner JR, Alverdy JC (2007) Recognition of intestinal epithelial HIF-1alpha activation by Pseudomonas aeruginosa. Am J Physiol 292: G134–G142 158. Laughlin RS, Musch MW, Hollbrook CJ, Rocha FM, Chang EB, Alverdy JC (2000) The key role of Pseudomonas aeruginosa PA-I lectin on experimental gut-derived sepsis. Ann Surg 232:133–142 159. Bajolet-Laudinat O, Girod-de Bentzmann S, Tournier JM, Madoulet C, Plotkowski MC, Chippaux C, Puchelle E (1994) Cytotoxicity of Pseudomonas aeruginosa internal lectin PA-I to respiratory epithelial cells in primary culture. Infect Immun 62:4481–4487 160. Fausther M, Pelletier J, Ribeiro CM, Se´vigny J, Picher M (2010) Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am J Physiol 298: L804–L818 161. Campodo´nico VL, Gadjeva M, Paradis-Bleau C, Uluer A, Pier GB (2008) Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med 14:120–133 162. McNamara N, Khong A, McKemy D, Caterina M, Boyer J, Julius D, Basbaum C (2001) ATP transduces signals from ASGM1, a glycolypid that functions as a bacterial receptor. Proc Natl Acad Sci USA 98:9086–9091 163. McNamara N, Gallup M, Sucher A, Maltseva I, McKemy D, Basbaum C (2006) AsialoGM1 and TLR5 cooperate in flagellin-induced nucleotide signaling to activate Erk1/2. Am J Respir Cell Mol Biol 34:653–660 164. Morello S, Ito K, Yamamura S, Lee K-Y, Jazrawi E, DeSouza P, Barnes P, Cicala C, Adcock IM (2006) IL-1beta and TNFalpha regulation of the adenosine receptor (A2A) expression: differential requirement for NFkB binding to the proximal promoter. J Immunol 177:7173–7183 165. Ribeiro CMP, Paradiso AM, Carew MA, Shears SB, Boucher RC (2005) Cystic fibrosis airway epithelial Ca2+i signaling: the mechanism for the larger agonist-mediated intracellular Ca2+ signal in human cystic fibrosis airway epithelia. J Biol Chem 280: 10202–10209 166. Ribeiro CM, Paradiso AM, Schwab U, Perez-Vilar J, Jones L, O’Neal WK, Boucher RC (2005) Chronic airway infection/inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J Biol Chem 280:17798–17806 167. Boots AW, Hristova M, Kasahara DI, Haenen GR, Bast A, van der Vliet A (2009) ATPmediated activation of the NADPH oxidase DUOX1 mediates airway epithelial responses to bacterial stimuli. J Biol Chem 284:17858–17867 168. Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC Jr, Luttmann W, Norgauer J, Di Virgilio F, Idzko M (2005) The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion. Am J Respir Cell Mol Biol 33:601–609 169. Theatre E, Bours V, Oury C (2009) A P2X ion channel-triggered NF-kappaB pathway enhances TNF-alpha-induced IL-8 expression in airway epithelial cells. Am J Respir Cell Mol Biol 41:705–713 170. Taylor AL, Schwiebert LM, Smith JJ, King C, Jones JR, Sorscher EJ, Schwiebert EM (1999) Epithelial P2X purinergic receptor channel expression and function. J Clin Invest 104:875–884
7 Purinergic Regulation of Airway Inflammation
193
171. Chung KF (2006) Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 7:675–681 172. Sun Y, Wu F, Sun F, Huang P (2008) Adenosine promotes IL-6 release in airway epithelia. J Immunol 180:4173–4181 173. Douillet CD, Robinson WP, Milano PM, Boucher RC, Rich PB (2006) Nucleotides induce IL-6 release from human airway epithelia via P2Y2 and p38 MAPK-dependent pathways. Am J Physiol 291:L734–L746 174. Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262–267 175. Rollins BM, Burn M, Coakley RD, Chambers LA, Hirsh AJ, Clunes MT, Lethem MI, Donaldson SH, Tarran R (2008) A2B adenosine receptors regulate the mucus clearance component of the lung’s innate defense system. Am J Respir Cell Mol Biol 39:190–197 176. Rada B, Lekstrom K, Damian S, Dupuy C, Leto TL (2008) The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J Immunol 181:4883–4893 177. Kim TB, Moon KA, Lee KY, Park CS, Bae YJ, Moon HB, Cho YS (2009) Chlamydophila pneumoniae triggers release of CCL20 and vascular endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation. J Clin Immunol 29:629–636 178. Schutyser E, Struyf S, Van Damme J (2003) The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14:409–426 179. Marcet B, Horckmans M, Libert F, Hassid S, Boeynaems JM, Communi D (2007) Extracellular nucleotides regulate CCL20 release from human primary airway epithelial cells, monocytes and monocyte-derived dendritic cells. J Cell Physiol 211:716–727 180. Huang F, Wachi S, Thai P, Loukoianov A, Tan KH, Forteza RM, Wu R (2008) Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma. J Allergy Clin Immunol 121:1415–1421 181. Zhong H, Wu Y, Belardinelli L, Zeng D (2006) A2B adenosine receptorsinduce IL-19 from bronchial epithelial cells, resulting in TNFalpha increase. Am J Respir Cell Mol Biol 35:587–592 182. Huang SK, Peters-Golden M (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442–1450 183. Lazarowski ER, Boucher RC, Harden TK (1994) Calcium-dependent release of arachidonic acid in response to purinergic receptor activation in airway epithelium. Am J Physiol 266: C406–C415 184. Laubinger W, Tulapurkar ME, Sch€afer R, Reiser G (2006) Distinct mono- and dinucleotidespecific P2Y receptors in A549 lung epithelial cells: different control of arachidonic acid release and nitric oxide synthase expression. Eur J Pharmacol 543:1–7 185. Picher M, Boucher RC (2000) Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:255–261 186. Marcet B, Libert F, Boeynaems J-M, Communi D (2007) Extracellular nucleotides induce COX-2 up-regulation and prostaglandin E2 production in human A549 alveolar type II epithelial cells. Eur J Pharmacol 566:167–171 187. Cobb BR, Ruiz F, King CM, Fortenberry J, Greer H, Kovacs T, Sorscher EJ, Clancy JP (2002) A2 adenosine receptors regulate CFTR through PKA and PLA2. Am J Physiol 282: L12–L25 188. Li Y, Wang W, Parker W, Clancy JP (2006) Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am J Respir Cell Mol Biol 34:600–608
Chapter 8
Animal Models of Airway Diseases Linda F. Thompson, Maryse Picher, and Michael R. Blackburn
Abstract Over the past 20 years, the growing awareness that purinergic signaling events literally shape the immune and inflammatory responses to infection and allergic reactions warranted the development of animal models to assess their importance in vivo in acute lung injury and chronic airway diseases. The pioneer work conducted with the adenosine deaminase (ADA)-deficient mouse provided irrefutable evidence that excess adenosine (ADO) accumulating in the lungs of asthmatic patients, constitutes a powerful mediator of disease severity. These original studies launched the development of murine strains for the two major ectonucleotidases responsible for the generation of airway ADO from ATP release: CD39 and CD73. The dramatic acute lung injury and chronic lung complications, manifested by these knockout mice in response to allergens and endotoxin, demonstrated the critical importance of regulating the availability of ATP and ADO for their receptors. Therapeutic targets are currently evaluated using knockout mice and agonists/antagonists for each ADO receptor (A1R, A2AR, A2BR, and A3R) and the predominant ATP receptors (P2Y2R and P2X7R). This chapter provides an indepth description of each in vivo study, and a critical view of the therapeutic potentials for the treatment of airway diseases. Keywords Adenosine deaminase CD73 CD39 Fibrosis Pulmonary edema
L.F. Thompson (*) Oklahoma Medical Research Foundation, Oklahoma City, OK, USA e-mail:
[email protected] M. Picher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected] M.R. Blackburn Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, Houston, TX, USA e-mail:
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_8, # Springer Science+Business Media B.V. 2011
195
196
8.1
L.F. Thompson et al.
Introduction: Pulmonary Edema
Pulmonary edema is a life-threatening complication of acute lung injury, acute respiratory distress syndrome and pneumonia, which affects both barriers separating the bloodstream from the airspace: hyper-permeability of the pulmonary endothelial and epithelial barriers to macromolecules and inflammatory cells, and reduction of alveolar fluid clearance capacity mediated by ion channels (review: [1]). This complication is routinely documented in murine models targeting the enzymes and receptors regulating purinergic signaling. Yet, considerable discrepancies are reported between the beneficial or detrimental effects of receptor agonists/antagonists. The following section summarizes the current knowledge on the purinergic regulation of pulmonary edema taking place at the endothelial and epithelial barriers, which reconciles all apparent disagreements. This information will allow the reader to appreciate the impact of excess airway ATP and ADO in respiratory complications in vivo, the usefulness of certain animal models for drug development, and the appropriate administration route for therapeutic compounds.
8.1.1
The Permeability of the Endothelial Barrier
Until recently, our understanding of endothelial barrier regulation was limited to ADO, which plays an essential role in resealing the gate after the transmigration of inflammatory cells (review: [2]). Then again, we have learned through the first seven chapters of this book that purinergic signaling generally initiates an ATPmediated pro-inflammatory response, which is followed by an ADO-mediated antiinflammatory response. Therefore, several groups tested the impact of P2 receptor agonists on the regulation of endothelial barrier permeability. While the use of stable analogues and P2 receptor antagonists clearly demonstrated the sensitivity of the barrier to ATP, these studies provided contradictory conclusions (review: [1]). In this section, we provide a thorough analysis of all data which reconciles the literature under a unifying concept: opposing regulations of barrier permeability by P2Y1Rs (ADP) and P2Y2Rs (ATP), depending on local ATP/ADP concentrations. While these studies were conducted on various endothelia, these receptors are co-localized on pulmonary endothelial cells [3]. In human pulmonary artery and lung microvascular endothelial cultures, the low micromolar ATP concentrations induced a dose-dependent increase in transendothelial electrical resistance (TER) [4]. Likewise, 10 mM ATP reduced the thrombin-mediated barrier permeability of cultured human umbilical vein endothelial cells [5]. Similar data were obtained with non-hydrolysable ATP analogs known to interact with P2Y receptors, ruling out the possibility that these effects were mediated by ADO after ATP metabolism by the CD39-CD73 tandem [4]. This ATP concentration also inhibited the passage of macromolecules across endothelial monolayers, thus labeling this nucleotide as barrier protective [6]. Pharmacological
8 Animal Models of Airway Diseases
197
Fig. 8.1 Purinergic regulation of fluid fluxes and barrier permeability in the lung. In the circulation, nucleotides regulate endothelial permeability to fluid and leukocytes by the balancing activities of ATP, ADP and ADO receptors. Whereas P2Y1R activation reduces the transmembrane electrical resistance (TER), P2Y2Rs, A2ARs and A2BRs all protect the lungs against vascular leakage. A second barrier protects the airways against excess fluid accumulation: the epithelial barrier. Alveolar cells express A1Rs and A2ARs which regulate fluid fluxes in and out of the airspace along ion gradients generated by the CFTR chloride (Cl–) channel and the ENaC sodium (Na+) channel. During viral infection, pulmonary edema is caused by the production, release and conversion of UTP into UDP, which activates P2Y6Rs to inhibit Na+ and fluid absorption via ENaC
analysis ascribed this response to P2Y2Rs which initiates a signaling cascade involving the activation of phospholipase C (PLC), but not PKC or Ca2+ mobilization. Incidentally, Kolosova et al. demonstrated that the enhancement of barrier integrity by low micromolar ATP involves reorganization of the intercellular tight junctions, which occurs independently of Ca2+ mobilization or ERK1/2 [4] (Fig. 8.1). The signaling cascade is reminiscent of P2Y2R-mediated induction of cell migration during epithelial repair (see Chap 6 for details). The P2Y2Rs located near tight junctions are coupled to G proteins Gq or Gi2 (not G12 or G13), which induce protein kinase A (PKA) activation, leading to the dephosphorylation of myosin light chain, and phosphorylation of vasodilator-stimulated phosphoprotein (VASP). When phosphorylated, VASP inhibits actin polymerization and the formation of stress fibers that would disrupt the barrier.
198
L.F. Thompson et al.
The barrier resistance of human umbilical vein endothelial cells is reduced by selective agonists of P2Y1Rs [7]. Contrary to P2Y2Rs, the signaling mechanism is Ca2+-dependent [7] and requires myosin light chain phosphorylation [8]. Incidentally, the use of ionomycin to trigger Ca2+ entry into the cells facilitated the passage of albumin across aortic endothelial monolayers [6]. On the other hand, this receptor is only activated by ADP, released at high micromolar concentrations by platelets and red blood cells. While CD39 expressed on the endothelial surface generates ADP from ATP, the enzyme does not allow this product to accumulate significantly before further dephosphorylation into AMP. This is an important point, since the affinity of P2Y1Rs for ADP (EC50 ¼ 8 mM) is considerably lower than P2Y2Rs for ATP (EC50 ¼ 0.2 mM) (review: [9]). Under normal conditions, low micromolar ATP would prevent pulmonary edema primarily via P2Y2Rs. On the other hand, massive local ADP release from platelets or red blood cells squeezing into the pulmonary vascular bed would transiently raise barrier permeability via P2Y1Rs, before the nucleotide is dephosphorylated by CD39. In vascular beds, P2Y1Rs have been shown to facilitate the passage of circulating cells through the narrow vessels by inducing nitric oxide-mediated vasodilatation [10]. However, conditions reducing CD39 activity, such as hypoxia/oxidative stress (see Chap. 4), may overwhelm the protective effects of P2Y2Rs and cause pulmonary edema. The highly efficient surface conversion of ATP and ADP into ADO generates a secondary wave of purinergic signaling for the regulation of endothelial barrier integrity. An in vivo study comparing the extent of hypoxia-induced vascular leakage among the knockout mice for each ADO receptor revealed that only the A2BR/ mice respond to hypoxia by significantly worse lung edema than wildtype mice, which was prevented by the A2BR agonist, BAY60-6583 [11]. The capacity of A2BR activation to raise endothelial TER was confirmed on human microvascular endothelial cultures using an antagonist (PSB 1115) and by RNA silencing technique [11]. In fact, Rounds et al. recently showed that A2ARs, A2BRs and ADO transporters work in concert to prevent pulmonary edema through endothelial barrier enhancement [12]. The adenosine deaminase inhibitor, pentostatin, raised surface ADO levels by tenfold, which enhanced the formation of endothelial adherens junction and focal adhesion through Rac1 GTPase activation. The fact that A1Rs and A3Rs were ineffective at regulating endothelial barrier permeability supports the well-established notion that barrier resistance is cyclic AMP (cAMP)-dependent (review: [2]). Under baseline conditions, ADO-mediated TER would be maintained by the high-affinity A2ARs (EC50 ¼ 0.560.95 mM) (review: [9]), whereas crisis situations raising circulating ADO levels (i.e. hypoxia or infection) would recruit the low-affinity A2BRs (EC50 ¼ 16.264.1 mM) (review: [9]) for additional protection against vascular leakage. The therapeutic potential of A2BR agonists for lung edema was demonstrated in a study conducted with endotoxemic pigs [13]. Endotoxin-induced acute lung injury and increase in lung extravascular water were, both, reduced by intravenously infused ADO. A similar response was obtained with the ADO receptor agonist, 2-chloroadenosine, in endotoxemic guinea-pigs [14]. Interestingly, the microvascular endothelial cells express predominantly ADO receptors causing an
8 Animal Models of Airway Diseases
199
increase in cyclic AMP (cAMP) production (A2ARs and A2BRs), which leads to PKA-dependent VASP phosphorylation, like for the abovementioned P2Y2Rs [15]. These data suggest that circulating nucleotides normally maintain TER by successive waves of ATP- and ADO-mediated signals, which by the same token, would regulate leukocyte migration induced by inflammatory mediators.
8.1.2
Fluid Clearance on Alveolar Epithelia
The respiratory tract is frequently subjected to mechanical stress and infections, which stimulate the release of nucleotides into the airways. Decades of research clearly established that extracellular nucleotides are the major regulators of airway hydration (review: [16]). More importantly, they showed that the epithelial barrier regulates fluid fluxes by purinergic regulation of ion channels. The vectorial movements of Na+ and Cl– ions across the barrier create an osmotic gradient for water to follow. The absorption of Na+ by the epithelial sodium channel (ENaC) mediates fluid clearance, and Cl secretion by the Ca2+-dependent Cl– channels (CaCC) and cystic fibrosis transmembrane regulator (CFTR) hydrates airway surfaces. This subject is covered in details in Chap. 5 for the large airways, where nucleotides are identified as stimulators of fluid accumulation into the airspace. This concept seems to apply to the regulation of alveolar fluid clearance (AFC), as intra-tracheal instillation of ATP caused lung edema in mice [17]. This initial observation launched various initiatives to clarify the involvement of purinergic signaling in the impaired epithelial fluid clearance observed during pulmonary edema. In mice, the respiratory syncytial virus (RSV) causes a transient reduction in AFC, likely to promote clearance by the mucociliary escalator [18]. Using in vivo and in vitro studies, Matalon et al. showed that RSV impairs Na+-driven AFC through ENaC in distal lung and upper airway epithelia [19–21]. In the H441 Clara cells, RSV-mediated ENaC inhibition was partially prevented by blockers of nitric oxide production (1,400 W), or de novo UTP synthesis (A77-1726). During RSV infection, the accumulation of both purines (ATP, ADP) and pyrimidines (UTP, UDP) in the alveolar space [20], and the prevention of fluid accumulation by P2Y receptor antagonists [19], support a role for UTP synthesis and release in the purinergic regulation of AFC. The predominant P2Y receptor capable of mediating pyrimidinergic signals in the respiratory tract is the P2Y2R, which is activated by ATP and UTP, not by ADP or UDP (Chap. 7, Table 7.1). On the other hand, only soluble enzymes degrading pyrimidines (UDP-glucose pyrophosphorylase or apyrase) prevented RSV-induced edema [19]. In addition, intratracheal UTP and UDP, both, reproduced RSVmediated AFC reduction [18]. And, UTP is readily dephosphorylated into UDP by ectonucleotidases on airway surfaces [22, 23]. Contrary to the endothelial surface, the ectonucleotidase population of the epithelial cells allows for significant accumulation of UDP before it is dephosphorylated further into UMP and uridine (see Chap. 2 for details). These results raised the possibility that UTP and UDP,
200
L.F. Thompson et al.
both, mediated their effects through P2Y6R activation. This receptor is functionally expressed on the apical surface of airway and alveolar epithelial cells (review: [24]). In A549 human alveolar Type 2 cells, P2Y6Rs activation accounts for the majority of Ca2+-dependent ATP secretion [25]. The identity of this receptor was later confirmed using mice infected with the influenza A virus [26]. Like RSV, this virus induced hypoxemia and inhibited AFC, and was associated with a rapid increase in ATP and UTP concentrations in the BAL fluid. The use of various ion channel blockers and P2Y receptor antagonists confirmed that viral infections induce de novo UTP synthesis and secretion, followed by UTP dephosphorylation into UDP and P2Y6R activation. This signaling cascade inhibits Na+ absorption by ENaC, allowing fluid to accumulate into the alveolar space. This purinergic receptor does not support the ATP-mediated pulmonary edema observed in mice during mechanical ventilation [17]. On the other hand, most purinergic networks accommodate a dual regulation of cellular functions mediated by the balancing effects of nucleotide (P2) receptors and ADO (P1) receptors. Davis et al. demonstrated that CFTR inhibitors, or agents preventing the formation of ADO from ATP metabolism, improved AFC during viral infection [26]. The use of selective P1 receptor antagonists identified the A1R as the culprit responsible for the CFTR-mediated reduction of AFC in infected mice. These findings were quite surprising considering the well established role of A2BRs in the stimulation of fluid secretion by CFTR in human airways (see Chap. 5). As will be described below, the purinergic network of the alveolar wall differs from the airways in terms of ectonucleotidases (see Chap. 2), as well as purinoceptors. We are grateful for Factor et al., who meticulously determined the identity and polarity of the ADO receptors on alveolar epithelial cells [27]. Based on laser capture microdissection and quantitative PCR, they showed that all four receptors are detected on the murine epithelial barrier. Contrary to the upper airways, alveolar cells predominantly express the A2AR, with an mRNA level at least fivefold higher than for the other receptors. Membrane fractionation indicated that A1Rs and A2ARs are concentrated on the apical surface, whereas A2BRs and A3Rs were undetected by Western blot. However, one must keep in mind that in vivo measurements of AFC will include the A2BR-mediated CFTR activation and fluid secretion taking place in the airways. Incidentally, the lung edema induced, in mice, by mechanical ventilation was significantly reduced by intratracheal instillation of an A2BR antagonist (PSB1115) [28]. To specifically study the purinergic regulation of alveolar ion channels, Factor et al. used two approaches: the alveolar cell monolayers and the isolated perfused lungs [27]. Both models revealed that low ADO concentrations (0.0110 nM) and A2AR agonists (CGS 21680) stimulate AFC via ENaC activation. In contrast, low micromolar ADO (1 mM) and A1R agonists (CCPA) reduce AFC via CFTR activation [27], as reported during viral infection [26]. Since both ADO receptors enhance opposing fluid fluxes across the epithelial barrier, the net directionality will depend on the local fluctuations in alveolar ADO concentrations. Collectively, these studies support a complex purinergic regulation of AFC which involves P2Y6Rs (UDP), A2ARs (ADO) and A1Rs (ADO) (Fig. 8.1). In healthy
8 Animal Models of Airway Diseases
201
lungs, the mechanical stress induced by normal rhythmic breathing induces the release of purines and pyrimidines into the airspace. Under these conditions, only the ADO concentration maintained by ATP release/metabolism reaches the activation thresholds of purinergic receptors, which mediates a balanced ENaC/CFTR activation to optimize AFC. During mechanical ventilation, the excessive ATP release raises ADO levels, tilting the balance toward the CFTR-mediated fluid accumulation into the lung. In addition, mechanical ventilation activates lung phosphoinositides 3-kinase gamma, which degrades cAMP [29], thereby weakening the protective effects of the ADO-A2AR-cAMP pathway against lung edema. Consequently, patients with chronic illnesses associated with high airway ADO levels would be particularly at risk of developing pulmonary edema during mechanical ventilation, combining a dominant A1R-mediated flooding and a weak A2ARmediated AFC. Likewise, bacterial infection causes ATP release from alveolar epithelial cells [30, 31], and thus initiates the same A1R/A2AR imbalance toward flooding. In the case of viral infection, the de novo synthesis and secretion of UTP provides additional UDP for P2Y6R activation, which causes alveolar flooding via ENaC inhibition. In terms of therapeutic application, simultaneous inhibition of CFTR (CFTRinh172), and prevention of ENaC inhibition using a blocker of UTP de novo synthesis (A77-1726), restored normal AFC in infected mice [26]. While this approach seem attractive for the treatment of pulmonary edema, clinical studies reported considerable side-effects during treatments involving A77-1726, or its prodrug leflunomide (review: [32]). Inhibition of UTP synthesis within the cells is expected to impair critical functions, including DNA synthesis. Instead, the development of drugs targeting A1Rs, A2ARs or P2Y6Rs would allow more flexibility in dose optimization with minimal side-effects. Since CFTR and ENaC are primarily regulated by P2Y2Rs and A2BRs in the large airways, targeting these receptors would not compromise the clearance of pathogens by the mucociliary escalator. This section emphasizes the distinct purinergic regulations of barrier permeability on the endothelial and epithelial barriers separating the bloodstream from the alveolar space. Armed with this information, we will begin our description of the murine models which were developed to appreciate the contribution of impaired ATP and ADO regulation in the development of acute and chronic disorders, with a critical eye on the therapeutic strategies proposed to restore lung homeostasis.
8.2
Murine Models of Aberrant Purine Regulation
Murine models were developed to determine the contribution of aberrant ATP and/ or ADO concentrations to the development and progression of complex disorders, including respiratory diseases. Most mammalian cells regulate surface ATP and ADO by the sequential activities of CD39, CD73 and ADA. First, CD39 dephosphorylates ATP and ADP into AMP, and then CD73 converts AMP into ADO.
202
L.F. Thompson et al.
Finally, cell surface ADA converts a fraction of the extracellular ADO into inosine, whereas the remaining portion is transported back into the cells through concentrative transporters (see Chap. 2 for details). Consequently, animal models were designed to target each of these ectonucleotidases. In the following section, we compare the phenotype of these mice to chronic respiratory diseases bearing the same metabolic disorders, to gain an appreciation of their role in the lung complications, and determine the potential of purinergic-based therapeutic approaches.
8.2.1
Too Much Adenosine in ADA-Deficient Mice
Humans with mutations in the ada gene resulting in a lack of enzyme activity suffer from severe combined immunodeficiency (ADA-SCID) [33]. Because ADA-deficient patients are extremely rare, considerable effort was expended in the generation of ada gene-targeted mice to better understand this genetic disease. Unfortunately, mice in which the ada gene was deleted in all tissues suffered from perinatal lethality [34, 35]. Surprisingly, the cause of death was not immunodeficiency, as they survive quite well in a clean animal facility, but rather hepatotoxicity. In an attempt to create viable ada/ mice, Blackburn et al. engineered an ada/ mouse strain that expressed an ada mini-gene in the placenta using trophoblast-specific controlling elements in the ada promoter [36]. These mice were viable and had normal liver function. However, they died at about 3 weeks of age from respiratory distress, characterized by severe inflammation, rapid and labored breathing. Their lifespan was extended by treatment with polyethylene glycol-conjugated bovine ADA (PEG-ADA) [37], the same material used for enzyme replacement therapy in ADA-deficient patients [38]. These mice received PEG-ADA intramuscularly every 4 days after birth, which partially suppressed the ADO-mediated lung inflammation. Contrary to intranasal instillation, intramuscular injection of PEG-ADA suppresses early events in the development of lung inflammation, like leukocyte and dendritic cell migration (see Chap. 7 for details). For the purpose of this review, these mice will be referred to as “ADA-deficient mice”. A second strain with partial ADA activity was generated by ectopic expression of a minigene in the gastrointestinal tract of ADA-deficient mice [39]. They developed a milder pulmonary disease and had a lifespan of about 5 months. They will be referred to as “partially ADA-deficient” mice. The ADA-deficient mice appeared normal at birth, but their lungs exhibited larger alveolar spaces by day 5 [36, 37]. There was no inflammatory cell in the lungs at that time, so the defect in alveogenesis preceded the onset of inflammation, which occurred around day 10. By day 18, abnormal alveogenesis was obvious, and was characterized by thickened vascular smooth muscles and marked enlargement of the alveolar spaces. There was also hypertrophy of bronchial epithelia with increased mucus production, and cell debris accumulated in the airways. Most inflammatory cells in bronchoalveolar (BAL) fluid were macrophages, in the form of enlarged and foamy multinucleated giant cells, clustered around bronchioles and
8 Animal Models of Airway Diseases
203
pulmonary vessels. Few eosinophils accumulated in the interstitium and the luminal space. It was suspected that these structural changes and inflammatory responses were caused by the excess ADO measured in the total lung tissue of ADA-deficient mice. Whereas lung ADO levels were barely detectable in wild-type mice, they rose about 20-fold in ADA-deficient mice, reaching a concentration of 4 nmolmg1 protein. The concentration of the other ADA substrate, deoxyADO was also elevated, but to a lesser extent (<0.05 nmolmg1 protein), suggesting that the toxicity of this molecule for DNA synthesis played a minor role in lung pathology. The critical role of ADO was clearly demonstrated by the fact that ADA-deficient mice were essentially “cured” by PEG-ADA treatments. The improvements in lung physiology and histology correlated with the decrease in lung ADO concentrations. Extensive gene profiling was conducted to gain insight into the lung pathology of the ADA-deficient mice. In the initial report [40], data were generated with Atlas mouse cDNA expression arrays containing 1,176 known genes and RNA isolated at day 18 of life, when the mice were near death. The two genes, whose expression levels were most altered in ADA-deficient mice, were vascular endothelial growth factor (VEGF) which was down-regulated by about 50%, and monocyte chemoattractant protein-3 (MCP-3) which was up-regulated about tenfold. These data are consistent with the inhibitory effect of ADO on the secretion of VEGF from neutrophils, a potent inducer of endothelial barrier permeability [41]. Therefore, these mice are not expected to develop vascular leakage or excessive leukocyte infiltration, as indicated by the vast majority of resident macrophages in the BAL fluid [36, 37]. Other genes related to eosinophil trafficking, cell adhesion, inflammation and fibrosis were also significantly up-regulated in the lungs of the ADA-deficient mice. Importantly, the expression of all these genes was largely normalized by treating the mice with PEG-ADA under dosing conditions that prevented lung pathology. The second study was more extensive and used arrays containing 7,056 oligonucleotides (70-mers) that were produced at the UCSF Sandler Center of Basic Research in Asthma [42]. The aim of this study was to identify the pathways causing abnormal alveogenesis in ADA-deficient mice. Therefore, RNA samples were collected at earlier time points: at birth and at 5 and 10 days of life. This study showed that ADA deficiency up-regulates genes involved in apoptosis, but down-regulates genes coding growth factors and their receptors, as well as surfactant proteins and angiogenic factors. As for the first study, these changes in gene expression were largely reversed by treatment with PEG-ADA. These data suggest that excess ADO, reported in the airways of patients with asthma and COPD [43, 44] impacts the developing lung via multiple pathways including apoptosis, proliferation and migration, which would promote the development of airway remodeling and sub-epithelial fibrosis. Yet, the short lifespan of the ADAdeficient mice did not allow for adequate documentation of these manifestations. The long-term consequences of high lung ADO concentrations were investigated using two different approaches: untreated partially-deficient ADA mice [39] and ADA-deficient mice treated with low doses of PEG-ADA over the course of 16 weeks [45]. Under these conditions, both cohorts eventually maintained comparable lung ADO levels (1.0 nmolmg1 protein), which were at least
204
L.F. Thompson et al.
fourfold lower than untreated ADA-deficient mice. As a consequence, both cohorts developed severe lung pathology and died from respiratory distress at about 5 months of age. These models allowed the authors to analyze the long-term impact of high ADO concentrations on the respiratory system to better understand the implications for chronic airway diseases. After completion of the 16 weeks of treatment, the ADA-deficient mice exhibited lung complications comparable to untreated partially ADA-deficient mice [45]. While the inflammatory response was still dominated by multinucleated macrophages, BAL fluid also accumulated lymphocytes, neutrophils and eosinophils. The histology revealed extensive remodeling, characterized by epithelial cell hyperplasia and hypertrophy, pulmonary fibrosis, matrix deposition and smooth muscle cell thickening. These observations were confirmed by real-time PCR analysis of the lung tissue, which showed that chronically-elevated ADO up-regulates several pro-fibrotic factors (TGFb1, osteopontin, plasminogen activator inhibitor-1 and matrix metalloproteinase-2) and pro-inflammatory Th2 cytokines (IL-1b and IL-13) [45]. Functional experiments conducted on dendritic cells showed that chronic exposure to excess ADO reduces the capacity to initiate and amplify a Th1 immune response [46]. These complications were largely reversed by 5 weeks of high-dose PEG-ADA in ADA-deficient mice initially treated 13 weeks with low-dose PEG-ADA [45]. The partially ADA-deficient mice also adopted Th2-skewed lung inflammatory responses typical of pulmonary fibrosis and asthma [47–49]. The transcript of IL-13 was undetected in the lung tissue of wild-type animals, but easily measured in partially ADA-deficient mice [50]. Other Th2 cytokines were up-regulated (IL-4 and IL-5), whereas the Th1 cytokine, IFNg, was down-regulated, compared to wildtype mice [50]. Interestingly, IL-13 transgenic mice share many lung complications with partially ADA-deficient mice [51, 52]. They develop inflammatory infiltrates enriched in macrophages and eosinophils, airway epithelial cell hypertrophy and fibrosis, mucus cell metaplasia and hypersecretion. Furthermore, IL-13 transgenic mice exhibit high lung ADO levels and a reduced ADA expression. The fact that most lung complications of IL-13 transgenic mice and partially-deficient ADA mice were resolved by PEG-ADA treatment supports the existence of a positive amplification pathway for IL-13 and ADO accumulation in the lungs. Whereas high ADO levels upregulate IL-13, the overexpression of this cytokine promotes ADO accumulation by a reduction in ADA activity. These findings are consistent with an in vitro study conducted on cultures of human bronchial epithelia cells, whereby chronic exposure to excess ADO raised IL-13 mRNA levels by sixfold [53]. This Th2 cytokine, which promotes eosinophilia, remodeling and fibrosis (review: [54]), likely plays a major role in the development of lung complications associated with excess airway ADO. Neovascularization is a major complication of chronic inflammatory disorders, including asthma (review: [55]). Inflammation stimulates the growth of new blood vessels, which enhances inflammatory cell recruitment, airway obstruction and hyper-responsiveness. The ADA-deficient mice exhibited significantly enhanced vascularity in the trachea than wild-type mice as early as 18 days after birth, which was quantified by immunolocalization of the endothelial cell marker CD31 [56]. This complication was prevented by PEG-ADA treatment, and was attributed to the
8 Animal Models of Airway Diseases
205
up-regulation of the pro-angiogenic chemokine, CXCL1, and its receptor CXCR2. These findings are consistent with the corneal micropocket assay of angiogenesis using lung extracts from wild-type and ADA-deficient mice. The angiogenic activity of lungs extract from ADA-deficient mice was inhibited by pre-treatment with PEG-ADA, or neutralizing antibodies to either CXCL1 or CXCR2. The source of CXCL1 appears to be macrophages, which accumulate in high numbers in the lung of ADA-deficient mice. While the gene expression surveys support an increased resistance against leukocyte transmigration into the airspace of the ADA-deficient mice, the longer lifespan of partially-deficient ADA mice and PEG-ADA treated ADA-deficient mice allows sufficient time to develop intense neovascularization as zones of vulnerability for leukocyte infiltration. Interestingly, genetic inactivation of A2ARs attenuated the pathological, but not developmental, angiogenesis in mouse retina [57]. Understanding the mechanisms by which excess ADO enhances neovascularization may lead to preventive therapies for airway remodeling and chronic inflammation.
8.2.2
Too Little Adenosine in CD73/ Mice
Most chronic respiratory diseases are associated with aberrances in extracellular nucleotide metabolism which maintain excess ADO in airway secretions (see Chap. 4 for details). Given the devastating consequences predicted from the ADA-deficient mice, therapeutic strategies are being formulated to restore normal airway ADO levels in these patients. The importance of careful dosing the pharmacological agents is emphasized by an animal model which restricts the production of this receptor agonist. Studies were conducted with Cd73/ mice to determine the impact of too little ADO on the overall health of the subject, as well as airway responses to acute insults and chronic conditions. Pulmonary hypoxia/ischemia initiates the translocation of inflammatory cells from the bloodstream into the interstitium as a pathological healing response (review: [58]). Hypoxic tissue releases ATP, which constitutes a powerful neutrophil chemoattractant to eliminate apoptotic cells as part of the repair process (see Chap. 7 for details). Without the existence of an efficient feedback mechanism, the excess recruitment of inflammatory cells would cause extensive tissue injury. Purinergic signaling provides a critical defense mechanism by terminating neutrophil transmigration across the endothelial barrier. The sequential activities of CD39 and CD73 on endothelial cells convert circulating ATP into ADO, which raises barrier resistance via A2ARs/A2BRs (Fig. 8.1). Although ADO induces the production of VEGF, a potent inducer of endothelial barrier permeability, in many circumstances, it can also block its secretion from neutrophils [41]. Incidentally, adherent neutrophils were shown to facilitate their transmigration by inhibiting CD73 activity on endothelial cells [59], which may explain the lack of CD73 on these inflammatory cells [60]. For all these reasons, ADO formation by the CD39-CD73 tandem is essential for the prevention of excessive inflammation and acute lung injury during hypoxia.
206
L.F. Thompson et al.
Hypoxia triggers the up-regulation of CD39, CD73 and A2BRs [11, 61, 62]. While CD39 up-regulation is mediated by the Sp1 transcription factor [61], CD73 and A2BR up-regulation require binding of the hypoxia inducible factor-1a (HIF1a) to their promoter site [11, 62]. The higher CD39-CD73 efficiency is expected to raise the circulating ADO concentration above the activation threshold of the A2BRs to enhance barrier resistance against vascular leakage and leukocyte transmigration (review: [2]). The importance of this purinergic regulation is demonstrated in mice denied CD73. The Cd73/ mice exhibit significant vascular leakage in multiple organs, including the lung [63]. Acute hypoxia (8% O2; 4 h) causes more severe vascular leakage in Cd73/ mice than in wild-type mice, characterized by perivascular edema and inflammatory infiltrates. These complications are partially reversed by the intraperitoneal injection of P1 receptor agonists, or soluble 50 -nucleotidase to replace CD73 [63, 64]. These results are consistent with the relative affinities of A2ARs and A2BRs, both involved in barrier protection (Fig. 8.1). While high-affinity A2ARs maintain baseline barrier resistance, the dramatic rise in circulating ADO level caused by hypoxia recruits the activities of low-affinity A2BRs. This study suggests that therapies aiming to suppress ADO production in chronic respiratory diseases could leave the patients vulnerable to hypoxia-induced pulmonary edema, and even aggravate lung inflammation, if the suppression of CD73 activity is not carefully optimized and restricted to the airways. Animal models are currently available to assess the potential of new therapies for acute lung injury (review: [65]). The intratracheal instillation of bleomycin ranks among the five most popular models, as it recapitulates most features: neutrophilic alveolitis, damage to alveolar epithelia and endothelia, hyaline membrane formation, and thrombus accumulation in the microvasculature. This antibiotic is isolated from Streptomyces verticillus and complexes with oxygen and metals, leading to the production of oxygen radicals, DNA breaks and ultimately cell death. Within 24 h, mice develop inflammation, depicted by the accumulation of macrophages, lymphocytes and neutrophils in the BAL fluid, which lasts about 11 days [66]. Lung tissue contains higher mRNA levels of pro-inflammatory cytokines (IL-1b and TNFa) and many pro-fibrotic factors (osteopontin, plasminogen activator inhibitor-1, TGFb1 and tissue inhibitor of metalloproteinase-1), as well as excess collagen. Fibrosis appears around day 11, and is reversed within 10 days. Acute lung injury reproduces the high airway ADO concentrations reported in asthmatic and COPD patients [43, 44]. The bleomycin-challenged mice maintain threefold higher total lung ADO levels, and a proportional increase in CD73 activity, during 14 days [66]. To determine whether this metabolic imbalance promotes or suppresses the pulmonary complications, Cd73/ mice were subjected to the bleomycin challenge [66]. These mice developed more severe complications to bleomycin, and died within 18 days. However, their lung ADO levels remained normal, identifying AMP dephosphorylation as the source of the agonist. These data suggest that a transient increase in airway ADO production is a defense mechanism to suppress acute lung injury. Incidentally, enzyme replacement therapy by intranasal instillation of 50 -nucleotidase restored the ability of Cd73/ mice to accumulate
8 Animal Models of Airway Diseases
207
lung ADO, which reduced all symptoms of inflammation and fibrosis. The fact that 50 -nucleotidase, given intranasally, was able to reduce the number of inflammatory cells in BAL fluid suggests that airway ADO can reach the interstitium to suppress leukocyte migration, or regulates epithelial permeability. Our current knowledge does not support a role for ADO in the regulation of neutrophil epithelial transmigration (Fig. 8.1). However, Hirsh et al. demonstrated that polarized bronchial epithelia support the vectorial transport of airway ADO into the interstitial tissue via apical concentrative, and basolateral equilibrative, nucleoside transporters [53]. Hence, the benefits of aerosolized drugs, given to acutely raise ADO levels during acute lung injury, may extend beyond the airways. The chronic model of allergic asthma supports the detrimental effects of chronic excess ADO in the airways. Mice are generally sensitized with ovalbumin (OVA) by intraperitoneal injections taking place over 14 days, followed by four challenges with nebulized OVA over an additional week [67]. Within 24 h after the last challenge, their lungs develop features of allergic asthma, including eosinophilic inflammation, goblet cell metaplasia and hyperresponsiveness to methacholine [68]. Furthermore, the BAL fluid of OVA-challenged mice contains eightfold higher ATP concentrations than in saline-challenged control mice, as reported for asthmatic patients following an allergen challenge [68]. Schreiber et al. tested the impact of preventing ADO production, from this excess nucleotide, in this model of allergic asthma [69]. The Cd73/ mice exhibited no baseline allergen-induced inflammation, and failed to develop hyperresponsiveness to methacholine following OVA treatment. These data demonstrate that the airway ADO produced by CD73, and not excess ATP, is responsible for the hyperresponsiveness of OVAchallenged mice. Aerosolized PEG-ADA may constitute a potential therapeutic intervention for airway hyperresponsiveness in asthmatic patients.
8.2.3
How Informative Are CD39/ Mice?
The impact of chronically-high airway ATP concentrations has been investigated by genetic deletion of the ATP/ADP-hydrolyzing ectonucleotidase, CD39. This choice was originally based on the predominant role of endothelial CD39 in the prevention of ADP-mediated thrombus formation (review: [70]). Consequently, it was quite surprising to find that Cd39/ mice exhibit no symptom of pulmonary complication, unless they are subjected to an insult. For instance, mechanical ventilation has been used as a model of acute lung injury in over 500 publications (review: [65]). Patients kept on a ventilator for less than 3 days usually recover from an acute inflammatory response, but prolonged intubation initiates tissue fibrosis and loss of lung function. For this reason, mechanical ventilation remains the focus of most animal studies on acute lung injury. Eckle et al. demonstrated that mice subjected 90 min to high-pressure mechanical ventilation develop typical manifestations of acute lung injury, characterized by vascular leakage, pulmonary edema, neutrophil infiltration and hemorrhage [71].
208
L.F. Thompson et al.
Interestingly, as in the case of hypoxia, this insult up-regulated both CD39 and CD73 by threefold within 2 h, resulting in a fourfold increase in total lung ADO concentration [71]. To test whether these metabolic disruptions constitute a defense mechanism, or promote the lung damage, Cd39/ and Cd73/ mice were subjected to the same insult. These knockout mice developed the same symptoms, but they were dramatically more severe than in the wild-type mice [71]. Surprisingly, similar BAL albumin level and neutrophil myeloperoxidase activity, as well as lung water content, were detected in the ventilated Cd39/ and Cd73/ mice. During acute insults, it is widely accepted that ATP mediates predominantly proinflammatory effects, whereas ADO generally provides a feedback anti-inflammatory response (review: [72]). Since Cd39/ mice allow ATP to accumulate and prevent ADO formation, we would have expected a more severe lung inflammation than in the Cd73/ mice, which simply deny ADO formation. This study highlights the critical protective role of excess ADO production during an acute insult, which outweighs any short-term detrimental effect of ATP accumulation. The significance of this purinergic protection was confirmed by the beneficial effects of enzyme replacement therapy on the ventilated wild-type mice. The intraperitoneal administration of apyrase (commercial form of CD39) or 50 -nucleotidase (commercial form of CD73), significantly reduced the accumulation of BAL albumin during mechanical ventilation. The excess circulating ADO, likely, provided additional endothelial barrier protection against vascular leakage via the low-affinity A2BRs (Fig. 8.1). Incidentally, this study also showed that intraperitoneal injection of an antagonist of A2BRs, not A2ARs, before the onset of mechanical ventilation reproduced the severity of the lung edema observed in the knockout mice. Consequently, this study confirms the protective role of excessive ADO against pulmonary edema during acute lung injury. Endothelial A2BRs should be targeted at the first manifestations of acute lung injury. Most animal models of acute lung injury are based on clinical disorders, including mechanical ventilation, gastric aspiration and sepsis (review: [65]). The intratracheal administration of bacterial lipopolysaccharide (LPS) is particularly suited to investigate the impact of purinergic signaling on neutrophil migration into the airways. Aside from the usual BAL fluid cytokines, vascular leakage and disruption of the lung architecture, the mice accumulate neutrophils in all compartments of the respiratory system. This LPS challenge also induced a coordinated up-regulation of CD39 and CD73 [73], as described above for hypoxia [74] and mechanical ventilation [71]. The exposure of Cd39/ mice and Cd73/ mice to intratracheal LPS generated more severe accumulation of neutrophils in the pulmonary tissue than in LPS-treated wild-type mice. To determine which step of neutrophil migration was affected in the knockout mice, Reutershan et al. labeled their neutrophils by intravenous injection of Alexa 633-labelled Gr-1 [73]. They showed that the absence of CD39 or CD73 raised neutrophil numbers in the interstitium and the airspace, but not in the bloodstream. Since both knockout mice respond similarly to the LPS challenge, this study suggests that the prevention of ADO formation in the Cd39/ mice and Cd73/ mice was responsible for the exaggerated lung neutrophilia. The fact that ADO deficiency allowed neutrophils to
8 Animal Models of Airway Diseases
209
accumulate to greater extent, both, in the interstitium and BAL fluid, suggest that this P1 receptor agonist normally restrict their transmigration across the endothelial and alveolar epithelial barriers. As in the other models of acute lung injury described above, the low circulating ADO levels of Cd39/ mice and Cd73/ mice were associated with a loss of endothelial barrier resistance, as determined by extravasation of Evans blue dye. On the other hand, this study provides the first evidence of a purinergic regulation of leukocyte migration across airway epithelia. A common pattern emerges from studies conducted with mouse models of aberrant purine regulation. The fact that Cd39/ mice and Cd73/ mice respond similarly to acute insults indicates that circulating/airway ADO, not ATP, significantly influences the short term and reversible inflammatory responses. In these situations, a robust and transient increase in circulating ADO appears essential to raise endothelial barrier integrity, which restricts pulmonary edema and the infiltration of inflammatory cells. In contrast, models of chronic airway diseases clearly show that the sustained elevation of airway ADO is associated with a wide array of detrimental effects, ranging from severe inflammation to airway remodeling and hyperresponsiveness. Therefore, any therapeutic strategy that will be envisioned to reduce purine-mediated lung complications must be carefully tailored with the most appropriate murine model.
8.3 8.3.1
Murine Models Targeting Adenosine Receptors Can A1Rs Go Either Way?
Ischemia-reperfusion injury causes significant morbidity and mortality, which remains a major obstacle after lung transplant. Neely et al. provided evidence that A1R antagonists attenuate inflammation and injury in a feline model of ischemic lung injury [75]. In these animals, ischemia-reperfusion induced lung edema and the infiltration of inflammatory cells (neutrophils, macrophages and red blood cells) in the alveolar space. Intralobar arterial infusion of an A1R antagonist, xanthine amine congener (XAC) or 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), before the onset of ischemia fully prevented alveolar injury. This study suggests that a proactive treatment with A1R antagonists may reduce the ischemia-reperfusion injury developing after lung transplant surgery. Bacterial LPS initiates a number of pro-inflammatory responses, such as priming of neutrophils and macrophages, and the EGFR-mediated signaling cascades of cytokine and growth factor secretion from airway epithelial cells (see Chaps. 6 and 7 for details). Yet, the specific mechanism by which LPS initiates these cascades of pathophysiological events in the lung has not been described. Neely et al. used an intralobar arterial injection of LPS as a model of acute lung injury in spontaneously breathing cats [76]. These animals developed a dose-dependent lung injury characterized by the presence of macrophages, neutrophils and red blood cells in the alveoli, alveolar edema and necrosis. Pre-treatment by intravenous bolus injection
210
L.F. Thompson et al.
of DPCPX prevented all aspects of the acute lung injury. This study suggests that A1R antagonists may decrease the symptoms of adult respiratory distress syndrome induced by sepsis. Based on the human model of fluid flux regulation, this approach may prevent edema by suppressing A1R-mediated CFTR activity and fluid secretion in the alveolar space (Fig. 8.1). On the other hand, since few studies documented purinergic signaling in cats, it would be reassuring to repeat these experiments in mice, especially in the light of the following study. In mice, the administration of aerosolized LPS triggers classic manifestations of acute lung injury, summarized by microvascular leakage and neutrophil accumulation in the vascular, interstitial and alveolar compartments. Interestingly, a study showed that LPS also causes a gradual increase in the total lung mRNA and protein level of A1Rs. This response was considerably weaker in mice depleted in neutrophils by injection of anti-granulocyte antibodies [77]. Therefore, the authors tested whether this receptor regulates neutrophil recruitment by exposing knockout mice to aerosolized LPS. These A1R/ mice developed exaggerated neutrophil migration and microvascular permeability to LPS, supporting an anti-inflammatory role for this ADO receptor. Incidentally, the pre-treatment of wild-type mice by intraperitoneal injection of the new A1R agonist, named 2’Me-2-chloro-N6-cyclopentyladenosine (20 Me-CCPA), significantly reduced vascular leakage and neutrophil counts in the interstitium and alveolar space. This agonist also reduced the accumulation of pro-inflammatory cytokines (TNF-a, IL-6 and CXCL2/3) in the BAL fluid. A combination of in vivo and in vitro experiments revealed that A1Rs protect against the loss of endothelial and epithelial barrier permeability induced by LPS through inhibition of cytoskeletal rearrangement. Also, pre-treatment of neutrophils with 20 Me-CCPA reduced their transmigration across endothelial cells, supporting a role for A1Rs on the inflammatory cells. Since the receptor specificity of 20 Me-CCPA has been fully assessed [78], this study supports the therapeutic potential of the agonist for the treatment of acute lung injury regarding airway bacterial infection. Chronic airway diseases are associated with higher mRNA levels of A1Rs in the animal models [39, 79, 80], as well as bronchial epithelial and airway smooth muscle cells from asthmatic patients [81]. An up-regulation of this receptor in asthma supports a role in the pathophysiology of this disease, and the potential of selective antagonists for the treatment of asthmatics. In the dust mite-conditioned allergic model of asthma, rabbits receiving aerosolized antisense oligodeoxynucleotides targeting A1Rs were desensitized to subsequent challenges with ADO or dust mite [82]. The intratracheal ingestion of the water soluble A1R antagonist, L-97-1, also attenuated bronchoconstriction in this model [83]. In addition, allergic animals pretreated with L-97-1 accumulated significantly less BAL eosinophils and neutrophils in response to a dust mite challenge than the untreated allergic animals [83]. Whether ADO-induced bronchoconstriction is mediated via A1Rs expressed on airway smooth muscle, inflammatory cells or nerve endings is not clear. A recent study conducted with A1R/ mice supports a neuronal component [84]. But the fact that aerosolized and gastric deliveries of the A1R antagonist reduce hyperresponsiveness supports a multi-cellular mechanism (see Chap. 9 for details). Detrimental roles for the A1Rs in chronic diseases also include the capacity to raise the
8 Animal Models of Airway Diseases
211
expression of MUC2 and MUC5AC [85], which contributes to mucus overproduction, a major feature of asthma. Murine models of chronically-high ADO concentrations in the lung are associated with enhanced or induced A1Rs expression, depending on the cell type [86]. In the ADA-deficient mice, the transcript levels of A1Rs were threefold higher in lung tissue, and 50-fold higher in BAL cell pellet, compared to wild-type mice. Immunolocalization showed enhanced protein expression on macrophages, and the receptor appeared on endothelial and epithelial cells. For these reasons, ADA/A1R double knockout mice were developed to determine the impact of A1R up-regulation on airway defenses. The genetic removal of A1Rs from the ADA-deficient mice resulted in an additional twofold increase in the total lung ADO level. Compared to the ADA-deficient mice, they had more severe pulmonary inflammation, mucus metaplasia and alveolar destruction, exaggerated expression of Th2 cytokines (IL-4 and IL-13) and matrix metalloproteinases. This study suggests that, in the presence of chronically-high ADO, A1Rs are anti-inflammatory in the respiratory system. On the other hand, it is important to note that these double knockout mice also exhibit a twofold decrease in A2AR transcript, which mediates potent anti-inflammatory responses in the lung, as described in the section below. A weaker protection by A2AR may account, at least partially, for the severity of lung complications in ADA/ A1R knockout, compared to ADA-deficient mice. These animal models provide important information on the contribution of A1Rs to acute and chronic lung disorders. However, work is needed to determine the role of this receptor, which is expected to appear on alveolar and airway epithelial cells of patients with high lung ADO content, as in asthma and COPD. The murine study, which used the new selective A1R agonist, 20 Me-CCPA [77], supports the benefits of this compound in chronic diseases. And yet, the delivery route is a key determinant in treatment design, as vascular administration reduces lung inflammation, whereas aerosolized agonists may induce bronchoconstriction. The A1R provides an excellent example for the importance of understanding the physiological background to develop a safe and efficient treatment.
8.3.2
The All Mighty A2ARs
The potent anti-inflammatory activities mediated by A2ARs on various cell types motivated the development of animal models to evaluate the potential of agonists for the treatment of inflammation and injury in pulmonary disorders (review: [87, 88]). Sharma et al. conducted a series of studies to investigate the impact of A2ARs on the acute lung injury caused by ischemia-reperfusion [89]. Perfused isolated lungs developed significant dysfunction (higher airway resistance, pulmonary artery pressure and lower compliance), tissue injury (vascular leakage and edema), and the accumulation of cytokines (TNFa, KC, MIP-2 and RANTES) in the BAL fluid. The addition of the selective A2AR agonist, ATL313, to the perfusate after ischemia reduced all reperfusion-related complications by at least 50%. This
212
L.F. Thompson et al.
study shows that A2ARs expressed by resident cells, such as alveolar macrophages, endothelial and epithelial cells, play a major role in the anti-inflammatory properties of these receptors during acute lung injury. The number of circulating neutrophils is regulated by IL-17A, a pro-inflammatory cytokine released by CD4+ T lymphocytes (review: [90]). Sharma et al. used an in vivo murine model of ischemia-reperfusion to test whether the anti-inflammatory roles of the A2AR include the suppression of CD4+ T cell activities [91]. As in the case of isolated lungs [89], perfusion of the agonist, ATL313, significantly prevented lung injury and the loss of compliance in mice [91]. The significant reduction of neutrophil infiltration was demonstrated by immunohistochemistry and BAL fluid myeloperoxidase activity. The mice subjected to ischemia-reperfusion after depletion of the CD4+ T cells or neutrophils also had significantly reduced lung injury and BAL fluid levels of inflammatory mediators, including IL-17A. However, ATL313 further reduced the symptoms only in neutrophil-depleted mice. This study shows that A2AR activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation, and the subsequent neutrophil infiltration in the lung. Systemic administration of A2AR agonists, before a transplant procedure, could offer two waves of protection against excessive inflammation and injury. The airway defenses supported by the A2AR are also sensitive to acute lung injury initiated within the airspace. Aerosolized LPS was associated with an up-regulation of the ADO receptor [92]. Therefore, the consequences of this deregulation were determined by exposing A2AR/ mice to aerosolized LPS. Consistent with the anti-inflammatory role of this receptor, knockout mice accumulated more neutrophils into the lungs in response to LPS than the wild-type mice. Accordingly, intranasal instillation of the selective agonist, ATL 202, only reduced neutrophil transmigration in wild-type mice [92]. Together, bone marrow transplant between wild-type and A2AR/ mice, and conditional knockout mice lacking A2ARs on macrophages, demonstrated that A2AR overexpression on macrophages plays a major role in the anti-inflammatory properties of airway ADO [92]. Since LPS was added to the airways, it is not expected to affect endothelial barrier permeability. Instead, LPS stimulates the secretion of pro-inflammatory cytokines (i.e. IL-1b, TNFa) from alveolar macrophages, which bind specific receptors on the epithelia to stimulate the release of neutrophil chemoattractants. On macrophages, A2AR activation suppresses the production and secretion of these cytokines [93–95]. During an acute airborne insult, the overexpression of A2ARs on resident macrophages would prevent the development of excessive inflammatory responses. The intense preclinical research on A2AR agonists currently conducted in murine models of chronic airway diseases is not surprising, given the multiple roles of this P1 receptor in the prevention of excessive and damaging airway inflammation. Interestingly, contrary to the up-regulating effect of acute insults, chronic exposures to ragweed or Th2 cytokines (IL-4 or IL-13) are all associated with a down-regulation of A2ARs [79, 80, 96]. Similar findings were observed in the ADA-deficient model of chronically-elevated lung ADO [39]. The ragweed sensitization/challenge caused more severe airway inflammation and hyperresponsiveness in the A2AR/ mice than in the wild-type mice [96]. Altogether, these studies suggest that the
8 Animal Models of Airway Diseases
213
down-regulation of A2ARs contributes to disease severity in Th2 driven chronic lung disorders. Therefore, preclinical studies support a substantial benefit for A2AR-based aerosolized therapies in chronic diseases. In mice subjected to the OVA sensitization/ challenge model of allergic asthma, the intratracheal instillation of CGS 21680 before the last challenge significantly reduced lung inflammation, quantified in BAL fluid in terms of leukocyte numbers, neutrophil myeloperoxidase and eosinophil peroxidase activities [97]. A similar protective effect of intratracheal CGS 21680 was reported in Norway rats subjected to this OVA exposure protocol [97]. On the other hand, airway hyperresponsiveness and mucus hypersecretion are not treated by A2AR agonists, in accordance with the lack of regulation of these functions by this receptor [84, 98]. Aerosolized A2AR agonists are expected to target specifically the activities of immune and inflammatory cells, and their recruitment (see Chap. 7 for details). Lung transplant is currently the preferred option for various end-stage pulmonary diseases. While remarkable progress in the outcome has been made, chronic allograft rejection still leads to the development of bronchiolitis obliterans, a chronic inflammatory disorder. Given the well established anti-inflammatory profile of A2AR signaling, a study examined the therapeutic potential of A2AR agonists in a murine model of transplant rejection [99]. Non-revascularized tracheal transplants exhibited precocious signs of rejection in A2AR knockout mice, compared to wild-type mice, manifested by enhanced inflammation, epithelial loss and fibrosis. Pre-treatment of the wild-type mice with an A2AR agonist (ATL 313) before receiving the transplant significantly protected against the infiltration of inflammatory cells (lymphocytes, macrophages and neutrophils) and luminal occlusion by collagen deposition, measured over 21 days. This approach shows potential for the prevention of bronchiolitis obliterans in lung transplant. Collectively, these studies support an anti-inflammatory role for A2ARs in acute and chronic lung diseases. The expression of this receptor on key regulatory and effector cells, such as lymphocytes, neutrophils and macrophages, suppresses their migration and the secretion of cytokines and chemokines to dampen immune responses. Hence, there is substantial preclinical evidence that A2AR agonists may be useful to treat inflammatory features in acute lung injuries and chronic lung diseases.
8.3.3
A2BRs: Balancing Clearance and Inflammation
Over the past 5 years, models of acute lung injury applied to A2BR/ mice have assigned a protective role to the receptor (review: [100]). The first model considered was the hypoxia-induced vascular leakage and recruitment of inflammatory mediators to the lungs. Initial profiling of each ADO receptor was obtained by silencing RNA techniques in human microvascular endothelial cells. The results showed that only A2BR elimination resulted in a significant increase in endothelial leakage in response to hypoxia [11]. The same selective response was reported in
214
L.F. Thompson et al.
knockout mice exposed to normobaric hypoxia [11]. Only the A2BR/ mice exhibited enhanced pulmonary edema and vascular leakage, compared to the hypoxic wild-type mice. Interestingly, hypoxia selectively up-regulated A2BRs, likely as a defense mechanism against vascular leakage [11]. Therefore, agonists and antagonists were evaluated in wild-type mice for their capacity to prevent acute lung injury. Pretreatment of the mice by intraperitoneal injection of an agonist (BAY60-6583) almost completely prevented hypoxia-induced injury, whereas an antagonist (PSB1115) aggravated these lung complications. To determine the relative contribution of A2BRs expressed on pulmonary or hematopoietic cells to the vascular leakage during hypoxia, the authors generated bone marrow chimeric mice. Mice expressing A2BRs on the tissues, but not on the hematopoietic cells, showed reduced Evan’s blue extravasation in response to BAY 60-6583, whereas the opposite chimera offered no protection. Taken together, these studies provide pharmacological and genetic evidence for vascular A2BR signaling as a central control point of hypoxia-associated vascular leak. These data are consistent with the purinergic regulation of vascular permeability in human lungs (Fig. 8.1), thereby supporting a role for A2BR agonists in the treatment of hypoxia-related acute lung injury. Bacterial infection triggers an acute increase in A2BR expression throughout the respiratory system, by a mechanism involving cytokine release and autocrine responses. In cultured human microvascular endothelial cells and A549 alveolar epithelial cells, IL-1b, IL-4, IL-6 and prostaglandin E2 induce a progressive increase in A2BR mRNA levels, reaching more than sixfold higher values after 12 h, then returning to baseline within 24 h [101]. These findings were reproduced in vivo, as mice responded to LPS inhalation by a nearly fivefold increase in total lung A2BR transcript and protein levels. When the mice were pre-treated by inhalation of an A2BR antagonist (MRS 1754), they reacted to LPS by dramatically more severe lung edema, higher BAL fluid cytokine concentrations (IL-1b and TNFa) and neutrophil myeloperoxidase activity. Similar findings were obtained with A2BR/ mice. As in the case of hypoxia [11], the bone marrow chimeric mice support a predominant role for A2BRs expressed on pulmonary cells, not hematopoietic cells, in the protection against acute lung injury. Accordingly, the A2BR agonist BAY 60-6583 clearly prevented LPS-mediated lung inflammation and edema. Collectively, these studies show that hypoxia and bacterial infection acutely up-regulate A2BRs as a defense mechanism, which offers a platform for the effective treatment of acute lung injury. Contrary to acute lung injury, abundant literature supports pro-fibrotic and tissue destructive roles for A2BRs in chronic lung diseases, such as asthma, COPD and fibrotic pulmonary diseases [102, 103]. Numerous studies demonstrated the ability of A2BR activation to induce the expression and secretion of pro-inflammatory mediators from various cell types, including IL-4, IL-8 and IL-13 from mast cells [104–106], IL-6 and IL-19 from airway epithelial cells [107, 108] and monocyte chemoattractant protein-1 from bronchial smooth muscle cells [109]. Consequently, it is not surprising that A2BR/ mice, subjected to the
8 Animal Models of Airway Diseases
215
OVA sensitization/challenge model of allergic asthma, develop milder features of pulmonary inflammation and airway remodeling than wild-type mice [110]. Major inflammatory findings included a reduced production of IL-4 and lower airway eosinophil numbers in A2BR/ mice chronically exposed to the allergen. With respect to airway remodeling, these mice presented lower levels of TGFb, mucus cell metaplasia and thickening of the smooth muscle layer surrounding bronchial airways. Similar data were reported for mice subjected to the ragweed sensitization/ NECA challenge model of allergic asthma [111]. In the sensitized mice, pretreatment by intraperitoneal injection of an A2BR antagonist (CVT-6883) significantly attenuated the airway inflammation and hyperresponsiveness induced by nebulized NECA. These studies provide evidence for the potential of A2BR antagonists in the treatment of chronic diseases, like asthma. The contribution of A2BRs to chronic lung disease is further supported by studies conducted in the ADA-deficient model of ADO-mediated lung injury [103]. These mice develop progressive increases in total lung ADO level, in association with inflammation and tissue remodeling [37, 45]. This model is characterized by the accumulation of activated alveolar macrophages producing various inflammatory mediators, alveolar airspace destruction, mucus cell metaplasia and fibrosis. The expression of the A2BR is elevated in the lungs of ADA-deficient mice. Once lung complications are established, the selective A2BR antagonist CVT-6883 significantly reduced the production of pro-inflammatory and pro-fibrotic mediators, alveolar airspace enlargement and fibrosis [112]. Similar findings were observed in the bleomycin model of pulmonary fibrosis [112]. Interestingly, A2BRs are also up-regulated in the lungs of IL-4 [80] and IL-13 [79] overexpressing mice which develop features of asthma, COPD and pulmonary fibrosis. Moreover, high A2BR expression was recently described as a feature of patients with accelerated pulmonary fibrosis [113]. Thus, the exaggerated activation of A2BR signaling pathways appears to constitute a widespread feature of chronic airway diseases with fibrosis. In support of this, A2BR activation has been shown to promote the differentiation of human pulmonary fibroblast into collagen producing myofibroblasts [114], and to stimulate the production of pro-fibrotic fibronectin in alveolar epithelial cells [115]. These findings suggest that the sustained up-regulation and engagement of A2BRs might collectively serve to enhance chronic remodeling features of chronic lung diseases. As in chronic lung diseases, the post-transplant bronchiolitis obliterans syndrome presents many histological characteristics of allograft injury and inflammation consistent with the pro-inflammatory and pro-fibrotic effects of A2BR activation (review: [116]). Therefore, a murine model of tracheal transplant rejection was used to determine the role of A2BRs in the development of bronchiolitis obliterans [117]. When the tracheas were transplanted into A2BR/ mice, they exhibited less luminal obliteration and inflammatory cell infiltration (macrophages, neutrophils, CD3+ T cells) after 21 days, than in wild-type recipients. In contrast, the allografts of the A2BR/ mice contained higher numbers of the immunosuppressive CD4/CD25/Foxp3 T regulatory (Treg) cells [117]. Therefore, apart from
216
L.F. Thompson et al.
the well-known pro-inflammatory and pro-fibrotic effects of A2BR activation, this receptor may also stimulate the development of bronchiolitis obliterans by inhibiting the recruitment of the immunosuppressive Treg cells into the allograft.
8.3.4
The A3R Models the Infiltrates
As with the other ADO receptors, A3Rs play complex roles in inflammation, with both pro- and anti-inflammatory functions being described in different models [118]. Pharmacological studies have demonstrated that treatment with A3R agonists is beneficial in the feline model of reperfusion injury [119], as documented above for A1Rs [75]. In spontaneously breathing cats subjected to ischemia-reperfusion in the left lower lobe, the perfusion of IB-MECA or MRS 3558 before ischemia reduced acute lung injury, which was quantified by the number of apoptotic cells, lung edema, and BAL fluid neutrophil myeloperoxidase assay. Western blots conducted on tissue samples collected over 10 h indicated that A3R engagement activates the secondary messengers extracellular signal-regulated kinases 1 and 2 (ERK1/2), but not c-Jun amino-terminal protein kinase (JNK) and p38, which essentially shifts the signaling balance from cell death to cell survival. Therefore, A3R agonists offer a therapeutic benefit for the treatment of acute lung injury related to ischemia-reperfusion. The role of A3Rs in acute lung injury was also recently documented in a murine model of airway infection [120]. In mice, LPS inhalation triggered general characteristics of acute lung injury, including neutrophil accumulation in all lung compartments, as well as an up-regulation of the A3R. Therefore, pharmacological experiments were initiated to determine the directionality of A3R-mediated responses, with respect to the neutrophilic inflammation. Mice pretreated by intralobar arterial infusion of the specific A3R agonist, Cl-IB-MECA, responded to aerosolized LPS by significantly lower neutrophil counts into the interstitium and alveolar airspace, but not the vasculature. Incidentally, measurement of Evans blue extravasation showed that Cl-IB-MECA inhibits the LPS-induced increases in endothelial barrier permeability. The mechanism was addressed in vitro using cultures of pulmonary microvascular endothelial cells. The A3R agonist interfered with the LPS-induced cytoskeletal rearrangement and cell retraction known to initiate vascular leakage. On the other hand, experiments conducted with bone marrow chimeric mice revealed that Cl-IB-MECA requires A3Rs expressed, both, on hematopoietic cells and pulmonary cells to suppress the transmigration of neutrophils in vivo. Possible mechanisms include cell adhesion or the secretion of mediators (see Chap. 7 for details). Regardless, this study proposes a new role for A3Rs in the recruitment of neutrophils to the airways. Whereas A3Rs expressed on neutrophils were shown to accelerate chemotaxis (review: [121]), the present study demonstrates that A3Rs also restricts neutrophil infiltration into the lung tissue and airspace. The administration of Cl-IB-MECA into the
8 Animal Models of Airway Diseases
217
bloodstream may be useful to suppress the damaging neutrophilic inflammation associated with sepsis. Intratracheal instillation of bleomycin ranks among the most popular models of acute lung injury. The mice transiently develop damage to the alveolar epithelial and endothelial barriers, extensive fibrosis, thrombus formation in the microvasculature and the accumulation of inflammatory cells in the interstitial space (review: [65]). Genetic deletion of the A3R yielded no significant phenotype, but the mice reacted more strongly to the bleomycin challenge [122]. After 14 days, the lungs of A3R/ mice accumulated three times more inflammatory cells than the wild-type mice, including eosinophils. Interestingly, whereas bleomycin caused an increase in eosinophil peroxidase activity in the BAL fluid of wildtype and A3R/ mice, the secreted enzyme activity was only higher in the wild-type mice. These data show that eosinophils require the A3R for degranulation. On the other hand, the loss of this receptor did not influence the formation of pulmonary fibrosis in response to bleomycin, as shown by measurement of collagen and a1procollagen in lung tissue. Altogether, these data suggest that A3Rs generally serve anti-inflammatory functions in the bleomycin model of acute lung injury, without affecting pulmonary fibrosis. On the other hand, lung complications associated with a predominant eosinophilic inflammation would ascribe a pro-inflammatory role to this receptor, such as asthma. This study highlights the disease-specificity of purinergic regulation which arises from the cell type specificity of receptor expression. Chronic lung diseases are generally associated with an up-regulation of the A3R, reported in the lung biopsies of asthmatic and COPD patients [123]. The importance of this disturbance in purinergic regulation is highlighted by three murine models of Th2-mediated airway inflammation and remodeling, which are also associated with enhanced A3R expression [67, 79, 124]. This receptor affects several aspects of the lung disease. First, human and murine eosinophils abundantly express A3Rs, to inhibit chemokine-induced migration [123–125], whereas it accelerates neutrophil chemotaxis [121]. The airway epithelial cells of wild-type mice do not normally express A3Rs. However, the receptor appears selectively on the hyperplastic mucin-secreting cells of the OVA sensitized/challenge mice, IL-13 transgenic mice and ADA-deficient mice [67, 79, 124]. Young et al. determined that the receptor does not regulate the mRNA expression or packaging of mucins into granules, as wild-type and A3R/ mice exhibit similar storage sizes following OVA sensitization/challenge [67]. In contrast, the selective A3R agonist, IBMECA, stimulated mucin secretion in the OVA challenged, but not the untreated, animals. This study supports a role for A3R induction in the mucin hypersecretion and airway obstruction reported in many chronic airway diseases, including asthma, COPD and CF (review: [126]). On the other hand, the induction of A3R expression during mucus cell metaplasia and hyperplasia remains to be confirmed in human airways, where mucin secretion is normally mediated by ATP (P2Y2) receptors (reviews: [98, 127]) (see Chap. 5 for details).
218
8.3.5
L.F. Thompson et al.
General Patterns in Acute and Chronic Disorders
This area of purinergic research is evolving so rapidly that the notions formulated when this book was initially designed had to be revised along the way. Thankfully, we can finally discern general patterns of behavior for each ADO receptor in murine models of acute and chronic lung complications. First, the literature shows that acute and chronic disorders up-regulate all ADO receptors, except for a downregulation of the A2AR in chronic lung diseases. Such general mobilization of the purinergic network is a testimony to the critical role of ADO in airway defenses against insults and intruders. Second, knockout mice do not present any intrinsic phenotype, but respond dramatically to insults or exposures, supporting the primary role of this network in alarm situations. This inductive behavior would prioritize the receptors responding to abnormally high ADO concentrations generated in circulation and airway secretions by ATP release and metabolism: A2ARs and A2BRs (see Chap. 7, Table 7.1). A summary of the effects of agonists/antagonists in the murine studies identify aspects of acute and chronic lung complications regulated by each ADO receptor (Fig. 8.2). Regardless of the exposure protocol, the engagement of all receptors initiated anti-inflammatory and protective responses against acute lung injury. This came as a surprise, considering their widespread biphasic effects on immune and inflammatory cells (see Chap. 7 for details). Then again, the initial inflammatory response to an insult is the recruitment of hematopoietic cells to the lung tissue. Since they must all cross the endothelial barrier, this site constitutes a bottle neck for airway defenses to efficiently regulate the extent of airway inflammatory responses. The fact that all ADO receptors participate in the maintenance of barrier integrity identifies the endothelium as primary site for therapeutic applications regarding hypoxia, acute lung injury and sepsis. The A2AR agonists represent the safest choice because the receptor only supports protective or anti-inflammatory responses. The ADA-deficient mouse model conceptualizes the consequences of maintaining lung ADO concentrations elevated in chronic respiratory diseases, including asthma, CF and COPD. The severity of the purine-related complications results from the combined effects of A2AR down-regulation and A2BR up-regulation, which dramatically shifts the balance in favor of pro-inflammatory and remodeling responses to ADO concentrations capable of significantly activating low-affinity receptors. The murine models of chronic lung diseases revealed that ADO receptors inhibiting cAMP production (A1Rs and A3Rs) promote mucin hypersecretion and bronchoconstriction. On the other hand, A2BR activation stimulates most aspects of the inflammatory responses, remodeling and fibrosis. The ideal aerosolized therapy would combine A1R and A2BR antagonists to address all aspects of inflammatory diseases associated with airway hyperresponsiveness. On the other hand, careful dosing will be required for A2BR antagonists to minimize side-effects regarding the mucociliary clearance of allergen and infectious particles, as this receptor plays
8 Animal Models of Airway Diseases
219
Fig. 8.2 Summary of the adenosine-mediated responses in murine models of acute lung injury and chronic lung disease. The blue boxes indicate anti-inflammatory and protective effects, the green boxes indicate pro-inflammatory and damaging responses
critical roles in fluid secretion and cilia beating (see Chap. 5 for details). The importance of findings in pre-clinical and cellular models will have to be validated in carefully designed clinical trials that take into account the potential impact of ADO receptors signaling in acute and chronic lung disorders.
220
8.4
L.F. Thompson et al.
Murine Models Targeting ATP Receptors
The field of purinergic inflammation formulated the unifying concept that ATP is released as a “danger signal” to induce inflammatory responses upon binding cell surface purinergic receptors (see Chap. 7 for details). Our current understanding of purinergic signaling in the respiratory system suggests that this concept can be extended to airway defenses against infection and obstruction (see Chap. 5 for details). The mouse models currently available for P2X and P2Y receptors, and for ectonucleotidases, highlight the airway functions particularly targeted by ATP and altered under pathological conditions. In general, these mice present no apparent phenotype or lung complication, unless they are subjected to an insult. As such, this section exposes the critical role of extracellular ATP in acute lung injury and chronic respiratory diseases.
8.4.1
The P2Y2R in Acute and Chronic Disorders
The most convincing evidence that the P2Y2R is engaged primarily during alarm situations is derived from studies conducted on the knockout mice [128, 129]. They are fertile, undistinguishable from their wild-type littermates, and show no abnormality in their organs, including the heart, lung, pancreas, intestines, kidneys and trachea. The fact that their airways are not obstructed is consistent with the distinct roles of P2Y2R-CaCC and A2BR-CFTR signaling pathways in mucociliary clearance (MCC), established using cultures of human airway epithelial cells (review: [24]). Under the steady-state (baseline) conditions, the surface ADO concentrations partially activate A2BRs, which maintains sufficient CFTR-mediated fluid secretion for MCC in a sterile environment. In contrast, the surface ATP concentrations periodically reach the activation threshold of P2Y2Rs during normal tidal breathing, as a result of mechanical stress-induced nucleotide release. This transient and weak activation stimulates fluid and mucin secretion to maintain a thin shield above the ciliated epithelium. Together, these ADO- and ATP-mediated signaling events continuously produce and evacuate this protective film along the ciliary escalator. On the other hand, an alarm situation, sensed by the interaction of an irritant or pathogen with the epithelium, initiates a robust and transient MCC response through ATP release and P2Y2R activation. The most powerful trigger for this flushing mechanism is a cough. The rapid metabolism of ATP into ADO by ectonucleotidases triggers a second wave of fluid secretion through enhanced A2BR-CFTR activity and ciliary beating, both gradually returning to baseline with ADO concentration. Hence, P2Y2R-mediated MCC only predominates during alarm situations. The possibility that different P2 receptors may predominate in humans and rodents was addressed by comparing the capacity of airway epithelia from wild-type and P2Y2R/ mice to regulate ion and fluid secretion. Measurements of ion channel activity in Ussing chambers indicated that the loss of P2Y2R decreases ATP-induced
8 Animal Models of Airway Diseases
221
Cl– secretion by 75% in the nose and 90% in the trachea [129]. Also, mucin secretion induced by the selective P2Y2R agonist, ATPgS, was reduced by >80% in P2Y2R/ mice, compared to their wild-type littermates [130]. These studies demonstrate that the “danger signal”, provided by stress-induced ATP release, triggers airway clearance primarily by P2Y2R activation in murine airway epithelia. The beneficial effects of P2Y2R signaling is extended to the mobilization of cells engaged in the destruction of inhaled pathogens, including monocytes/macrophages and leukocytes. In most instances, these actions are essential to resolve airway infection. On the other hand, chronic or exaggerated activation of these functions lead to irreversible damage to the respiratory system. Whether P2Y2Rs are beneficial or detrimental in these two scenarios was examined using models of acute and chronic lung complications. The overall impact of P2Y receptors on the susceptibility to airway infection was investigated using P2Y1R/P2Y2R double knockout mice [131]. When subjected to intra-tracheal instillation of the common airway pathogen, Pseudomonas aeruginosa, all the double knockout mice succumbed within 30 h, whereas 85% of the wild-type mice lived a normal lifespan. After 24 h, the BAL fluid of P2Y1R/ P2Y2R/ mice contained more proteins as a measure of edema, but less proinflammatory mediators (IL-1b, IL-6, GM-GSF and MIP-2). In contrast, the two mouse groups presented similar total cell counts and cell composition, which were primarily neutrophils (>80%). These data suggest that P2Y receptors exert a protective role during lung infection by suppressing pulmonary edema, while promoting the inflammatory responses required to eradicate the infection. The severe pulmonary edema developed by the P2Y1R/P2Y2R/ mice is consistent with our model of fluid regulation (Fig. 8.1), whereby the loss of endothelial P2Y2Rs would prevent ATP from protecting barrier functions. On the other hand, it is intriguing that these mice accumulate BAL neutrophils to the same extent as the wild-type mice, given the critical role of P2Y2Rs for their chemotaxis (see Chap. 7 for details). Unfortunately, double knockout mice are of limited value to discriminate the roles of each receptor. An acute model of airway infection was used to determine the impact of P2Y2Rs localized in the vasculature, on circulating cells or the endothelial surface [132]. Wild-type mice received intravenous saline, or a selective P2Y2R agonist (ATPgS), before intranasal instillation of LPS. The mice which received the P2Y2R agonist exhibited about 50% less inflammatory cells, cytokines and proteins in the BAL fluid, than the saline-treated LPS-exposed mice. The protective effect of ATPgS against vascular leakage was confirmed by Evans blue albumin extravasation into the lung tissue, pointing toward a primary function at the endothelial barrier. This was confirmed in vitro in human lung microvascular endothelial cultures, where ATPgS significantly inhibited the LPS-mediated reduction of transmembrane electrical resistance. These data suggest that intravenous P2Y2R agonists may reduce the airway inflammatory responses and lung injury caused by airborne pathogens. Using this administration route, ATPgS would not promote neutrophil chemotaxis through tissue along a chemotactic gradient [121], which is a major role postulated for this P2Y receptor.
222
L.F. Thompson et al.
On inflammatory cells, P2Y2R activation initiates the pro-inflammatory responses required to eradicate microbial pathogens through a series of highly coordinated events culminating in phagocytosis and destruction. In pathological circumstances, like sepsis, they release antimicrobial compounds which cause injury and death of bacteria and host cells (see Chap. 7 for details). The lung damage associated with excessive neutrophilia contributes to a wide array of respiratory complications, including ARDS, COPD and CF (review: [133]). Incidentally, genetic deletion of the P2Y2R improves the survival of mice subjected to sepsis by cecal ligation and puncture [134]. These mice exhibited fewer lung neutrophils and less pulmonary damage than wild-type mice. Since P2Y2R activation provides directionality during neutrophil chemotaxis [121], the leukocytes of P2Y2R/ mice lack the ability to follow an ATP gradient toward the lung. This study suggests that intraperitoneal P2Y2R antagonists may improve the survival of sepsis patients. Chronic respiratory diseases are commonly associated with elevated airway ATP concentrations, as reported in CF, IPF and COPD patients [135–138], and they are raised by allergens in asthmatic patients [68]. The expression of P2Y2Rs is also expected to be elevated in these diseases, as chronic exposure to pathogens or allergens up-regulate the receptor in animal models. For instance, house dust mites caused an increase in P2Y2R expression in eosinophils and dendritic cells from asthmatic patients, which significantly enhanced chemotaxis [139]. It is important to point out that cells from healthy subjects did not up-regulate P2Y2Rs in response to house dust mites, indicating that the purinergic regulation of inflammatory responses is not normally modified by allergens in the general population. On the other hand, rat alveolar Type 2 cells exposed overnight to LPS reacted by raising P2Y2R transcripts by threefold, which resulted in a significant increase in the ATPmediated surfactant secretion [30]. Whereas P2Y2R overexpression may improve MCC, the pro-inflammatory reactions of immune and inflammatory cells may aggravate airway inflammation. Therefore, it is particularly important to understand the costs and benefits of P2Y2Rs in chronic diseases before we can envision therapeutic applications. Asthmatic patients maintain normal airway ATP levels, but these concentrations rise tenfold in response to an allergen [68]. The consequences of this excess ATP were examined in the OVA sensitization/challenge model of allergic asthma [68]. The mice are sensitized by intra-peritoneal injection, and then challenged by nebulization 10 days later. After 24 h, their BAL fluid had accumulated eightfold higher ATP concentrations than in the saline-challenged control animals, as reported in the allergen-challenged asthmatic patients. They also developed all major features of allergic asthma, including eosinophil-dominant lung infiltrates, goblet cell metaplasia, hyperresponsiveness to methacholine and Th2 inflammation in the lymph nodes (IL-4, IL-5 and IL-13). These complications were significantly reduced when the OVA challenges were conducted in the presence of an ATPmetabolizing enzyme (apyrase) or P2Y receptor antagonist (PPADS or suramin). Through a series of elegant in vivo and in vitro protocols, Idzko et al. demonstrated that the excess ATP generated after an allergen challenge triggers airway inflammation by the activation of resident dendritic cells, and their mobilization to the
8 Animal Models of Airway Diseases
223
lymph nodes to trigger a Th2 type of inflammation. It is interesting that excess ATP in the BAL fluid was not detected 10 min, but rather 24 h, after the challenge in asthmatic patients and in the mice. The mechanisms behind the delayed accumulation of ATP into the airways have not been identified. However, oxidative stress building gradually with airway inflammation has been shown to inhibit CD39 [140], and ATP-hydrolyzing ectonucleotidases expressed on airway epithelial [141], immune and inflammatory [142] cells. Consequently, this study supports the therapeutic potential of P2Y receptor antagonists for the treatment of airway inflammation in asthmatic patients. More recently, P2Y2R/ mice were subjected to this model of allergic asthma to identify the mechanism by which P2Y2Rs promote eosinophilia [139, 143]. The P2Y2R/ mice exhibited a weaker capacity to recruit eosinophils in response to the OVA exposure protocol than the wild-type mice [143]. In vitro assays showed that circulating dendritic cells and bone marrow eosinophils collected from P2Y2R/ mice fail to migrate within an ATP gradient [139]. Three findings support a role for the P2Y2R-mediated up-regulation of VCAM-1 in the purinergic stimulation of lung eosinophilia. This molecule is a potent chemoattractant and adhesion molecule for eosinophils (review: [144]). First, the OVA challenge caused the accumulation of soluble VCAM-1 in the BAL fluid, but to a lower level in P2Y2R/ mice [143]. Second, OVA also induced an up-regulation of membranebound VCAM-1 at the surface of lung endothelial cells, but to a lower extent in P2Y2R/ mice. Finally, adhesion assays confirmed that ATP promotes eosinophil adhesion to the endothelial surface through a P2Y2R-mediated increase in VCAM-1 surface expression. Collectively, these studies suggest that an amplification of the ATP-P2Y2R signaling in asthmatic patients during an allergic reaction, contributes to the development of lung eosinophilia. Accordingly, asthmatic patients may benefit from the intravenous injection of P2Y2R antagonists to suppress eosinophil recruitment to the airways. Chronic obstructive pulmonary disease is another interesting example of P2Y2Rdominant lung pathology. The discovery that the murine model of smoke-induced lung inflammation and emphysema reproduces the high airway ATP concentrations of COPD patients provided the necessary tools to investigate the role of purinergic deregulation in the pathogenesis of this disease [145]. First, the role of ATP in the early events of airway inflammation was investigated using an acute cigarette smoke exposure protocol, which consisted of a daily 20 min session for 4 days. This acute insult caused an eightfold increase in BAL fluid ATP level, the typical macrophage and neutrophil infiltrates, and the accumulation of their cytokines (IL-1b, IL-6, IFNg, MIP-2 and KC). Intratracheal instillation of the ATP-metabolizing apyrase, or a P2Y receptor antagonist (PPADS or suramin), before each smoke inhalation reduced all inflammatory parameters by more than 50%. This acute protocol shows that the excess ATP, accumulating after the first cigarettes, is critical to the early development of smoke-induced airway inflammation. The contribution of ATP-induced inflammatory responses to the development of emphysema was studied using a chronic smoke exposure protocol lasting 4 months [145]. These mice developed foci of emphysema throughout the parenchyma,
224
L.F. Thompson et al.
which was essentially prevented by oral administration of a P2Y receptor antagonists, suramin or PPADS. Real-time PCR analysis of P2 receptor expression in the inflammatory cells and lung parenchyma revealed a dramatic (eightfold) and selective up-regulation of P2Y2Rs in the neutrophils of smoke-exposed, compared to air-exposed, animals. The importance of the amplified ATP-P2Y2R signaling axis in the development of smoke-induced airway inflammation and emphysema was clearly demonstrated using P2Y2R/ mice and chimera [137]. While the source of BAL fluid ATP has not been addressed, in vitro experiments showed that human neutrophils release ATP in response to cigarette smoke in a dosedependent manner, and as efficiently as fMLP [137]. Also, cigarette smoke induced an ATP-dependent secretion of neutrophil elastase, which is an important mediator of lung destruction in emphysema (review: [146]). These studies suggest that the initial increase in BAL fluid ATP concentration detected after the first cigarette exposures initiates the development of airway inflammation, which is amplified over time by an up-regulation of P2Y2Rs on immune and inflammatory cells (see Chap. 7 for details). Therefore, the oral prescription of apyrase, or a P2 receptor antagonist, could prevent and reduce the irreversible lung damage and loss of lung function in COPD patients.
8.4.2
The P2X7R in Chronic Lung Diseases
For years, the importance of P2X7Rs for ATP-mediated inflammatory responses has been largely underestimated on the premise that the EC50 of this receptor is orders of magnitude above that of P2Y2Rs (review: [9]). However, the elegant work of Di Virgilio et al. clearly demonstrated that sites of inflammation or tissue injury accumulate ATP in the high micromolar range in vivo, above the activation threshold of P2X7Rs (Chap. 7, Figs. 7.1 and 7.2). The recent finding that major pro-inflammatory cytokines involved in the initiation of airway inflammatory responses (i.e. IL-1b) depend on the P2X7R for their production, maturation and secretion (see Chap. 7 for details) is only one example of the many critical roles emerging for this receptor. Therefore, it is not surprising that the inhibition or deletion of P2X7Rs has such profound implications for airway defenses. The mouse model of COPD, described above by Idzko et al., revealed a remarkable up-regulating effect (10- to 20-fold) of cigarette smoke on the P2X7Rs of neutrophils and macrophages within 4 days [145]. The use of selective antagonists demonstrated that P2X7R activation on these cells promotes all aspects of airway inflammation and fibrosis leading to the development of COPD and emphysema. In wild-type mice subjected to the acute smoke protocol, intratracheal injection of KN62 or A438079, before each exposure, markedly reduced the accumulation of macrophages, neutrophils and their cytokines (IL-1b, IL-6, IFNg, MIP-2 and KC) in the BAL fluid [147]. In mice subjected to the chronic exposure protocol, these agents prevented the development of fibrosis and emphysema. The widespread
8 Animal Models of Airway Diseases
225
effects of P2X7Rs on airway inflammation are explained by their pivotal role in the secretion of IL-1b from the resident macrophages, which initiate the events leading to leukocyte recruitment. Furthermore, P2X7R-overexpressing neutrophils and macrophages would cause considerable lung destruction by massive discharge of potent cytotoxic molecules which do not discriminate between the bacteria and host cells [146] (see Chap. 7 for details). Since smoke triggers such dramatic increases in BAL fluid ATP level [145] and P2X7R expression, an early treatment with aerosolized antagonists may reduce disease progression and prevent emphysema. Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disorder characterized by inflammation, tissue fibrosis and destruction of the alveolar architecture. Since the IPF patients maintain high airway ATP concentrations [138], the bleomycininduced murine model of lung fibrosis was used to test the contribution of purinergic deregulation to the pathogenesis of this disease [138]. In mice, the intratracheal administration of bleomycin initiates neutrophil recruitment within 24 h, which normalizes around day 11. First signs of fibrosis appear around day 11, and are reversed within 10 days (review: [65]). Time-course analysis indicated that bleomycin induces a transient increase in BAL fluid ATP level over the first 6 h, which is followed by the initiation of neutrophil recruitment. This time line supports a role for an ATP gradient in neutrophil recruitment to the lungs. Disruption of this ATP gradient by apyrase treatment reduced by >60% the BAL content in neutrophils, myeloperoxidase and metalloproteinases. Similar findings were obtained when comparing wild-type and P2X7R/ mice after bleomycin exposure [138]. This study suggests that the higher availability of ATP for P2X7R activation contributes to the inflammatory processes launching tissue fibrosis and lung destruction. In asthmatic patients, airway ATP concentrations only rise following an allergen challenge [68]. On the other hand, the purinergic network is permanently altered in these patients, as P2X7R expression is up-regulated in BAL fluid macrophages and circulating eosinophils, compared to healthy subjects [148]. A murine model of allergic asthma was used to determine the consequences for airway defenses. Mice sensitized and challenged with OVA summarize the inflammatory responses of asthmatic patients during an allergic reaction [148]. The lung infiltrates contain mainly eosinophils, followed by mast cells, neutrophils and lymphocytes, whereas BAL fluid exhibits the typical Th2 inflammation (IL-4, IL-5 and IL-13). As reported in asthmatic patients, the P2X7R was up-regulated 15-fold in the inflammatory cells and lung tissue of OVA-treated mice. The use of a selective P2X7R antagonist (KN62) on OVA-treated wild-type mice, or OVA-treated P2X7R/ mice, was associated with milder lung inflammation compared to OVA-treated wild-type mice. The mechanism behind the pro-inflammatory role of P2X7Rs in allergic asthma was investigated using bone marrow-derived dendritic cells from wild-type and P2X7R/ mice. The loss of P2X7Rs reduced the capacity of OVA-treated dendritic cells to induce Th2 immunity in vivo. This study highlights another critical role of P2X7Rs in the early events initiating an inflammatory response to an airborne insult, and the potential of selective antagonists for the suppression of Th2 inflammation in asthma.
226
8.5
L.F. Thompson et al.
Conclusion
All animal models of acute lung injury and chronic lung diseases are associated with an accumulation of extracellular purines, and an up-regulation of their receptors, except for the anti-inflammatory A2AR. Such massive amplification of purinergic signals in response to hypoxia, ischemia-reperfusion, mechanical ventilation, bacterial products and allergens supports critical and widespread functions in airway defenses. During an acute lung injury, all ADO receptors provide protection against excessive lung inflammation, damage and pulmonary edema. The intravenous administration of agonists yielded the most effective resolution of all lung complications, which identified the microvascular endothelial barrier as primary target. Treatments should focus on agonists of the high-capacity A2ARs and A2BRs to minimize receptor desensitization (Chap. 7, Table 7.1). Whereas P2Y2R agonists may also be considered, possible side-effects may arise from their role in neutrophil and eosinophil recruitment. All models of chronic lung diseases are associated with a down-regulation of the anti-inflammatory A2ARs in inflammatory cells and lung tissue, which tilts the balance toward pro-inflammatory responses to ADO. Whereas A2AR agonists were shown to suppress airway inflammation, they would not address airway hyper-responsiveness, remodeling and fibrosis. Alternatively, the models of asthma, COPD and emphysema suggest that aerosolized antagonists of A2BRs, P2Y2Rs and P2X7Rs resolve most lung complications. However, the A2BR or P2Y2R antagonists must be carefully dosed to avoid any significant impairment of the mucociliary clearance mechanisms. Of particular interest are the P2X7R antagonists, which show tremendous benefits in reducing the development of COPD and emphysema in smokers through a reduction of macrophage activities responsible for the initiation of leukocyte recruitment to the airways. In asthma, aerosolized P2X7R antagonists may prevent resident dendritic cells from initiating the Th2 immunity. One important point to remember is that delivery route will dictate the cost/benefits of a purine drug depending on the local effects of the target receptor, and whether a treatment is corrective or preventive.
References 1. Lucas R, Verin AD, Black SM, Catravas JD (2009) Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol 77:1763–1772 2. Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006) Physiological roles for ecto-50 nucleotidase (CD73). Purinergic Signal 2:351–360 3. Balestrieri ML, Malik KU, Balestrieri C, Lee TC (1998) Types of purinoceptors and phospholipase A2 involved in the activation of the platelet-activating factor-dependent transacetylase activity and arachidonate release by ATP in endothelial cells. Prostaglandins Other Lipid Mediat 56:363–375 4. Kolosova IA, Mirzapoiazova T, Adyshev D, Usatyuk P, Romer LH, Jacobson JR, Natarajan V, Pearse DB, Garcia JGN, Verin AD (2005) Signaling pathways involved in adenosine triphosphate-induced endothelial cell barrier enhancement. Circ Res 97:115–124
8 Animal Models of Airway Diseases
227
5. Gunduz D, Hirche F, Hartel FV, Rodewald CW, Schafer M, Pfitzer G, Piper HM, Noll T (2003) ATP antagonism of thrombin-induced endothelial barrier permeability. Cardiovasc Res 59:470–478 6. Noll T, Holschermann H, Koprek K, Gunduz D, Haberbosch W, Tillmanns H, Piper HM (1999) ATP reduces macromolecule permeability of endothelial monolayers despite increasing [Ca2+]i. Am J Physiol 276:H1892–H1901 7. Tanaka N, Kawasaki K, Nejime N, Kubota Y, Nakamura K, Kunitomo M, Takahashi K, Hashimoto M, Shinozuka K (2004) P2Y receptor-mediated Ca2+ signaling increases human vascular endothelial cell permeability. J Pharmacol Sci 95:174–180 8. Tanaka N, Nejime N, Kubota Y, Kagota S, Yudo K, Nakamura K, Kunitomo M, Takahashi K, Hashimoto M, Shinozuka K (2005) Myosin light chain kinase and Rho-kinase participate in P2Y receptor-mediated acceleration of permeability through the endothelial cell layer. J Pharm Pharmacol 57:335–340 9. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 50 triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358–404 10. Buvinic S, Briones R, Huidobro-Toro JP (2002) P2Y1 and P2Y2 receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed. Br J Pharmacol 136:847–856 11. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK (2008) A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111:2024–2035 12. Lu Q, Harrington EO, Newton J, Casserly B, Radin G, Warburton R, Zhou Y, Blackburn MR, Rounds S (2010) Adenosine protected against pulmonary edema through transporterand receptor A2-mediated endothelial barrier enhancement. Am J Physiol 298:L755–L767 13. Kutzsche S, Lyberg T, Bjertnaes LJ (2001) Effects of adenosine on extravascular lung water content in endotoxemic pigs. Crit Care Med 29:2371–2376 14. Sakamaki F, Ishizaka A, Urano T, Sayama K, Nakamura H, Terashima T, Waki Y, Soejima K, Tasaka S, Sawafuji M, Kobayashi K, Yamaguchi K, Kanazawa M (2003) Attenuation by intravenous 2-chloroadenosine of acute lung injury induced by live Escherichia coli or latex particles added to endotoxin in the neutropenic state. J Lab Clin Med 142:128–135 15. Schlegel N, Waschke J (2009) VASP is involved in cAMP-mediated Rac 1 activation in microvascular endothelial cells. Am J Physiol 296:C453–C462 16. Chambers LA, Rollins BM, Tarran R (2007) Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol 159:256–270 17. Rich PB, Douillet CD, Mahler SA, Husain SA, Boucher RC (2003) Adenosine triphosphate is released during injurious mechanical ventilation and contributes to lung edema. J Trauma 55:290–297 18. Song W, Wei S, Matalon S (2010) Inhibition of epithelial sodium channels by respiratory syncytial virus in vitro and in vivo. Ann NY Acad Sci 1203:79–84 19. Davis IC, Sullender WM, Hickman-Davis JM, Lindsey JR, Matalon S (2004) Nucleotidemediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infection. Am J Physiol 286:L112–L120 20. Davis IC, Lazarowski ER, Hickman-Davis JM, Fortenberry JA, Chen F-P, Zhao X, Sorscher E, Graves LM, Sullender WM, Matalon S (2006) Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus. Am J Respir Crit Care Med 173:673–682 21. Song W, Liu G, Bosworth CA, Walker JR, Megaw GA, Lazrak A, Abraham E, Sullender WM, Matalon S (2009) Respiratory syncytial virus inhibits lung epithelial Na+ channels by up-regulating inducible nitric-oxide synthase. J Biol Chem 284:7294–7306 22. Picher M, Boucher RC (2000) Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:255–261 23. Picher M, Burch LH, Boucher RC (2004) Metabolism of P2 receptor agonists in human airways: implications for mucociliary clearance and cystic fibrosis. J Biol Chem 279:20234–20241
228
L.F. Thompson et al.
24. Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262–267 25. Tatur S, Groulx N, Orlov SN, Grygorczyk R (2007) Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by co-released uridine nucleotides. J Physiol 584:419–435 26. Wolk KE, Lazarowski ER, Traylor ZP, Yu ENZ, Jewell NA, Durbin RK, Durbin JE, Davis IC (2008) Influenza A virus inhibits alveolar fluid clearance in BALB/c mice. Am J Respir Crit Care Med 178:969–976 27. Factor P, Mutlu GM, Chen L, Mohameed J, Akhmedov AT, Meng FJ, Jilling T, Lewis ER, Johnson MD, Xu A, Kass D, Martino JM, Bellmeyer A, Albazi JS, Emala C, Lee HT, Dobbs LG, Matalon S (2007) Adenosine regulation of alveolar fluid clearance. Proc Natl Acad Sci 104:4083–4088 28. Eckle T, Grenz A, Laucher S, Eltzschig HK (2008) A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118:3301–3315 29. Fanelli V, Puntorieri V, Assenzio B, Martin EL, Elia V, Bosco M, Delsedime L, Del Sorbo L, Ferrari A, Italiano S, Ghigo A, Slutsky AS, Hirsch E, Ranieri VM (2010) Pulmonary-derived phosphoinositide 3-kinase gamma (PI3Kg) contributes to ventilator-induced lung injury and edema. Intensive Care Med 36:1935–1945 30. Garcia-Verdugo I, Ravasio A, de Paco EG, Synguelakis M, Ivanova N, Kanellopoulos J, Haller T (2008) Long-term exposure to LPS enhances the rate of stimulated exocytosis and surfactant secretion in alveolar type II cells and upregulates P2Y2 receptor expression. Am J Physiol 295:L708–L717 31. Boncoeur E, Tardif V, Tessier M-C, Morneau F, Lavoie J, Gendreau-Berthiaume E, Grygorczyk R, Dagenais A, Berthiaume Y (2010) Modulation of epithelial sodium channel activity by lipopolysaccharide in alveolar type II cells: involvement of purinergic signaling. Am J Physiol 298:L417–L426 32. Chikura B, Lane S, Dawson JK (2009) Clinical expression of leflunomide-induced pneumonitis. Rheumatology 48:1065–1068 33. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ (1972) Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067–1069 34. Wakamiya M, Blackburn MR, Jurecic R, McArthur MJ, Geske RS, Cartwright J, Mitani K, Vaishnav S, Belmont JW, Kellems RE (1995) Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 92:3673–3677 35. Migchielsen AAJ, Breuer ML, van Roon MA, Riele Ht, Zurcher C, Ossendorp F, Toutain S, Hershfield MS, Berns A, Valerio D (1995) Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 10:279–287 36. Blackburn MR, Datta SK, Kellems RE (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273:5093–5100 37. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE (2000) Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 192:159–170 38. Hershfield MS (1995) PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 76:S228–S232 39. Chunn JL, Young HWJ, Banerjee SK, Colasurdo GN, Blackburn MR (2001) Adenosinedependent airway inflammation and hyperresponsiveness in partially adenosine deaminasedeficient mice. J Immunol 167:4676–4685
8 Animal Models of Airway Diseases
229
40. Banerjee SK, Young HWJ, Volmer JB, Blackburn MR (2002) Gene expression profiling in inflammatory airway disease associated with elevated adenosine. Am J Physiol 282: L169–L182 41. Wakai A, Wang JH, Winter DC, Street JT, O’Sullivan RG, Redmond HP (2001) Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock 15:297–301 42. Banerjee SK, Young HWJ, Barczak A, Erle DJ, Blackburn MR (2004) Abnormal alveolar development associated with elevated adenine nucleosides. Am J Respir Cell Mol Biol 30:38–50 43. Esther CR Jr, Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, Boucher RC (2009) Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol 296:L987–L993 44. Esther CR Jr, Lazaar A (2009) Airway adenosine is elevated in COPD and correlates with disease severity. Am J Respir Crit Care Med 179:A3764 45. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR (2005) Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 175:1937–1946 46. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, Girolomoni G, Norgauer J (2003) Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 101:3985–3990 47. Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18:60–65 48. Prior C, Haslam PL (1992) In vivo levels and in vitro production of interferon-gamma in fibrotic interstitial lung diseases. Clin Exp Immunol 88:280–287 49. O’Byrne PM (2006) Cytokines or their antagonists for the treatment of asthma. Chest 130:244–250 50. Chunn JL, Mohsenin A, Young HWJ, Lee CG, Elias JA, Kellems RE, Blackburn MR (2006) Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am J Physiol 290:L579–L587 51. Elias JA, Zheng T, Lee CG, Homer RJ, Chen Q, Ma B, Blackburn M, Zhu Z (2003) Transgenic modeling of interleukin-13 in the lung. Chest 123:339S–345S 52. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, sub-epithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103:779–788 53. Hirsh AJ, Stonebraker J, van Heusden CA, Lazarowski ER, Boucher RC, Picher M (2007) Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases. Biochemistry 46:10373–10383 54. Kasaian MT, Miller DK (2008) IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 76:147–155 55. Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A (2010) Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 65:946–958 56. Mohsenin A, Burdick MD, Molina JG, Keane MP, Blackburn MR (2007) Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease. FASEB J 21:1026–1036 57. Liu X, Zhou R, Pan Q, Jia XL, Gao WN, Wu J, Lin J, Chen J (2010) Genetic inactivation of the adenosine A2A receptor attenuates pathological but not developmental angiogenesis in mouse retina. Invest Ophthalmol Vis Sci 51:6625–6632 58. Moore TM, Khimenko PL, Taylor AE (1996) Endothelial damage caused by ischemia and reperfusion and different ventilatory strategies in the lung. Chin J Physiol 39:65–81 59. Henttinen T, Jalkanen S, Yegutkin GG (2003) Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto-50 -nucleotidase/CD73-dependent mechanism. J Biol Chem 278:24888–24895
230
L.F. Thompson et al.
60. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG (2008) Ectonucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283:28480–28486 61. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP (2009) Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113:224–232 62. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-50 -nucleotidase (CD73) regulation by hypoxiainducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110:993–1002 63. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP (2004) Crucial role for ecto-50 -nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 200:1395–1405 64. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP (2004) Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104:3986–3992 65. Matute-Bello G, Frevert CW, Martin TR (2008) Animal models of acute lung injury. Am J Physiol 295:L379–L399 66. Volmer JB, Thompson LF, Blackburn MR (2006) Ecto-50 -nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 176:4449–4458 67. Young HWJ, Sun C-X, Evans CM, Dickey BF, Blackburn MR (2006) A3 Adenosine receptor signaling contributes to airway mucin secretion after allergen challenge. Am J Respir Cell Mol Biol 35:549–558 68. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MAM, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC, Lambrecht BN (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13:913–919 69. Schreiber R, Castrop H, Kunzelmann K (2008) Allergen-induced airway hyperresponsiveness is absent in ecto-50 -nucleotidase (CD73)-deficient mice. Pflugers Arch 457:431–440 70. Atkinson B, Dwyer KM, Enjyoji K, Robson SC (2006) Ecto-nucleotidases of the CD39/ NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells Mol Dis 36:217–222 71. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, Eltzschig HK (2007) Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 178:8127–8137 72. Di Virgilio F (2007) Purinergic signaling in the immune system. Purinergic Signal 3:1–3 73. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri K-C, Eltzschig HK (2009) Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23:473–482 74. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP (2003) Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198:783–796 75. Neely CF, Keith IM (1995) A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am J Physiol 268:L1036–L1046 76. Neely CF, Jin J, Keith IM (1997) A1-adenosine receptor antagonists block endotoxininduced lung injury. Am J Physiol 272:L353–L361 77. Ngamsri K-C, Wagner R, Vollmer I, Stark S, Reutershan J (2010) Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. J Immunol 185:4374–4384 78. Cappellacci L, Franchetti P, Vita P, Petrelli R, Lavecchia A, Costa B, Spinetti F, Martini C, Klotz KN, Grifantini M (2008) 50 -Carbamoyl derivatives of 2’-C-methyl-purine nucleosides
8 Animal Models of Airway Diseases
79.
80.
81.
82. 83. 84.
85. 86.
87. 88. 89. 90. 91.
92.
93.
94.
95. 96.
97.
98.
231
as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem 16:336–353 Blackburn MR, Chun GL, Young HWJ, Chunn JL, Banerjee SK, Elias JA (2003) Adenosine mediates IL-13-induced inflammation and remodeling in the lung: evidence for an IL-13adenosine amplification pathway. J Clin Invest 112:332–344 Ma B, Blackburn MR, Lee CG, Homer RJ, Liu W, Flavell RA, Boyden L, Lifton RP, Sun CX, Young HW, Elias JA (2006) Adenosine metabolism and murine strain-specific IL-4induced inflammation, emphysema, and fibrosis. J Clin Invest 116:1274–1283 Brown RA, Clarke GW, Ledbetter CL, Hurle MJ, Denyer JC, Simcock DE, Coote JE, Savage TJ, Murdoch RD, Page CP, Spina D, O’Connor BJ (2008) Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects. Eur Respir J 31:311–319 Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model. Nature 385:721–725 Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ (2006) Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol 551:116–124 Hua X, Erikson CJ, Chason KD, Rosebrock CN, Deshpande DA, Penn RB, Tilley SL (2007) Involvement of A1 adenosine receptors and neural pathways in adenosine induced bronchoconstriction in mice. Am J Physiol 293:L25–L32 McNamara N, Gallup M, Khong A, Sucher A, Maltseva I, Fahy J, Basbaum C (2004) Adenosine up-regulation of the mucin gene, MUC2, in asthma. FASEB J 18:1770–1772 Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR (2005) A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 115:35–43 Hasko G, Pacher P (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83:447–455 Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770 Sharma AK, Linden J, Kron IL, Laubach VE (2009) Protection from pulmonary ischemiareperfusion injury by adenosine A2A receptor activation. Respir Res 10:58 Ley K, Smith E, Stark MA (2006) IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res 34:229–242 Sharma AK, Laubach VE, Ramos SI, Zhao Y, Stukenborg G, Linden J, Kron IL, Yang Z (2010) Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 139:474–482 Reutershan J, Cagnina RE, Chang D, Linden J, Ley K (2007) Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol 179:1254–1263 Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C (2000) Adenosine inhibits IL-12 and TNF-alpha production via adenosine A2A receptordependent and independent mechanisms. FASEB J 14:2065–2074 Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, Wilder RL, Elenkov IJ (2000) Ligand-activation of the adenosine A2A receptors inhibits IL-12 production by human monocytes. J Immunol 164:436–442 Lappas CM, Rieger JM, Linden J (2005) A2A adenosine receptor induction inhibits IFNgamma production in murine CD4+ T cells. J Immunol 174:1073–1080 Nadeem A, Fan M, Ansari HR, Ledent C, Jamal Mustafa J (2007) Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice. Am J Physiol 292:L1335–L1344 Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A (2006) Effect of adenosine A2A receptor activation in murine models of respiratory disorders. Am J Physiol 290:L1036–L1043 Davis CW, Dickey BF (2008) Regulated airway goblet cell mucin secretion. Ann Rev Physiol 70:487–512
232
L.F. Thompson et al.
99. Lau CL, Zhao Y, Kron IL, Stoler MH, Laubach VE, Ailawadi G, Linden J (2009) The role of adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg 88:1071–1078 100. Eckle T, Koeppen M, Eltzschig HK (2009) Role of extracellular adenosine in acute lung injury. Physiology 24:298–306 101. Schingnitz U, Hartmann K, Macmanus C, Eckle T, Zug S, Colgan SP, Eltzschig HK (2010) Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol 184:5271–5279 102. Fozard JR, Hannon JP (1999) Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 12:111–114 103. Zhou Y, Schneider DJ, Blackburn MR (2009) Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 123:105–116 104. Feoktistov I, Biaggioni I (1995) Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96:1979–1986 105. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I (2004) Adenosineactivated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172:7726–7733 106. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Dikov MM, Blackburn MR, Biaggioni I, Feoktistov I (2008) Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. J Immunol 180:7212–7220 107. Sun Y, Wu F, Sun F, Huang P (2008) Adenosine promotes IL-6 release in airway epithelia. J Immunol 180:4173–4181 108. Zhong H, Wu Y, Belardinelli L, Zeng D (2006) A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 35:587–592 109. Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D (2003) A2B Adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 30:118–125 110. Zaynagetdinov R, Ryzhov S, Goldstein AE, Yin H, Novitskiy SV, Goleniewska K, Polosukhin VV, Newcomb DC, Mitchell D, Morschl E, Zhou Y, Blackburn MR, Peebles RS Jr, Biaggioni I, Feoktistov I (2010) Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. Am J Respir Cell Mol Biol 42:564–571 111. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D (2007) Effect of a specific and selective A2B adenosine receptor antagonist on adenosine agonist AMP and allergeninduced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246–1251 112. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR (2006) Role of A2B receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116:1–10 113. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Perez-Padilla R, Navarro C, Richards T, Dauber J, King TE Jr, Pardo A, Kaminski N (2007) Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2:e482 114. Zhong H, Belardinelli L, Maa T, Zeng D (2005) Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32:2–8 115. Roman J, Rivera HN, Roser-Page S, Sitaraman SV, Ritzenthaler JD (2006) Adenosine induces fibronectin expression in lung epithelial cells: implications for airway remodeling. Am J Physiol 290:L317–L325 116. Robertson AG, Griffin SM, Murphy DM, Pearson JP, Forrest IA, Dark JH, Corris PA, Ward C (2009) Targeting allograft injury and inflammation in the management of post-lung transplant bronchiolitis obliterans syndrome. Am J Transplant 9:1272–1278
8 Animal Models of Airway Diseases
233
117. Zhao Y, Lapar DJ, Steidle J, Emaminia A, Kron IL, Ailawadi G, Linden J, Lau CL (2010) Adenosine signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans development. J Heart Lung Transplant 29:1405–1414 118. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123–140 119. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA (2006) A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10:R65 120. Wagner R, Ngamsri K-C, Stark S, Vollmer I, Reutershan J (2010) Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol 299:L502–L512 121. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, Inoue Y, Woehrle T, Zhang Q, Hauser C, Junger WG (2010) Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci Signal 3:ra45 122. Morschl E, Molina JG, Volmer JB, Mohsenin A, Pero RS, Hong JS, Kheradmand F, Lee JJ, Blackburn MR (2008) A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 39:697–705 123. Walker BA, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou D, Bai TR (1997) Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 16:531–537 124. Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, Chan L-NL, Chan T-S, Lee JJ, Blackburn MR (2004) A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 173:1380–1389 125. Knight D, Zheng X, Rocchini C, Jacobson M, Bai T, Walker B (1997) Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 62:465–468 126. Voynow JA, Rubin BK (2009) Mucins, mucus, and sputum. Chest 135:505–512 127. Evans CM, Kim K, Tuvim MJ, Dickey BF (2009) Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 15:4–11 128. Homolya L, Watt WC, Lazarowski ER, Koller BH, Boucher RC (1999) Nucleotide-regulated calcium signaling in lung fibroblasts and epithelial cells from normal and P2Y2 receptor (-/-) mice. J Biol Chem 274:26454–26460 129. Cressman VL, Lazarowski E, Homolya L, Boucher RC, Koller BH, Grubb BR (1999) Effect of loss of P2Y2 receptor gene expression on nucleotide regulation of murine epithelial Cltransport. J Biol Chem 274:26461–26468 130. Ehre C, Zhu Y, Abdullah LH, Olsen J, Nakayama KI, Nakayama K, Messing RO, Davis CW (2007) nPKCepsilon, a P2Y2-R downstream effector in regulated mucin secretion from airway goblet cells. Am J Physiol 293:C1445–C1454 131. Geary C, Akinbi HT, Korfhagen T, Fabre J-E, Boucher R, Rice WR (2005) Increased susceptibility of purinergic receptor deficient mice to lung infection with Pseudomonas aeruginosa. Am J Physiol 289:L890–L895 132. Kolosova IA, Mirzapoiazova T, Moreno-Vinasco L, Sammani S, Garcia JGN, Verin AD (2007) Protective effect of purinergic agonist ATPgS against acute lung injury. Am J Physiol 294:L319–L324 133. Zemans RL, Colgan SP, Downey GP (2009) Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol 40:519–535 134. Inoue Y, Chen Y, Hirsh MI, Yip L, Junger WG (2008) A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 30:173–177 135. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 136. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Durk T, Zissel G, Ferrari D, Di Virgilio F, Sorichter S, Lungarella G, Virchow JC, Idzko M (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934
234
L.F. Thompson et al.
137. Mortaz E, Braber S, Nazary M, Givi ME, Nijkamp FP, Folkerts G (2009) ATP in the pathogenesis of lung emphysema. Eur J Pharmacol 619:92–96 138. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VFJ, Marchand-Adam S, Crestani B, Ryffel B, Couillin I (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774–783 139. M€uller T, Robaye B, Vieira RP, Ferrari D, Grimm M, Jakob T, Martin SF, Di Virgilio F, Boeynaems JM, Virchow JC, Idzko M (2010) The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65:1545–1553 140. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, Hancock WW, Bach FH (1997) Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185:153–164 141. Fausther M, Pelletier J, Ribeiro CM, Se´vigny J, Picher M (2010) Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am J Physiol 298: L804–L818 142. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC (2007) CD39 and control of cellular immune responses. Purinergic Signal 3:171–180 143. Vanderstocken G, Bondue B, Horckmans M, Di Pietrantonio L, Robaye B, Boeynaems J-M, Communi D (2010) P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation. J Immunol 185:3702–3707 144. Resnick MB, Weller PF (1993) Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 8:349–355 145. Cicko S, Lucattelli M, M€ uller T, Lommatzsch M, De Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, D€urk T, Zissel G, Boeynaems JM, Sorichter S, Ferrari D, Di Virgilio F, Virchow JC, Lungarella G, Idzko M (2010) Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol 185:688–697 146. Abboud RT, Vimalanathan S (2008) Pathogenesis of COPD. Part I. the role of proteaseantiprotease imbalance in emphysema. Int J Tuberc Lung Dis 12:361–367 147. Lucattelli M, Cicko S, Muller T, Lommatzsch M, de Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, Durk T, Zissel G, Sorichter S, Ferrari D, di Virgilio F, Virchow JC, Lungarella G, Idzko M (2011) P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 44:423–429 148. Muller T, Paula Vieira R, Grimm M, Durk T, Cicko S, Zeiser R, Jakob T, Martin SF, Blumenthal B, Sorichter S, Ferrari D, di Virgilio F, Idzko M (2010) A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol (in press)
Chapter 9
Therapeutic Applications Stephen Tilley, Jon Volmer, and Maryse Picher
Abstract The current treatments offered to patients with chronic respiratory diseases are being re-evaluated based on the loss of potency during long-term treatments or because they only provide significant clinical benefits to a subset of the patient population. For instance, glucocorticoids are considered the most effective anti-inflammatory therapies for chronic inflammatory and immune diseases, such as asthma. But they are relatively ineffective in asthmatic smokers, and patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). As such, the pharmaceutical industry is exploring new therapeutic approaches to address all major respiratory diseases. The previous chapters demonstrated the widespread influence of purinergic signaling on all pulmonary functions and defense mechanisms. In Chap. 8, we described animal studies which highlighted the critical role of aberrant purinergic activities in the development and maintenance of chronic airway diseases. This last chapter covers all clinical and pharmaceutical applications currently developed based on purinergic receptor agonists and antagonists. We use the information acquired in the previous chapters on purinergic signaling and lung functions to scrutinize the preclinical and clinical data, and to realign the efforts of the pharmaceutical industry. Keywords Airway obstruction Bronchoconstriction Ischemia-reperfusion Lung transplant Pulmonary fibrosis
S. Tilley (*) Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, NC 29799, USA e-mail:
[email protected] J. Volmer and M. Picher Cystic Fibrosis Pulmonary Research and Treatment Center, University of North Carolina, 7011 Thurston-Bowles building, Chapel Hill, NC 27599, USA e-mail:
[email protected];
[email protected]
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1_9, # Springer Science+Business Media B.V. 2011
235
236
9.1
S. Tilley et al.
Introduction
For nearly 30 years, extracellular purines have been suspected to play important roles in the pathogenesis of chronic respiratory diseases. In the 1980s, Cushley et al. reported that inhaled ADO causes bronchoconstriction in asthmatic patients, but not in healthy subjects [1]. Later, it was discovered that asthmatics maintain high airway ADO levels, which is further raised following a challenge [2, 3]. In the past 5 years, the list of respiratory diseases with aberrant airway ADO and/or ATP regulation was extended to CF, COPD and idiopathic pulmonary fibrosis [4–6] (see Chap. 4 for details). Also, the recent finding that ADO induces bronchoconstriction in smokers with COPD supports a role in the “overlapping syndrome” [7–9]. Such widespread occurrence of excess airway ADO motivated scientists and clinicians to investigate the implications of this metabolic aberrance in all aspects of chronic respiratory diseases. The consequences of excess ADO for lung homeostasis were clearly demonstrated by mice lacking adenosine deaminase (ADA) (review: [10]). These ADA/ mice develop bronchial hyperresponsiveness (BHR), severe lung inflammation, mucin hypersecretion, sub-epithelial fibrosis, basement membrane thickening, smooth muscle cell hyperplasia and a disruption of the alveolar network typical of emphysema (see Chap. 8 for details). This stunning discovery launched a series of initiatives to identify which ADO and ATP receptors promote, or attenuate, lung complications. The previous chapters were carefully organized to describe all purinergic receptors, their properties, distribution and roles on the lung resident, immune and inflammatory cells. Chapter 8 described the animal studies that were conducted to compare their impact on lung homeostasis and the potential of selective ligands for the treatment of chronic respiratory diseases. This final chapter describes the progress made, over the past 15 years, in this new field of drug development. First, evidence is provided for the higher diagnostic stringency of ADO-induced BHR for asthma, with respect to histamine and methacholine. Then, we tell the tale of Adagen (Enzon Pharmaceuticals), which was designed for the treatment of ADA-related severe combined immunodeficiency (ADA-SCID), but shows considerable potential for the correction of airway ADO levels in chronic airway diseases. Finally, this chapter covers the ADO and ATP receptor ligands selected by pharmaceutical companies for the treatment of acute lung injury and chronic respiratory diseases, and to improve the outcome of lung transplant. Based on the current understanding of purinergic signaling in the respiratory system, this section offers a critical view on the design of the ligands and the delivery route, which may assist the pharmaceutical industry in future drug discovery.
9.2
AMP Challenges: Diagnostic Tool and Signaling Pathways
Airflow obstruction is a characteristic feature of airway diseases, including asthma and COPD. Adenine nucleotides and nucleosides have been shown to trigger immediate airflow obstruction in asthmatic patients following aerosolized administration.
9 Therapeutic Applications
237
Since the bronchoconstriction does not occur in normal subjects, adenosine monophosphate (AMP) has been used worldwide to detect and monitor bronchial hyperresponsiveness (BHR), as a tool to diagnose asthma and guide therapy. In this section, we review the clinical use of AMP challenges, and the current knowledge on the mechanism of action.
9.2.1
Using AMP as a Diagnostic Tool
In 1983, Cushley, Tattersfield and Holgate were the first to report that inhalational exposure to ADO resulted in a concentration-dependent bronchoconstriction in allergic and non-allergic asthmatic patients [1]. In contrast, ADO concentrations up to 30-fold higher had no effect on the airway caliber of normal subjects [11]. Adenine nucleotides, ADP and AMP, also elicited airway narrowing in asthmatics, while the ADO metabolite, inosine, did not induce bronchoconstriction [12]. The airway epithelial surfaces express ectonucleotidases which rapidly dephosphorylate adenine nucleotides into ADO (see Chap. 2 for details). While it is well accepted that the effects of these nucleotides on airway caliber are mediated by ADO, AMP remains the drug of preference for solubility purposes (review: [13]). Prior to the observations of Cushley et al. [1], pharmacological tests for BHR relied on direct airway challenges with methacholine or histamine. These substances activate M3 muscarinic receptors and H1 histamine receptors on airway smooth muscle (ASM) to elicit bronchoconstriction in asthmatics at concentrations having no effect in the airways of normal subjects. While the sensitivity and negative predictive values of methacholine and histamine challenges approach 100%, their specificity and positive predictive values for asthma are very low [14–17]. In fact, adult COPD patients and children with bronchiectasis, bronchiolitis obliterans or CF, typically develop BHR in response to methacholine and histamine [18–22]. In contrast, nonsmoking adults with COPD and children with airway diseases other than asthma are less responsive to an AMP challenge [7–9, 22, 23]. This higher specificity for asthma suggests that aerosol AMP may constitute a powerful diagnostic test to differentiate these airway diseases in children and non-smoking adults. Furthermore, contrary to methacholine, the magnitude of the BHR response to AMP is highly correlated with the degree of underlying airway inflammation in asthmatics [24, 25]. For these reasons, measurement of BHR by AMP challenge has been endorsed by the European Respiratory Society Task Force on indirect airway challenges [26]. It is more specific for asthma than methacholine and histamine challenges [22, 27], correlates more closely with the degree of inflammation in the lower airways [24, 25], and may be used to evaluate the efficacy and potency of inhaled steroids [28–31]. However, the sensitivity of an AMP challenge to detect asthma is limited, the rate of AMP responsiveness varying from 39% to 95.5% in children [32–35] and 50% to 89% in adults [24, 36]. The studies reporting a high degree of sensitivity included large numbers of atopic asthmatics. Accordingly, a study designed to elucidate the determinants of AMP responsiveness revealed that atopic sensitization, assessed by positive skin prick testing, was the major variable affecting AMP
238
S. Tilley et al.
sensitivity [32]. Compared to non-atopic asthmatics, atopic asthmatics exhibit exaggerated mast cell activation by antigens and allergens. Consequently, these cells have been the focus of intense investigation to better understand the mechanisms of ADO-induced bronchoconstriction.
9.2.2
Signaling Pathways of Bronchoconstriction
The signaling pathways responsible for AMP-induced BHR have been extensively investigated using its active metabolite: ADO. This ubiquitous signaling molecule has been shown to regulate the activities of all mammalian cell types through the activation of cell surface G protein-coupled receptors. Four P1 receptors have been identified and are widely expressed: A1Rs, A2ARs, A2BRs, and A3Rs. The studies conducted in humans and animals support three potential mechanisms for ADO-induced bronchoconstriction targeting different cell types: mast cells, ASM and neurons (Fig. 9.1). The first argument supporting a mast cell-dependent mechanism was provided by a clinical study reporting the accumulation of histamine in the airways of asthmatic patients in response to endobronchial ADO [37]. Accordingly, ADO-induced
Fig. 9.1 Mechanisms of adenosine-induced bronchoconstriction in human airways. Adenosine (ADO; red) can induce muscle contraction directly via A1 receptors (A1R) located on airway smooth muscle (ASM). These receptors are also expressed by the sensory neurons, allowing ADO to induce the release of acetylcholine (Ach; green). This neurotransmitter can induce muscle contraction directly via muscarinic receptors on ASM, or indirectly by the stimulation of histamine release (blue) from mast cells
9 Therapeutic Applications
239
BHR was attenuated by mast cell stabilizing agents (i.e. nedocromil) [38–40] and antagonists of the histamine receptor (i.e. terfenadine) [41–43] or leukotriene receptor (i.e. Montelukast) [44]. These studies led many to believe that ADO-induced bronchoconstriction results from mast cell activation. In rodents, the P1 receptor causing mast cell degranulation was identified as the A3R [45–48], whereas this role was ascribed to the A2BR in human mast cells [49–51]. Nonetheless, aerosolized treatment with a dual A2BR/A3R antagonist (QAF805) failed to affect PC20 (provocative concentration required to induce a 20% fall in lung function) in asthmatics [52], suggesting that ADO induces bronchoconstriction by other mechanisms. Human and animal studies suggest that A1Rs located on ASM mediate the ADOinduced bronchoconstriction. On cultures of human ASM, A1R activation stimulated cell contraction by the mobilization of intracellular Ca2+ stores [53]. Their tissue expression was confirmed by immunolocalization in biopsy sections, which also showed that A1Rs are overexpressed in the airway epithelium and ASM of asthmatics [54]. Furthermore, the incubation of normal ASM cultures with serum from asthmatic patients induced the up-regulation of A1Rs [55]. Incidentally, animal studies conducted with A1R agonists and antagonists also support a role for A1Rs located on ASM in ADO-induced BHR [56–58]. The use of knockout mice targeting each P1 receptor revealed that only A1R/ mice fail to react to an ADO challenge [59]. On the other hand, ADO-induced bronchoconstriction was abolished following bilateral vagotomy [59], suggesting a role for sensory neurons. In asthmatic patients, AMP-mediated BHR was attenuated by the anticholinergic drug ipratropium, and by depletion of contractile neuropeptides with bradykinin [60, 61]. These studies support a role for cholinergic neural pathways in the bronchoconstrictor response to ADO. In allergic (not naı¨ve) guinea pigs, the fact that bilateral vagotomy or capsaicin strongly inhibited airway obstruction to AMP (75%), or an A1R agonist (N(6)-cyclopentyladenosine; CPA) (50%), suggests that cholinergic neural input to the ASM is critical for A1R-mediated bronchoconstriction [62]. In human airways, acetylcholine can activate muscarinic receptors on ASM and mast cells (review: [63]). Whether cholinergic mediators induce ASM contraction directly, or through mast cell activation, has not been determined.
9.2.3
Summary
Recent studies on the signaling pathways responsible for ADO-induced BHR have revealed important clues about the airway pathophysiology of asthma, by uncovering a complex interplay between mast cells, neurons and ASM. The continuous investigation of the mechanisms by which nucleotides and nucleosides influence airway caliber in the asthmatic lung may lead to the exploitation of these pathways for therapeutic approaches. For instance, future studies comparing the relative impact of A1R and A2BR antagonists on AMP-mediated BHR may reveal a more prominent role for A2BR-mast cell signaling in the atopic asthmatic patients. Meanwhile, AMP challenges remain an important tool for clinicians and researchers sharing common interests in the diagnosis and treatment of asthma and other respiratory disease.
240
9.3 9.3.1
S. Tilley et al.
Adenosine Deaminase Replacement Therapies Current Clinical Application for ADA-SCID
As part of the purine salvage pathway, intracellular ADA is responsible for the deamination of ADO and deoxyadenosine into inosine and deoxyinosine, respectively [64]. Over 50 mutations spanning the entire Ada gene have been identified, 29 of them resulting in >85% reduction of ADA activity [65, 66]. These functional mutations allow toxic levels of substrates to accumulate and interfere with the development of thymocytes in the thymus and bone marrow, which prevents or weakens the immune responses to infection [67]. Accordingly, inherited ADA deficiency is catalogued as an autosomal recessive immunodeficiency disorder exhibiting a wide range of severity, depending on the level of residual activity: (1) a neonatal and fatal severe combined immunodeficiency disease (SCID) characterized by the absence of cellular and humoral immunity; (2) a delayed onset progressive disease retaining some humoral immunity; (3) a late juvenile onset with progressive attrition of immune defenses; (4) an adult onset disorder [66]. With respect to lung complications, they exhibit recurrent otitis, sinusitis, chronic bronchitis and pneumonia, the severity correlating negatively with ADA activity [68]. Over the years, many therapeutic approaches have been explored for ADA-SCID patients. The best option remains an allogenic bone marrow transplant, which generally leads to complete recovery [69]. In the event that a histocompatible sibling is unavailable, these patients are administered irradiated purified erythrocytes as a source of functional ADA [70]. Unfortunately, this approach only provides a partial and transient recovery of immune functions, and long-term infusions give rise to various complications [71]. In 1981, Stephen Davis proposed that covalent linking of purified bovine ADA to polyethylene glycol (PEG) would prolong its half-life and reduce its antigenicity [71]. This approach proved successful in laboratory animals, extending the half-life of ADA activity in mouse serum from 30 min for the naked protein to 28 h for PEG-ADA. The antigenic properties were virtually eliminated as well, as the serum from mice receiving intravenous PEG-ADA was unable to immunoprecipitate ADA or PEG-ADA, even after repeated injections over a period of several weeks. The circulating PEG-ADA was also able to reduce the intracellular levels of ADO [71] due to the ubiquitous expression of transporters in the plasma membrane of mammalian cells (see Chap. 2 for details). In 1985, Michael Herschfield initiated the therapeutic evaluation of PEG-ADA (Adagen; Enzon Pharmaceuticals) in ADA-SCID patients. The therapy successfully reduced tissue ADO concentrations and dramatically improved immune functions [69]. However, the levels of T, B and natural killer lymphocytes rose over the first few years, but never reached normal values. Also, about 65% of the patients developed antibodies against PEG-ADA within the first year. Their lymphocyte levels began to drop, as they faced a steady decline in immune function. Another major obstacle to this therapy was the cost of biweekly injections of PEG-ADA,
9 Therapeutic Applications
241
which rose to $200,000/year [72]. These serious limitations called for alternative approaches for the restoration of ADA. Future directions in the treatment of ADA-SCID include the genetic replacement of ADA function (review: [73]). Over nearly two decades, the gene therapy consisted almost exclusively in the use of retroviral vectors targeting the lymphocytes and hematopoietic progenitors. Patients were successfully colonized by hematopoietic stem cells transfected with the ADA gene, following partial ablation of the bone marrow [74]. However, this groundbreaking approach came with the risk of inspectional mutagenesis. Recent studies suggest that this highly invasive protocol may be replaced by ex vivo lentiviral therapy. In ADA-deficient mice, the intravenous injection of human immunodeficiency virus 1-based lentiviral vector at birth induced the long-term expression of enzymatically active ADA at levels comparable to long-term PEG-ADA treatments [72]. This approach effectively restored immune function and significantly extended survival. As such, this non-invasive method may provide long-term restoration of ADA activity in ADA-SCID patients.
9.3.2
Long-Term Treatments for Pulmonary Diseases
Despite the development of successful treatments for ADA-SCID, the underlying causal link between the metabolic disturbances and associated immunodeficiency were unknown. An animal model of ADA deficiency was developed to investigate this link, but the ADA/ mice suffered from a perinatal lethality due to hepatotoxicity [75]. This complication was circumvented using an ADA minigene possessing only the promoter elements required for expression in the trophoblast, which preserved liver function [76]. These partially ADA-deficient mice were born without ADA activity, as evidenced by a steady accumulation of the ADA substrates: ADO and deoxyadenosine. They displayed typical immunodeficiency in the lymphoid line for ADA-SCID patients [77]. In addition, these mice developed severe pulmonary complications, characterized by BHR to inhaled ADO [78], inflammatory cell infiltration and mucus hypersecretion [77]. The defective alveogenesis resulted in an emphysema-like phenotype by postnatal day 10, and the mice died by postnatal day 21 due to respiratory distress [79] (see Chap. 8 for details). These studies demonstrate that the high systemic ADO levels of SCID patients are responsible for the development of severe lung complications. More importantly, they suggested that the high airway ADO levels of asthmatic [3, 80, 81] and COPD [82] patients promote the inflammation, remodeling and fibrosis leading to BHR and the loss of lung function. The therapeutic potential of PEG-ADA for chronic respiratory diseases was tested in the ADA/ mice. The animals treated with intramuscular PEG-ADA from birth did not develop any lung complication [83]. On the other hand, ADA/ mice which develop lung inflammation over 20 days completely recovered after 3 days of PEGADA treatment at a dose that fully restored normal lung ADO levels [79].
242
S. Tilley et al.
Interestingly, the microarray analysis of lung tissue revealed that PEG-ADA restored the normal expression of genes critical for inflammatory responses, as well as factors promoting remodeling and fibrosis. This observation supported the therapeutic potential of PEG-ADA for patients with well-established chronic respiratory diseases. This hypothesis was tested using ADA/ mice maintained on a low-dose PEG-ADA regimen from birth, which prolonged their lifespan to 4–5 months [84]. After 3 months, the resulting intermediate ADO level fostered the development of severe pulmonary inflammation, collagen deposition and alteration in airway structure. Their BAL fluid accumulated, both, pro-inflammatory and pro-fibrotic mediators (IL1b, osteopontin, MMP12, TGFb, and PAI-1). All these complications were fully resolved by shifting these mice to high-dose PEG-ADA for 5 weeks. This animal model clearly demonstrated the dramatic consequences of high ADO levels reported in the airways of asthmatic and COPD patients (see Chap. 4 for details), and the therapeutic potential of PEG-ADA for all lung complications, including fibrosis.
9.3.3
Suppression of the ADO/IL-13 Amplification Cycle
Clinical studies showed that the airways of asthmatic, CF and COPD patients also accumulate the cytokine: IL-13 [85–87]. An earlier report of normal IL-13 concentration in COPD sputum [88] may have resulted from the use of enzyme-linked immunoassay, instead of the more sensitive cytometric bead array, as the authors only detected IL-13 in 6/34 patients. In CF patients, a significant negative relationship was established between airway IL-13 levels and lung functions [86]. The significance of IL-13 for chronic airway diseases is supported by the plethora of studies which identified this cytokine as upstream element responsible for the imbalance in metalloproteinase production promoting airway remodeling (reviews: [89, 90]). Incidentally, IL-13 transgenic mice develop mucus cell metaplasia, hypersecretion and sub-epithelial fibrosis [91, 92]. Interestingly, they share many phenotypic traits with the ADA-deficient mice, including eosinophilia, emphysema and fibrosis, and they survive less than 4 months [92]. The development of these lung complications coincides with a steady rise in lung ADO level and reduction in lung ADA activity. One month of PEG-ADA treatment corrected the ADO levels and significantly reduced inflammation, mucin secretion, collagen deposition and emphysema [91]. The existence of an amplification cycle for lung IL-13 and ADO regulation is also supported by the fact that ADA/ mice overexpress IL-13, which was corrected by PEG-ADA treatment [91]. It is proposed that excess ADO, generated in stressed and damaged tissues, induces an up-regulation of IL-13 and recruits inflammatory cells. This cytokine initiates airway remodeling and down-regulates ADA, resulting in further ADO accumulation, which completes the cycle. Consequently, many aspects of chronic airway diseases could be addressed by ADA replacement therapy, by the concomitant reduction of ADO- and IL-13-mediated responses.
9 Therapeutic Applications
9.3.4
243
Summary
The current literature highlights the tremendous potential of PEG-ADA to identify the inflammatory, remodeling and fibrotic processes targeted by the excess airway ADO of asthmatic and COPD patients. This remarkably stable compound also has the potential of becoming an effective therapy for a variety of lung diseases dominated by fibrosis and emphysema, that is, if the pharmaceutical industry can reduce the cost of the treatments. At Enzon Pharmaceuticals, PEG-ADA (pegademase bovine) has been prescribed for over 20 years for the treatment of ADA-SCID under the name: Adagen. Patents were recently issued for therapeutic applications in pulmonary diseases, and clinical trials are pending. It is important to note that ADA offers no therapeutic benefit unless pegylated, which provides the metabolic stability. Since this discovery, this stabilizing technique has been applied to a number of bioagents, including interferons (review: [93]).
9.4
Clinical Trials Involving Adenosine Receptors
There are dozens of ADO receptor ligands currently designed by various research laboratories and pharmaceutical companies. This activity has provided pharmacological tools to distinguish the roles of each ADO receptor in the regulation of airway defenses. For details on the strategies behind their structural design, the readers are redirected to excellent reviews for A1Rs [94], A2ARs [95, 96], A2BRs [97, 98] and A3Rs [99]. This chapter focuses on the ligands selected for preclinical and clinical evaluation. In each case, the experimental designs (animal models, delivery routes) chosen to evaluate their therapeutic potential are weighed against the knowledge we have acquired in the first eight chapters of this book, regarding ADO regulation and cell-specific functions.
9.4.1
The A1R Antagonists
The animal models of chronic respiratory diseases predict that A1R antagonists may attenuate BHR, mucin hypersecretion and lung inflammation (see Chap. 8 for details). These bioagents would take advantage of the high A1R expression reported on the airway epithelial and smooth muscle cells of asthmatic patients [54]. On the other hand, smoking was recently reported to down-regulate A1Rs on inflammatory cells [100], suggesting that A1R antagonists may be less effective in smoking asthmatics and most COPD patients. In terms of delivery route, systemic delivery of A1R antagonists in oral capsules would more efficiently prevent the migration of dendritic cell to the lymph nodes, as well as leukocyte adhesion to the endothelial barrier (see Chap. 7 for details). With all this information in mind, we will review the current preclinical and clinical studies with a critical view of the drug development strategies adopted for A1R antagonists.
244
9.4.1.1
S. Tilley et al.
Mixed Theophylline/Corticosteroid Treatments
Chemical structure: 1,3-dimethylxanthine The first report of methylxanthines for the treatment of bronchoconstriction was published in 1859 by an asthmatic, Henry Hyde Salter, who described the effects of a strong coffee on his airway symptoms (review: [101]). In the 1920s, Theophylline was demonstrated to relax airway smooth muscle, and was prescribed orally for the treatment of airway hyperresponsiveness [102]. In the 1970s, Theophylline was a popular treatment for stable asthmatic patients. Unfortunately, the dose needed to initiate bronchodilation often induces cardiovascular and gastric side-effects. This drug became less popular as more effective b2 adrenoceptor agonists became available. Over the past decade, Theophylline was revisited using lower doses (0.1–0.5 mg) avoiding most side-effects caused by phosphodiesterase inhibition. Under these conditions, Theophylline exerts potent anti-inflammatory effects, predominantly as an A1R antagonist (review: [103]). In the OVA sensitization/challenge model of allergic asthma, low dose Aminophylline (Theophylline pro-drug) given intraperitoneal prevented early and late phase airway hyperresponsiveness to an OVA challenge, and reduced the inflammatory markers in BAL fluid (IL-4, IL-5, IL-6, IL-10 and TNFa) [104]. In 2006, the anti-inflammatory potential of low-dose Theophylline for asthmatic patients was tested in a clinical study using Aminophylline [105]. A single intravenous injection significantly improved the lung functions, measured as peak expiratory flow (PEF) and peripheral oxygen saturation (SpO2). These clinical benefits were comparable to those of aerosolized Salbutamol, a b2 adrenoceptor agonist. Also, Aminophylline (but not Salbutamol) reduced pulmonary inflammation, measured in BAL fluid as eosinophil cationic protein, histamine, serotonin, thromboxane B2, leukotriene C4. Nowadays, clinicians refine the treatment of asthma and COPD by combining the bronchodilating effect of inhaled corticosteroids with the anti-inflammatory effect of low dose oral Theophylline [106–108] (Table 9.1). In July 2010, the Theophylline extended-release tablet was granted marketing approval by the United States FDA. Table 9.1 Antagonists of the A1R in the pipeline Delivery Proof of Drug Disease route concept Theophylline Asthma and Oral COPD Bamiphylline Asthma and Oral COPD L-97-1
Asthma
Oral
EPI-2010
Asthma
Nebulizer
Clinical trials terminated
Preclinical
Phase Phase 1 2a
Phase 2b
Phase 3
9 Therapeutic Applications
9.4.1.2
245
Bamiphylline Approved in Europe
Chemical structure: 8-benzyl-7,[2-[ethyl(2-hydroxyethyl)amino]-ethyl] Theophylline Trentadil; bamifylline; benzetamophylline, Cloperastine Over the years, more selective A1R antagonists were designed to avoid the sideeffects associated with Theophylline. Several clinical trials, conducted over the past 20 years, reported the potential of Bamiphylline for the treatment of bronchoconstriction and mucin clearance in asthmatic and COPD patients. In 1991, a placebocontrolled study was conducted with COPD patients matched for age [109]. The 7-day oral treatment significantly improved lung functions, based on the breathing pattern, inspiratory muscle strength, neural drive and index of inspiratory neuromuscular coupling. In 1995, a double-blind clinical study assessed the effect of Bamiphylline on mucus clearance in 20 smokers with chronic bronchitis, compared to healthy controls [110]. All subjects received oral Bamiphylline (600 mg per day) or placebo during 15 days. Only the Bamiphylline treated COPD patients exhibited better mucus clearance, clinical score and pulmonary function, with no reported sideeffects. This study suggests that Bamiphylline could improve mucus clearance in other chronic obstructive diseases, such as CF. Oral Bamiphylline has been approved for the treatment of asthma and COPD in Europe, where it shows low incidence of side-effects, such as headaches or gastralgia (1/100,000 patients) [111]. This drug is also sold, as a cough suppressant, by Biocure Pharmaceutical under the name of cloperastine.
9.4.1.3
Is L-97-1 Better than Montelukast?
Chemical structure: [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxyethyl)-amino-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione] Based on the success story of Bamiphylline, Mustafa et al. developed a selective antagonist of this receptor: L-97-1 [57]. Radioligand binding analysis showed a strong affinity for A1Rs (IC50 ¼ 1.42 mM) compared to A2ARs and A2BRs (IC50 > 100 mM). This is a considerable improvement from Bamiphylline, in terms of affinity and selectivity. In the house dust mite sensitization/challenge model of allergic asthma, the oral gavage of L-97-1 prevented the BHR to the final challenge for at least 6 h [57]. This treatment also inhibited late allergic responses, measured after 24 h, by histamine-induced bronchoconstriction. Therefore, L-97-1 has the potential to prevent early and late allergic responses in asthmatic patients. Mustafa et al. also used this animal model to compare the efficiencies of L-97-1 and Montelukast [112], a cysteinyl leukotriene-1 receptor antagonist regularly prescribed to asthmatic patients for the treatment of reversible airflow limitation [113]. First, L-97-1 pretreatment maintained lung dynamic compliance higher than Montelukast over at least 5 h after a house dust mite challenge. Second, L-97-1
246
S. Tilley et al.
blocked both early and late allergic responses, whereas Montelukast only blocked the late response. Finally, both drugs caused comparable anti-inflammatory effects, in terms of leukocyte accumulation in BAL fluid. In summary, L-97-1 is an antiinflammatory drug as potent as Montelukast, with the added benefit of a more efficient treatment of reversible airflow limitation. The small water-soluble molecule, L-97-1, is under development as oral treatment for asthmatics by Andacea Inc., a company devoted to purinoceptor-based technologies.
9.4.1.4
EPI-2010: A Respiratory Antisense Oligodeoxynucleotide
In 2006, Drs Fire and Mello were awarded the Nobel Prize for discovering the mechanism behind RNA interference in 1998 (review: [114]). The regulation of gene expression through “silencing” was found essential for many cellular processes. The immense impact of this discovery on biomedical research led to the development of a new generation of aerosolized drugs for chronic respiratory diseases. In 1999, Metzger and Nyce designed respirable antisense oligonucleotides (RASONs) as short, single-stranded nucleic acid sequences modified to enhance their stability [58]. They bind the initiation codon of the messenger RNA (mRNA), which prevents translation and targets the message for degradation by RNAses. A clear advantage over traditional drugs is that they are metabolized locally by endogenous nucleases, confining their reactivity to the airways (review: [115]). During a joined venture with Chiesi Pharmaceuticals and Taisho Pharmaceuticals, EpiGenesis Pharmaceutical developed the A1R-specific RASON, named EPI-2010, for the treatment of asthma [116]. A fortuitous homology between the human and rabbit mRNA sequences of the A1R allowed EPI-2010 to be tested in the model of allergic asthma described above for L-97-1. Following house dust mite sensitization, nebulized EPI-2010 caused a dose-dependent attenuation of airway hyperresponsiveness to ADO [58]. The fact that EPI-2010 also reduced airway obstruction caused by house dust mite and histamine challenges supported the existence of an anti-inflammatory effect. In these animals, EPI-2010 was deposited throughout the lung, with no detectable systemic active metabolites, and was excreted primarily in the urine. This original study demonstrated that RASONs can be efficiently delivered to the peripheral lung, where they potently and selectively attenuate the expression of disease-associated genes. In primates, EPI-2010 attenuated the allergen responses to Ascaris lumbricoides for about 7 days, which corresponds to the kinetics of A1R expression. Hence, EPI-2010 may represent the first once-a-week treatment for asthma. In 2003, a Phase 1 clinical trial conducted on asthmatic patients demonstrated that aerosolized EPI-2010 is well-tolerated and shows indications of efficacy [116]. A single dose reduced the need for bronchodilator drugs and the symptom scores during about 1 week. However, because of the disappointing results of a Phase 2 clinical trial, EPI-2010 was discontinued from clinical testing [117]. In this study, 146 patients with persistent airway obstruction (FEV1 ¼ 74.5% predicted;
9 Therapeutic Applications
247
12% reversibility), currently receiving inhaled corticosteroids, were administered EPI-2010 (1, 3, or 9 mg) through a nebulizer once or twice weekly. In asthmatic patients under corticosteroid treatment, EPI-2010 caused no significant change in lung function or inflammatory responses over 29 days. Some arguments still support the therapeutic potential of inhaled EPI-2010 for asthmatic patients. In the above clinical trial, the patients had mild-to-moderate asthma, depending on the frequency of symptoms and the variability in peak expiratory flow rate. Despite the apparent stable FEV1 of 74.5% predicted, corticosteroids will raise the FEV1 values to 90–100% of predicted between exacerbations. Consequently, measurements of FEV1 do not constitute a sensitive assessment of asthma severity, compared to the acute changes in airway function caused by bronchoprovocation. This trial should have tested the therapeutic potential of EPI-2010 in asthmatic patients not receiving corticosteroid treatments, and using challenged BHR responses as parameter of clinical benefit. Also, because of safety concerns about the use of antisense oligonucleotides in humans, the doses of EPI-2010 may have been sub-therapeutic. For these reasons, the scientific and clinical communities both support further investigation of aerosolized EPI-2010 for the attenuation of BHR in asthma and COPD. On the other hand, the current information on A1Rs suggests that oral delivery would provide a more potent anti-inflammatory treatment of chronic lung diseases.
9.4.2
The A2AR Agonists
The animal studies and known functions of A2ARs predict that agonists would be prescribed primarily for the treatment of chronic lung inflammation (see Chap. 8 for details). However, this approach faces a serious challenge, as A2AR expression and/or surface affinity are reduced in the lungs of asthmatic and COPD patients [100, 118]. Since these ligands have been shown to cause significant cardiovascular side-effects, including hypotension, strategies have been designed to confine the drugs to the airways. On the other hand, this flaw has been exploited for the benefit of patients undergoing elaborate surgical procedures, such as lung transplant, to prevent the resulting increase in pulmonary arterial blood pressure. This section reviews the A2AR agonists which were selected for preclinical and clinical evaluation of these two major applications. 9.4.2.1
CGS21680 More Efficient than Budesonide
Chemical structure: 2-p-(2-carboxyethyl)phenethylamino-5’-N ethylcarboxamido adenosine hydrochloride The animal studies described in Chap. 8 clearly support the use of A2AR agonists for the treatment of lung inflammation in chronic respiratory diseases. However, the drug should be administered as an aerosol because systemic injection has been
248
S. Tilley et al.
shown to cause considerable cardiovascular side-effects, including hypotension in human subjects [119]. Therefore, studies were conducted to test the safety and efficacy of the aerosolized A2AR agonists in animal models of airway diseases. The first study evaluated the potential of CGS21680 in an animal model of allergic asthma. In OVA sensitized/challenged Norway rats, intratracheal CGS21680 given 15 min before and after the final challenge reduced eosinophil and neutrophil counts in the BAL fluid [120]. Similar findings were obtained in OVA sensitized/challenged mice [121]. In addition, CGS21680 was found ten times more efficient than Budesonide [121], a corticosteroid currently prescribed to asthmatic patients (review: [122]). On the other hand, CGS21680 did not address OVA-induced bronchoconstriction or mucin secretion, as expected from the pharmacological properties of the A2AR (see Chap. 8 for details). And these doses caused significant hypotension in the anesthetized animals, which may limit the clinical utility (Table 9.2). Aerosolized CGS21680 did not prevent the development of lung inflammation in two models of acute lung injury: intranasal LPS and cigarette smoke inhalation [121]. In Chap. 8, we provided evidence that the microvascular endothelial barrier constitutes the primary target for the treatment of acute lung injury, as A2AR activation inhibits vascular leakage and inflammatory cell infiltration. In the LPSand smoke-challenged mice, the lack of effect of intranasal CGS21680 may reflect a poor choice of delivery route. A study showed that rats subjected to hemorrhagic shock, then given intravenous CGS21680 during resuscitation, developed significantly less acute lung injury than the untreated animals, in terms of vascular leakage and BAL myeloperoxidase activity [123]. This study suggests that the systemic administration of CGS21680 may prevent the acute development of lung injury in situations where blood pressure is monitored. Table 9.2 Agonists of the A2AR in the pipeline Delivery Proof of Drug Disease route concept CGS21680 Asthma Intratracheal Trauma GW328267X Allergic rhinitis
Systemic Intranasal
Asthma
Diskhaler
UK371,104
COPD
Intratracheal
UK432,097
COPD
Inhaled
Cough
Powder
Stedivaze
Sepsis Sickle cell disease
ATL313
Intravenous
Lung Intravenous transplant
Heart/lung Intravenous bypass Clinical trials terminated
Preclinical
Phase Phase 1 2a
Phase 2b
Phase 3
9 Therapeutic Applications
9.4.2.2
249
GW328267X: Flaw in the Design
Chemical structure: (2R,3R,4S,5R)-2-{6-amino-2-[(1-benzyl-2-hydroxyethyl)amino]9H-purin-9-yl}-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydrofuran-3,4- diol The company GlaxoSmithKline identified a new selective agonist for the A2AR: GW328267X [124]. Binding studies conducted in Chinese hamster ovary cells showed that this high-affinity (pKi ¼ 7.8) ligand is a potent agonist (pEC50 ¼ 9.0) of the A2AR. This compound has a lower affinity for A1Rs and A2BRs (pKi 6) and shows relatively weak agonist activity at these receptors. In vitro assays demonstrated that GW328267X inhibits neutrophil and eosinophil activities (oxidative stress and degranulation), which are antagonized by an A2AR antagonist, CGS15943. However, GW328267X also binds A3Rs (pKi ¼ 7.8) as a competitive antagonist. Hence, GW328267X activates A2ARs and blocks A3R-mediated responses equally well. Since A3Rs mediate neutrophil elastase secretion [125], this drug would offer additional protection as a blocker of this receptor. In 2007, the company published results from two clinical studies conducted to evaluate the therapeutic potential of GW328267X for allergic rhinitis [126] and allergic asthma [127]. In a randomized, double-blind, placebo-controlled, threeway balanced, crossover study, 48 men with allergic rhinitis where challenged with house dust mite. Then, they received a nasal spray of GW328267X (50 mg) or Fluticasone (200 mg) twice daily [126]. The corticosteroid is currently prescribed for the treatment of allergic rhinitis. After 7 days, the patients given GW328267X had improved nasal blockage, but not peak nasal inspiratory flow, whereas Fluticasone significantly improved both parameters. Intranasal GW328267X also produced a small, but significant, reduction of inflammatory marker concentrations in the BAL fluid (tryptase and eosinophil cationic protein), while Fluticasone normalized the concentrations of eosinophil cationic protein and neutrophil chemoattractant IL-8. It was concluded that this novel A2AR agonists has limited clinical benefit for the treatment of allergic responses. In the second double-blind, placebo-controlled, three-way balanced crossover study, 15 non-smoking atopic asthmatic patients, not under corticosteroid treatments, were challenged with house dust mite, then inhaled GW328267X (25 mg) or Fluticasone (200 mg) twice daily for 7 days [127]. The A2AR ligand did not protect against early and late asthmatic reactions, or significantly attenuate the inflammatory responses. And higher doses caused considerable side-effects, in terms of hypotension and tachycardia. In contrast, Fluticasone completely inhibited the early and late asthmatic responses, and significantly suppressed inflammation, including the lung eosinophilia. Given such low therapeutic index, GlaxoSmithKline discontinued the evaluation of GW328267X. The failure of GW328267X to provide therapeutic benefits to allergic patients is consistent with the properties of this complex ligand. First, chronic airway diseases, in humans and animal models, are associated with a dramatic down-regulation of A2ARs (see Chap. 8 for details). Second, the antagonistic effect of GW328267X on A3Rs is expected to inhibit the degranulation of eosinophils, but to promote their recruitment to the lungs [128]. As such, this drug could not suppress allergic airway inflammation.
250
9.4.2.3
S. Tilley et al.
New UK371,104 Remains in the Lungs
Chemical structure: N-(2,2-diphenylethyl)-2-{[(2-piperidin-1-ylethyl)amino] carbonyl} adenosine In 2008, Pfizer Inc. presented a new selective A2AR agonist carefully designed to minimize side-effects by restricting the molecule to the airways (review: [119]). In rats given an intratracheal dose of 1 mg/kg, the maximum free plasma concentration (Cmax) of UK371,104 was 20 nM, compared to 271 nM for CGS21680. This tenfold difference results from the higher lipophilicity, molecular weight, in vivo clearance and plasma protein binding capacity of UK371,104. The safety and potency of UK371,104 were evaluated in anesthetized guineapigs monitored simultaneously for pulmonary and cardiovascular functions [129]. Whereas intratracheal CGS21680 or UK371,104 prevented capsaicin-induced bronchoconstriction, only CGS21680 provoked hypotension [129]. Furthermore, the protective effect of the new drug against BHR lasted more than tenfold longer than with CGS21680. Overall, UK371,104 offers a sevenfold improvement in potency and 150-fold reduction in side-effect over the lead compound, CGS21680 [119]. These data suggest that aerosolized UK371,104 constitutes the drug of choice for the treatment of chronic airway diseases. The company further refined the structure of UK371,104 to generate UK432,097, [130]. In Phase 1 clinical trial, healthy subjects administered UK432,097 as an inhaled dry powder presented very little dispersal outside of the airways, and no effect on heart rate. In a Phase 2, randomized, double-blind, placebo controlled, parallel group clinical trial designed to evaluate the efficacy and safety of UK432,097 in adults with moderate-to-severe COPD, the patients showed no improvement in lung function over 6 weeks [131]. At the moment, alternative applications are considered for UK432,097, including cough suppression and improving the outcome of mechanically ventilated patients.
9.4.2.4
The ATL Family of A2AR Agonists
Stedivaze was originally developed by Clinical Data Inc. as pharmacological stress agent for myocardial perfusion imaging, to avoid the bronchoconstrictive effects of ADO in patients with asthma and COPD. In summer 2010, a Phase 2 clinical trial showed that a fixed dose, bolus injection, of Stedivaze generates sufficient coronary artery vasodilation for myocardial perfusion imaging, and without causing bronchoconstriction. This study constitutes a milestone toward the goal of developing a safe and well tolerated coronary vasodilator for these patients. Stedivaze is currently in Phase 3 trial for this application. Given the potent anti-inflammatory properties of A2ARs, Stedivaze could represent an asset for the treatment of chronic respiratory diseases, while avoiding bronchospasms. Incidentally, the company Adenosine Therapeutics LLC (acquired by Clinical Data Inc. in 2008) was awarded funding in 2010 by the National Institute of Allergy and Infectious Diseases to explore applications for the treatment of asthma, arthritis and sepsis.
9 Therapeutic Applications
251
Stedivaze (Apadenoson; BMS 068645 or ATL146e) Chemical Structure: 4-(3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydrofuran-2-yl)-9H-purin-2-yl]-prop-2-ynyl)-cyclohexanecarboxylic acid methyl ester In 2001, Linden et al. synthesized and characterized Stedivaze as a potent inhibitor of human neutrophil oxidative activity [132]. This compound was found to have 50 times more affinity for the human neutrophil A2AR than CGS21680. Since LPS causes a rapid up-regulation of A2ARs on inflammatory cells [133], a bacterial infection would provide additional binding sites for Stedivaze to suppress inflammation. In 2004, Linden et al. provided evidence that Stedivaze may constitute a potent anti-inflammatory agent for the treatment of sepsis [134]. Human neutrophils primed by LPS responded to the bacterial chemoattractant, formyl-Met-Leu-Phe (fMLP), by an up-regulation of a4/b1 integrin, as reported for the circulating neutrophils of sepsis patients [135]. This sepsis-like neutrophil phenotype has been shown to bind more readily to the vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, which facilitates their transmigration into the lung tissue. Stedivaze, added before or after priming, was equally effective in inhibiting the up-regulation of a4/b1 integrin, which reduced the neutrophil adhesive properties. In 2010, Linden et al. presented in vivo evidence for the therapeutic potential of Stedivaze in pulmonary diseases. In sickle cell disease, misshapen erythrocytes trigger transient episodes of microvascular ischemia-reperfusion, which reduces the baseline lung functions and maintains lung inflammation. Therefore, they used the murine model of sickle cell disease, NY1DD mice, to test Stedivaze. In these mice, continuous infusion of Stedivaze (10 ng/mg/min) initiated a dose-dependent improvement of the baseline lung functions, which reached maximal efficacy within 3 days [136]. In the NY1DD mice subjected to hypoxia-reperfusion, stedivaze added at the onset of reperfusion prevented further lung injury. This study supports the potential of stedivaze for the treatment of the lung inflammation caused by recurrent ischemia-reperfusion in sickle cell disease. On the other hand, this study did not document the impact the circulating A2AR agonist on blood pressure, which is a major concern for this class of bioagent.
The Next Generation of ATL Derivatives: ATL313 Chemical Structure: 4-(3-(6-amino-9-(5-cyclopropylcarbamoyl-3,4 dihydroxy tetra hydrofuran-2-yl)-9H-purin-2-yl)prop-2-ynyl) piperidine-1- carboxylic acid methyl ester In collaboration with Adenosine Therapeutics Inc., Dr. Linden et al. designed and characterized a series of derivatives of Stedivaze. In 2007, they conducted radioligand binding experiments which yielded the following ranked order of affinity: ATL313 (IC50 ¼ 1.9 nM) > ATL309 and ATL310 > ATL202 [137]. This class of compounds offers an additional improvement from Stedivaze, with 100-fold higher
252
S. Tilley et al.
affinity for the A2AR than CGS21680. Functional assays conducted with equine neutrophils showed that all these compounds stimulate cAMP formation, and inhibit the production of reactive oxygen species induced by LPS, while respecting this order of potency. Their therapeutic potential for respiratory diseases was first tested with ATL202 in a model of LPS-induced lung injury [138]. Most animal studies, described in Chaps. 8 and 9, were conducted by giving the drug before the challenge. In the present work, the authors compared the efficiency of aerosolized ATL202 given before or after aerosolized LPS. They showed that both strategies significantly decreased the number of neutrophils and cytokine concentrations measured in the BAL fluid. On the other hand, ATL202 only reduced extravasation when administered before a challenge. This experimental design is critical to identify the best delivery route for a specific treatment. The most promising ATL derivative is ATL313, which exhibits a 100-fold higher selectivity for A2ARs than for A1Rs and A3Rs. Since 2007, more than 30 studies have been published on this ligand. This section reviews only those addressing the impact of ATL313 on lung injury and inflammation. Linden’s group conducted a series of ex vivo and in vivo experiments to test whether the vascular administration of ATL313 protects the lungs against ischemia-reperfusion injury, which remains a major complication after organ transplant. In the first study, they used isolated, buffer-perfused murine lungs to determine whether the therapeutic potential of ATL313 targets the resident cells [139]. Their model of ischemiareperfusion significantly impaired pulmonary functions (higher airway resistance and pulmonary artery pressure, lower compliance), caused extensive tissue injury (vascular leakage and edema) and lung inflammation (BAL levels of TNFa, KC, MIP-2 and RANTES). These lung complications were all significantly attenuated by a bolus dose of ATL313 (30 nM) added to the perfusate at the onset of reperfusion. This dose had no significant effect on the lung functions or hemodynamics of control animals. The specificity of the receptor agonist was demonstrated using lung isolated from A2AR/ mice, which showed no reduction in lung complications in response to ATL313. The fact that vascular ATL313 attenuated lung inflammation in the absence of circulating blood reiterates the critical role of the A2AR for the maintenance endothelial barrier integrity (see Chap. 8, Fig. 8.1). As such, ATL313 administered intravenous before the surgical procedure may significantly improve the outcome of lung transplant. In Chap. 8, we provided evidence that all four ADO receptors mediate protection against vascular leakage, edema and inflammation in models of acute lung injury, such as ischemia-reperfusion (Table 9.1). Therefore, experiments were conducted to determine the relative potency of ATL313 using isolated, blood-perfused lungs infused with a selective agonist/antagonist of the A1R (CCPA/DCPCX), the A2AR (ATL313/ZM241385) or the A3R (IB-MECA/MRS1191) during reperfusion [140]. As expected, all receptor agonists significantly improved the lung functions (increased compliance and oxygenation, and decreased pulmonary artery pressure), reduced edema and inflammation (BAL levels of neutrophil
9 Therapeutic Applications
253
myeloperoxidase and TNFa), compared to the untreated animals. When each agonist was paired with its antagonist, the protective effects were lost. More importantly, the ATL313 treatment improved lung functions and reduced neutrophil recruitment more efficiently than the A1R and A3R agonists, supporting a superior protective effect during lung transplant. In another study, these authors used the same protocol to show that the addition of ATL313 1 h before ischemia offers the same degree of protection [141]. Together, these studies suggest that ATL-313 infusion before, or at the time of transplant, may protect the lungs against the development of injury and rejection. Incidentally, this drug was reported to improve the outcome of organ islet transplant [142], supporting broad applications for clinical transplantation. Another surgical application currently proposed for ATL313 is the protection of patients against the post-operative trauma caused by cardiopulmonary bypass. In the rats subjected to this procedure, addition of ATL313 to the blood priming solution completely prevented the development of lung edema, tissue injury and inflammation (IL-1b, IL-6, IFNg, and neutrophil myeloperoxidase activity) [143]. This study suggests that ATL313 may prevent acute lung injury caused by cardiopulmonary bypass. The protective anti-inflammatory effect of ATL313 during ischemia-reperfusion extends beyond the lungs’ resident cells [144]. In mice subjected to hilar occlusion, the intravenous injection of ATL313 before the onset of reperfusion significantly preserved lung function and prevented vascular leakage, compared to control animals. Based on BAL neutrophil myeloperoxidase activity and immunohistochemistry, ATL313 was also shown to inhibit the infiltration of neutrophils and CD4+ T cells during reperfusion. It is common knowledge that the number of circulating neutrophils is regulated by IL-17A, a cytokine released by the CD4+ T lymphocytes (review: [145]). The mice subjected to ischemia-reperfusion, after depletion of the CD4+ T cells or neutrophils, had significantly reduced lung injury, but ATL313 did not provide additional protection. In contrast, the BAL fluid levels of IL-17, KC, MCP-1, MIP-1 and RANTES were significantly lower in the neutrophil- and CD4+ T cell-depleted mice, but only further reduced by ATL313 in the neutrophil-depleted mice. This study demonstrates that ATL313 attenuates acute lung injury and inflammation by inhibiting the secretion of IL-17 by CD4+ T cells, and the subsequent neutrophil recruitment to the lungs. This A2AR agonist is currently the focus of negotiations between Clinical Data Inc. and Santen Pharmaceutical Co. regarding ophthalmic diseases, while Clinical Data Inc. is reserving the rights to explore other applications. In this section, all A2AR agonists evaluated for the treatment of chronic respiratory diseases were intensely scrutinized with respect to cardiovascular side-effects, especially hypotension. Yet, in the case of acute insults, such as surgical procedures or trauma, the above studies suggest that short-term vascular administration of an A2AR agonist would essentially normalize the arterial blood pressure raised by ischemia-reperfusion. Thus, a detrimental property for chronic lung diseases may be beneficial for acute lung injury.
254
9.4.3
S. Tilley et al.
The A2BR Antagonists
The animal models of chronic respiratory diseases revealed that A2BR activation promotes BHR, inflammation, mucin hypersecretion, airway remodeling, fibrosis and emphysema (see Chap. 8 for details). This impressive portfolio suggests that A2BR antagonists may address all major pulmonary complications of patients diagnosed with asthma, COPD and fibrotic pulmonary diseases. In terms of delivery, inhalation should be avoided to preserve the A2BR-mediated airway clearance of mucins and pathogens (see Chap. 5 for details). Pharmaceutical companies have selected three A2BR antagonists, which are now emerging in the pipeline. The report that A2BR expression increases with disease severity in COPD and IPF [146] should be taken into consideration during clinical trials with respect to the targeted population and expected therapeutic index.
9.4.3.1
Comparing CVT-6883 and Montelukast
Chemical Structure: [3-ethyl-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol4- yl]-3,7-dihydropurine-2,6-dione] Over the past 5 years, chemists at CV Therapeutics synthesized a large number of Theophylline derivatives in search of a selective A2BR antagonist for the treatment of asthma (review: [147]). Based on binding assays, they selected CVT-6883, which has an affinity for A2BRs (Ki ¼ 8 nM) at least 1,000-fold higher than for the other ADO receptors [148]. In various human cell lines, CVT-6883 inhibits cAMP production induced by the stable ADO analog: N-ethyl-carboxamidoadenosine (NECA). The pharmacodynamic and pharmacokinetic properties of CVT-6883 were determined in the rat. An oral dose of 2.0 mg/kg displayed an excellent systemic exposure, a Cmax of 1,100 ng/ml, a dose adjusted under the curve of (dAUC) of 6,500 ng.h/ml, and a half-life of 4 h. The preclinical evaluation of CVT-6883 was conducted in mice using the ragweed sensitization/challenge model of allergic asthma [149]. The intraperitoneal injection of CVT-6883 completely prevented airway hyperresponsiveness to aerosol AMP, the pro-drug of ADO. Interestingly, CVT-6883 was as potent as an optimal dose of Montelukast [112], the cysteinyl leukotriene-1 receptor antagonist currently prescribed to asthmatic patients (review: [113]). The intraperitoneal delivery of CVT-6883 also inhibited the late allergic responses of these mice to ragweed for at least 5 h. On the other hand, the authors chose aerosol delivery to compare the anti-inflammatory properties of CVT-6883 and Theophylline. The drugs were nebulized prior to the last aerosol ragweed challenge, and the BAL fluid analyzed after 5 h. The optimal dose of each drug reduced total cell counts by nearly 50%. While they were similarly efficient in suppressing eosinophil recruitment, only CVT-6883 significantly reduced the lymphocyte counts. Therefore, aerosol CVT6883 shows promises for the treatment of inflammation in allergic asthma.
9 Therapeutic Applications Table 9.3 Antagonists of A2BRs in the pipeline Delivery Proof of Drug Disease route concept CVT-6883 Asthma Oral
255
Preclinical
Phase Phase 1 2a
Phase 2b
Phase 3
MRE 2029- Inflammation F20 LAS38096
Asthma
Oral
The potential of long-term treatment with CVT-6883 to resolve all complications of chronic respiratory diseases was addressed using an animal model which develops the airway hyperresponsiveness, inflammation, remodeling, fibrosis and alveolar destruction: ADA-deficient mice [148]. The 14-day treatment consisted of intraperitoneal injections, administered twice daily to animals after they developed significant lung complications. The CVT-6883-treated mice presented significantly reduced airway inflammation (BAL cytokine levels, lymphocytes, eosinophils, neutrophils and macrophages), fibrosis (a1-procollagen and collagen deposition) and alveolar airspace enlargement. These results support substantial benefits for the long-term treatment of chronic lung diseases. In 2008, CV Therapeutics had completed two randomized, single-blind, placebo-controlled, ascending dose clinical trials, in which CVT-6883 was determined to be safe and well tolerated by healthy volunteers [150]. The pharmacokinetic data support the use of one daily oral dose of CVT-6883 for the long-term treatment of chronic respiratory diseases (Table 9.3). This delivery route would also minimize the inhibitory effect of A2BR antagonists on the airway clearance of mucin and pathogens (see Chap. 5 for details). In 2009, Gilead took over CV Therapeutics, which may cause a reorganization of their priorities, with respect to the drugs currently in the pipeline.
9.4.3.2
Anti-Inflammatory MRE 2029-F20
Chemical Structure: N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy] acetamide In 2004, Baraldi et al. announced that they synthesized a large number of xanthine derivatives as potential A2BR antagonists [151]. The most selective compound was named MRE 2029-F20 (KiA2BR ¼ 5.5 nM; KiA1R ¼ 200 nM; KiA2AR, A3R > 1,000). Using isolated human neutrophils, lymphocytes or mast cells, MRE 2029-F20 was shown to inhibit the NECA-mediated cAMP production with IC50 values in the low nanomolar range, which supported a potent anti-inflammatory property. Therefore, MRE 2029-F20 was selected for further evaluation by King Pharmaceuticals [151]. In 2005, Borea et al. developed a radiolabelled MRE 2029-F20 [152, 153], which has been instrumental in the discovery that A2BR expression rises with disease
256
S. Tilley et al.
severity in the lungs of COPD patients [118]. In recombinant systems, tritiated MRE 2029-F20 binds selectively to A2BRs, with KD values around 2 nM [153]. The same year, they tested the selectivity of MRE 2029-F20 in a human melanoma cell line [154]. The cell proliferation induced by the selective A3R agonist, Cl-IB-MECA, was not inhibited by this A2BR antagonist. Preclinical data in animal models have not yet been reported for this bioagent.
9.4.3.3
LAS38096 for the Treatment of Asthma
Chemical Structure: 4’-(2-furyl)-N-pyridin-3-yl-4,5’-bipyrimidin-2’-amine In 2007, a third compound, LAS38096 was discovered by Almirall Prodesfarma, which exhibits high affinity and selectivity for the A2BR (KiA2BR ¼ 17 nM; KiA1R > 1,000 nM; KiA2AR > 2,500 nM; and KiA3R > 1,000 nM) [155]. In heterologous systems expressing human or murine A2BRs, LAS38096 inhibited NECA-mediated cAMP production with IC50 values in the 320–350 nM range. The capacity of LAS38096 to inhibit inflammatory responses was tested using human and mouse dermal fibroblasts. The bioagent induced a dose-dependent decrease in NECAmediated IL-6 secretion, with IC50 values of 340 and 640 nM, respectively [155]. These data demonstrate that LAS38096 is a functional A2BR antagonist with similar affinity on the human and murine receptor. The pharmacokinetic parameters of an oral dose of LAS38096 were determined in the rat, mouse and dog [155]. The drug exhibited excellent bioavailability in all species. It was absorbed rapidly (tmax < 60 min), with an AUC of 4.0 mM.h and a moderate-to-high plasma clearance. The efficacy of LAS38096 was tested in vivo in the OVA sensitization/challenge model of allergic asthma [156]. Mice treated with the bioagent showed significantly less airway hyperresponsiveness, mucus production, eosinophil infiltration and OVA-specific IgE in the BAL fluid than untreated animals. LAS38096 has been advanced for evaluation of safety and toxicology.
9.4.4
The A3R Agonists
The terms “complex” and “enigmatic” are frequently ascribed to the A3R because this receptor has been shown to induce inflammatory and anti-inflammatory responses (review: [157]). For instance, it stimulates neutrophil chemotaxis, but inhibits eosinophil recruitment to the airways. Nonetheless, A3R-mediated responses are predominantly anti-inflammatory, as demonstrated by the knockout mouse (see Chap. 8 for details). Thus, while agonists and antagonists are available as pharmacological agents, only agonists are currently tested for the treatment of chronic inflammatory disorders.
9 Therapeutic Applications
257
Over the last decade, new approaches have been introduced for the treatment of autoimmune diseases (review: [158]). Among the most potent drugs, TNFa antibodies are prescribed for arthritis, psoriasis and Crohn’s diseases. However, to block all TNFa-mediated inflammatory responses compromises host defenses and causes severe adverse effects. Recent studies revealed that the secretion of TNFa from inflammatory cells is inhibited by ADO acting selectively on A3Rs [159, 160]. Since the A3R is not expressed on airway epithelial cells, this approach may reduce lung inflammation by focusing on non-resident cells, with minimal effects on defenses mediated by the epithelial barrier. Major concerns about the use of aerosolized A3R agonists were fueled by reports of BHR in murine models [45–48]. However, it is important to mention that histamine secretion is mediated by A2BRs in canine and human mast cells [49–51], which motivated the use of canine models for the evaluation of A3R agonists as anti-inflammatory agents. Furthermore, our current understanding of ADO-mediated BHR in asthmatics supports an A1R-mediated neural signal upstream from mast cell activation (see Sect. 9.2). As such, the A3R-mediated bronchospasms observed in murine models of asthma are not expected in human subjects. Hopefully, these precisions will stimulate the pharmaceutical industry to develop selective A3R agonists for chronic inflammatory lung diseases.
9.4.4.1
Rebirth of IB-MECA as CF101
Chemical Structure: 1-deoxy-1-[6-[[(iodophenyl)methyl]amino]9H-purine-9-yl]-Nmethyl-(-D-ribofuranuronamide) We owe a dept of gratitude to Dr. Kenneth A. Jacobson, who devoted his career to the development of ADO receptor ligands (review: [99]). In 1993, he designed the first selective A3R agonist, IB-MECA, which has been used in over 300 in vitro and in vivo studies. This metabolically stable molecule binds and activates the human A3R with an affinity (Ki ¼ 0.5 nM) 1,000-fold higher than on the other ADO receptors (review: [157]). In 2000, Dr. Pnina Fishman obtained an exclusive license for IB-MECA, which was renamed CF101, and launched the company Can-Fite Biopharma. The therapeutic potential of CF101 for lung complications was assessed mainly in models of acute lung injury. In isolated, blood-perfused rabbit lungs subjected to 18 h of cold ischemia, the addition of CF101 before reperfusion improved lung compliance and oxygenation, without affecting arterial pressure [140]. With respect to the inflammatory mediators measured in the BAL fluid, the A3R agonist reduced TNFa concentrations by 50% and neutrophil myeloperoxidase activity by 30%. Acute lung injury, quantified in terms of vascular leakage and edema, was also significantly lower in the animals treated with CF101. This study highlights the pleitropic protective effects of intravenous CF101 against acute lung inflammation and injury initiated by episodes of ischemia-reperfusion. Interestingly, Methotrexate was recently shown to enhance the anti-inflammatory
258
S. Tilley et al.
effects of CF101 by causing an up-regulation of the A3R on monocytes and macrophages [161], which could offer additional clinical benefits for the treatment of acute lung injury. The signaling mechanisms by which CF101 protects the lungs against injury and apoptosis during ischemia-reperfusion were investigated in spontaneously breathing cats [162, 163]. The presence of systemic CF101 during reperfusion significantly reduced the acute lung injury (% injured alveoli, wet/dry weight ratio) and apoptosis (TdT-mediated dUTP nick-end labeling positive cells and caspase 3 activity). Using selective inhibitors, the protective effects of CF101 were found to require ATP-sensitive K+ channels, but not nitric oxide production [163]. The signaling pathways activated by CF101 were identified by monitoring the expression of major protein kinases by SDS-PAGE and Western blot analysis of lung tissue specimens [162]. The A3R agonist induced a gradual up-regulation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2), but not the c-Jun amino-terminal protein kinase (JNK) or p38. Injection of a selective A3R antagonist (MRS1191), before CF101, abolished the response of ERK1/2 without affecting p38 and JNK. These data suggest that the CF101-A3R signals are mediated predominantly by the ERK1/2-dependent pathways. However, A3Rs have been reported to regulate apoptosis via other signaling cascades, such as the phosphoinositide-3 kinase (PI3K)-dependent pathway (review: [157]). Therefore, future studies should verify the impact of selective ERK1/2 inhibitors on the acute lung injury and inflammation caused by ischemia-reperfusion. In two controlled, double-blind, single ascending Phase 1 clinical trials conducted on healthy subjects, oral CF101 was demonstrated to be safe and well tolerated [164]. In oral solution, CF101 was readily absorbed (Tmax ¼ 1–2 h) with a half-life of 9 h. In December 2010, Can-Fite BioPharma announced that CF101 entered Phase 2 or 3 clinical trials for the treatment of cancer, dry eye syndrome, psoriasis and rheumatoid arthritis (Table 9.4). They retained the services of Plexus Ventures for the identification of a partner to support the clinical development and commercialization of CF101 in the United States and Europe, while it is already licensed in Japan and South Korea. Table 9.4 Agonists of A3Rs in the pipeline Drug CF101 (IBMECA)
Disease Acute lung injury
Proof of PrePhase Phase Delivery route concept clinical 1 2a Intravenous
Arthritis Oral psoriasis CF102 (Cl-IBMECA)
Sepsis
Intraperitoneal
Liver Oral diseases
CF502 Acute lung (MRS3558) injury
Intraperitoneal
Phase 2b
Phase 3
9 Therapeutic Applications
9.4.4.2
259
The More Selective Cl-IB-MECA (CF102)
Chemical structure: 2-chloro-N6-(3-lodobenzyl)-adenosine-5’-N-methyluronamide Can-Fite BioPharma is also evaluating the potential of Cl-IB-MECA (CF102), a more selective analogue of IB-MECA (CF101) with binding affinities of 1.4 nM for the A3R, compared to 220 nM for the A1R, and 5,400 nM for the A2AR (review: [157]). Like his close relative, CF102 has been widely used as a pharmacological agent to identify the complex pharmacological properties of the A3R in mammalian tissues. Wagner et al. tested the impact of CF102 on the lung inflammation induced by aerosolized LPS in wild-type and A3R/ mice [165]. The endotoxin induced a linear increase in A3R expression over time in whole lung tissue, reaching sixfold above the baseline after 3 h. In addition, LPS inhalation stimulated leukocyte recruitment into the pulmonary vasculature, lung tissue and airspace. Pretreatment by intraperitoneal injection of CF102 significantly reduced the number of leukocytes in all compartments in the wild-type mice, but not in the A3R/ mice. The CF102 treatment significantly reduced the levels of inflammatory cytokines (TNFa and IL-6) in the BAL fluid of LPS-exposed wild-type mice. In accordance with the barrier protective role of A3Rs during acute lung injury (see Chap. 8 for details), CF102 suppressed the LPS-induced vascular leakage in wild-type mice. One foreseeable side-effect of intraperitoneal CF102 is the enhancement of neutrophil migration speed (review: [166]). Nonetheless, the ligand did not affect the leukocyte counts in the pulmonary vasculature in the control and LPS-exposed animals. In November 2010, Can-Fite Biopharma completed a Phase 1 clinical trial to assess the safety and pharmacokinetic behavior of CF102 in patients with advanced liver cancer. The patients received oral doses of 1, 5 or 25 mg (twice daily) over 28 days. Overall, the drug is safe and well tolerated at doses up to 25 mg, shows good oral bioavailability and linear pharmacokinetic behavior. Also, patient infected with hepatitis virus C experience a significant reduction in virus titer with CF102, consistent with its preclinical anti-viral activity. This A3R agonist hold promises as a novel therapeutic strategy in the treatment of cancer and viral infections.
9.4.4.3
New Generation MRS3558 (CF502)
Chemical Structure: [(10 R,20 R,30 S,40 R,50 S)-4-{2-chloro-6-[(3-chlorophenylmethyl) amino] purin-9-yl}-1-(methylaminocarbonyl)bicyclo [3.1.0] hexane-2,3-diol] A novel A3R agonist, CF502, was recently synthesized at the National Institutes of Health (review: [157]). This molecule displays enhanced selectivity and specificity with >1,000-fold more affinity for the A3R than the A1R, A2AR, and A2BR. Functionally, this molecule represents a significant improvement from the first generation compounds. In the breathing cat model of ischemia-reperfusion, CF502 was found more efficient than CF101 against acute lung injury [162].
260
S. Tilley et al.
Jacobson et al. used the breathing cat model of ischemia-reperfusion to assess the potential of CF502 for the treatment of acute lung injury [167]. Interestingly, the sedated animals were monitored over 27 h of reperfusion, instead of the usual <3 h, to determine the long-term effects of ischemia-reperfusion and CF502. The immediate responses to in vivo ischemia-reperfusion were inflammation, apoptosis and edema, restricted to the left lobe subjected to ischemia. After 27 h of reperfusion, this lobe became more edematous, with evidence of hypoxemia, but exhibited less apoptosis and no change in inflammation. The control perfused right lobe presented edema after 27 h, suggesting a systemic effect of ischemia-reperfusion. The animals treated with one bolus dose of CF502, added to the left lobe perfusate during ischemia, developed milder inflammation and injury during at least 27 h of reperfusion. In addition, CF502 further reduced the parameters of apoptosis from the 3 h, to the 27 h, reperfusion time-point. Finally, this treatment also protected the lungs against the increase in blood pressure caused by ischemia-reperfusion. This study supports long-term clinical benefits for a bolus dose of CF502 during surgical procedures associated with acute lung injury, such as organ transplant. Can-Fite Biopharma is currently developing CF502 as a second generation antiinflammatory drug.
9.4.5
Crossing Swords with Other Therapies
9.4.5.1
Aspirin-Intolerant Asthma and Adenosine
Acetyl salicylic acid (ASA; aspirin) has been used for decades for the treatment of various inflammatory conditions. However, a subset of asthmatic patients exhibit violent allergic reactions to this common drug (review: [168]). Aspirin-intolerant asthma, also known as ASA-exacerbated respiratory disease, is associated with aspirin-induced BHR and a severe eosinophilic inflammation of the upper and lower airways, which maintains chronic rhinitis, sinusitis and polyposis. This disease is caused by an aberrant metabolism of arachidonic acid (review: [169]). The two products, prostaglandins and leukotrienes, bind to specific cell surface G protein-coupled receptors to orchestrate airway defenses. Prostaglandins stimulate mucociliary clearance, inhibit the development of fibrosis and the activities of inflammatory cells. In contrast, leukotrienes promote the recruitment and activation of inflammatory cells, mucus secretion, vascular permeability, fibrosis and bronchoconstriction. In aspirin-intolerant asthmatic patients, the metabolic balance of arachidonic acid is tilted toward leukotrienes, which leads to dramatic increases in the airway concentrations following ASA exposure (review: [170]). A recent clinical study suggests that ASA-induced leukotriene accumulation in exhaled breadth condensate may constitute a diagnostic tool to identify the aspirin-intolerant asthmatic patients [171]. In 2009, Kim et al. compared aspirin-tolerant and -intolerant asthmatics for the presence of single nucleotide polymorphisms (SNPs) in the sequences of
9 Therapeutic Applications
261
ADA and the ADO receptors [172]. Using multivariate logistic regression analysis, they compared the frequencies of SNP genotypes and haplotypes in 136 aspirinintolerant asthmatics, 181 aspirin-tolerant asthmatics and 183 normal individuals. They identified SNPs specific to the A1R and the A2AR which were significantly associated with aspirin intolerance. This survey suggests that airway ADO may contribute to the allergic reactions. In 2010, Moon et al. provided evidence that ASA exacerbates lung eosinophilic inflammation by interfering with ADO regulation [173]. In this study, murine models of asthma were developed by intraperitoneal sensitization with OVA or OVA/LPS, followed by OVA challenges. Only the OVA/LPS-sensitized mice responded to intraperitoneal ASA by developing the aspirin-intolerant asthma phenotype of severe eosinophilia in the upper and lower tissue, and in BAL fluid. Since eosinophils represent <10% of all cells recruited to the airways, their response to ASA would be overlooked by total cell counts. Interestingly, ASA also caused a dramatic increase in lung ADO levels in the OVA/LPS mice. Expression analysis of the enzymes regulating ADO indicated that LPS selectively up-regulates ADA. This protective mechanism against excess ADO was obliterated by ASA. In addition, ASA-treated OVA/LPS mice accumulated lung IL-13, which has been shown to maintain an ADO/IL-13 amplification cycle by suppressing ADA expression (see Chap. 8 for details). These data predict that aspirin-intolerant asthmatic patients maintain higher airway ADO concentrations than the other asthmatics. This excess lung ADO, exacerbated by ASA, caused a down-regulation of Th17 responses via A1R and A3R engagement [173], which shifted the lung inflammation from a neutrophilic to an eosinophilic phenotype. Collectively, these studies suggest that ASA intolerance results from the combined bronchoconstrictive effects of excess ADO accumulating in the airways of all asthmatics, and the high leukotriene concentrations reported only in the aspirinintolerant subjects. Furthermore, the high ADO levels are expected to contribute to the severe eosinophilic inflammation through modulation of Th17 cell functions. As such, treatments reducing airway ADO levels (see Sect. 9.3) would be particularly beneficial for these patients.
9.4.5.2
Hypertonic Saline and the A2AR/A3R Balance
During severe trauma or elaborate surgical operations, like organ transplantation, the massive release of cytotoxic mediators by activated neutrophils causes major lung complications, such as acute lung injury and acute respiratory distress syndrome (ARDS). Since the early 1980s, resuscitation by small-volume injection of hypertonic saline (HS; 7.5% NaCl/6% dextran 70) is routinely performed to attenuate neutrophil-related trauma (reviews: [174, 175]). This procedure stems from several in vitro studies showing that HS inhibits neutrophil degranulation. However, some patients respond to HS resuscitation by an exacerbation of the complications. In a murine model of hemorrhagic shock, an early HS resuscitation prevented lung tissue damage, whereas delayed treatment aggravated the
262
S. Tilley et al.
complications [176]. Since early treatments rarely occur within clinical settings, a better understanding of HS-mediated neutrophil activation was required to design resuscitation regimens that would minimize the risks of side-effects. Junger et al. demonstrated that the dual regulation of neutrophil degranulation by HS is caused by a shift in ADO receptor expression during cell activation [125]. Naı¨ve neutrophils express predominantly A2ARs, which inhibit cell degranulation by cAMP-dependent signaling pathways (review: [166]). Their stimulation by bacterial products, like formyl methionyl-leucyl-phenylalanine (fMLP), induces the expression and surface translocation of A3Rs, which stimulate degranulation by inhibition of cAMP production. Junger et al. showed that HS treatment of human neutrophils, before fMLP, prevented A3R induction and cell degranulation, whereas HS treatment after fMLP enhanced the A3R-mediated release of cytotoxic compounds [177]. In a model of sepsis, the addition of an A3R antagonist (MRS1191) to the HS solution enhanced the beneficial effects of resuscitation by avoiding the side-effects resulting from delayed administration [125]. This study supports a new therapeutic application for MRS1191 administration during HS resuscitation procedures, which may be required during lung transplant.
9.4.6
Summary
Finally, we have acquired sufficient maturity in the evaluation of ADO receptor ligands for the treatment of acute and chronic lung complications to formulate general principles and guidelines. With respect to A1Rs, the pharmaceutical industry understands the need to administer antagonists to suppress pulmonary inflammation (Table 9.1). The first two compounds developed, Theophylline and Bamiphylline, are currently available as oral prescriptions for asthmatic and COPD patients. On the other hand, the nebulized antisense oligodeoxynucleotide, EPI-2010, designed to remain in the airways to address BHR presented no clinical benefit in clinical trials. The story of Theophylline discovery tells us that the bronchodilating properties of the drug were mediated by the non-specific inhibition of phosphodiesterase. While in vitro and animal studies support a role for A1Rs in BHR, the importance of this mechanism in human subjects remains to be determined. With respect to A2ARs, everyone agrees on the benefits of selective agonists, but dosages which avoid cardiovascular side-effects (i.e. hypotension) were shown ineffective in the clinical trials, regardless of the selectivity or affinity of the compound (Table 9.2). On the other hand, these agonists hold promises for the reduction of lung complications resulting from cardiopulmonary bypass or lung transplant. The three A2BR antagonists selected for clinical evaluation all remain in the pipeline and the choice of oral delivery is consistent with the need to preserve A2BR-mediated airway clearance (Table 9.3). Finally, the highly controversial A3R is targeted for the development of selective agonists, which appear to provide effective anti-inflammatory protection for various disorders, including arthritis and psoriasis. Given the recent success of these drugs in animal models of lung disorders, clinical testing should be on the horizon.
9 Therapeutic Applications
9.5
263
Clinical Trials Involving ATP Receptors
The vast majority of the P2 receptor ligands selected for clinical applications are P2Y12R antagonists which target cardiovascular disorders and coagulation, including PLAVIX (clopidogrel; Sanofi Aventis/Bristol-Myers Squibb), Cangrelor (The Medicines Co.), Ticagrelor (AstraZeneca) and Eelinogrel (Portola/Norvatis). Among the receptors expressed along the airways, only one P2Y2R ligand is currently the subject of clinical trials for chronic respiratory diseases: denufosol (Inspire Pharmaceutical). This section also describes the first application of soluble apyrases to the treatment of lung injury.
9.5.1
The P2Y2R Agonist Denufosol and Airway Clearance
The most promising therapeutic approaches currently developed for the treatment of CF are designed to improve mucociliary clearance (MCC), a process which combines the activities of ion channels and transporters expressed at the surface of airway epithelia (see Chap. 5 for details). This disease is driven by a severe dehydration of the airway surfaces due to mutations in the cystic fibrosis transmembrane regulator (CFTR). The restoration of airway surface hydration would facilitate cilia beating, dislodge adhesive mucus plaques and facilitate MCC (review: [178]). The current strategy explored by the company Inspire Pharmaceutical is centered on P2Y2Rs, because their engagement can bypass the defective CFTR Cl channel by activating the Ca2+-activated Cl channel. The resulting osmotic gradient causes water to leave the cells to hydrate the surface. A decade of research conducted in collaboration between Inspire Pharmaceutical and the Cystic Fibrosis Pulmonary Research/Treatment Center (NC, USA) demonstrated the therapeutic potential of metabolically-stable P2Y2R agonists (review: [179]). Their original work showed that the endogenous selective agonist, UTP, is highly unstable on human airway surfaces [180]. Therefore, they turned to dinucleotides because the tertiary structure offers more stability to the phosphate chain. From this first round of synthesis, they selected the potent P2Y2R agonist: Up4U (INS365; diquafosol). This molecule was further stabilized by substituting one uridine moiety by a deoxycytidine, which generated dCP4U (INS37217; denufosol) [180, 181]. The affinity of denufosol for the P2Y2R (EC50 ¼ 0.3 mM) is over five times higher than for the other P2 receptors activated by uridine-based agonists on airway epithelia, namely the P2Y4R (EC50 ¼ 1.2 mM) and the P2Y6R (EC50 ¼ 16.0 mM) [181]. Preclinical studies demonstrated that denufosol restores normal surface hydration on cultures of human airway epithelial cells from CF patients, and also improves MCC in animals with impaired clearance [180, 181]. Given the severe lung complications experienced by CF patients, the tolerability of aerosolized denufosol was first tested in healthy subjects and smokers. The randomized double-blind placebo-controlled study, conducted with a wide concentration range (20–200 mg), provided evidence of tolerability and set the stage for clinical testing in CF.
264
S. Tilley et al.
In 2005, they conducted a double-blind, placebo-controlled, multicenter clinical trial to test the safety and tolerability of aerosolized denufosol in adult and pediatric (5–17 years of age) CF subjects [182]. Ascending single doses (10, 20, 40, and 60 mg) were followed by twice-daily administration of the maximum tolerated dose for 5 days. In summary, doses up to 60 mg of denufosol were well-tolerated by most subjects. In 2007, Inspire Pharmaceutical and the Therapeutics Development Network of the Cystic Fibrosis Foundation presented results of a multicenter Phase 2 safety and efficacy clinical trial for denufosol inhalation in CF subjects with mild disease (FEV1 > 75% of predicted) [183]. The randomized, double-blind, placebocontrolled study showed that 20–60 mg denufosol significantly improved lung functions during 28 days. This study provided the first evidence of clinical benefit for denufosol. In 2008, a placebo-controlled Phase 3 clinical trial (TIGER-1) tested the impact of 60 mg denufosol on 350 adolescent CF patients with FEV1 75% of predicted. Results showed that TIGER-1 met the primary end-point, with significant improvement of FEV1 from baseline compared to the placebo group, and with limited systemic exposure. This study supports the therapeutic potential of early interventions with denufosol, in young CF patients, to prevent the accelerated loss of lung function. In November 2009, Inspire Pharmaceuticals completed the patient enrollment for the second Phase 3 clinical trial (TIGER-2). This randomized, double-blind, placebo-controlled study of 48 days will test the long-term clinical benefits of 60 mg aerosolized denufosol in 450 patients with mild CF lung disease (FEV1 75% of predicted). Results are expected to become available in the first quarter of 2011.
9.5.2
APT102: A Soluble Apyrase for Acute Lung Injury
Endothelial cells are well known to express the membrane-bound surface enzyme named the ecto nucleoside diphosphate triphosphohydrolase1 (NTPDase1; CD39). This enzyme is responsible for limiting thrombus formation through dephosphorylation of the circulating ATP/ADP released by activated platelets and red blood cells (review: [184]). Numerous in vivo and in vitro studies showed that oxidative stress caused by ischemia-reperfusion causes a dramatic down-regulation of endothelial CD39 (review: [185]). The potential of enzyme replacement therapy for cardiovascular and pulmonary diseases was originally tested using a soluble form of CD39 (apyrase) derived from the potato [186]. Eventually, the growing interest for therapeutic applications motivated the development of soluble human CD39 (review: [184]). In 2006, Medina et al. generated a soluble recombinant apyrase named APT102 [187]. They demonstrated that APT102 inhibits tumor cell-induced platelet aggregation in colon cancer, which provided evidence of functional expression.
9 Therapeutic Applications
265
In 2008, APT Therapeutics determined the pharmacokinetic properties of APT102. [188]. Rats received a bolus intravenous injection (0.75 mg/kg), then serum samples were collected over time to monitor the metabolism of ATP and ADP using a malachite green assay. After 24 h, the enzyme activity remained tenfold above baseline, with a half-life of about 20 h. This study demonstrated the potential of a bolus injection of APT102 for the prevention of acute lung injury caused by trauma or extensive surgical procedures. This success prompted APT Therapeutics to test whether APT102 could protect the lungs during their transport and transplant [189]. They preserved rat lungs in cold low K+ dextrose solution in the absence or presence of APT102 for 18 h before transplant. After the procedure, the recipients received a bolus dose of saline or APT102. Four hours later, the lungs that received APT102 showed significantly less damage (apoptotic endothelial cells and pulmonary edema) and were better oxygenated than the untreated transplanted lungs. The apyrase also attenuated lung inflammation, in terms of neutrophil infiltration and BAL fluid concentrations of pro-inflammatory mediators and myeloperoxidase. This study supports that APT102 can limit lung damage during prolonged cold storage and significantly improve the outcome of lung transplantation. In 2009, APT Therapeutics received an award to evaluate therapeutic applications of human apyrase.
9.6
Conclusion
This final chapter is a testimony to the concerted efforts of research laboratories and pharmaceutical companies to develop therapeutic approaches safe and effective for the entire asthmatic population, as well as patients with COPD or fibrotic lung diseases. We have reached a point where we can learn from success stories and failures to refine our drug development strategies. For instance, we heard about the potential of the “low-hanging fruits”, like Adagen (PEG-ADA) initially developed for ADA-SCID. The tale of the A1R antagonist, Theophylline, shows how revisiting the properties of an inefficient bronchodilator lead to the discovery of a welltolerated anti-inflammatory drug currently prescribed to asthmatics, in combination with a b-adrenergic bronchodilator. While A2AR agonists were once perceived as the most promising anti-inflammatory drugs for chronic respiratory diseases, the frequent reports of cardiovascular side-effects are redirecting these compounds toward surgical applications, to prevent the hypertension and acute lung injury resulting from ischemia-reperfusion. Our gaze is turned toward A2BR antagonists for the suppression of airway hyperresponsiveness. Furthermore, animal studies suggest that long-term treatments could reverse airway remodeling and fibrosis in chronic airway diseases. Finally, clinical trials support the benefits of A3R agonists for inflammatory disorders and acute lung injury. Therapeutic applications for ATP receptor ligands are also emerging. For instance, denufosol has entered the final stage of clinical evaluation for the improvement of P2Y2R-mediated airway
266
S. Tilley et al.
clearance in CF patients. And animal studies suggest that P2X7R antagonists may suppress the production of the “first wave” pro-inflammatory mediator, IL-1b, as well as tissue damage by apoptosis. In conclusion, we are clearly witnessing the maturation of a young field of clinical research which will, no doubt, continue to fascinate and surprise us for years to come.
References 1. Cushley M, Tattersfield A, Holgate S (1983) Inhaled adenosine and guanosine on airway resistance in normal asthmatic subjects. Br J Clin Pharmacol 15:161–165 2. Driver AG, Kukoly CA, Ali S, Mustafa SJ (1993) Adenosine in the bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148:91–97 3. Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G, Herjavecz I, Horvath I (2002) Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 20:1393–1398 4. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Durk T, Zissel G, Ferrari D, Di Virgilio F, Sorichter S, Lungarella G, Virchow JC, Idzko M (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934 5. Esther CR Jr, Alexis NE, Clas ML, Lazarowski ER, Donaldson SH, Ribeiro CM, Moore CG, Davis SD, Boucher RC (2008) Extracellular purines are biomarkers of neutrophilic airway inflammation. Eur Respir J 31:949–956 6. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VFJ, Marchand-Adam S, Crestani B, Ryffel B, Couillin I (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774–783 7. Oosterhoff Y, de Jong JW, Jansen MA, Koeter GH, Postma DS (1993) Airway responsiveness to adenosine 50 -monophosphate in chronic obstructive pulmonary disease is determined by smoking. Am Rev Respir Dis 147:553–558 8. Rutgers SR, Kerstjens HA, Timens W, Tzanakis N, Kauffman HF, Postma DS (2000) Airway inflammation and hyperresponsiveness to adenosine 50 -monophosphate in COPD. Chest 117:285S 9. Rutgers SR, ten Hacken NH, Koeter GH, Postma DS (2000) Borg scores before and after challenge with adenosine 50 -monophosphate and methacholine in subjects with COPD and asthma. Eur Respir J 16:486–490 10. Zhou Y, Schneider DJ, Blackburn MR (2009) Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 123:105–116 11. Cushley MJ, Tattersfield AE, Holgate ST (1983) Adenosine antagonism as an alternative mechanism of action of methylxanthines in asthma. Agents Actions Suppl 13:109–113 12. Mann JS, Holgate ST, Renwick AG, Cushley MJ (1986) Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma. J Appl Physiol 61:1667–1676 13. Rorke S, Holgate ST (2002) Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am J Respir Med 1:99–105 14. Townley RG, Bewtra AK, Nair NM, Brodkey FD, Watt GD, Burke KM (1979) Methacholine inhalation challenge studies. J Allergy Clin Immunol 64:569–574 15. Hopp RJ, Bewtra AK, Nair NM, Townley RG (1984) Specificity and sensitivity of methacholine inhalation challenge in normal and asthmatic children. J Allergy Clin Immunol 74:154–158
9 Therapeutic Applications
267
16. Backer V, Groth S, Dirksen A, Bach-Mortensen N, Hansen KK, Laursen EM, Wendelboe D (1991) Sensitivity and specificity of the histamine challenge test for the diagnosis of asthma in an unselected sample of children and adolescents. Eur Respir J 4:1093–1100 17. Cockcroft DW, Murdock KY, Berscheid BA, Gore BP (1992) Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol 89:23–30 18. Ramsdell JW, Nachtwey FJ, Moser KM (1982) Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis 126:829–832 19. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE (1984) Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 39:912–918 20. Ramsdale EH, Roberts RS, Morris MM, Hargreave FE (1985) Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis. Thorax 40:422–426 21. Verma VK, Cockcroft DW, Dosman JA (1988) Airway responsiveness to inhaled histamine in chronic obstructive airways disease. Chronic bronchitis vs emphysema. Chest 94:457–461 22. Avital A, Springer C, Bar-Yishay E, Godfrey S (1995) Adenosine, methacholine, and exercise challenges in children with asthma or pediatric chronic obstructive pulmonary disease. Thorax 50:511–516 23. Godfrey S, Springer C, Noviski N, Maayan C, Avital A (1991) Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax 46:488–492 24. Van Den Berge M, Meijer RJ, Kerstjens HA, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) PC(20) adenosine 50 -monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 163:1546–1550 25. van den Berge M, Kerstjens HA, Meijer RJ, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164:1127–1132 26. Joos GF, O’Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, DiMaria G, Foresi A, Hargreave FE, Holgate ST, Inman M, Lotvall J, Magnussen H, Polosa R, Postma DS, Riedler J (2003) Indirect airway challenges. Eur Respir J 21:1050–1068 27. Avital A, Picard E, Uwyyed K, Springer C (1995) Comparison of adenosine 50 -monophosphate and methacholine for the differentiation of asthma from chronic airway diseases with the use of the auscultative method in very young children. J Pediatr 127:438–440 28. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O’Connor BJ (2002) Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 50 -monophosphate in mild asthma. J Allergy Clin Immunol 110:603–606 29. Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JW (2004) Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 23:559–564 30. Holgate ST, Arshad H, Stryszak P, Harrison JE (2000) Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol 105:906–911 31. Taylor DA, Jensen MW, Kanabar V, Engelstatter R, Steinijans VW, Barnes PJ, O’Connor BJ (1999) A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-50 -monophosphate in asthmatic patients. Am J Respir Crit Care Med 160:237–243 32. Bakirtas A, Turktas I (2006) Determinants of airway responsiveness to adenosine 50 monophosphate in school-age children with asthma. Pediatr Pulmonol 41:515–521 33. Avital A, Godfrey S, Springer C (2000) Exercise, methacholine, and adenosine 50 monophosphate challenges in children with asthma: relation to severity of the disease. Pediatr Pulmonol 30:207–214
268
S. Tilley et al.
34. Doull J, Sandall D, Smith S, Schreiber J, Freezer NJ, Holgate ST (1997) Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 50 monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol 23:404–411 35. Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S (2005) Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 60:383–388 36. Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ (2000) Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta2-receptor genotype. Am J Respir Crit Care Med 162:1318–1322 37. Polosa R, Ng WH, Crimi N, Vancheri C, Holgate ST, Church MK, Mistretta A (1995) Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 151:624–629 38. Crimi N, Palermo F, Oliveri R, Vancheri C, Polosa R, Palermo B, Maccarrone C, Mistretta A (1988) Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects. Clin Allergy 18:367–374 39. Phillips GD, Scott VL, Richards R, Holgate ST (1989) Effect of nedocromil sodium and sodium cromoglycate against bronchoconstriction induced by inhaled adenosine 50 -monophosphate. Eur Respir J 2:210–217 40. Summers QA, Honeywell R, Renwick AG, Holgate ST (1990) The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-50 -monophosphateinduced bronchoconstriction in asthmatic volunteers. Pulm Pharmacol 3:190–197 41. Phillips GD, Rafferty P, Beasley R, Holgate ST (1987) Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 50 -monophosphate in non-atopic asthma. Thorax 42:939–945 42. Rafferty P, Beasley R, Holgate ST (1987) The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 50 monophosphate in atopic asthma. Am Rev Respir Dis 136:369–373 43. Phillips GD, Polosa R, Holgate ST (1989) The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma. Clin Exp Allergy 19:405–409 44. Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST (2002) Role of cysteinyl leukotrienes in adenosine 50 -monophosphate induced bronchoconstriction in asthma. Thorax 57:323–327 45. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA (2000) Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275:4429–4434 46. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH (2000) Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells. J Clin Invest 105:361–367 47. Tilley SL, Tsai M, Williams CM, Wang ZS, Erikson CJ, Galli SJ, Koller BH (2003) Identification of A3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. J Immunol 171:331–337 48. Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, Blackburn MR (2003) Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 171:338–345 49. Feoktistov I, Biaggioni I (1995) Adenosine A2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96:1979–1986 50. Forsythe P, McGarvey LP, Heaney LG, MacMahon J, Ennis M (1999) Adenosine induces histamine release from human bronchoalveolar lavage mast cells. Clin Sci 96:349–355
9 Therapeutic Applications
269
51. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I (2004) Adenosineactivated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172:7726–7733 52. Pascoe SJ, Knight H, Woessner R (2007) QAF805, an A2B/A3 antagonist, does not attenuate AMP challenge in sujects with asthma. Proc Am Thorac Soc A682 53. Ethier MF, Madison JM (2006) Adenosine A1 receptors mediate mobilization of calcium in human bronchial smooth muscle cells. Am J Respir Cell Mol Biol 35:496–502 54. Brown RA, Clarke GW, Ledbetter CL, Hurle MJ, Denyer JC, Simcock DE, Coote JE, Savage TJ, Murdoch RD, Page CP, Spina D, O’Connor BJ (2008) Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects. Eur Respir J 31:311–319 55. Hakonarson H, Shanbaky I, Guerra FM, Grunstein MM (1998) Modulation of adenosine A1, bradykinin B1, and histamine H1 receptor expression and function in atopic asthmatic sensitized airway smooth muscle. Am J Respir Crit Care Med C56 56. Abebe W, Mustafa SJ (1998) A1 adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle. Am J Physiol 275:L990–L997 57. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ (2005) A novel A1 adenosine receptor antagonist, L-97–1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2ethyl-(2-hydroxy-ethyl)-amino]- ethyl}-1-propyl-3, 7-dihydro-purine-2, 6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 315:329–336 58. Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model. Nature 385:721–725 59. Hua X, Erikson CJ, Chason KD, Rosebrock CN, Deshpande DA, Penn RB, Tilley SL (2007) Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. Am J Physiol 293:L25–L32 60. Polosa R, Phillips GD, Rajakulasingam K, Holgate ST (1991) The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 50 -monophosphate and histamine in asthma. J Allergy Clin Immunol 87:939–947 61. Polosa R, Rajakulasingam K, Church MK, Holgate ST (1992) Repeated inhalation of bradykinin attenuates adenosine 50 -monophosphate (AMP) induced bronchoconstriction in asthmatic airways. Eur Respir J 5:700–706 62. Keir S, Boswell-Smith V, Spina D, Page C (2006) Mechanism of adenosine-induced airways obstruction in allergic guinea pigs. Br J Pharmacol 147:720–728 63. Gosens R, Zaagsma J, Meurs H, Halayko A (2006) Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7:73 64. Hirschhorn R, Ratech H (1980) Isozymes of adenosine deaminase. Isozymes Curr Top Biol Med Res 4:131–157 65. Silver JN, Flotte TR (2008) Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Pharmacogenomics 9:947–968 66. Hershfield MS (1998) Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol 35:291–298 67. Aldrich MB, Blackburn MR, Kellems RE (2000) The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res Commun 272:311–315 68. Hershfield M (2006) Adenosine deaminase deficiency. In: Pagon RA, Bird TC, Dolan CR, Stephens K (eds) Genereviews. University of Washington, Seattle 69. Hershfield MS (1993) Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). Immunodeficiency 4:93–97 70. Bax BE, Bain MD, Fairbanks LD, Webster AD, Chalmers RA (2000) In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 109:549–554
270
S. Tilley et al.
71. Davis S, Abuchowski A, Park YK, Davis FF (1981) Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 46:649–652 72. Carbonaro DA, Jin X, Petersen D, Wang X, Dorey F, Kil KS, Aldrich M, Blackburn MR, Kellems RE, Kohn DB (2006) In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 13:1110–1120 73. Aiuti A, Roncarolo MG (2009) Ten years of gene therapy for primary immune deficiencies. Hematology 2009:682–689 74. Kaptein LC, Einerhand MP, Braakman E, Valerio D, van Beusechem VW (1993) Bone marrow gene therapy for adenosine deaminase deficiency. Immunodeficiency 4:335–345 75. Wakamiya M, Blackburn MR, Jurecic R, McArthur MJ, Geske RS, Cartwright J Jr, Mitani K, Vaishnav S, Belmont JW, Kellems RE et al (1995) Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 92:3673–3677 76. Blackburn MR, Datta SK, Kellems RE (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273:5093–5100 77. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE (1996) Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem 271:15203–15210 78. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR (2001) Adenosinedependent airway inflammation and hyperresponsiveness in partially adenosine deaminasedeficient mice. J Immunol 167:4676–4685 79. Banerjee SK, Young HW, Volmer JB, Blackburn MR (2002) Gene expression profiling in inflammatory airway disease associated with elevated adenosine. Am J Physiol 282: L169–L182 80. Vass G, Huszar E, Augusztinovicz M, Baktai G, Barat E, Herjavecz I, Horvath I (2006) The effect of allergic rhinitis on adenosine concentration in exhaled breath condensate. Clin Exp Allergy 36:742–747 81. Esther CR Jr, Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, Boucher RC (2009) Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. Am J Physiol 296:L987–L993 82. Esther CR Jr, Lazaar A (2009) Airway adenosine is elevated in COPD and correlates with disease severity. Am J Respir Crit Care Med 179:A3764 83. Blackburn MR, Aldrich M, Volmer JB, Chen W, Zhong H, Kelly S, Hershfield MS, Datta SK, Kellems RE (2000) The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J Biol Chem 275:32114–32121 84. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR (2005) Adenosinedependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 175:1937–1946 85. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE (2008) Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 121:685–691 86. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, Schendel DJ, KraussEtschmann S (2006) Pulmonary TH2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 117:204–211 87. Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, Buhl R, SchmittGrohe´ S, Zielen S, Schubert R (2010) Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 50:152–157
9 Therapeutic Applications
271
88. Saha S, Mistry V, Siva R, Parker D, May R, Bradding P, Pavord ID, Brightling CE (2008) Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease. Allergy 63:1239–1243 89. Doherty T, Broide D (2007) Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 19:676–680 90. Blease K (2008) Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 9:1180–1184 91. Blackburn MR, Lee CG, Young HW, Zhu Z, Chunn JL, Kang MJ, Banerjee SK, Elias JA (2003) Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest 112:332–344 92. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103:779–788 93. Kang JS, DeLuca PP, Lee KC (2009) Emerging PEGylated drugs. Expert Opin Emerg Drugs 14:363–380 94. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M (2010) A1 receptors ligands: past, present and future trends. Curr Top Med Chem 10:878–901 95. Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003) Medicinal chemistry of adenosine A2A receptor agonists. Curr Top Med Chem 3:387–401 96. Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008) A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 14:1525–1552 97. Beukers MW, Meurs I, Ijzerman AP (2006) Structure-affinity relationships of adenosine A2B receptor ligands. Med Res Rev 26:667–698 98. Kalla RV, Zablocki J, Tabrizi MA, Baraldi PG (2009) Recent developments in A2B adenosine receptor ligands. Handb Exp Pharmacol 193:99–122 99. Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG (2009) Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol 193:123–159 100. Versluis M, Van Den Berge M, Timens W, Luijk B, Rutgers B, Lammers JWJ, Postma DS, Hylkema MN (2008) Allergen inhalation decreases adenosine receptor expression in sputum and blood of asthma patients. Allergy 63:1186–1194 101. Persson CG (1985) On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter. Thorax 40:881–886 102. Macht DI, Ting GC (1921) A study of antispasmodic drugs drugs on the bronchus. Pharmacol Exp Ther 18:373–398 103. Rabe KF, Dent G (1998) Theophylline and airway inflammation. Clin Exp Allergy 28:35–41 104. Lin CC, Lin CY, Liaw SF, Chen A (2002) Pulmonary function changes and immunomodulation of Th 2 cytokine expression induced by aminophylline after sensitization and allergen challenge in brown Norway rats. Ann Allergy Asthma Immunol 88:215–222 105. Nakano J, Yano T, Yamamura K, Yoshihara H, Ohbayashi O, Yamashita N, Ohta K (2006) Aminophilline suppresses the release of chemical mediators in treatment of acute asthma. Respir Med 100:542–550 106. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, Chaudhuri R, Braganza G, Adcock IM, Barnes PJ, Wood S, Thomson NC (2009) Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 33:1010–1017 107. Cowman S, Butler J (2008) Bet 3. The use of intravenous aminophylline in addition to betaagonists and steroids in acute asthma. Emerg Med J 25:289–290 108. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338–1344
272
S. Tilley et al.
109. Spinelli A, Fanelli A, Gorini M, Sanna A, Franc¸ois C, Scano G (1991) Control of breathing in patients with chronic pulmonary obstructive disease: response to bamiphylline. Respiration 58:241–248 110. Todisco T, Baglioni S, Amir E, Palumbo R (1995) Effect of bamiphylline on tracheobronchial mucus clearance in subjects with smokers’ simple chronic bronchitis. Respiration 62:16–20 111. Cogo R, Monzani GP, Fusillo M, Vota M (1991) Therapeutic effectiveness of bamifylline in elderly patients with COPD. Minerva Med 82:115–118 112. Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ (2006) Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol 551:116–124 113. Castro-Rodriguez JA, Rodrigo GJ (2010) The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with metaanalysis. Arch Dis Child 95:365–370 114. Lele RD (2009) Epigenetics-gene silencing. J Assoc Physicians India 57:60–66 115. Nyce JW (1999) Insight into adenosine receptor function using antisense and gene-knockout approaches. Trends Pharmacol Sci 20:79–83 116. Ball HA, Sandrasagra A, Tang L, Van Scott M, Wild J, Nyce JW (2003) Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics 3:97–106 117. Langley SJ, Allen DJ, Houghton C, Woodcock A (2005) Efficacy of EPI-2010 (An inhaled respirable anti-sense oligonucleotide: RASON) in moderate/severe persistent asthma. Am J Respir Crit Care Med 171:A360 118. Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, MacLennan S, Gessi S, Morello S, Barnes PJ, Ito K, Chung KF, Cavallesco G, Azzena G, Papi A, Borea PA (2006) Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:398–406 119. Mantell SJ, Stephenson PT, Monaghan SM, Maw GN, Trevethick MA, Yeadon M, Keir RF, Walker DK, Jones RM, Selby MD, Batchelor DV, Rozze S, Chavaroche H, Hobson TJ, Dodd PG, Lemaitre A, Wright KN, Stuart EF (2008) Inhaled adenosine A2A receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett 18:1284–1287 120. Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L (2002) Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 438:183–188 121. Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A (2006) Effect of adenosine A2A receptor activation in murine models of respiratory disorders. Am J Physiol 290:L1036–L1043 122. Chipps BE (2009) Inhaled corticosteroid therapy for patients with persistent asthma: learnings from studies of inhaled budesonide. Allergy Asthma Proc 30:217–228 123. Hasko G, Xu DZ, Lu Q, Nemeth ZH, Jabush J, Berezina TL, Zaets SB, Csoka B, Deitch EA (2006) Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic shock. Crit Care Med 34:1119–1125 124. Bevan N, Butchers PR, Cousins R, Coates J, Edgar EV, Morrison V, Sheehan MJ, Reeves J, Wilson DJ (2007) Pharmacological characterization and inhibitory effects of (2R, 3R, 4 S, 5R)-2-(6-amino-2-{[(1 S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9 H-purin-9-yl)-5(2-ethyl-2 H-tetrazol-5-yl)tetrahydro-3, 4-furandiol, a novel ligand that demonstrates both adenosine A2A receptor agonist and adenosine A3 receptor antagonist activity. Eur J Pharmacol 564:219–225 125. Inoue Y, Tanaka H, Sumi Y, Woehrle T, Chen Y, Hirsh MI, Junger WG (2011) A3 Adenosine receptor inhibition improves the efficacy of hypertonic saline resuscitation. Shock 35(2):178–183 126. Rimmer J, Peake HL, Santos CMC, Lean M, Bardin P, Robson R, Haumann B, Loehrer F, Handel ML (2007) Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 37:8–14
9 Therapeutic Applications
273
127. Luijk B, Van Den Berge M, Kerstjens HAM, Postma DS, Cass L, Sabin A, Lammers JWJ (2008) Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 63:75–80 128. Morschl E, Molina JG, Volmer JB, Mohsenin A, Pero RS, Hong JS, Kheradmand F, Lee JJ, Blackburn MR (2008) A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 39:697–705 129. Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M (2009) Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol 155:463–474 130. Mantell SJ, Stephenson PT, Monaghan SM, Maw GN, Trevethick MA, Yeadon M, Walker DK, Selby MD, Batchelor DV, Rozze S, Chavaroche H, Lemaitre A, Wright KN, Whitlock L, Stuart EF, Wright PA, Macintyre F (2009) SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg Med Chem Lett 19:4471–4475 131. Polosa R, Blackburn MR (2009) Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 30:528–535 132. Sullivan GW, Rieger JM, Michael Scheld W, Macdonald TL, Linden J (2001) Cyclic AMPdependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists. Br J Pharmacol 132:1017–1026 133. Murphree LJ, Sullivan GW, Marshall MA, Linden J (2005) Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NFkappaB in A2A adenosine receptor induction. Biochem J 391:575–580 134. Sullivan GW, Lee DD, Ross WG, DiVietro JA, Lappas CM, Lawrence MB, Linden J (2004) Activation of A2A adenosine receptors inhibits expression of a4/b1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol 75:127–134 135. Ibbotson GC, Doig C, Kaur J, Gill V, Ostrovsky L, Fairhead T, Kubes P (2001) Functional alpha4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat Med 7:465–470 136. Wallace KL, Linden J (2010) Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116:5010–5020 137. W-c S, Moore JN, Hurley DJ, Vandenplas ML, Linden JM, Murray TF (2007) Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils. Am J Vet Res 68:981–987 138. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K (2007) Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2A stimulation in lipopolysaccharide-induced lung injury. J Immunol 179:1254–1263 139. Sharma AK, Linden J, Kron IL, Laubach VE (2009) Protection from pulmonary ischemiareperfusion injury by adenosine A2A receptor activation. Respir Res 10:58 140. Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, Laubach VE (2010) Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 140:440–446 141. Gazoni LM, Laubach VE, Mulloy DP, Bellizzi AM, Unger EB, Linden J, Ellman PI, Lisle TC, Kron IL (2008) Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg 135:156–165 142. Chhabra P, Wang K, Zeng Q, Jecmenica M, Langman L, Linden J, Ketchum RJ, Brayman KL (2010) Adenosine A2A agonist administration improves islet transplant outcome: evidence for the role of innateimmunity in Islet graft rejection. Cell Transplant 19:597–612 143. Lisle TC, Gazoni LM, Fernandez LG, Sharma AK, Bellizzi AM, Schifflett GD, Laubach VE, Kron IL (2008) Inflammatory lung injury after cardiopulmonary bypass is attenuated by adenosine A2A receptor activation. J Thorac Cardiovasc Surg 136:1280–1287
274
S. Tilley et al.
144. Sharma AK, Laubach VE, Ramos SI, Zhao Y, Stukenborg G, Linden J, Kron IL, Yang Z (2010) Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 139:474–482 145. Ley K, Smith E, Stark MA (2006) IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res 34:229–242 146. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR (2010) Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 5:e9224 147. Kalla RV, Zablocki J (2009) Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates. Purinergic Signal 5:21–29 148. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR (2006) Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116:2173–2182 149. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D (2007) Effect of a specific and selective A2B adenosine receptor antagonist on adenosine agonist AMP and allergeninduced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246–1251 150. Wilson CN, Mustafa SJ, Kalla RV, Zablocki J, Tabrizi MA, Baraldi PG (2009) Recent developments in A2B adenosine receptor ligands. Handb Exp Pharmacol 193:99–122 151. Baraldi PG, Tabrizi MA, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid NA, Moorman AR, Varani K, Gessi S, Merighi S, Borea PA (2004) Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem 47:1434–1447 152. Baraldi PG, Aghazadeh Tabrizi M, Preti D, Bovero A, Fruttarolo F, Romagnoli R, Moorman AR, Gessi S, Merighi S, Varani K, Andrea Borea P (2004) [3 H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorg Med Chem Lett 14:3607–3610 153. Gessi S, Varani K, Merighi S, Cattabriga E, Pancaldi C, Szabadkai Y, Rizzuto R, Klotz K-N, Leung E, Mac Lennan S, Baraldi PG, Borea PA (2005) Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3 H]MRE 2029-F20. Mol Pharmacol 67:2137–2147 154. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA (2005) A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-Kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280:19516–19526 155. Vidal B, Nueda A, Esteve C, Domenech T, Benito S, Reinoso RF, Pont M, Calbet M, Lopez R, Cadavid MI, Loza MI, Cardenas A, Godessart N, Beleta J, Warrellow G, Ryder H (2007) Discovery and characterization of 4’-(2-Furyl)-N-pyridin-3-yl-4, 50 -bipyrimidin-2’-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. J Med Chem 50:2732–2736 156. Aparici M, Nueda A, Beleta J, Prats N, Fernandes R, Miralpeix M (2006) A potent adenosine A2B antagonist attenuates methacholine-induced hyperresponsiveness, mucus production and IgE levels in an allergic mouse model. CIA Symposium Abstract162 157. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123–140 158. Borea PA, Gessi S, Bar-Yehuda S, Fishman P (2009) A3 adenosine receptor: pharmacology and role in disease. Handb Exp Pharmacol 193:297–327 159. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, Ha J, Yoon KS, Kim SS, Kang I (2006) Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 396:1–6
9 Therapeutic Applications
275
160. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR (2006) The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177:1956–1966 161. Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman P (2006) Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther 8:R169 162. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA (2006) A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10:R65 163. Rivo J, Zeira E, Galun E, Matot I (2004) Activation of A3 adenosine receptors attenuates lung injury after in vivo reperfusion. Anesthesiology 101:1153–1159 164. Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P (2007) The antiinflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 16:1601–1613 165. Wagner R, Ngamsri K-C, Stark S, Vollmer I, Reutershan J (2010) Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol 299:L502–L512 166. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, Inoue Y, Woehrle T, Zhang Q, Hauser C, Junger WG (2010) Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci Signal 3:ra45 167. Matot I, Einav S, Weiniger CF, Pearl RG, Abramovitch R, Joshi BV, Jacobson KA (2008) Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion. Anesthesiology 109:269–278 168. Palikhe NS, Kim J-H, Park H-S (2009) Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J 50:744–750 169. Drakatos P, Lykouras D, Sampsonas F, Karkoulias K, Spiropoulos K (2009) Targeting leukotrienes for the treatment of COPD? Inflamm Allergy Drug Targets 8:297–306 170. Huang SK, Peters-Golden M (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442–1450 171. Sanak M, Kiełbasa B, Bochenek G, Szczeklik A (2004) Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy 34:1899–1904 172. Kim SH, Kim YK, Park HW, Kim SH, Kim SH, Ye YM, Min KU, Park HS (2009) Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir Med 103:356–363 173. Moon HG, Tae YM, Kim YS, Gyu Jeon S, Oh SY, Song Gho Y, Zhu Z, Kim YK (2010) Conversion of Th17-type into Th2-type inflammation by acetyl salicylic acid via the adenosine and uric acid pathway in the lung. Allergy 65:1093–1103 174. Kramer GC (2003) Hypertonic resuscitation: physiologic mechanisms and recommendations for trauma care. J Trauma 54:S89–S99 175. Rocha-e-Silva M, Poli de Figueiredo LF (2005) Small volume hypertonic resuscitation of circulatory shock. Clinics 60:159–172 176. Murao Y, Hoyt DB, Loomis W, Namiki S, Patel N, Wolf P, Junger WG (2000) Does the timing of hypertonic saline resuscitation affect its potential to prevent lung damage? Shock 14:18–23 177. Inoue Y, Chen Y, Pauzenberger R, Hirsh MI, Junger WG (2008) Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis. Crit Care Med 36:2569–2575 178. Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261:5–16 179. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L (2008) Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulm Pharmacol Ther 21:600–607
276
S. Tilley et al.
180. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R, Boyer J, Abraham WM, Boucher RC (2002) Pharmacology of INS37217 [P(1)-(uridine 50 )-P(4)-(2’-deoxycytidine 5’)tetraphosphate, tetrasodium salt], a nextgeneration P2Y2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 302:871–880 181. Shaver SR, Rideout JL, Perdergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC, Picher M, Yerxa BR (2005) Structure-activity relationship of dinucleotides: potent and selective agonists of P2Y receptors. Purinergic Signal 1:183–191 182. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B (2005) Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 39:339–348 183. Deterding RR, LaVange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW (2007) Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 176:362–369 184. Fung CY, Marcus AJ, Broekman MJ, Mahaut-Smith MP (2009) P2X1 receptor inhibition and soluble CD39 administration as novel approaches to widen cardiovascular therapeutic window. Trends Cardiovasc Med 19:1–5 185. Van Linden A, Eltzschig HK (2007) Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther 7:1437–1447 186. Beaudoin AR, Sevigny J, Picher M (1996) ATP-diphosphohydrolases, apyrases and nucleotide phosphohydrolases: biochemical properties and functions. JAI Press, Greenwich 187. Medina C, Jurasz P, Santos-Martinez MJ, Jeong SS, Mitsky T, Chen R, Radomski MW (2006) Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 317:739–745 ¨ , Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior 188. Uluc¸kan O JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K (2008) APT102, a novel ADPase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 104:1311–1323 189. Sugimoto S, Lin X, Lai J, Okazaki M, Das NA, Li W, Krupnick AS, Chen R, Jeong SS, Patterson GA, Kreisel D, Gelman AE (2009) Apyrase treatment prevents ischemiareperfusion injury in rat lung isografts. J Thorac Cardiovasc Surg 138:752–7759
Index
A Acquired immunodeficiency syndrome (AIDS), 34 Acute lung injury, 196, 198, 205–214, 216–220, 226, 236, 248, 252, 253, 257–261, 264, 265 Acute respiratory distress syndrome (ARDS), 196, 222, 261 Adenosine A2B receptor signaling pathway, 21 Adenosine deaminase (ADA) ADA-deficient mouse, 218 adenosine deaminase complexing protein (ADCP), 35 cat eye syndrome critical region candidate 1 (ADA2), 35 secretion of cytosolic ADA1 and ADA2, 35 A Disintegin and Metalloproteinase (ADAM) family, 146 ADO/IL–13 amplification cycle, 150, 151, 242, 261 Airflow obstruction, 84, 122–124, 150, 204, 217, 236, 239, 246 Airway fluid secretion, 96–100, 200, 210, 218, 220 Airway hyperresponsiveness, 77, 142, 150, 207, 209, 210, 212, 213, 215, 218, 222, 244, 246, 254–256, 265 Airway remodeling, 82, 139–151, 203, 205, 209, 215, 242, 254, 265 Airway surface liquid (ASL), 3, 4, 8, 20, 26, 27, 32, 33, 36, 52–58, 60–72, 80, 96–101, 121–124, 180, 182 Alkaline phosphatase PLAP on Type 1 pneumocytes, 20 TNAP on Type 2 pneumocytes, 20 Allogenic bone marrow transplant, 240 Allograft rejection, 213 Alpha1-antitrypsin deficiency (aAT), 81
Alveolar enlargement, 215, 255 Alveolar fluid clearance (AFC), 196, 199–201 Alveolar pneumocyte, 112, 113 AMP challenge, 236–239 Angiogenesis, 142, 147–149, 205 Aquaporin, 26, 38, 83 Arachidonic acid metabolism, 98, 182, 183, 260 Arginine-glycine-aspartic acid (RGD) domain, 143 Aspirin-intolerant asthma, 260, 261 Asthma, 8, 77–80, 82, 84, 85, 87, 123, 142, 149–151, 163, 168, 173, 175, 176, 178, 182, 203, 204, 206, 207, 210, 211, 213–215, 217, 218, 222, 223, 225, 226, 236–239, 241–250, 254–257, 260–262, 265 ATP-diphosphohydrolase, 22, 24 ATP release, 3–11, 33, 54, 55, 61–63, 65–67, 70, 79, 80, 84, 97, 99, 112, 113, 123, 124, 140–143, 145–147, 163–166, 168, 169, 176, 177, 179, 181, 201, 218, 220, 221 Autotaxin, 27, 28 Azide-sensitive ATPase, 27
B Bone marrow chimeric mice, 214, 216 Bronchial hyperresponsiveness (BHR), 236–239, 241, 243, 245, 247, 250, 254, 257, 260, 262 Bronchiolitis obliterans, 213, 215, 216, 237 Bronchoalveolar lavage fluid (BAL), 20, 32, 36, 76–80, 82, 85, 111, 112, 163, 183, 200, 202–204, 206–214, 216, 217, 221–225, 242, 244, 246, 248, 249, 252–257, 261, 265
M. Picher and R.C. Boucher (eds.), Purinergic Regulation of Respiratory Diseases, Subcellular Biochemistry 55, DOI 10.1007/978-94-007-1217-1, # Springer Science+Business Media B.V. 2011
277
278 Bronchoconstriction, 77, 78, 84, 210, 211, 218, 236–239, 244, 245, 248, 250, 260
C Calcium-activated chloride channel (CaCC), 2, 3, 52, 65, 96–100, 122–124, 199 Calcium-dependent ATP release, 8 Capillary electrophoresis, 24, 29, 35 CD26-ADA1 complex, 34 CD39-CD73 regulation cAMP-responsive element (CRE), 87 ischemia-reperfusion, 86 SP1 transcription factor, 85, 206 Ceramides, 19, 29, 117 Chemotaxis, 143, 147, 149, 166–169, 216, 217, 221, 222, 256 Chronic obstructive pulmonary disease (COPD), 8, 52, 71, 78–80, 82–85, 87, 122, 123, 142, 149–151, 173, 176, 178, 203, 206, 211, 214, 215, 217, 218, 222–224, 226, 236, 237, 241–245, 247, 248, 250, 254, 256, 262, 265 Ciliary beating frequency (CBF), 3, 119–122, 151 Collagen deposition, 213, 242, 255 Computerized model, 51–72 Connexins, 9–11 Constitutive ATP release, 4, 70, 98 Corneal micropocket assay, 205 Cough clearance, 122, 123 Crohn’s disease, 22, 257 Cystic fibrosis (CF), 3, 8, 52, 63, 64, 66, 71, 72, 79–87, 121–124, 149–151, 173–175, 178, 180, 182, 183, 199, 217, 218, 222, 236, 237, 242, 245, 263, 264, 266
D Damage-associated molecular pattern (DAMP), 173 Degranulation, 170, 217, 239, 249, 261, 262 Dendritic cells (DCs), 163, 165–167, 171–177, 181, 183, 202, 204, 222, 223, 225, 226, 243 Dust mite sensitization/challenge, 210, 245, 246, 249 Dyspnea, 123
E Ecto-adenylate kinase high-density lipoprotein exocytosis, 33 long-distance conduits, 32
Index Emphysema, 37, 79, 84, 123, 174, 223–226, 236, 241–243, 254 Endothelial barrier permeability, 196, 198, 203, 205, 212, 216 Endotoxin dephosphorylation, 21 Enzymatic network, 21, 37, 80–87 Eosinophil cationic proteins, 173, 244, 249 Epidermal growth factor receptor (EGFR), 140, 144–147, 149, 151, 181, 209 Epithelial cell migration, 141, 142, 197 Epithelial “repair transcriptome,” 140 European Respiratory Society Task Force, 237 Evans blue extravasation, 216 Exhaled breadth condensate (EBC), 76–80, 260 Exocytosis, 4, 5, 7, 8, 70, 105, 109–112, 114, 115, 117, 172 Experimental colitis, 162 Extracellular matrix, 148
F First wave cytokines, 172, 181, 182 Focal adhesions, 143, 145, 148, 198
G Gap junction complex, 9, 149 Goblet cell hyperplasia, 8, 149, 150 Golgi UDP-galactose transporter, 6
H Hemichannels, 9–11 Histamine, 30, 236–239, 244–246, 257 Hypersensitivity pneumonitis, 173 Hypertonic saline, 261, 262 Hypotension, 247–250, 253, 262 Hypoxia-inducible factor–1a (HIF–1a), 85, 206
I Idiopathic pulmonary fibrosis (IPF), 80, 82, 83, 149, 150, 173, 174, 222, 225, 236, 254 Immunosuppressive CD4/CD25/Foxp3 T regulatory (Treg) cells, 215 Infant respiratory distress syndrome, 111 Inflammasome, 172 Influenza A virus, 200 Intercellular adhesion molecule–1 (ICAM–1), 178–200 Intracellular pathogens, 172
Index Ion channels calcium-activated chloride channel (CaCC), 2, 3, 52, 96–100, 122, 123, 199 cystic fibrosis transmembrane regulator (CFTR), 3, 38, 52, 64, 96–99, 101, 121–124, 181, 183, 197, 199–201, 210, 220, 263 epithelial sodium channel (ENaC), 2, 38, 96–98, 100, 101, 121–123, 197, 199–201 Ischemia-reperfusion, 22, 86, 209, 211, 212, 216, 226, 251–253, 257–260, 264, 265
L Lamellar body, 20, 111, 112, 114–117 Leukotrienes, 98, 182, 183, 239, 244, 260, 261 Liddle syndrome, 100 Lipopolysaccharide neutralization, 21 Luciferase, plasma membrane, 160–162 Lung compliance, 212, 245, 252, 257 Lung transplant, 122, 209, 213, 236, 247, 248, 252, 253, 262, 265 Lymph node, 166, 167, 174, 175, 222, 223, 243 Lymphocyte-endothelium interaction, 176 Lymphoproliferative disorder, 35 Lysophosphatidic acid (LPA), 9, 29, 32
M Mathematical modeling, 52–61, 65, 70–72 Mechanical stress-induced nucleotide release, 52, 220 Mechanical ventilation, 37, 200, 201, 207, 208, 226 Methacholine, 78, 207, 222, 236, 237 Mixed theophylline/corticosteroid treatment, 244 Monocyte-macrophage transition, 83, 167, 168 Mucin exocytotic apparatus, 7 granules, 5, 7, 8, 26, 38, 70, 105, 106, 109, 217 MUC5AC, 7, 8, 123, 146, 150, 180 Mucociliary clearance (MCC), 3, 4, 10, 33, 38, 52, 59, 72, 85, 96, 98, 101, 102, 118, 120–124, 140, 178, 180, 182, 183, 218, 220, 222, 226, 260, 263 Mucus cell hyperplasia, 122, 150, 217, 236 Mucus cell metaplasia, 82, 122, 123, 149–151, 204, 211, 215, 217, 242 Multinucleated giant cells (MGCs), 173–174, 202
279 N Neovascularization, 142, 147–149, 151, 204, 205 Neural regulation of bronchoconstriction, 238–239 Neutrophil extracellular trap (NET), 170, 171, 183 Neutrophil myeloperoxidase, 208, 213, 214, 216, 225, 252, 253, 257 Nucleoside diphosphate kinases (NDPKs), 32 Nucleoside transporters concentrative (CNTs), 36, 37, 53, 207 equilibrative (ENTs), 36, 37, 207 Nucleotide metabolism, 65, 71, 80, 168, 205 Nucleotide pyrophosphatase/ phosphodiesterases (NPPs), 18, 24, 27–33, 53, 54, 61, 67, 68, 71, 72, 87 Nucleotide triphosphate diphosphohydrolases (NTPDases) NTPDase1, 22–27, 29, 33, 37, 38, 53, 54, 67, 68, 71, 72, 80, 149, 264 NTPDase3, 23–26, 29, 37, 38, 54, 66–68, 76, 80–84
O Ovalbumin sensitization/challenge, 78, 168 Overlapping syndrome, 236 Oxidative burst, 85, 170, 171
P Pannexin, 9–11, 172 Pathogen-associated molecular patterns (PAMPs), 172, 173 Pentostatin, 35, 83, 198 Phagocytosis, 170, 171, 178, 180, 183, 222 “Phagocytosis-resistant” pathogens, 173 Pneumonia, 36, 196, 240 Polymorphonuclear granulocytes, 168–170, 178 Polyoxometalates, 25 Primary ciliary dyskinesia (PCD), 71, 81, 122 Prostaglandins, 98, 144, 182, 183, 214, 260 Protease-activated receptor–1 (PAR1), 9 Proteases and protease inhibitors extracellular channel-activating proteases (CAPs), 100 furin-type proteases, 27, 100 short palate, lung, and nasal epithelial clone 1 (SPLUNC1), 101 Pulmonary artery pressure, 211, 252
280 Pulmonary edema, 196–201, 206–209, 214, 221, 226, 265 Pulmonary fibrosis, 79, 80, 174, 204, 215, 217 Pulmonary vascular remodeling, 142 Purinome, 21, 24, 38
R Ragweed sensitization/challenge, 212, 215, 254 Reduction-oxidation (redox) balance, 85, 146 Respirable antisense oligodeoxynucleotides (RASONs), 246 Respiratory syncytial virus (RSV), 85, 199, 200 Rho-Dependent ATP release, 8–9
S Scinderin and actin filaments, 104, 105, 116 Sentinel dendritic cells, 166, 167 Sepsis, 169, 180, 208, 210, 217, 218, 222, 248, 250, 251, 258, 262 Severe combined immunodeficiency disease (SCID), 34, 202, 236, 240, 241 Sickle cell disease, 248, 251 Signal transducer and activator of transcription 1 (STAT–1), 151 Smooth muscle cell thickening, 204 SNARE complex and secretory granule secretion, 103–105, 110, 116 Sphingomyelin metabolism, 29 Sphingosine–1-phosphate (S1P), 29, 30 Statins, 30 Steady-state nucleotide concentration, 55, 61, 63–66, 72 Sub-epithelial fibrosis, 150, 203, 236, 242 Submucosal glands, 26, 27, 31, 38, 80, 102, 122, 123 Surfactant secretion signaling pathways hemifusion, merging membrane leaflets, 114 post-fusion and content release, 114, 116, 117 pre-fusion, trafficking and docking, 114, 115 Synaptotagmin, 105, 106, 110, 111, 115, 116
Index T Teratocarcinoma cell line, 27, 29 Theophylline, 98, 244, 245, 254, 262, 265 TMEM16A, 99 TNFa-converting enzyme (TACE), 145–147 Transepithelial migration, 178 Transphosphorylation reactions ecto-AK, 32, 33, 70 NDPK, 32 Type 1 pseudohypoaldosteronism, 100
U UDP-glucose (UDP-Glc), 6–8, 27, 30, 165, 181, 199 UDP-sugar, 2, 6, 7, 102 Ulcerative colitis, 22
V Vagotomy, 239 Vascular cell adhesion molecule–1 (VCAM–1), 178, 180, 223, 251 Vascular endothelial growth factor (VEGF), 148, 179, 203, 205 Vascular leakage, 85, 197, 198, 203, 206–211, 213, 214, 216, 221, 248, 252, 253, 257, 259 Vascular remodeling, 142 Vasodilator-stimulated phosphoprotein (VASP), 197, 199 Vesicular release, 5, 6
W Wheezing, 100, 123 Wound closure, 141, 147–149 Wound healing signaling cascade, 139–151
Y Yeast ATP release, 5